{
  "doc_id": "S3-Leitlinie_Lungenkarzinom_2025_IC",
  "created_date": "2025",
  "country": "AT",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "(long © guidelines gv nprogra Pr Th de Versi AWM versio amm Oncolog rävention, Diagno herapie und Nach es Lungenkarzino ion 4.0 – April 2025 MF-registration number: 020-007OL on) gie",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Inhalt",
      "text": "Main innovations ..................................... 1 Information on this guideline .. 1.1 Publishers .................................. 1.2 Lead specialist company(s) ............. 1.3 Funding of the guideline ............. 1.4 Contact ................................................................ 1.5 Citizens ..................... 1.6 Special note ..................... 1.7 Objectives of the Oncology guidance programme ..................... 1.8 Further documents on this guideline ..................... 1.9 Composition of the guideline group ..................... 1.9.1 Coordination ..................................... 1.9.2 Subject societies and organisations involved 1.9.3 Working groups ..................................................... 1.9.4 Patient participation ..................... 1.9.5 Methodological monitoring ............................. 1.10 List of abbreviations .................................. 2 Introduction ................. 2.1.1 Objectives and questions ..................... 2.1.2 Addressees ............................. 2.1.3 Duration of validity and updating fa 2.2 Basics of methodology ............................. 2.2.1 Scheme of evidence classification ............. 2.2.2 Scheme of recommendation classification ........ 2.2.3 Statements ............. 2.2.4 Expert consensus (EC) .......... 2.2.5 Independence and interpretation of guidelines .............",
      "start_page": 3,
      "end_page": 8
    },
    {
      "heading": "11 Psychooncological care of patients with",
      "text": "In the event of an epidemiology of the disease............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................14.3 Definition of pain ....................................................................................................................................................................................................................................................................................................................................................................................................................14................................................................................................................................................................................................................. 14................................................................................................................................................. 14................................. 14.................14................................. 14.................................14................. 14..2.2.3 Pain pain detection detection detection detection ................................................................................................................................................................................................................................................................................................................................",
      "start_page": 9,
      "end_page": 13
    },
    {
      "heading": "1.9.1 Coordination",
      "text": "Coordination: Prof. Dr. Wolfgang Schütte (Halle) Dr. Sylvia Gütz (Leipzig) Dr. Wiebke Nehls (Berlin) Policy Secretariat: Katja Maertins (Halle)",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "1.9.2 Professional societies and organisations involved",
      "text": "Table 1 lists the members of the working groups for Aktu Guideline (Version 3). Table 1: Participating societies and organisations (alphabetic) Participating societies and organisati persons onen (alphabetisch) Arbeitsgemeinschaft Deutscher Tumorzentren Prof. Dr. med. Torsten Gerriet Blum (ADT) Arbeitsgemeinschaft Internistische Onkologie in PD Dr. Akin Atmaca der DKG (AIO) Prof. Dr. Annalen Bleckmann PD Dr. Wilfried Eberhardt Dr. Nikolaj Frost Dr. Tobias Overbeck Prof. Dr. Martin Reck Dr. Martin Sebastian PD Dr. Amanda Tufman Prof. Dr. Jürgen Wolf Arbeitsgemeinschaft Onkologische Pharmazie Stephan Liersch (OPH) Arbeitsgemeinschaft Onkologische Rehabilita- Prof. Dr. Oliver Rickung und Sozialmedizin in der DKG (AGORS) Arbeitsgemeinschaft Onkologische Thorax- Dr. Stephan Egge Rugler Dr.",
      "start_page": 14,
      "end_page": 29
    },
    {
      "heading": "2.2.2 Scheme of Recommendation Graduation",
      "text": "The methodology of the Oncology guidance programme provides for the award of levels of recommendation by the authors of the guidelines in the framework of a formal consensus procedure. Accordingly, a group process or structured consensus conference moderated by the AWMF and DGG was carried out. In the context of these processes, the recommendations were formally coordinated by the authorised mandate holders. The results of the respective votes (consensus strength) are assigned to the recommendations according to the categories in the table on consensus strength. In the guideline, the evidence level of the underlying studies and, in the case of recommendations, the strength of the recommendation (level of recommendation) are also indicated in the guideline in relation to all evidence-based statements and recommendations. In terms of the strength of the recommendation, three levels of recommendation are distinguished in this guideline (see table on degree of recommendation), which are also reflected in the formulation of the recommendations, Table 5: Scheme of degree of recommendation Recommendation Description A Strong recommendation for or against a measure - should = not B Recommendation for or",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "2.2.3 Statements",
      "text": "Statements are described as statements or explanations of specific expertise or questions without direct call for action. They are adopted in accordance with the approach of the recommendations in a 2.2 framework of methodology 31 formal consensus procedure and can be based either on study results or expert opinions. Expert consensus (EK) Statements/recommendations for which a study has been decided on the basis of expert consensus of the guideline group and for which no systematic literature research has been carried out are identified as expert consensus (EK). For the graduation of these recommendations, no letters (A,B,0 etc.) are used, the strength of the recommendation is derived from the wording used (should/should/can) according to the gradation in the recommendation grade table. Independence and definition of possible interest conflicts The German Cancer Aid provided the financial means through the Oncology (OL) guidance programme. These funds were used for personnel costs, disclosure of the editorial and the declaration of consensus in the independence conference.",
      "start_page": 30,
      "end_page": 34
    },
    {
      "heading": "3.3 Trend",
      "text": "Table C33 – C Alter Schwe Österr Deutsc Source: d e 8: Al C34, 2 sstand eiz reich chlan : Centre-standardised death rates by gender in international comparison, ICD-10 2017 – 2018 (alter Europastandard) death rate 2017-2018 Women Males nd 22.1 43.4 rum for cancer register data at the Robert Koch Institute Trend The incidence rate in Germany reached its peak in men at the end of the 1980s. Since then, the incidence rate has declined. In contrast, the incidence rate for women continues to increase continuously (Source: Report on cancer events in Germany, 2016). Quite similar is the development in Austria and Switzerland, but in both countries the rates for women seem to stabilize in recent years. Despite the fall in incidence rates for men, the RKI in Germany is still expecting an increase in absolute cases to 59,700, given the increasing incidence of women and demographic developments until 2022.",
      "start_page": 35,
      "end_page": 46
    },
    {
      "heading": "BK 4104",
      "text": "Lung cancer or larynx cancer or ovarian cancer: • associated with asbestos dust disease (asbestosis), • associated with asbestos dust-related diseases of pleura or • exposed to a cumulative dose of asbestos fibre dust at the workplace of at least 25 fibre years {25 x 106[(fibers/m3) x years]}",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "BK 4105",
      "text": "7 Risik kofakto oren 47 Asbestos-induced mesothelioma of the rib skin, peritoneum or pericardium.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "BK 4114",
      "text": "Lung cancer due to the interaction of asbestos fibre dust and polycyclic aromatic hydrocarbons with evidence of the action of a cumulative dose, which corresponds to a probability of at least 50 per cent in accordance with Appendix 2. Polycyclic aromatic hydrocarbons (PAH) In the Federal Republic of Germany, only BK No. 4110 \"Bössigen neubildungen der Respiratoren durch Kokereirohgase\" (\"Bössigen Neubildungen der Respiratorium durch Kokereirohgase\"). In 2009 there were scientific recommendations for two new occupational diseases: The legal definition of BK 4113 is \"lung cancer by polycyclic aromatic hydrocarbons with evidence of the effect of a cumulative dose of at least 100 benzo(a)pyrene-yrene-yrene [(μg/m3)x years]. Under the term \"cookereirohgase\" in the meaning of BK 4110, the technical product thus described as such as the air pollutions are understood as being of special significance for the respiratory agents.",
      "start_page": 47,
      "end_page": 60
    },
    {
      "heading": "A",
      "text": "Level of Evidence Recommendation",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "A",
      "text": "Level of Evidence , Introduction 60 Prevention Definition, Introduction Primary Prevention includes measures to avoid the development of a disease. Secondary prevention aims at early disease detection and is therefore treated in the early detection chapter, while tertiary prevention as measures",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "to reduce the negative effects of an already occurring disease",
      "text": "In the case of lung cancer, the main topic of supportive therapy and palliative medicine is smoking. The outstanding role of smoking, which is associated with more than 85% of all lung cancer cases and causes a 20-fold increased risk to the non-smoker, also influences the recognition and calculation of other parameters that have a negative or positive influence on the development of the disease. This applies both to occupational risk factors as well as to private consumption methods. Tobacco smoking and lung cancer Evidence-based recommendation tested 2025 degrees Tobacco smoking should be consistently avoided or terminated. nce Consensus Evidence-based recommendation tested 2025 degrees Passive smoking exposure should be avoided in every way. nce Consensus 4.2 Tabakrauc Recommendation g A Level of Evidence Recommendation g A Level of Evidence and Lung Carcinoma 61 Evidence-based recommendation tested 2025 degrees In patients with lung cancer, tobacco consumption should be regularly questioned and documented. nce Consensus Evidence-based recommendation tested 2025 degrees Patients with lung cancer, who are still to be motivated to smoke,",
      "start_page": 60,
      "end_page": 70
    },
    {
      "heading": "1b",
      "text": "i kamen lungsg f Eviden ntöse Primary and Secondary Prevention (Chemoprevention) 70 Drugous Primary and Secondary Prevention (Chemoprevention) Evidence-based recommendation tested 2025 degrees So far, drug-related primary or secondary prevention cannot be recommended outside studies. nce [123], [124], [125], [126], [127], [128], [129], [130], [131], [132] Consensus Based on experimental data and further observations [99], which supported the hypothesis that β-carotenes and retinoids may be chemopreventive, three large randomised, double-blind, placebo-controlled chemoprevention studies in high-risk populations (strong smokers) [125], [126], [123] were initiated.",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "In addition, in two studies β-carotene administration was",
      "text": "Also negative results were found in large studies for the administration of aspirin [127], [128], [124], vitamin E [129], retinyl palmitate [130], [131], N-acetylcysteine [131] and other substances (overview in: [131]). These overall sobering results indicate that the role of mic-roneral carcinogenesis in chemopreventing is more complex than initially assumed. Likewise, the data situation in secondary prevention studies of lung cancer is rather sobering. N-(4-hydroxyphenyl)retinamide (4-HPR) was not effective in the study of sympathomimetical carcinogenesis.",
      "start_page": 70,
      "end_page": 72
    },
    {
      "heading": "1a",
      "text": "In case of asymptomatic risk persons for a lung carcinoma, an early detection of lung carcinoma in patients with imaging procedures should not be performed alone or in combination with cytological sputum examinations. nce [135] Strong consensus Background Studies on the early detection of lung carcinoma in patients with imaging procedures were initially carried out using the X-ray thorax survey data only and in combination with cytological sputum tests in the United States [136], [137], [138], [139] and the then Czechoslovakia [140]. The US-American PLCO study (Prostate, Colorectal, Ovarian) [139] and the then Czechoslovakia [140] were used in randomised multicentre studies in the USA [139].",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "5.1 Imaging procedures 73",
      "text": "At the same time, the LuKrFrühErkV forms the basis for the modification of the Cancer Early Disease Directive (KFE-RL) currently under preparation by the Joint Federal Committee (G-BA) for the introduction of early lung cancer detection by means of low-dose CT in smokers. The LuKrFrühErkV lays down legally binding requirements for medical treatment in the context of early lung cancer detection by means of low-dose CT in Germany, which are listed in Table 10. Table 11: Legal requirements in the Lung Cancer Early Detection Regulation (Lung Cancer Early Detection Regulation (LukrFrühErkV) for medical treatment in the context of early lung cancer detection by means of low-dose CT in Germany Statutory requirements in the Lung Cancer Early Detection Regulation Paragraph in the (LukrFrühErkV) LuKrFrühErkV Admissibility of studies on lung cancer early detection by means of § 2 of age, tobacco smoking exposure, duration of nicotincarenz and medical aptitude profile, as well as a report on the suitability of the radiopropositability of the test of the test of the participant.",
      "start_page": 73,
      "end_page": 92
    },
    {
      "heading": "5.1 Imaging procedures 93",
      "text": "• Vulnerabilities/failure sources in the context of potential consequences/damage of unstructured lung cancer screening years of life) and risks of scree- ning (wrongly positive findings, prolonged lifetime with tumor diagnosis and overdiagnosis) • higher rates of false positive findings missing/inadequate treatment algorithms with subsequently unnecessary invasive, infrastructure and expertise in the context of diagnostic investigations and further investigation of positive rative interventions screening findings • increased morbidity, let-ality and cos- sence due to inadequately stable or qualitatively inferior treatment of missing documentation and central archivia - no possibility of epidemiological quantification of screening findings and later assurance of health: health-related endpoints; therefore: • no possibility of systematic • no comparison with cancer registries (centralised) detection of false, for detecting cancer incidence positive screening findings (non-sensitivity)",
      "start_page": 93,
      "end_page": 94
    },
    {
      "heading": "3) the examination and treatment process.",
      "text": "In the identification and invitation process, potential participants with a high lung cancer risk profile are identified in accordance with the defined entry criteria and included in the national lung cancer screening program. The early detection process includes the selection, aptitude testing and clarification of the participants, the actual early detection tests including early control tests by means of low dose CT and their findings, as well as the ongoing documentation and comparison of the findings within a longitudinal quality-assured screening program. The examination and treatment process begins as soon as the participants in the context of the low dose CT screening receive a clinically clear result and the participants then undergo the further diagnosis and, if necessary, therapy as patients. Both from the participant and the health economic point of view, it is essential for the success of a national lung cancer screening program in Germany that all efforts are made to clearly address and integrate the 3 named components and to submit them to the best possible structure.",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "5.1 Imaging methods 95",
      "text": "Table 14: Core elements of an organized early detection programme according to § 25a SGB V (points 1-6) and scientifically reasonable minimum requirements for the transition phase after the entry into force of the transitional phase after the entry into force of the BMUV lung cancer early detection regulation or the G-BA early detection directive according to § 25 SGB V (points 2-5) until the implementation of the organized early detection programme including a guidance-based tobacco cessation. Core elements of an organized early detection programme lung cancer early detection 1. Invitation and regular re-invitation of the insured by means of low-dose CT in egg containing a low-threshold offer nem organized early identification programme according to § 25a SGB V 2. Individual risk assessment and detection of the medical fitness profile by qualified physicians from the fields of general medizine, internal medicine and work medicine 3. Structured diagnosis of the minimum requirements for LDCT and evaluation of the transition phase after in-funds (modified Lung RADS occurs with the BMU early detection regulation 22.",
      "start_page": 95,
      "end_page": 95
    },
    {
      "heading": "5.1 Imaging methods 96",
      "text": "The need for the coupling of lung cancer early detection measures as well as an organized lung cancer early detection programme according to § 25a SGB V to centres specialised in the treatment of lung cancer lung cancer early detection measures according to § 25 SGB V as well as an organized lung cancer early detection programme according to § 25a SGB V should go beyond the pure outpatient medical care and be coupled to centres specialized in the treatment of lung cancer. The reason lies in the higher complexity of lung cancer screening by means of low dose CT in terms of risk population, optimization of the benefit-risk ratio including quality assurance and ensuring seamless interface solutions between the early detection and the clarification/treatment processes. This is in line with the S3 guideline lung cancer, the BfS report and the previous opinions of the German and European specialist societies, which demand an early detection of the investigation and treatment of lung cancer specialized institutions through a multi-disciplinary treatment team (specialists for radiology, pneumology, thorax surgery, radiation therapy and on-the-field certified).",
      "start_page": 96,
      "end_page": 113
    },
    {
      "heading": "6.2 History, clinical examination, laboratory examination 114",
      "text": "The general state of a patient and its performance can be quantified using the Karnofsky index and the ECOG/WHO performance status (see Table 19). The basic laboratory tests include the blood count including differential blood count, electrolytes, liver and kidney parameters, and coagulation values. It remains unchanged that due to the limited specificity and sensitivity, a routine determination of tumour markers such as CEA, NSE or CYFRA 21-21 is not recommended in primary diagnostics as well as in the relapse diagnosis of lung cancer [278]. Table 19: General state and performance of a patient ECOG/WHO Grade Karnofsky Index Normal, unrestricted bodyli- 0 Normal activity, no complication of activity, no indication of tumour disease Moderately reduced physical activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity low activity",
      "start_page": 114,
      "end_page": 117
    },
    {
      "heading": "2a",
      "text": "The X-ray examination of the thoracic organs can be used as initial radiological procedure. nce [284], [285], [286] Strong consensus consensus-based recommendation tested 2025 In patients suspected of a lung carcinoma and foreseeable therapy surgery, a CT examination of the thoracic organs should be carried out. Strong consensus imaging studies using ionizing radiation (rays, radioactive isotopes) can only be carried out in patients if a medical expert in radiation protection prior to the examination provided the justification for the use of ionizing radiation according to § 83 of the Radiation Protection Act (StrlSchG). This includes in particular the testing that the health benefit outweighs the radiation risk. In the diagnosis of the lung carcinoma, the last three methods are predominantly used for the use of the thoracic radiation, the last one for the use of the thoracic radiation, the second one for the use of the radiation.",
      "start_page": 117,
      "end_page": 122
    },
    {
      "heading": "2a",
      "text": "General recommendations Evidence-based recommendation tested 2025 degrees In case of suspected or proven lung carcinoma and existing thera-pieoption the following imaging studies should be carried out: • Full diagnostic CT of thoracic and abdomen (upper abdomen and buffing) with contrast agents, if necessary within the framework of a PET-CT • MRI of the brain skull, if contraindication against MRI replacement CT of the brain skull with contrast agent nce [302] Strong consensus However, with the CT diagnosis of thoracic and buffling within the framework of the staging, most of the usual metastasis of lung carcinoma are represented: loco- regional lymph nodes, lungs, liver and adrenal glands. However, there are diag- nostic gaps in the likewise frequent brain metastases and bone metastases. For the latter, a whole-body is required for the treatment of the brain, as well as for the treatment of the brain.",
      "start_page": 122,
      "end_page": 123
    },
    {
      "heading": "2a",
      "text": "In spite of the sparse data situation, it is useful to avoid the best possible exclusion of remote metastases from curative intended therapy or as initial findings for system therapy. Evidence-based recommendation tested 2025 degrees In case of suspected or proven non-small cell lung cancer and existing therapy option in clinical stage IB–IIIB and oligometastase stage IV, a whole body FDG-PET/CT should be performed for staging. If an FDG- PET examination cannot be performed for medical reasons (e.g. diabetic metabolic situation), an examination on extrathoracic metastases is conducted either by means of whole body MRT or bone scintigraphy plus CT abdomen or bone scintigraphy plus sonography abdomen. nce [309] Strong consensus-based recommendation 2025 In case of suspected FDI-cell and non-small cell disease, the FDI-CT can be used in the clinical stage and the substantial stage of the disease.",
      "start_page": 123,
      "end_page": 124
    },
    {
      "heading": "2a",
      "text": "In nine studies with 707 patients, PET/CT showed a sensitivity for the detection of adrenal metastases of 88.7% at a specificity of 90.8%. In a monocentric study with 98 patients after curatively intended treatment of a non-small cell lung carcinoma, no advantage could be demonstrated during a two-year follow-up period in the use of PET/CT in the follow-up to CT with contrast agents ([311]). Evidence-based recommendation tested 2025 degrees In case of detected small cell lung carcinoma, an FDG-PET/CT should be used to determine the tumour stage including the detection of remote metastases if no M1 stage (extensive disease) was previously established.",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "([313]; [312]). These were evaluated with evidence level 1a and 2a respectively.",
      "text": "A 2016 analysis with 7 included studies (total of 408 patients) found little evi- dent for the benefit of PET/CT in small cell lung carcinoma, but only in the detection of bone metastases PET/CT proved to be superior to skeletal scintigra- tion ([312]). However, a recent analysis of 2019 with 9 included studies and a total of 721 patients found a change in the stage (limited vs. extensive disease) in 15% of cases without, however, being able to identify an advantage for survival ([313]). Nevertheless, in both an American and an English guideline, the use of PET-CT (American College of Radiology 2018; National 6.3 Bildg EK EK g and Diagnosis Protection 125 Institute for Health and Care Excellence (NICE) is recommended, in the latter of all cases limited to cases with curative therapy intension.",
      "start_page": 124,
      "end_page": 128
    },
    {
      "heading": "2a",
      "text": "Recommendation B Level of Evidence",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "2a",
      "text": "EK g und Diagnossicherung 128 Diagnosesicherung und Invasive Staging-Aussuchungen Bronchoskopie Consensus-based recommendation tested 2025 Bronchoskopie (BRSK) is the most important method for diagnosing. For bronchoscopy a current CT examination of the thoracic organs is to be available. Strong consensus evidence-based recommendation tested 2025 degrees In a central tumor the BRSK should be performed with different methods of sampling as primary method of diagnosing. nce [326] Strong consensus evidence-based recommendation tested 2025 degrees In a peripheral lung tumor ≥ 2 cm diameter, the TTLB or BRSK should be performed with different methods of sampling under radiological control, such as X-ray illumination. nce [327], [328], [329] Strong consensus-based recommendation tested 2025 If a curative treatment intension exists, mediastinal lymph node enlargement in the CT (short axis >10 mm) or malignity of the lymph node.",
      "start_page": 128,
      "end_page": 129
    },
    {
      "heading": "1b",
      "text": "EK ligung f Eviden g und Diagnosesicherung 129 Evidence-based recommendation tested 2025 degrees For the pathological evaluation of mediastinal lymph node status, endoscopic examination methods with ultrasonic controlled sampling (bronchoscopy with endobronchial ultrasonic and with needle biopsy/aspiration [EBUS-TBNA]; oesophagoscopy with oeso- phageal ultrasound and needle biopsy/aspiration [EUS-FNA]; combination of EBUS-/EUS-methods) should be used. nce [330], [331], [332] Strong consensus-based recommendation tested 2025 In the case of discrepancy with metastasus-spicious mediastinal lymph nodes in imaging (CT or PET) and negative pathological detection of a needle aspiration method (e.g. EBUS-TBNA, EUS-FNA) a mediastinosis method is used.",
      "start_page": 129,
      "end_page": 131
    },
    {
      "heading": "2a",
      "text": "The cytological diagnosis of a non-small cell lung carcinoma (e.g. bronchoscopy, needle puncture method) can be accepted for therapeutic management, provided that a complete molecular analysis can be performed. nce [351], [330], [352] Strong consensus-based recommendation tested 2025 If the cytological diagnosis of a small cell lung carcinoma shows a clinical appearance or the clinical course rather than a small cell lung carcinoma, a bioptic procedure for histological and immunohistochemical diagnosis should be carried out. Strong consensus In patients with a lung carcinoma, the differentiation between small cell and non-small cell carcinoma is considered to be of the greatest importance, as their therapy differs in principle.",
      "start_page": 131,
      "end_page": 150
    },
    {
      "heading": "6.5 Staging 151",
      "text": "T-category explanation T1b Tumor more than 1cm and up to and including 2cm in largest extent T1c Tumor more than 2cm and up to and including 3cm in largest extent T2 Tumor more than 3cm, but not more than 5cm in largest extent or Tumor with at least one of the following characteristics: Tumor infests main bronchus, 2cm or further distal of carina without infestation of Carina Tumor infiltrates visceral pleura associated atelectase or obstructive inflammation up to Hilus, either parts of the lungs or the whole lung taking T2a Tumor up to and including 4cm T2b Tumor more than 4cm and up to and including 5cm T3 Tumor more than 5cm, but not more than 7cm in largest extent or Tumor with direct infiltration of one of the following structures: Pleura parietalis, Breast wall (including Sulcus superior tumor), Nervus phrenicus, parietal pericard; or separate tumor nodes in the same lap as the primary tumor T4 Tumor greater than 7cm or Tumor",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "6.5 Staging 152",
      "text": "6.5.1.1.2 The N classification Table 22: The N category N category Explanation Nx regional lymph nodes cannot be assessed N0 no regional lymph node metastases N1 metastases in ipsilateral peribronchial and/or ipsilateral Hilus or intrapulmonal lymph nodes (including an infestation by direct spread of the primary tumor) N2 metastases in ipsilateral mediastinal and/or subcarinal lymph nodes N3 metastases in contralateral mediastinal, contralateral hilus, ipsi or contralateral scalenus or supraclavikular lymph nodes Common explanations for the N classification: The regional lymph nodes are the intrahoracal, the skalenus lymph nodes, and the supraclavikular lymph nodes should be considered as right-wing, if there are no evidence-based guidelines for the number of lymph nodes that are considered to be N classed as 2 in a surgical procedure, and if there is an adequate response to the sample, if there is an adequate response to the frequency of the frequency of the frequency.",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "6.5 Staggering 153",
      "text": "Table 23: Classification of subgroups of stage IIIA(N2) subgroup Description III A1 Incidental detection of mediastinal lymph node metastases in a lymph node station in the postoperative histological examination of resectate III A2 Intraoperative detection of lymph node metastases in a lymph node stage III A3 Preoperative detection of lymph node metastases in one or more lymph node stations by staging by means of mediastinoscopy, fine needle biospy or PET III A4 bulky (extended) or fixed N2 metastases or metastases in several lymph node stations (mediastinal lymph nodes >2-3 cm with extracapsular infiltration; infestation of several N2 lymph node positions; groups of multiple be-falling smaller (1-2 cm) lymph nodes according to Robinson et al. [404], [405] 6.5 Stage classification (Sta 6.5.1.1.3 Anatom Table 24: Anatomisc IASLC lymph node station # 1 (pre-left and right)",
      "start_page": 153,
      "end_page": 157
    },
    {
      "heading": "6.5 Staging 158",
      "text": "6.5.1.1.4 The M-classification Table 25: The M-classification M-category Explanation M0 no remote metastases M1 remote metastases M1a tumors separated from the primary tumor in a contralateral lung lobe or tumor with pleural or pericardial metastases or with malignant pleural or pericardial effusion M1b an extrathoracic metastasis in an organ (this also includes the involvement of a non-regional lymph node) M1c multiple extrathoracic metastases in one or more organs A second malignant effluent of the lung (spiculated, increase in size, PET-poisitv) may be a time tumor, a distant metastasis or benign (granuloma). The definition and the further procedure should be decided in the interdisciplinary tumor conference in Abh. of the available information. [366] B: several non-solid pulmonary herds Pleural or pericardial effusions are classified as M1a. However, in the case of a few human periformary cancers, the incidences can be attributed to one.",
      "start_page": 158,
      "end_page": 162
    },
    {
      "heading": "6.6 Pathological-anatomical diagnostics 163",
      "text": "The corresponding prognostic and therapeutically relevant results are included as pN status in the TNM classification [408] (see Chapter 6.6.6) The number of affected lymph nodes and the lymph nodes examined should be specified as far as possible. To optimise interdisciplinary communication, the sum of affected lymph nodes and the lymph nodes examined should be specified in the TNM classification, e.g. pN1 (3/26). In the preoperative staging, the material obtained by a fine needle biopsy is available for the assessment of the regional lymph nodes.",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "6.50 Consensus-based recommendation reviewed 2025",
      "text": "EK The histological typing of lung tumours in resection preparations as well as small biopsies and cytological preparations should be carried out according to the criteria of the respective WHO classification. Strong consensus Background The recommendation is based on an expert consensus (see Chapter 2.2.4). The respective valid WHO classification forms the internationally recognized basis of the histopathological typing of lung tumours. In the 5th edition of the WHO classification of thoracal tumors [410] the following histopathological tumour types are distinguished for the lungs: Table 27: Histopathological typing of lung tumours according to WHO classification of thoracal tumors (5th edition, 2021) Epithelial tumors • Papillome • Adenome • Glandular precursor lesions o Atypical adenomatous hyperplasia o Adenocarcinoma in situ ▪ Adenocarcinoma in situ, non-muzine esein esein ▪ Adenocarcinoma diagnosis",
      "start_page": 163,
      "end_page": 170
    },
    {
      "heading": "6.6 Pathological-anatomical diagnostics 171",
      "text": "The following degrees of regression (RG) are distinguished: RG I: no tumour regression or only spontaneous tumour regression in the area of primary tumor and regional lymph nodes RG IIa: morphological evidence of therapy-induced tumour regression with at least 10% vital residual tumor in the area of primary tumor and/or more than small-scale detection of vital tumor tissue in the regional lymph nodes RG IIb: morphological evidence of therapy-induced tumour regression with less than 10% vital residual tumor in the area of primary tumor and/or only small-scale detection of vital tumor tissue in the regional lymph nodes. RG III: complete therapy-induced tumour regression without detection of vital tumor tissue in the area of primary tumor and regional lymph nodes.",
      "start_page": 171,
      "end_page": 171
    },
    {
      "heading": "6.58 Consensus-based recommendation modified 2025",
      "text": "EK A test for EGFR mutations in exonen 19 and 21 and ALK fusions is to be performed on the basis of the available tumour tissue/cells in NSCLC in early tumour stages (IB – IIIA, with respect to ALK in tumours ≥ 4 cm).",
      "start_page": 171,
      "end_page": 171
    },
    {
      "heading": "6.59 Consensus-based recommendation new 2025",
      "text": "EK In all non-resectable NSCLC in stage III, molecular pathological investigations with respect to EGFR mutations in exonen 19 and 21 as well as ALK and ROS1 alterations should be carried out on the basis of the tumour tissue/tumour cells available. Strong consensus 6.6 Patho EK EK ologis sch-anatomische Diagnosung 172 Consensus-based recommendation new 2025 In patients with non-small cell lung cancer in stage IB-III, an immunohistochemical examination for PD-L1 expression should be carried out in parallel with the molecular pathological studies. The result should be shown as a percentage of membraneous pro portion score (TPS) of positive tumour cells (Tumour Pro portion Score). An external quality assurance in the context of ring trials should be demonstrated. Strong consensus-based recommendation modified 2025 Based on the available tumour tissue/tumour cells of al- len NSCLC in stage IV.",
      "start_page": 171,
      "end_page": 179
    },
    {
      "heading": "6.7 Evaluation of clinical and functional operability 180",
      "text": "The preoperative lung function diagnosis should be performed only when the patient is in a clinically stable state under maximum, optimised therapy, including smoking exposure [469], [470]. An evidence-based algorithm for estimating clinical and functio- nele oper- tability before lung carcinoma resection is shown in Figure 11. 6.7.2.3 Calculation of postoperative lung function The calculation of postoperatively expected parameters of lung function (FEV1, CO-transfer factor) for estimating the risk of pneumonectomy and lobectomy is shown in Table 28. Perioperative resection risks are in relation to the absolute predictive postoperative FEV1, [456], [449], [472], [458], [473], [474], [474], [474], [474]. This is analogous to the corresponding values of the CO-transferfactor [472], [443], [475], [44] pre-operatively resection appears to be measured by the FE-rection.",
      "start_page": 180,
      "end_page": 182
    },
    {
      "heading": "6.7 Estimation",
      "text": "Recommendation",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "A",
      "text": "Level of Evidence Recommendationg B Level of Evidence Recommendationg B Level of Evidence of Clinical and Functional Operability 183 Evidence-based Recommendation 2010 grade An ECG is to be recorded prior to a planned lung resection.",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "In case of conspicuous cardiac auscultation or clinical signs",
      "text": "the heart failure should be performed an echocardiography. nce Consensus evidence-based recommendation 2010 grade In the first 6 weeks after a myocardial infarction no lung resection should be performed. nce Consensus evidence-based recommendation 2010 grade In patients with myocardial infarction over the past 6 months prior to a planned lung resection a cardiological examination should be performed. nce Consensus evidence-based recommendation 2010",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "the history or current noises over the carotids a carotid dopp-",
      "text": "In the case of symptomatic or high-grade but asymptomatic stenosis (>70%) of extracranial",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "brain-providing arteries should be an interventional or an interventional arteries prior to lung resection.",
      "text": "There are no clinical studies on the duration of the interval between acute myocardial infarction and planned lung resection. According to experts, a period of at least 6 weeks is sufficient [431], [435] for lung resection in the first 6 months after myocardial infarction. Preoperatively, a cardiological examination (basic programme: ECG, echocardiography) with risk assessment is recommended for lung resection in the first 6 months after myocardial infarction [431], [278]. 6.7 Absc Table Modifiz High Mean Corrosion of Clinical and Functional Operability 184 2 Previous Aortocoronary bypass surgery In lung resections, patients with a post-successful aortocoronary bypass surgery have no increased perioperative risk for at least 5 years unless symptoms of coronary heart disease or heart failure occur again [431]. 3 Preoperative evaluation of cardiovascular risks The American College of Cardiology have a table of anti-cardiology recommendations.",
      "start_page": 183,
      "end_page": 189
    },
    {
      "heading": "1b",
      "text": "EK entenz hlungsg f Eviden zentratierte Kommunikation 189 document. These include the fact that the information has been clarified, location and timing as well as the essential content of the Enlightenment Talk. If an Enlightenment Document has been used, it must be attached to the files. If the Enlightenment has been lost, because the patient has already been informed or has renounced, this must also be documented. In the S3 guideline Palliative Medicine [505] as well as other organ guidelines of the guideline Oncology, numerous aspects for communication with oncolytic patients have been developed. In the context of the revision of the S3 guideline Lung Carcinoma, in particular, the recommendations from the S3 guideline on palliative medicine [505] for the patient group with a lung carcinoma crane were reviewed. The recommendations were modified regarding the specific characteristics of this patient group.",
      "start_page": 189,
      "end_page": 199
    },
    {
      "heading": "8.2 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation Patients with non-healable lung carcinoma disease should receive early on the offer of an integration of palliative counselling and care according to Diag- A nosestellung. Level of Evidence [607], [568], [597], [564]",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "2b",
      "text": "Konsens",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "8.3 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation The offer for the integration of palliative counselling and care in patients B with non-healable lung cancer should be made early (within the first 2 months) after diagnosis. Level of Evidence [568]",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "2b",
      "text": "Konsens",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "8.4 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation Palliative care should be provided by palliative medical qualified specialists in all palliative medically relevant dimensions (physical, psychiatric, social and spiritual needs) and documented. Level of Evidence [607], [568], [597], [564]",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "2b",
      "text": "Konsens\n8.2 Konz\nEmpfeh\nB\nLevel of",
      "start_page": 200,
      "end_page": 201
    },
    {
      "heading": "2b",
      "text": "EK EK zept der vorrühen Integration palliativmedizinischer Versorgung 201 Evidence-based Recommendation examined 2025 Degree of difficulty In the context of palliative counselling and care of patients with non-healing lung cancer, the following tasks should be addressed: • regular assessment of physical, psychosocial and spiritual stress and treatment of the corresponding symptoms • counselling and coordination of assistance • active initiation of discussions on pre-requisites with a view to possible complications and aspects of the end of life • perception of stress in the family and friends with the requirement of support Consultation and mediation of hospice, nursing and other care services. f Evidence [607], [568], [608], [597], [564], [609] consensus-based statement assessed 2025 In studies, the positive effects of early palliative counselling and care were achieved when: (a) contacts were conducted at least in monthly intervals and (b) after a primary contact 3 follow-up response to a consensus-based recommendation were examined in a consensus-based patient decision-making process.",
      "start_page": 201,
      "end_page": 203
    },
    {
      "heading": "8.2 Concept of early integration of palliative care 204",
      "text": "Study Study population Intervention/ Control Results Usual palliative care Temel, J.S. Number of cases: N=77 Intervention(s) QoL(tFAC-L) et al., 2010 98.0/91.5/59/53.21/19 Setting: USA, single Early palliative care, [564], center monthly, with palliative total mortality care team Patient characteris- 12.9/22.9% tica: 55% female, age routine oncology care bias risk: average: 64 years, 95% control Caucasian standard palliative care ECOG 0 41% and routine oncology ECOG 1 47% care brain metastases: 26% room count: N=461 intervention(s) No sign. Difference in mann, C. et the LQ Setting: Canada, single Early palliative care inter- al., 2014 center, 16 medical on- convention with only breast disease, 24 patients were able to follow up studies.",
      "start_page": 204,
      "end_page": 206
    },
    {
      "heading": "1b",
      "text": "EK EK ium I/ hlungsg f Eviden /II 206 Evidence-based recommendation tested 2025 grade In general or functionally inoperable patients with a NSCLC stage I and IIA a stereotactic radiation therapy should be offered. nce [650], [644], [652], [653], [654] Strong consensus consensus-based recommendation tested 2025 In the dose prescription for pulmonary sterotaxia the tumor localisation should be taken into account. For central tumours adjusted dose regimens with at least 4 fracti- nes and a BED10 of 100-135 Gy should be used. Of these, very central tumours in the proximal bronchial tree or in close relationship to the oesophagus are excluded. In this case, a pulmonary sterotaxia with strict dose limitation of the corresponding riskor gane at specialized centres should be performed, otherwise a correction in conventional fractionation is performed. Strong consensus-based recommendation tested 2025 In the absence of pathological diagnosis typical of FT-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T",
      "start_page": 206,
      "end_page": 211
    },
    {
      "heading": "2a",
      "text": "Recommendation A Level of Evidence",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "1b",
      "text": "Recommendation B Level of Evidence",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "2a",
      "text": "[II 211 Treatment in functionally operable patients] Evidence-based recommendation tested 2025 degrees Patients with NSCLC in stage I / II should be offered a radical resection in case of adequate lung function and fea- ble contraindications, the aim of which is R0 tumour removal. nce [592], [659], [660], [661], [662], [663], [665], [665], [666], [657], [667], [668] Strong Consensus Evidence-based recommendation tested 2025 degrees NSCLC in stage I/II is intended to perform radical resection as lobectomy in case of sufficient cardiopulmonary function.",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "8.17 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In patients receiving curative resection, systemic lymph node dissection should be performed to enable accurate staging and possibly to improve prognosis.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "1b",
      "text": "Strong consensus",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "8.18 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In patients with chest wall infiltration, an R0 situation is crucial and an en bloc resection should be sought.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "Level of Evidence [592], [688], [689], [690], [691], [692], [693]",
      "text": "Strong consensus",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "8.19 Consensus-based recommendation reviewed 2025",
      "text": "EK In pleurainvasion without deeper chest wall infiltration, an extrapleural lysis can occur.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "8.20 Consensus-based recommendation reviewed 2025",
      "text": "EK A full wall resection is to be carried out with deeper chest wall infiltration. Strong consensus 8.3 Stadi recommendation B Level of",
      "start_page": 212,
      "end_page": 213
    },
    {
      "heading": "3b",
      "text": "ium I/I lung sg f Eviden II 213 Evidence-based recommendation tested 2025 degrees After R1 resection, the Thorax oncological tumor board should discuss further treatment options (e.g. post-resection or radiotherapy). nce [694] Strong consensus background 8.14 and 8.15 The surgery in curative intention is the method of choice in functionally operable patients in stage I and II. An adequate cardiopulmonary reserve is required. Lobectomy including systematic dissection of ipsilateral lymph nodes is the recommended surgical measure. In rare cases, pneumonectomy is required. In certain tumour localization, a cuff resection is required, provided a sufficient safety margin can be ensured. In a recent randomised multicenter study, this has been confirmed in two other studies [65].",
      "start_page": 213,
      "end_page": 217
    },
    {
      "heading": "8.3 Stage I/",
      "text": "Recommendationg B Level of Evidence Recommendationg B Level of Evidence Recommendationg B Level of Evidence",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "/II 218",
      "text": "[694]. In principle, however, the further procedure should be discussed in the thoracic oncological tumor board and the further treatment options (e.g. re-resection, radiotherapy, systemic therapy) should be determined after weighing the benefit and risk for the patient. Preoperative system therapy Evidence-based recommendation tested 2025 degrees Pre-operative chemotherapy in randomised studies did not lead to an extension of the relapse-free or overall survival time at NSCLC in stage I and is therefore not recommended outside studies.",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "nce [714], [715], [716], [717], [718]",
      "text": "Strong consensus Evidence-based recommendation tested 2025 degrees NSCLC in stage II should be discussed in an interdisciplinary manner as to whether systemic anti-neoplastic induction therapy, followed by resection, is performed as an alternative therapy option.",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "of PD-L1, risks R1/R2 resection, comorbidities, compliance assessment",
      "text": "and patient request.",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "nce [714], [715], [719], [716], [717], [718], [720]",
      "text": "Consensus Evidence-based recommendation modifies 2025 grade NSCLC patients with resectable tumours in stage II (without EGFR and ALK alteration) and recommendation of induction therapy, should be offered a combined immunchemotherapy. Checkpoint inhibitor therapy can be continued postoperatively depending on the approval status.",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "nce [720], [721], [722], [723]",
      "text": "Strong Consensus 3 Stadi ium I/I II 219 Background sole neoadjuvant chemotherapy The neoadjuvant chemotherapy for preoperative tumour reduction as part of the \"multimodal\" therapy has so far been predominantly studied in stage III. However, in a randomized study, a significant survival advantage in favour of neoadjuvant chemotherapy for patients in stage N0 or N1 (p = 0.027, RR: 0.68) was not shown in the multivariance analysis for patients in stage N2 (p = 0.85, RR: 1.04) [714) [714). In two other randomized phase III studies, the effectiveness of neoadjuvant chemotherapy was assessed in patients with a NSCLC in stage I – IIIA, with most patients in stage I and II receiving it. While in one study neither for the progression-free survival time (HR 0.98; 95% CI 0.77, 1.23) nor for the overall survival time (HR 1.04, 0 0 % CI81 advantage) was shown in favour of another chemotherapy.",
      "start_page": 218,
      "end_page": 222
    },
    {
      "heading": "8.25 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation After R0-resection and systematic lymph node dissection, patients with A NSCLC in stage II in good general condition (ECOG 0/1) should be offered adjuvant chemotherapy if no neoadjuvant therapy has been performed. Level of Evidence [726], [727], [728], [729], [730]",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "1a",
      "text": "Strong consensus",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "8.26 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation Adjuvant chemotherapy should begin within 60 days of resection after completion of wound healing. Level of Evidence [731], [732], [733]",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "2b",
      "text": "Strong consensus",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "8.27 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In adjuvant chemotherapy, patients with stage II NSCLC in A good general condition (ECOG 0/1) should be given cisplatin-containing combination over 4 cycles. Level of Evidence [734], [729], [730], [726]",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "1a",
      "text": "Strong Consensus 8.3 Stage I/ Recommendation B Level of Evidence up to Recommendationg A Level of Evidence up to Recommendationg B Level of Evidence up to /II Evidence-based Recommendation new 2025 grade Patients with NSCLC in stage IB and an activating EGFR mutation (exon 19 deletion only, exon 21 L858R) should be offered ad- juvant therapy with osimertinib over 3 years after primary R0 resection. nce [735], [736]",
      "start_page": 223,
      "end_page": 224
    },
    {
      "heading": "To the end of this period, the Commission shall take the necessary measures to ensure that the measures taken by the Member State concerned are compatible with the internal market and that the measures taken by the Member State concerned are compatible with the internal market and that they are compatible with the internal market.",
      "text": "Strong Consensus Evidence-based recommendation tested 2025 grade patients with stage II NSCLC and EGFR activating mutation (exon 19 deletion only, exon 21 L858R) should be considered adjuvant therapy with osimertinib for 3 years after primary R0 resection and adjuvant chemotherapy. nce [737], [736]",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "To the end of this period, the Commission shall take the necessary measures to ensure that the measures taken by the Member State concerned are compatible with the internal market and that the measures taken by the Member State concerned are compatible with the internal market and that they are compatible with the internal market.",
      "text": "Consensus evidence-based recommendation new 2025 grade patients with NSCLC in stage II and an activating EGFR mutation (exon 19 deletion only, exon 21 L858R), in which adjuvant chemotherapy cannot be performed after primary R0 resection, should be offered an adjuvant thera with osimertinib over 3 years. nce [738], [736]",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "To the end of this period, the Commission shall take the necessary measures to ensure that the measures taken by the Member State concerned are compatible with the internal market and that the measures taken by the Member State concerned are compatible with the internal market and that they are compatible with the internal market.",
      "text": "Strong consensus r n- bo- e apie 8.3 Stadium I/ Empfehlungsg B Level of Evidence up to Recommendationg A Level of Evidence up to EK /II 225 Evidence-based recommendation new 2025 grade Patients with NSCLC in stage II and an ALK translocation should be offered adjuvant therapy with alectinib over 2 years after primary R0 resection. nce [739]",
      "start_page": 224,
      "end_page": 225
    },
    {
      "heading": "To the left: see evidence report",
      "text": "Strong Consensus Evidence-based recommendation tested 2025 grade patients with stage II NSCLC with PD-L1 expression ≥ 50% (without EGFR or ALK alteration) should be offered adjuvant therapy with atezolizumab for 1 year after primary R0 resection and ad- juvant chemotherapy. nce [740], [741]",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "To the left: see evidence report",
      "text": "Strong Consensus-based recommendation tested 2025 patients with NSCLC in stage II (without EGFR or ALK alteration) should be provided with adjuvant therapy with pembrolizumab for 1 year after primary R0 resection and adjuvant chemotherapy, regardless of PD-L1 status. Strong Consensus Background 8.25 - 8.27 (adjuvant chemotherapy) The efficacy of adjuvant chemotherapy was investigated in a series of randomised studies. In addition, a summary analysis of data in the form of various meta-analyses is available [726], [729], [730]. In two studies, a combined adjuvant chemoradiotherapy against alleine adjuvant radiotherapy was investigated [742], [683]. 3 stadi current mium I/I II 226. In several studies, the results were possibly influenced by the use of old chemotherapy combinations [742], [743], [744], [4], [4], [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4] [4]",
      "start_page": 225,
      "end_page": 230
    },
    {
      "heading": "1a",
      "text": "The survival benefit in the individual PD-L1 expression groups was very heterogeneous and different from studies of pembrolizumab at stage IV: In the cohort with PD-L1 expression ≥ 50%, the improvement in DFS was not significant (hazard ratio 0.82; 95% confidence interval 0.57–1.18); in a PD-L1 expresion of 1-49%, the effect was greatest (hazard ratio 0.67; 0.48–0.92), and in a single PD-L1 expression < 1%, the hazard ratio 0.78 (0.58–1.03). In patients without prior adjuvant chemotherapy, pembrolizumab therapy was associated with kein DFS improvement (hazard ratio 1JT, 0,7–1.03), and in a placebo-L1 expression < 1%, the haemoglobin ratio 0.78 (0.58–1.03).",
      "start_page": 230,
      "end_page": 232
    },
    {
      "heading": "8.3.6 Flowchart Stage I/II",
      "text": "Figure 12: Flowchart for the treatment of non-small cell lung carcinoma oncology oncology oncology oncology oncology oncology oncology oncology oncology in the stadi carcinoma oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology oncology on",
      "start_page": 232,
      "end_page": 233
    },
    {
      "heading": "3b",
      "text": "Recommendation B Level of Evidence",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "3b",
      "text": "T-Tumor 233 Pancoast-Tumor Consensus-based recommendation tested 2025 Patients with non-small cell lung cancer (NSCLC) in the form of pancoast tumour (Sulcus-Superior-Tumor) of stages T3-4 N0-1 M0 should be evaluated in the thoracic oncological tumor board (pneumologists, oncologists, thoracic surgeons, radiation therapists, pathologists, radiologists and nuclear physicians) with regard to the feasibility of a trimodal therapy concept (induction therapy based on simultaneous radiochemotherapy followed by resection). Strong Consensus Evidence-based recommendation tested 2025 degrees In patients with non-small cell lung carcinoma (NSCLC) in the form of pancoast-Tumor (Sulcus-Superior-Tumors) of stages T3 N0-1 M0 should be followed by a general approach for this stage group with existing technical and functional operability based on Tsimulation76.",
      "start_page": 233,
      "end_page": 234
    },
    {
      "heading": "2b",
      "text": "In patients with non-small cell lung carcinoma (NSCLC) in the form of the pan-coast tumor (sulcus-superior tumor) of the stages T3-4 N0-1 M0 and non-existent as well as potentially achievable technical and functional operability, the therapy should be performed as in the case of tumours of this stage group at other location (Chapter 8.5.6). nce [767] Strong consensus As pancoast tumors, lung carcinomas (T3 or T4) with pancoast syndrome (e.g. infiltration of plexus brachialis, ganglion stellatum, ribs, vertebral bodies) are formed in the lung apex and grow into the o.g. structures by continuitatem. They often infiltrate the upper thorax wall with ribs and vertebral bodies. A growth in the plexus brachis, the gaitrium is frequent in the vessels.",
      "start_page": 234,
      "end_page": 237
    },
    {
      "heading": "8.5 Stage III (T1-3N2 / T1-3N3 / T4N0-3)",
      "text": "8.5.1 Stage III heterogeneity in NSCLC – clinical diagnosing, stage classification and relevant prognostic factors from a clinical therapeutic point of view",
      "start_page": 238,
      "end_page": 238
    },
    {
      "heading": "8.39 Evidence-based statement reviewed 2025",
      "text": "Level of Evidence The distinction of subgroups in the NSCLC in stage III is of great importance for therapy selection and prognosis. To this end, the clinical TNM classification (version 8) and the sub-division of the N2 stage according to Robinson are to be used. Strong consensus The stage III of non-small cell lung carcinoma contains locally differentiated tumour forms. It includes prognostically heterogeneous groups, which are also treated differently in multimodal concepts. Since 2017 the stage according to the version 8 of the TNM classification is divided. For stage III, this results in a sub-division in IIIA, IIIB and IIIC. But also these sub-groups are still heterogeneous in terms of tumour spread and partially produce a different procedure. The stage III A includes the categories T4 N0, T3 N1, T4 N1 and T2 N2. Stadium III B includes T3 N2, T1 N3 and T2 N3. In the T3 and T3 stage III T3 and T3 T3-C",
      "start_page": 238,
      "end_page": 238
    },
    {
      "heading": "III C 13 12",
      "text": "Modified according to [775], data from [401]",
      "start_page": 238,
      "end_page": 238
    },
    {
      "heading": "8.5 Stage III (T1-3N2 / T1-3N3 / T4N0-3) 239",
      "text": "The weak point of the current TNM classification continues to be the absence of the further differentiation of the ipsilateral mediastinal lymph nodes (N2). The N2 situ- tion has prognostic consequences, which also influence the therapeutic procedure. For example, André was able to show these differences in a French multicenter examination of 702 curatively operated patients who received systemic therapy and in 65% thoracic radiation therapy [776]. In the patients, a radical mediastinal lymph node dissection was performed. He distinguished the microscopic infestation of a single lymph node level (mN2L1), the microscopic infestation of several lymph node stations (mN2L2+), the preoperatively detected in the computer tomogram from a single lymph node station (cN2L1) and the preoperatively known infestation of several lymph node stations (cN2L2+). Between the four groups there were significant differences in survival, which are already found in the table of \"diagnosis of 30\" and \"diagnosis of 30\".",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "cN2L2+ 3",
      "text": "Source: [776] mN2L1: microscopic infestation of a single lymph node level, mN2L2+: microscopic infestation of several lymph node states, cN2L1: preoperatively in the computer tomogram of a single lymph node station, cN2L2+: preoperatively infestation of several lymph node stations known in the computer tomogram. Based on such data, a further subdivision of the mediastinal ipsilateral lymph node infestation is useful. In the TNM system, a sub-division of N2 is recommended for prospective detection of data [777]. For everyday clinical use, the Ame-rican College of Chest Physicians has proposed the following classification in its guidelines according to Ro- binson and colleagues [405], [404] IIIA1 (mediasti- nal lymph node metastases) in the postoperative histological reprocessing of one or more lymph nodes, IIIA2 (intraoperative determination of the pre-false III lymph node).",
      "start_page": 239,
      "end_page": 241
    },
    {
      "heading": "1b",
      "text": "ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 241 In total, there is a rich literature and discussion on the advantages of PET CT for spread diagnosis [779], [290], [783], [784], [785]. A participation of mediastinal lymph nodes suspected in PET-CT must be finely investigated, since the positive predictive value is low and not sufficient [786]-despite negative PET-CT is a finely woven clarification recommended, if the CT contains suspicious N1 lymph nodes or the primary tumor in diameter is greater than 3 cm and has high FDG activity, since in these Si- titrations the occult mediastinal lymph node metastases are frequently present for the fine-woven examination of the mediastinal lymph nodes. The most commonly used are the penetrine-diagnosis-diagnosis of the ultrasound.",
      "start_page": 241,
      "end_page": 242
    },
    {
      "heading": "I (T1-3N2 / T1-3N3 / T4N0-3) 242",
      "text": "Stage III, after completion of chemoradiotherapy and at least stable disease, was randomised for one year to an arm with consolidation therapy with durvalumab or an arm with observation. Data on staging and exact TNM stage were missing. A significant PFS advantage was shown with a median of 16.8 months (95% CI 13.0–18.1) versus 5.6 months (95% CI 4.6–7.8) with a stratified",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "The adverse reactions were also significantly prolonged (p=0.0025).",
      "text": "In the EORTC questionnaires QLQ.C30 and QLQ-LC13 there was no significant impairment due to the additional administration of Durvalumab [797]. Data on relapse therapy were missing. 15.4% of patients in the Durvalumab arm and 9.8% of patients in the observation arm ended the study due to side effects. A subgroup analysis required by the EMA showed no survival advantage for patients who did not have PD-L1 expression [795]. Accordingly, approval in the EMA range was limited to tumours that exhibit PD-L1 expansion. In the operable stage III, Phase I and II studies showed highly promising results in in induction therapy by adding PD-1 and PD-L1 inhibitors [805], [806], [807], [808], [809], [810], and randomised phase III studies were also an adjuvant in the adjuvant study.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "Evidence-based recommendation reviewed 2025",
      "text": "In patients with NSCLC in stage III, molecular analyses of driver mutations that are relevant at this stage are to be carried out. *EGFR and ALK",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "nce [811], [812], [813], [737], [814], [815], [816], [817], [818]",
      "text": "Consensus Background In the multimodal treatment of the NSCLC, molecularly targeted therapy has not yet played an established role in patients with locally-limited or locally-advanced disease [814], [815], [816], [817], [818], [811]. However, for patients in stage IB to IIIA, there were already initial data from randomised studies, which only represented subgroup analyses of these studies [814], [811]. These studies were not primary for patients with molecular alteration (e.g. EGF-R 8.5 Stadi Empfeh B Level of ium III hlungsg f Eviden",
      "start_page": 242,
      "end_page": 243
    },
    {
      "heading": "I (T1-3N2 / T1-3N3 / T4N0-3) 243",
      "text": "Only one Chinese study had primary patients with EGF-R mutation as inclusion criteria [812]. The data of this study showed a condition in the disease-free survival but not in the overall survival [812]. Therefore, adjuvant therapy with EGF-R TKI has not been established so far. Now the first data of the ADAURA study have been presented and published in patients with classical EGF-R mutation (del 19, L858R) in the stages IB, IIA and IIIA randomi.",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "test the adjuvant administration of the EGF-R TKI osimertinib against placebo [737].",
      "text": "Not all patients had received adjuvant chemotherapy before. However, the data show a significant benefit in the disease-free survival for the arm, which received the mo- lecular-targeted therapy [819]. However, the results are still preliminary in terms of overall survival. We only expect the final data of overall survival [819] this year or next. However, since the benefit in the DFS already indicates the assessment of ADAURA as a Landmark study (extremely favorable hazard rate for osimertinib administration) this treatment is already standard in the EMA after critical evaluation of the risk-benefit profile.",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "[819], [813]. In addition, it is already of considerable importance to the",
      "text": "It was therefore included as an expert recommendation after coordination in the guideline to determine the molecular markers for patients in stage III in which a consecutive drug treatment option has been demonstrated as a relevant evidence-based measure. Data on patients with ALK translo cation and ROS1 mutation as well as Braf mutation V600E are not yet available in marginalised comparison. Evidence-based recommendation tested 2025 grade Life age should not be a single exclusion criterion for definitive multi-timodal therapy at NSCLC in stage III. This requires special, also internistic/geriatric follow-up evaluation.",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]",
      "text": "Strong consensus studies of multimodal therapy in stage III, which specifically examine age as an essential parameter for effectiveness and side effects, are rare. In particular, age is not considered independently of comorbidities. Likewise, no geriatric assessment is usually carried out. Of the thorax surgical situation we know that age per se is not a contraindication against surgery, but age is often associated with comorbidities. Similar is known from the systemic therapy in stage IV. However, for adjuvant chemotherapy after curative resection in stage II and IIIA, there are retrospective analyses from the JBR.10 study [820] and LACE metaanalysis [821]. The older patients were underrepresented in these studies. However, it shows favourable survival and acceptable toxicity. The cancer register of E 5 Stadi EKium III I (T1-3N2 / T1-3N3 / T4N0-3) of this survival in Canada also shows an adjuvant 244 of this survival in Canada.",
      "start_page": 243,
      "end_page": 245
    },
    {
      "heading": "1a",
      "text": "ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 245 Statements on the prognostic effect of different tumour histologies in Sta-dium III [845]. Incidental stage IIIA(N2) at NSCLC – stage IIIA1 and IIIA2 after Robinson classification – multimodal therapy concepts Evidence-based recommendation tested 2025 degrees At NSCLC in Sta- III with non-identical N2 status (IIIA1 or IIIA2), complete resection (R0) and systematic lymph node dissection, in case of feasive contraindication, adjuvant combination chemotherapy should be performed after completion of wound healing within 60 days after resection. nce [846], last [847], [849], [757, [851], [729] pre-operative, [77] [4]",
      "start_page": 245,
      "end_page": 245
    },
    {
      "heading": "1. Italian ALPI study",
      "text": "2. Shares of the Big Lung Trial (BLT)",
      "start_page": 245,
      "end_page": 245
    },
    {
      "heading": "6. CALGB study",
      "text": "8.5 Stadi Empfehl A Level of 1b ium III lungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 246 These studies and the meta-analysis generated from them based on individual patient data have then finally positively fixed the routine use of adjuvant platinum-based chemotherapy after complete resection in non-small cell lung carcinoma (NSCLC). In stage II and III, the data for posto-perative chemotherapy were significant, so that in patients with macroscopic or microscopic N2 intraoperatively – which we are talking about here in this opinion – the recommendation can clearly be pronounced for adjuvant chemotherapy. The time window of 60 days results from the inclusion criteria of all phase III studies, which were respectively two months/60 days from surgery until the start of adjuvant chemotherapy application [729]. For a later start of adjuvant chemotherapy, however, there is no very interesting evidence from the data available from a randomised study.",
      "start_page": 246,
      "end_page": 249
    },
    {
      "heading": "8.51 Evidence-based recommendation new 2025",
      "text": "Level of recommendation patients with stage IIIA NSCLC and EGFR activation mutation (only",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "A Exon 19 Deletion, Exon 21 L858R) in which no",
      "text": "Adjuvant chemotherapy should be offered for an adjuvant treatment with osimertinib over 3 years. Level of Evidence [738], [736] to Strong Consensus See background text on osimertinib in chapter 8.3.4. (same study)",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "8.52 Evidence-based recommendation new 2025",
      "text": "Degree of recommendation Patients with stage IIIA NSCLC and ALK translocation should be offered adjuvant therapy with alectinib for 2 years after prior B mär R0 resection. Level of Evidence [739]",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "To the left: see evidence report",
      "text": "To Strong Consensus See background text on alectinib in chapter 8.3.4. (same study)",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "Degree of recommendation Patients with Stage IIIA NSCLC with PD-L1 expression ≥ 50 % (excluding:",
      "text": "A EGFR or ALK alteration) after primary R0 resection and",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "adjuvant chemotherapy, adjuvant therapy with atezolizumab for 1 year",
      "text": "==References==",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "Level of Evidence [740], [741]",
      "text": "Starker Konsens\n8.5 Stadi\nEK\nEmpfeh\nA\nLevel of",
      "start_page": 250,
      "end_page": 251
    },
    {
      "heading": "2a",
      "text": "In the absence of R0-resection, see chapter 8.3.4. (same studies) Evidence-based recommendation is to be tested 2025 degrees For patients with incompleted resection, the primary possibility of post-resection should be examined.",
      "start_page": 251,
      "end_page": 252
    },
    {
      "heading": "1a",
      "text": "ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 252 Stadium IIIA-N2 an R+ resection, of which 76 patients were R1. Median survival was 52 months for patients with post-irradiation versus 22 months for patients without local therapy. Patients with R2 resection did not benefit. In the NCI Regis ter study (3395 patients with R1 resection between 2005 and 2011), 1207 patients received post-operative radiation between 50 and 74 Gy. In a case series from Warsaw(81 irradiated patients after R1 resection), survival in the irradiated group was significantly better (5-year survival 32.4% versus 23.7%; HR 0.8 (CI 0.7 – 0.92) [ Wang EH]. In a case series from Warsaw(81 irradiated patients after R1 resection), the in-field control was 85% at 3 years of survival of 36%. Isolated, at the incidence of the lymph nodes was only increased.",
      "start_page": 252,
      "end_page": 255
    },
    {
      "heading": "4. SAKK study [872]",
      "text": "The German Lung Cancer Study Group Trial treated all patients initially with platinum-based induction chemotherapy (cisplatin and etoposid) and in a marginalisation arm, the patients were then operated on and treated only in R1 or R2-resecti- onsstaus postoperatively with radiotherapy [929]. In the second margin arm, the patients were then administered simultaneous chemotherapy (albeit carboplatin and vindesine as chemotherapy component) after initial induction chemotherapy and then, if feasible, operated on. However, the patient population in the study included patients with IIIA (N2) and also a large number of IIIB patients (at that time with 6th edition of UICC T4 or N3). PET/PET-CT was not regularly used as an inclusion criterion in the study. However, the patients received virtually all mediastinoscopia. EBUS was not performed at this time.",
      "start_page": 255,
      "end_page": 258
    },
    {
      "heading": "1b",
      "text": "EK ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 258 Evidence-based recommendation tested 2025 degrees If a phase of induction is used in patients with NSCLC stage IIIA3, preferentially a combination of cisplatin and a taxane should be used. nce [771], [863], [872], [930], [931], [932], [933] Consensus-based recommendation modified 2025 In NSCLC patients with recessable tumours in stage IIIA3 (without EGFR or ALK alteration) and recommendation of a drug-related induction therapy, combined immunochemotherapy should be offered. Checkpoint inhibitor therapy can be continued regardless of the approval status. Consensus Background The aforementioned arguments from the SAKK and ESPATUE study are intended to support induction chemotherapy with cisplatin and combination thereof1.",
      "start_page": 258,
      "end_page": 270
    },
    {
      "heading": "3a",
      "text": "ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 270. Among the patients enrolled in the Pacific study, 27% of patients received induction chemotherapy. It was notable that Severe Ad- verse events were less frequently observed under Durvalumab consolidation in patients with induction chemotherapy than in patients without induction (18% vs. 33%, [794]. However, an effectiveness of induction chemotherapy was found in randomised studies prior to surgery in patients with NSCLC in stage III. 2-3 cycles were applied here [724]. Overall, general condition and comorbidity and age of patients must be taken into account in the individual therapy selection. Thus, older patients have more adverse reactions up to deaths under simultaneous radiochemotherapy [827]. In individual cases, low-dose daily carboplatin or cisplatin therapy are not suitable for combination therapy.",
      "start_page": 270,
      "end_page": 271
    },
    {
      "heading": "2a",
      "text": "Recommendation A Level of Evidence",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "I (T1-3N2 / T1-3N3 / T4N0-3) 271",
      "text": "The RTOG 0617 study was also based on PET-based best practice planning, where PET or CT-positive lymph nodes were included in the Gross Target Volume. This was extended by 0.5 -1.0 cm to the clinical target volume in order to detect microscopic tumor extruders. In addition, breathing movement and set-up errors were generously taken into account when determining the planning target volume (Bradley 2020). For the target volume contouring according to the involved field principle of PET-CT and clinical pathological findings, reference was made to the consensus-based reports of the ESTRO-ACROP and the EORTC working groups [655], and for heart and lung protection, the high dose range can be closely adapted to the target volume by means of intensity modi- lation therapy (IMRT) with static fields or volume modulated rotational IMRT (VMAT) and thus the ri- siko of pneumonitis or heart load in comparison to the 3D-compliant IMRT (VMAT) and the RTOG 0617 study could be compared to the 3D-conformal",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "In the case of radiation therapy [942], data on a relationship between radiation therapy and radiation therapy should be reduced [942].",
      "text": "Dose-volume parameters of heart load and long-term survival of patients are contradictory [991]. The substructures of the heart to be taken into account especially when forming the dose distribution are subject to ongoing investigations [992]. Interactions between drug tumour therapy and radiotherapy should be taken into account in particular [993]. Evidence-based recommendation tested 2025 degrees The dose of radiation therapy should correspond biologically to a total dose between 60 and 70 Gy with conventional fractionation (1,8-2 Gy/the).",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "nce [771], [994], [995], [996], [997], [998]",
      "text": "Strong consensus Evidence-based recommendation tested 2025 grade Prolongation of radiotherapy through interruptions should be avoided.",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "nce [771], [994], [995], [996], [997], [998]",
      "text": "Strong Consensus A dose of 60 Gy in six weeks is more effective than lower total doses",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "[994], [995]. The CHART study (without concomitant chemotherapy) suggested that:",
      "text": "an increase in the biologically effective dose beyond 60 Gy can bring an improvement in the long-term results [996]. With the development of high-conformity 8.5 Stadi Empfeh A Level of",
      "start_page": 271,
      "end_page": 272
    },
    {
      "heading": "1b",
      "text": "ium III hungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 272 irradiation techniques were partly studied significant dose escalations (up to 90 Gy, mostly in phase I/II studies). However, the meta-analysis of Ramroth (3795 patients from 25 randomised comparisons of radiation dose) showed that dose escalation over 70 Gy in simultaneous chemotherapy results in worse survival. In the studies with radiotherapy alone, the increase in biologically effective dose with better tumour control and a survival advantage was correlated. RTOG 0617 randomised two dose levels (n = 544; 60 Gy/30 fractions versus 74 Gy/37 fractions) of simultaneous radiochemotherapy (2 cycles of carboplatin/ paclitaxel) followed by two additional doses of carboplatin/ paclitaxel. The high-dosis arm showed significant worsening survival (HR 1.8 CI 1.09-1.76).",
      "start_page": 272,
      "end_page": 274
    },
    {
      "heading": "1b",
      "text": "The median progression-free survival was 39.1 months in the osimertinib arm and 5.6 months in the placebo arm (HR 0.16, 95% CI: 0.10 - 0.24, p<0.001). The 1-year progression-free survival was 74% (95% Cl: 65 - 80%) in the osimertinib arm and 22% (95% CI: 13 - 32%) in the placebo arm. Preliminary data on overall 3-year survival was 84% for osimertinib and 74% for placebo (HR 0.81, 95% Cl 0.42 - 1.56, p=0.53). Toxins Grade 3 or higher occurred in approximately 35% in osimertinib versus placebo.",
      "start_page": 274,
      "end_page": 275
    },
    {
      "heading": "2a",
      "text": "ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 275 Meaning of additional chemotherapy after less dosed radiochemotherapy (e.g. weekly administration of carboplatin/taxanes). Consensus-based recommendation tested 2025 In the case of non-small cell lung cancer stage III, prophylactic whole brain irradiation should not be performed. Strong consensus between 20 and 40 % of patients with NSCLC develop brain metastases [109]. In contrast to the situation in the case of small cell lung cancer, prophylactic whole brain irradiation in the non-small cell lung cancer does not lead to an improvement in overall survival, although a highly significant reduction in the incidence of brain metastases was detectable in all previously published 8 randomized study cases. However, the majority of doses of 30 Gy in the non-small cell lung carcinoma were used in 10-15 fractions. In the metaanalysis of Li etal. [10], for the detection of 1568 patients, the hazard ratio of PCI-1.2 was equivalent to 0,9.",
      "start_page": 275,
      "end_page": 276
    },
    {
      "heading": "2a",
      "text": "ium III hlungsg f Eviden I (T1-3N2 / T1-3N3 / T4N0-3) 276 were validated in prospectively randomized studies. Regarding effectiveness, there were no significant differences between the fractionations examined in both the Cochrane Review of Stevens et al. [1015] and the metaanalysis of Fairchild et al. [1016]. Median survival was just under 9 months. However, some patients in good general condition with respect to 2 annual survival benefit from higher total doses (> 35 Gy BED10). Also, the updated ASTRO guideline on palliative thoracic radiation therapy from 2018 [1017], which is based on 3 marginalized studies [1018], [1019] and [1020] are recommended to be clearly defined as survival benefits by simultaneous radiochemotherapy in patients who are eligible for chemotherapy, recommend that the duration and intensity of the exposure to indi-di-vidual exposure are not defined by the clinical criteria.",
      "start_page": 276,
      "end_page": 277
    },
    {
      "heading": "8.5.7 Flowcharts Stage III",
      "text": "Figure 14: Flowchart NSCLC Stadium IIIA © Guidelinesprogra amm Oncology",
      "start_page": 277,
      "end_page": 284
    },
    {
      "heading": "1b",
      "text": "In the metastatic situation, there are potentially curative situations called OMD (oligometastatic disease) and should be clearly demarcated from the purely palliative approach in stage IV. These patients should be treated systemically as patients in the limited stages under curative concept (see chapter 8.6.14). System therapy in patients with squamous cell carcinoma without treatmentable genetic alterations The treatment of NSCLC patients stage IV with plate epithelial histology should be performed systemically. The initial assessment of the patient's symptom load, the total tumour load and the resulting remission pressure are, in addition to the ECOG-PS and patient preference, important parameters for the selection of substances or substance combination. 1 system therapy (first line) in patients with squamous cell carcinoma and the resulting remission pressure are evaluated in addition to the patient's patient's preference for the selection of substances or substance combinations. 1 system therapy (first line) in patients with squamous cell carcinoma with no therapy genetic cancer.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "8.84 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In stage IV NSCLC patients with squamous cell carcinoma that do not have the- A rapable mutations (e.g. EGFR, EML4-ALK, ROS1) and that exhibit PD-L1 expression ≥ 50% of tumour cells or > 10% on immune cells in tissue samples, monotherapy should be offered with • atezolizumab (≥ 50% of tumour cells or 10% of tumour infiltrating lymphocytes), • cemiplimab (≥ 50% of tumour cells) or • pembrolizumab (≥ 50% of tumour cells) as first-line therapy, provided that non-patient or tumour-bezogenic reasons for combination treatment speak. Level of Evidence [1030], [1032], [1034], [1033], [1035]",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "1b",
      "text": "Strong consensus",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "8.85 Consensus-based recommendation reviewed 2025",
      "text": "EK As a rule, radiological follow-up should be performed at NSCLC in stage IV after 2 cycles of therapy (6 weeks), but at the latest after 3 cycles (9 weeks).",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "8.86 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In stage IV NSCLC patients with radiological response or stability and appropriate tolerability, maintenance therapy should be performed after study-analogous cycles of platinum-containing chemo/immune therapy. Level of Evidence [1033], [728], [1038], [1030], [882], [1039], [1040], [880], [1041], [1042], [1043], [1035], [1034]",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "1a",
      "text": "Strong Consensus 8.6 Stadi EK ium IV (without indication for definitive local therapy) 286 Consensus-based recommendation reviewed 2025 The overall duration of chemo-immune therapy or immuno-monotherapy at NSCLC stage IV is not yet sufficiently clarified. The checkpoint inhibitors pembrolizumab and cemiplimab were administered in the pivotal studies over two years. A continuation of therapy beyond this interval can be offered to the patient in case of continued tumour control and tolerability. For atezolizumab, no limitation of the duration of the therapy was specified in the approval study. Strong Consensus-based recommendation reviewed 2025 patients with NSCLC stage IV with special risk factors for immuno-therapy Patients with autoimmune diseases and good general condition (ECOG 0-1) can be offered immuno- (combined) therapy if the autoimmune disease is not life-threatening and not active. An intimate mo- nitoring is particularly necessary in such cases.",
      "start_page": 285,
      "end_page": 287
    },
    {
      "heading": "1a",
      "text": "The following regimens are recommended: • carboplatin + nab-paclitaxel, • cisplatin/carboplatin + paclitaxel, • cisplatin/carboplatin + paclitaxel, • cisplatin/carboplatin + paclitaxel, • cisplatin/carboplatin + vinorelbine, • cisplatin/carboplatin + docetaxel, • cisplatin/carboplatin + gemcitabine. nce [1044], [1045], [1046], [1047], [1049], [1050], [1052], [1052] Strong consensus of patients with background placebo.",
      "start_page": 287,
      "end_page": 289
    },
    {
      "heading": "% CI 0.80-1.30).",
      "text": "A pooled analysis of KEYNOTE-001, -024 and -042 studies [1056] investigated the benefit of pembrolizumab monotherapy in elderly patients > 75 years of age. 132 elderly patients with PD-L1 expression > 50% were taken into account in the analysis. First-line therapy with pembrolizumab resulted in an increase in overall survival compared to chemotherapy. Adverse reactions with pembrolizumab monotherapy were less frequent compared to chemotherapy. KEYNOTE 407 [1057] investigated the concomitant administration of chemotherapy (carboplatin and paclitaxel or nabPaclitaxel) with pembrolizumab vs. chemotherapy al-lein in untreated patients with advanced squamous cell carcinoma in the lungs regardless of PD-L1 expression. A subgroup of patients had PD-L1 expression for more than 50% of tumour cells in the biopsies.",
      "start_page": 289,
      "end_page": 294
    },
    {
      "heading": "70 years, normal values for LDH, lactate and calcium.",
      "text": "Regular monitoring is also required during ongoing therapy to detect acute symptoms requiring intervention (bronchological intervention; pallia- tive radiotherapy; palliative surgery). For all patients with lung cancer, access to the above techniques and procedures must be ensured in a timely manner. 8.6.2.2 System therapy (second line) in patients with squamous cell carcinoma without treatmentable genetic alterations The goal of second line therapy is to improve survival time and control of tumour-associated symptoms. In phase III studies, which examined the importance of a second line therapy, patients with ECOG 0-1 were examined. The treatment options have become more differentiated, so that an image of immunohistochemical phenotype is made.",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "8.90 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation NSCLC patients with stage IV squamous cell carcinoma in good general condition (ECOG 0.1) with disease progression after primary combination chemotherapy with immunocheckpoint inhibitor therapy should be offered a second-line therapie up to progression or occurrence of toxicity. Level of Evidence [1075], [1076], [1077], [1078], [1079], [878], [1080]",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "1b",
      "text": "Strong consensus",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "8.91 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation NSCLC patients with stage IV squamous cell carcinoma after first-line combination chemotherapy in good general condition (ECOG 0.1) and without contraindications to immunocheckpoint inhibitor therapy, a PD1 or PD-L1 antibody should be offered in second-line therapy. Level of Evidence [878]",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "1b",
      "text": "Strong consensus",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "8.92 Consensus-based recommendation reviewed 2025",
      "text": "EK NSCLC patients with stage IV squamous cell carcinoma with PD-L1 ex-",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "pressure ≥50% and ECOG 0-2 without contraindication, which in the first line",
      "text": "muncheckpoint inhibitor as monotherapy should be offered platinum-based chemotherapy for the second line. Treatment options are: cis or carboplatin + taxan or gemcitabine or vinorelbin. Strong consensus",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "8.93 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In NSCLC patients with stage IV squamous cell carcinoma after first-line 0 combination chemotherapy with ECOG 2 without contraindications to an immune checkpoint inhibitor therapy, • atezolizumab or nivolumab (independent of PD-L1 status or • pembrolizumab (PD-L1 ≥1%) can be offered in second-line therapy. Level of Evidence Strong Consensus",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "8.94 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation NSCLC patients with squamous cell carcinoma Stage IV after first-line combina B tion chemotherapy with/without immunocheckpoint inhibitor therapy in good general condition (ECOG 0.1) and without contraindications against an angioge- nese inhibitor should be offered second-line therapy with docetaxel +/- ramucirumab. Third-line therapy up to progression or occurrence of toxicity, with single therapy such as gemcitabine or vinorelbine, can be offered with good ECOG (-1) Level of Evidence [1080]",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "1b",
      "text": "Konsens\n8.6 Stadi\nEmpfeh\nLevel of",
      "start_page": 296,
      "end_page": 297
    },
    {
      "heading": "1b",
      "text": "297 Evidence-based recommendation tested 2025 degrees In NSCLC patients with squamous cell carcinoma in stage IV, who received immunocheckpoint inhibitor therapy as second-line therapy and have no contraindications against third-line therapy, docetaxel +/- ramucirumab can be offered. nce [878], [1081] Strong consensus background The receptors that play a clinically relevant role in lung cancer are PD-1 and PDL-1: The receptor PD1 is typically expressed on T cells, the associated ligand on dendritic cells and tumour cells. The receptor-ligand interaction leads to an inhibition of the cytotoxic effector function of T-lymphocytes. The first immune checkpoint inhibitor that has been approved for pulmonary carcinoma therapy, the fully humanised anti-antibodies-PD1 was activated in the anti-bodies-PD1-1.",
      "start_page": 297,
      "end_page": 303
    },
    {
      "heading": "8.100 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In NSCLC patients with non-plattenepithele carcinoma at stage IV who have no",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "Tissue samples have a PD-L1 expression of ≥ 50 % of tumour cells or > 10 % on",
      "text": "Immune cells should be treated with monotherapy with:",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "• atezolizumab (≥ 50% of tumour cells or 10% of tumour infiltrating",
      "text": "Lymphocyte) or • Cemiplimab (≥ 50% of tumour cells) or • Pembrolizumab (≥ 50% of tumour cells) are offered as first-line therapy unless there are patient or tumour-related reasons for combination treatment.",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "Level of Evidence [1033], [1030], [1032]",
      "text": "Konsens",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "8.101 Consensus-based recommendation reviewed 2025",
      "text": "EK As a rule, radiological follow-up should be performed at NSCLC in stage IV after 2 cycles of therapy (6 weeks), but at the latest after 3 cycles (9 weeks).",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "8.102 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In stage IV NSCLC patients with radiological response or stability and appropriate tolerability, maintenance therapy should be performed after study-analogous cycles of platinum-containing chemo/immune therapy.",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "1a",
      "text": "Strong Consensus 8.6 Stadi EK ium IV (without indication for definitive local therapy) 305 3 Consensus-based recommendation reviewed 2025 The overall duration of chemo-immune therapy or immuno-monotherapy at NSCLC stage IV has not yet been sufficiently clarified. The checkpoint inhibitors pembrolizumab and cemiplimab were administered in the pivotal studies over two years. Continued therapy beyond this in- terval can be offered to the patient in the case of continued tumour control and tolerability. For atezolizumab, an immuno- (combination) therapy can be offered in the approval study that does not limit the duration of the therapy. Strong Consensus-based recommendation tested 2025 patients with NSCLC stage IV with special risk factors for immuno-therapy Patients with autoimmune diseases and good general condition (ECOG 0-1) can be offered if the autoimmune disease is not life-threatening and not active. An intimate mo- nitoring is particularly necessary in such cases.",
      "start_page": 304,
      "end_page": 320
    },
    {
      "heading": "8.6 Stage IV (without indication for definitive local therapy) 321",
      "text": "However, in the published metaanalysis, neither studies with beva- cizumab, in which carboplatin was frequently used as a combination partner, nor the data of the pemetrexed combination therapy, which are considered as a chemotherapy standard for the non-plate epithelial NSCLC in the first place and also represent the basic therapy for the approved chemo immunotherapy in this indication. Also, the data on the combination of nab-paclitaxel and carboplatin are not considered in the metaanalysis. The question whether the avoidable differences in platinum derivatives with respect to efficacy and tolerability are emphasized or weakened by the increase of one (or two) ICI in initial line therapy remains to be answered at this stage. Therefore, for expected complications due to cisplatin or patient's wish for higher side effects, combinations with carboplatin are recommended. 8.6.3.2 System therapy (second line) in patients with non-plate epithelicarcinosis without age",
      "start_page": 321,
      "end_page": 321
    },
    {
      "heading": "8.106 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation NSCLC patients with non-plattenepithel carcinoma in stage IV with ECOG 0-2 B without contraindications should be offered a further therapy line, which is based on the first-line therapy. Level of Evidence [1138], [1139], [1140], [1081], [1082], [1141], [1142], [1143]",
      "start_page": 321,
      "end_page": 321
    },
    {
      "heading": "1b",
      "text": "Strong consensus",
      "start_page": 321,
      "end_page": 321
    },
    {
      "heading": "8.107 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation NSCLC patients with stage IV non-plattenepithel carcinoma with PD-L1 B expression ≥50% and ECOG 0-2 without contraindications received in the first line ate- zolizumab or cemiplimab or pembrolizumab should be offered platinum-based chemotherapy for the second line. Therapeutic opti- ies are: • cis- or carboplatin, pemetrexed, gemcitabine or vinorelbin • carboplatin, (nab-) paclitaxel ± bevacizumab Level of Evidence [1144], [1140]",
      "start_page": 321,
      "end_page": 321
    },
    {
      "heading": "1b",
      "text": "Starker Konsens\n8.6 Stadi\nEmpfeh\nB\nLevel of",
      "start_page": 321,
      "end_page": 322
    },
    {
      "heading": "1b",
      "text": "322 Evidence-based recommendation tested 2025 grade NSCLC patients with stage IV non-platene epithelial carcinoma who have received immunochemotherapy in the first phase should be offered another therapy line. Treatment options are: • Docetaxel ± nintedanib or ramucirumab • Pemetrexed nce [1145], [1080] Strong consensus background At the time of the guideline, most patients in the first line received immuno- and/or immuno-chemotherapy depending on PD-L1 status. Therefore, it should be noted that no pros- pective randomised study data can be used for this treatment situation. Studies on docetaxel, possibly in combination with angiogenesis, or multikinase inhibitors, have been shown to be successful in this treatment situation.",
      "start_page": 322,
      "end_page": 335
    },
    {
      "heading": "8.112 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In NSCLC stage IV and the presence of a typical activating EGFR mutati A (del 19, L858R), patients with ECOG 0-2 should be offered an EGFR-T in first-line therapy. Level of Evidence [1170], [1171], [1172], [1173], [1174], [1175], [1176], [1177], [1178], [1179], [1180], [1181], [1182]",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "1a",
      "text": "Strong consensus 8.113 Evidence-based recommendation modifies 202 Degree of recommendation a) At NSCLC stage IV, Osimertini B/0 should be offered in first-line therapy at EGFR Exon 19 Deletion at NSCLC stage IV, in particular in the group with CNS metastases, a combination of osimertinib and chemotherap (pemetrexed and platinum with pemetrexed maintenance therapy) can be offered. c) At NSCLC stage IV with EGFR Exon 19 Deletion, a combination of lazertinib and amivantamab can be offered. Level of Evidence [1183], [1184], [1185], [1186] 1 (Oxford 2011): a)",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "(b) see evidence report",
      "text": "(a) In NSCLC stage IV with EGFR L858R mutations, the selection of first-line TKI with eGFR L858R mutations should be made dependent on the effectiveness and toxicity of approved TKI (afatinib, dacomiti nib, erlotinib, gefitinib, osimertinib, erlotinib in combination with bevacizumab, erlotinib in combination with ramucirumab). (b) In NSCLC stage IV with EGFR L858R mutations, in particular in the group with ZNS metastases, a combination of osimertinib and chemotherapy (pemetrexed and platinum with pemetrexed maintenance therapy) may be offered. (c) In NSCLC stage IV with EGFR L85R combination with EGFR-Mudine, EGFR-Mudine can be offered.",
      "start_page": 335,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report",
      "text": "Consensus 5 Consensus-based recommendation reviewed 2025 In NSCLC stage IV and in the presence of an activating EGFR mutation, an EGFR-TKI should be offered in patients with ECOG 3 in the first-line therapy. Strong Consensus 6 Consensus-based recommendation reviewed 2025 In NSCLC stage IV and in the presence of an activating EGFR mutation, an EGFR-TKI can be offered in the first-line therapy in patients with ECOG 4.",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "8.117 Evidence-based recommendation modified 2025",
      "text": "Degree of recommendation Patients with NSCLC stage IV and uncommon mutations in EGFR in group 1 B should be offered treatment with EGFR-TKI afatinib or alternative osimertinib. Level of Evidence [1181], [1187], [1188]",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "3b",
      "text": "Strong consensus",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "8.118 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In patients with NSCLC stage IV with EGFR T790M, treatment with the A EGFR-TKI osimertinib should be offered. Level of Evidence [1189]",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "1b",
      "text": "Strong consensus",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "8.119 Evidence-based recommendation modified 2025",
      "text": "Degree of recommendation NSCLC stage IV with exon-20 insertion mutations should be discussed in a molecula- BR tumor board. In the first-line therapy, chemotherapy should be offered in combination with avivantamab. If platinum-containing first-line combination therapy (without avivantamab) fails, targeted treatment with avivantamab should be offered. Level of Evidence [1190]",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "3a",
      "text": "Strong Consensus Background The evidence of the first generation of studies (Phase III study: IPASS [1170], [1191]; FIRST Signal: Phase III [1171]; NEJ002 Study by Maemondo et al. [1172]; WJTOG3405 Mitsudoliet al., Lancet Oncology 2010 [1192]; EURTAC, Rosell et al., Lancet Oncol- ogy 2012 [1193]; OPTIMAL [1180]; LUX LUNG 3 [1177], [1179]; Lux Lung 6 [1194]; Phase IIB Study Head to Head Comparison TKI: Lux Lung 7 [1195], [1196]; Phase III Study Head to Head Comparison TKI First vs Second Generation: ARCHER [1197]) were last discussed in detail in version 3.0 (see guide archive under:",
      "start_page": 337,
      "end_page": 338
    },
    {
      "heading": "FLAURA",
      "text": "Phase III Study Head to Head Comparison TKI First vs Third Generation TKI:",
      "start_page": 338,
      "end_page": 338
    },
    {
      "heading": "FLAURA",
      "text": "The flalaura study compared treatment with first-generation EGFR TKI (gefitinib or erlotinib) with the third-generation TKI [1198]. 556 patients with common mutations (Exon 19, Exon 21) were randomised, primary endpoint was PFS. Strati- fi cation characteristics were ethnicity (asian vs. non-asian), exon 19 vs. exon 21 mutations and CNS metastases. The median PFS in the osimertinib arm was significantly longer than in the first-generation TKI arm (18.9 months vs. 10.2 months, HR 0.46; 95% CI: 0.37 to 0.57; p<0.001) [1198]. The response rate (ORR) was comparable with 80% for osimerib and 76% for first-generation TKI (OR (oddds ratio): 1.27; 95% CI, 0.8 to 0.690 in the mid-range analysis.",
      "start_page": 338,
      "end_page": 338
    },
    {
      "heading": "In the FLAURA study, PFS in the CNS was not obligato-",
      "text": "Roughly checked with regular imaging.",
      "start_page": 338,
      "end_page": 338
    },
    {
      "heading": "FLAURA 2",
      "text": "Phase III Study Head to Head Comparison TKI First vs Third Generation TKI:",
      "start_page": 338,
      "end_page": 338
    },
    {
      "heading": "In the FLAURA 2 study, patients with common mutations were included.",
      "text": "(Exon 19 and Exon 21, uncommon mutations included, T790M were eliminated). Patients received either standard osimertinb or experimen- telle therapy with osimertinib and chemotherapy pemetrexed and platinum (Cis or carboplatin) followed by pemtrexed maintenance therapy. The primary endpoint of the study was PFS via ‘investigator', secondary endpoints were survival, response, length of response, quality of life, safety and PFS2. The data were first presented at WCLC in 2023. There was no difference in PFS (independent review and investigator) with HR of 0.62 (95% CI 0.48-0, p<0.0002), the PFS was improved from 19.9 to 29.4 months. There was no differential advantage of E19 vs. E21 mutations (EGFR Exon 19 del: HR 0.60 – 0.44 – 0.83) in one study in one patient's CIT group (95% CI4 – 0.63).",
      "start_page": 338,
      "end_page": 339
    },
    {
      "heading": "MARIPOSA",
      "text": "Phase III Head to Head Comparison Amivantamab + lazertinib vs. osimertinib:",
      "start_page": 339,
      "end_page": 339
    },
    {
      "heading": "In Phase III MARIPOSA [1186], as in FLAURA 2, patients with:",
      "text": "A common EGFR mutation (EGFR Exon 19 Deletion, L858R mutation) was included in the study, which tested osimertinib monotherapy against combination therapy lazertinib + amivatamab. The third arm (Randomization 2:2:1) was lazertinib monotherapy designed as an explosive arm. The primary endpoint was the BICR PFS of osimertinib vs. lazertinib and amivatamab, secondary endpoints were survival, response rate, duration of response, PFS2, time to symptomatic progression, intracranial PFS with systematically unrelated MRI imaging, and safety. The study was presented at ESMO 2023. The primary endpoint was achieved with a statis-tic significant PFS benefit with an HR of 0.7 (95% CI 0.58-0, p<0.001), 23.7 vs. 16.6 months of combination therapy.",
      "start_page": 339,
      "end_page": 345
    },
    {
      "heading": "1b",
      "text": "EK EK ium IV hlungsg f Eviden V (without indication for definitive local therapy) 345 resistance mechanisms to first/second generation TKI vs. third-generation TKI and corresponding second-line therapy for EGFR mutated patients Evidence-based recommendation tested 2025 degrees NSCLC stage IV with evidence of acquired EGFR TKI resistance by acquisition of EGFR T790M mutation and if osimertinib was not used in the first-line trial, osimertinib therapy should be offered. nce [1195], [1214] Strong consensus consensus-based recommendation tested 2025 In case of detection of resistance mechanisms that are potentially therapeutic, EGFR positive NSCLC patients stage IV should be included in studies. If this is not possible, the use of potentially active substances, possibly after discussion in a thorax oncological tumour board, should be considered independently of the approval status.",
      "start_page": 345,
      "end_page": 355
    },
    {
      "heading": "1b",
      "text": "The results of the quality of life analyses are however subject to a high risk of distortion, since only a few responders could be taken into account for quality of life analyses after the 2nd cycle of chemotherapie. Gastrointestinal side effects of ceritinib therapy can be reduced by taking a reduced dose of 450 mg together with a light meal [1233]. The bioavailability of ceritinib increases by the simultaneous food intake. The dosage \"450 mg with a light meal\" is bioequivalent to a dose of \"750 mg on a sober stomach\". A head-to-head comparison between crizotinib and ceritinib is not available. Second-line therapy after failure of a platinum-based standard chemo-therapy Evadence-based recommendation is tested 2025 degrees ALK positive NSCLC patients stage IV Progressor-based first-line ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT-type ALT",
      "start_page": 355,
      "end_page": 356
    },
    {
      "heading": "1b",
      "text": "EK EK ium IV hlungsg f Eviden V (without indication for definitive local therapy) 356 Crizotinib failure therapy Evidence-based recommendation tested 2025 grade Second or third generation ALK-positive NSCLC patients Stage IV should be offered in case of crizotinib failure. nce [1246] Strong consensus Consensus-based recommendation tested 2025 NSCLC stage IV with acquired ALK-TKI resistance should be followed by tissue biopsy and/or liquid biopsy to determine resistance mechanisms prior to system therapy. Strong consensus-based recommendation tested 2025 In case of evidence of \"off-target\", ALK-independent resistance mechanisms, which are potential therapy-able, ALK positive NSCLC patients Stage IV should be included in study if this is not possible, the use of potentially active substances, possibly after discussion in a thorax-oncolytic tumour board, should continue to be considered as a follow-up to the clinical outcome of a disease.",
      "start_page": 356,
      "end_page": 358
    },
    {
      "heading": "1b",
      "text": "EK ium IV (without indication for definitive local therapy) 358 275 patients), hypertriglyceridaemia (166 [60%] patients), oedema (119 [43%] patients), and peripheral neuropathy (82 [30%] patients). The most common Grade 3–4 adverse reactions were hypercholesterolaemia and hypertriglyceraemia (each in 43 [16%] of 275 patients). Severely associated therapy adverse reactions were observed in 19 (7%) of 275 patients, and the most common were cognitive (two [1%] patients). Among the 262 patients evaluated for weight gain, 80 (31%) had a 10–20% weight gain compared to their baseline ge-wicht and 33 (13%) had an increase of 20% or more [1256]. 4 therapy after failure of secondary and third-generation ALK inhibitors 2 Consensus-based recommendation 2025 In oligoprogedient cases, the possibility of a local intercipligeneration should be evaluated in patients with high frequency HC.",
      "start_page": 358,
      "end_page": 360
    },
    {
      "heading": "2b",
      "text": "ium IV hlungsg f Eviden V (without indication for definitive local therapy) 360 Therapy after failure of the approved ALK inhibitors Consensus-based recommendation tested 2025 In oligoprogressive cases, the possibility of a local therapy should be interdisciplinarily examined. Due to the possibilities of local therapy in CNS metastases, regular imaging of the CNS should be performed in ALK + tumors, also in asymptomatic patients, every 3-9 months. Strong consensus consensus-based recommendation tested 2025 In case of detection of \"off-target\", ALK-independent resistance mechanisms, which are potentially therapeutic, ALK + NSCLC patients stage IV should be included in studies. If this is not possible, the use of potentially active substances, possibly after discussion in a thorax-oncological tubeboard, should be considered, regardless of the approval status. Strong consensus evidence-based recommendation tested 2025 degrees follow-up of the molecularly targeted therapy options in ALK+K should be considered in the case of ALK therapy.",
      "start_page": 360,
      "end_page": 361
    },
    {
      "heading": "3b",
      "text": "ium IV lung sg f Eviden V (without indication for definitive local therapy) 361 more possible, these patients are treated with EGFR/ ALK negative NSCLC analogously depending on their general condition. For previously treated EGFR+/ ALK+ NSCLC patients, the immunotherapy with PD-1/PD- L1 inhibitors has shown less efficacy in several studies than in NSCLC patients without driver mutation and a lack of survival advantage compared to all-in chemotherapy [1224], [1225], [1128], [1082], [1081]. The only exception so far is the Impower150 study in which atezolizumab was given in combination with bevacizumab, paclitaxel and carboplatin [1226]. The response rate of (in the majority of TKI-pre-treated) EGFR/ ALK+ NSCLC patients in combination with bevacizumab, paclitaxel and carboplatin [1226] was very low in the number of patients with 4 subjects, in the number of 4 subjects, the number of 4 subjects is very common.",
      "start_page": 361,
      "end_page": 366
    },
    {
      "heading": "2b",
      "text": "ium IV hlungsg f Eviden V (without indication for definitive local therapy) 366 System therapy in patients with BRAF V600 mutation Evidence-based recommendation modifies 2025 degrees patients with NSCLC stage IV with proven BRAF V600 mutation should be offered a combination of dabrafenib and trametinib or encorafenib and binimeti nib. Alternatively, a combined immunochemotherapy can be offered. In the event of failure, a combination of dabrafenib and trametinib or encorafenib and binimetinib should be offered. Non-V600 mutations+ NSCLC patients should be discussed in a molecular tumor board. nce [1281], [1282], [1283] consensus background In approximately 2 to 4 % of NSCLC patients there is a mutation of BRAF kinase. In turn, 1 to 2 % of these patients can be followed by a BRAF V600 mutation. Thus, activation of the inhibitor K is a pathway of BRAF and a pathway of BRAF response.",
      "start_page": 366,
      "end_page": 368
    },
    {
      "heading": "3b",
      "text": "EK ium IV (without indication for definitive local therapy) results in 368 binimetinib in 15 (15%) patients. A single Grade 5 TRAE with intracranial bleeding was observed. These studies show that • targeted system therapy in BRAF mutation could be significantly superior to cytostatic chemotherapy effectiveness (directly absent) • dual MAPK pathway blockade (MAPK=mitogen-activated protein kinase) with dabrafenib and trametinib related to response rates and progression-free survival is more effective than monotherapy with dabrafenib • tolerability of combination therapy is significantly better than single therapy with dabrafenib • the combination dabrafenib and trametinib due to their efficacy represents an important therapy option in BRAF V600E-positive NSCLC. According to the authorisation, combinations of dabrafenib and trametinib and also encorfenib can be used in combination lines.",
      "start_page": 368,
      "end_page": 371
    },
    {
      "heading": "3a",
      "text": "371 CI 8.8 – 16.8) (HR 0.46; 95% CI 0.31-0.70, p<0.001). The advantage for selipercatinib over the control arm was 65% (95% CI, 54-75). HR for the time to progression in the CNS was 0.28 (95% CI, 0.12-0.68). The results for the superiority of selipercatinib were comparable to the overall population in the intention-to-treat-pemb-rolizumab population. The side-effect spectrum was similar to that already known (see above). The RET inhibitor praletinib showed comparable results in a phase I/ II study [1292], [1293], [1295], [1296]. In 281 patients with advanced RET fusion positive NSCLC, the pre-treatment regimen was found to be over-ly-activated in a phase I/ II study.",
      "start_page": 371,
      "end_page": 373
    },
    {
      "heading": "System therapy in patients with KRAS-G12C mutation",
      "text": "Evidence-based recommendation modified 2025",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "patients with NSCLC stage IV and a KRAS-G12C mutation should be",
      "text": "the use of the KRAS inhibitor sotorasib.",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "nce [1301], [1302]",
      "text": "Strong consensus Consensus-based recommendation new 2025",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Patients with NSCLC stage IV and a KRAS-G12C mutation should be treated with",
      "text": "* Cave: currently not available in DE Strong Consensus In a Phase II study in patients, more than 80% of whom had received pre-treatment with plat-inclusive chemotherapy and immunocheckpoint inhibitor, the use of a combination of chemotherapy and immunocheckpoint inhibitor therapy could lead to a targeted treatment with the KRAS inhibitor adagrasib*.",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "a response rate of 37.1%, a median response duration of 11.1 months, a",
      "text": "median progression-free survival of 6.8 months and a median overall survival rate of",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "In this phase III study, 375 patients with KRAS G12C were treated after a pre-",
      "text": "treatment with combination therapy containing platinum and a",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Immuncheckpoint-Inhibitor in der Zweit- oder Drittlinientherapie 1:1 randomisiert für",
      "text": "Sotorasib 960 mg p.o. per docetaxel 75 mg/m2 every 3 weeks i.e. primary endpoint was the PFS by independent assessment, secondary endpoints the OS, response rate, duration of response, disease control rate, and quality of life. The study was originally powered for the OS, but from ethical green the cross-over was allowed from the control arm to sotorasib, so that the primary endpoint to PFS was changed and the number of included pati-",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "of 174 patients randomised to docetaxel, only 151 patients were treated with docetaxel.",
      "text": "Docetaxel therapy. Patient characteristics were balanced, the median age was 64 years. The primary endpoint PFS was statistically significantly achieved.",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "with an HR of 0.66 (p=0.002), the median difference in PFS was 1.1 months",
      "text": "For the benefit of Sotorasib, subgroup analyses showed no differences in benefits with respect to the primary endpoint PFS.",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "The ORR was significantly better at 80.4 vs. 62.8%, with 28.1 vs. 13.2",
      "text": "6 Stadi ium IV V (without indication for definitive local therapy) 374 significantly better, the DCR with 82.5 vs. 60.3 % and the depth of response in confirmed response was also better in favour of sotorasib. The median duration of response was also better at 8.6 months vs. 6.8 months in favour of soto rasib. A survival benefit could not be shown, probably due to the cross-over to a KRAS inhibitor in the control arm (34% of the control arm). Despite the pre-treatment of all patients with an immune checkpoint inhibitor, the number of treatment-dependent AEs > Grade 3 after WHO was significantly less on sotorasib (10.7%) vs. docetaxel (22.5%). The clinically relevant parameter of discontinuation of therapy was 9.5 vs. 11.3, dose reductions with 15.4 vs. 26.5 gunst of sotorasib, only dose Pauses were with 35.5 vs. 15.2 in favour of the che-proportant therapy.",
      "start_page": 374,
      "end_page": 375
    },
    {
      "heading": "nce [1303], [1304], [1305]",
      "text": "Strong consensus",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "the mutations in the exonen 8 or 17-20 of HER2 (ERBB2), could be",
      "text": "6.4 mg/kg trastuzumab deruxtecan (T-DXd) every 3 weeks a response rate of 55%, a median response duration of 9.3 months, a median progression-free",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "(DESTINY-Lung01) [1303].",
      "text": "Approval study of T-DXd for pre-existing patients (DESTINY-Lung02)",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "≥ second or later line 2:1 randomised to T-DXd 5.4 mg vs 6.4 mg",
      "text": "i.v. every 3 weeks. Primary endpoint was the confirmed response rate (cORR) by independent assessment, secondary endpoints including the PFS, OS, duration of response, disease control rate, as well as the rate of AEs, AEs grade ≥3 and AEs of particular interest (AESI). The study was powered for response rate, which was the upper 95% confidence interval from response rate with docetaxel",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "und Ramucirumab in der REVEL Studie (ORR, 22.9%; 95% CI, 19.7 to 26.4%) überstei-",
      "text": "Overall, the study was positive for both arms.",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "Dian response duration of 16.8 (95% CI, 6.4 to non-reached [NE]) and NE (95% CI,",
      "text": "8.3 to NE), median duration of therapy 7.7 (range 0.7-20.8) and 8.3 months respectively.",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "(12.9%) and 14/50 (28.0%) patients (2.0% grade ≥ 3 in each arm).",
      "text": "These results have led to FDA and EMA approval of T-DXd for platinum pre-trade NSCLC patients with activating HER2 mutations at dose 5.4 mg/kg every 3 weeks.",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-",
      "text": "In addition, Lung02 demonstrated intracranial efficacy of T-DXd in both 8.6 Stadi EKium IV V (without indication for definitive local therapy) at 376 doses. The results demonstrated an IC-cORR of 50% (95% CI, 23.0 - 77.0) and 30% (95% CI, 14.7 to 49.4) for T-DXd 5.4 and 6.4 mg/kg for patients with baseline brain metastases (Annals of Oncology (2023) 34 (suppl_2): S755- S851. 10.1016/S0923-7534(23)01943-9]. For T-DXd, the results of the first-line study vs. chemoimmun therapy (DESTINY-Lung04) are pending, while other promising HER2-directed medications are also examined in clinical studies for T-DXd. Treatment of other driver mutations in NSCLC In addition to the previously treated alternations, there is still a better stimulant response to these stimulants.",
      "start_page": 375,
      "end_page": 377
    },
    {
      "heading": "8.157 Consensus-based recommendation reviewed 2025",
      "text": "In order to confirm the diagnosis of oligometastasis, a full body FDG-PET CT examination and a cranial MRI should be performed. If the presence of a solitary liver metastasis is considered, an MRI and possibly KM sonography of the liver should also be performed and thoracoscopy with biopsy should be performed in case of possible iso-lated pleura metastases in the imaging. Locoregional staging should be performed as in non-metastatic patients.",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "8.158 Consensus-based recommendation reviewed 2025",
      "text": "EK System therapy is to be offered for oligometastase NSCLC. The indication for system therapy and the criteria for the choice of system therapy should be based on the current approval and guidelines in metastatic stage IV of the NSCLC.",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "8.159 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In case of synchronous oligometastasis, local ablative therapy of all oligo-B metastases and locoregional primary tumours should be performed in addition to sys- tem therapy. Level of Evidence [1307], [1308], [884]",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "2a",
      "text": "Strong consensus",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "8.160 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation Local ablative therapy with oligomestatic NSCLC is to be integrated into a multimodal treatment concept with a syste-A mixed therapy, which is defined in the thorax oncological tumor board. Level of Evidence [1308], [1307], [884]",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "2a",
      "text": "Starker Konsens\n8.6 Stadi\nEmpfeh\nB\nLevel of",
      "start_page": 378,
      "end_page": 379
    },
    {
      "heading": "2b",
      "text": "EK EK ium IV (without indication for definitive local therapy) 379 1 Evidence-based recommendation tested 2025 Degree of elevation An optimal sequence of system therapy and locally ablative therapy is not established in oligomestatic NSCLC. An induction therapy over 3-4 months should be performed before a local ablative therapy of lokoregionar primaryius as well as oligometastases in the absence of progress. f Evidence [1307], [884] Strong consensus 2 Consensus-based recommendation tested 2025 In oligometastatic NSCLC, depending on tumour load, presence of brain metastases or local tumour-related complications, following interdisciplinary discussion, local ablative therapy prior to system therapy. Strong consensus 3 Consensus-based recommendation tested 2025 As a modality for the local ablative therapy of locoregionar primary tumor as well as cerebral and extracebrale oligometastases should be decided on radia- peutical and surgical restabulation procedures.",
      "start_page": 379,
      "end_page": 380
    },
    {
      "heading": "2b",
      "text": "ium IV hlungsg f Eviden V (without indication for definitive local therapy) 380 evidence-based recommendation tested 2025 degrees A general advantage of the (especially) stereotactic radiotherapy in the same way as surgery in oligometastase NSCLC is not established, so that, despite less evidence regarding the importance of surgery compared to radiotherapy in oligometastase stage, both options should be considered complete and interdisciplinarily evaluated. nce [1308], [1307], [884] Consensus The principles of the therapy of metachronic oligometastase NSCLC are based on the algorithm of synchronous metastatic NSCLC. Introduction In the metastatic stage, non-small cell lung carcinoma has a poor prognosis. The backbone of the treatment is palliative system therapy, possibly supplemented by palliative radiotherapy; palliative operations are rare. The oligometase non-small cell lung carcinoma (OM-NSC) is not a rule of the disease.",
      "start_page": 380,
      "end_page": 393
    },
    {
      "heading": "8.6.15 Flowcharts to NSCLC Stage IV",
      "text": "Figure 18: Flowchart NSCLC IV with therapeutic driver mutations - EGFR & ALK © Guide programme oncology - Lung carcinoma - 4.0 - April 2025 8.6 Stage IV (without indication for the definitive locality Figure 19: Flowchart NSCLC IV with therapie © Guidelines herapie) the active activity programme onco ermutations - ROS, BRAF, NTRK, RET, MET, KRAS, HER2 ologie - Lung carcinoma - 4.0 - April 2025 8.6 Stage IV (without indication for the definitive local therapy) Figure 20: Flowchart NSCLC IV Plate epithelial carcinoma without therapist Download option: Figure as high-resolution SVG file © Guide programme oncology --Lungska the active activity of the driver muzinoma ---Lengver utations rsion - 4.0 April 2025 8.6 Stadium IV (without indication for the definitive local therapy) Figure 21: Flowchart NSCLC IV Non-Platform 9.",
      "start_page": 393,
      "end_page": 399
    },
    {
      "heading": "1b",
      "text": "andlun hungsg f Eviden ngstrategy in the overview 399 Treatment strategy in the overview Status of treatment options Evidence-based recommendation tested 2025 degrees In all patients with SCLC a combination system therapy is to be performed. Patients and stadia-dependent it should be combined with local measures, e.g. surgery or radiation therapy. nce Strong consensus Central therapy measure in all stages of SCLC is the implementation of a combination chemotherapy. This is supplemented by local therapy measures depending on stadia. Functionally operable patients in stage I-II should be subjected to multi-mo-dal therapy with inclusion of the operation. In case of inoperability, irradiation should be carried out as a local therapy in case of lack of remote metastasis and irradiable tumour spread as a local therapy. In addition, in all stages, prophylactic cranial radiation lowers intra-cerebral recurrence rate and can prolong survival in case of inoperability.",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "response as monotherapy (evidence level 1b) [1362].",
      "text": "treatment can be assessed after the first cycle. Patients with progressive disease should be immediately switched to another therapy.",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "the [1363] (degree of evidence 1b).",
      "text": "A primary alternance approach is a sequential approach with therapy",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "change in Progress not superior (evidence level 1b) [1362], [1364], [1365], [1366],",
      "text": "9.4 Beha\nEmpfeh\nA\nLevel of",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "2a",
      "text": "The duration of treatment should be 4 to 6 cycles, whereas in patients with loose disease and additional radiation therapy it is more likely to be 4 cycles. In patients with metastatic disease who do not receive complementary immunotherapy, 6 cycles should be used. Longer duration of therapy prolongs pro-gression-free survival, but overall survival is not affected or at most marginally [1372], [1373] (Evidence level 1b). Treatment in stage T1-2N0-M0 (VLD) In stage T1-2N0-M0, either multimodal therapy can be performed including surgery or combined chemo-radiation therapy. Decisive for the choice of therapy modality are the patient's comorbidities, as well as functional operability. Evidence-based recommendation tested 2025 degrees In patients with SCLC in stage I/II without mediatinal lymph nodes, a multimodal therapy should be performed as a combination of therapy13, in particular, a multimodal therapy, a system.",
      "start_page": 400,
      "end_page": 405
    },
    {
      "heading": "1b",
      "text": "andlun hungsg f Eviden ng in stage T1-2N0-1M0 (VLD) 405 Option of the primary definitive chemo-ray therapy Evidence-based recommendation modified 2025 degrees In patients with a SCLC in stage I/II, especially at high surgical risk, a primary definitive chemo-ray therapy should be performed analogously to the procedure at SCLC stage III (Chapter 9.5) and be completed when remission is achieved by prophylactic cranial irradiation. Inoperable patients without progression after chemo-ray therapy should be offered, analogous to the procedure at SCLC stage III (Chapter 9.5), a 24-month maintenance therapy with durvalumab. nce [1391], [1392] Strong consensus background In a stadia-dependent subgroup analysis of the prospectively randomized CONVERT study, which was compared with the conventionally fracti- based gy-ray therapy in the course of a primary definitive radiochemotherapy.",
      "start_page": 405,
      "end_page": 411
    },
    {
      "heading": "1a",
      "text": "andlun hungsg f Eviden ng der Tumorstadien T3-4 und/or N2-3, M0 (Limited disease) 411 Substances of the third generation of chemotherapy have so far been insufficiently tested in the LD patient group and in the context of simultaneous chemotherapy concepts. Phase II studies show the fundamental feasibility of integrating substances such as paclitaxel and irinotecan into chemotherapy concepts [1412], [1413], but the results of these studies do not suggest any obvious advantage compared to the standard PE plus RT approach. A ja panic phase 3 study investigated the effectiveness of cisplatin-Irinotecan versus cisplatin-Etoposide after a cycle of combined chemotherapy with cis- platin-Etoposide and found no difference between the two combinations in the endpoint overall survival [1416]. Studies with triple combinations in the context of simultane chemo-radiation do not detect an obvious advantage of radiation14.",
      "start_page": 411,
      "end_page": 412
    },
    {
      "heading": "2b",
      "text": "Recommendation A Level of Evidence",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "1b",
      "text": "ng the tumour stages T3-4 and/or N2-3, M0 (Limited disease) 412 Evidence-based recommendation tested 2025 degrees Patients receiving simultaneous chemo-ray therapy should be able to respond to smoking. nce [80] Strong consensus It is particularly important that patients with cessation of cigarette use with simultaneous chemo-ray therapy have a better prognosis than patients who continue smoking [80]. Therefore, smoke abstinence should also be encouraged for thera- peutic and prognostic reasons. Simultaneous vs. consecutive chemo-ray therapy Evidence-based recommendation tested 2025 degrees The application of radiation therapy to SCLC in the tumour stages T3-4 N0-1 and T1-4N2-3M0 (Limited disease) is expected to be simultaneous to chemotherapy with cisplatin and etoposided. nce [1425], [1426] Strong consensus on the basis of a Phase II study of radiation, and in the study of 3 weeks.",
      "start_page": 412,
      "end_page": 415
    },
    {
      "heading": "1a",
      "text": "In patients with good general condition, a higher degree of hyperfractional radiation can be considered. Prophylactic cranial radiation Evidence-based recommendation tested 2025 degrees In all patients with SCLC stage III with remission after completion of chemo-therapy, prophylactic cranial radiation should be offered. Preferably, a GHD to 25 Gy should be used in single doses of 2.5 Gy or 30 Gy in single doses of 2 Gy daily. nce [1446], [1447], [1448], [1449], [1450] Consensual background Two controlled studies of Arriagada et al. 2002 [1451] with a total of 505 pati- ents with LD or ED and complete remission after induction showed a reduction of brain metastasis as a first recurrence of 37% in the control group.",
      "start_page": 415,
      "end_page": 418
    },
    {
      "heading": "1b",
      "text": "Recommendation A Level of Evidence",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "1b",
      "text": "In this situation palliative systemic chemotherapy has so far been rod-dard therapy with initial good response, but also high recurrence rate. The average overall survival of metastatic SCLC in the last 30 years was 9-12 months and the 2-year survival rate was only 5-10%. [1453] By adding a checkpoint inhibitor to chemotherapy, a new standard could be established, with a marked improvement in progression-free survival as well as overall survival. For the first time, data from patients with long-term survival of 3 years are also available, which was combined with a plat- indoublette with etoposide and added durvalumab at 17.6% [1454]. Data on ate zolizumab from an explorative analysis of the IMpower 133 study (IMbrella A), in which 11 patients of the original 201 were still alive after 5 years [1455].",
      "start_page": 418,
      "end_page": 422
    },
    {
      "heading": "anti-PD-L1 [HR 0.73] and anti-PD-1 [HR 0.76], but not for anti-CTLA-4 [HR 0.90]",
      "text": "Also the progression-free survival was under all immune therapies",
      "start_page": 422,
      "end_page": 422
    },
    {
      "heading": "less favourable without difference between PD-L1 and PD-1 inhibitors. Response rates",
      "text": "However, the response after 12 months was more favourable under the combination of chemo-immunotherapy. Severe unwanted events (grade 3⁄4 AEs) were seen under the combination more frequently [OR 1.18]. Compared with chemotherapy alone, the metaanalysis showed no benefit for patients with brain metastases at the time of diagnosis [HR 1.14 p = 0.34]. The survival advantage under the immuno-chemotherapy combination was found in all patient subgroups, regardless of age (<65 or",
      "start_page": 422,
      "end_page": 422
    },
    {
      "heading": "The benefit for anti-PD-L1 and anti-PD-1",
      "text": "Checkpoint inhibitors were clear. No benefit was obtained from anti-CTLA-4 therapy alone or in combination. For maintenance therapy, the large randomised Checkmate 451 study [1471] was available. Here, 835 patients with response or stable finding after 4 cycles of platinum and etoposide were included. Randomization was performed on nivolumab al- lein, nivolumab plus ipilimumab or placebo. The study could not demonstrate a significant OS benefit. The 1-year survival rates were 44% for nivolumab monotherapy, 40% for nivolumab plus ipilimumab and 41% for placebo. The 2-year survival rates were 22%, 21% and 15%. The HR for OS was equal to 0.85 for nivolumab monotherapy and 0.92 for combination. Biomarkers:",
      "start_page": 422,
      "end_page": 422
    },
    {
      "heading": "PD-L1: PD-L1-expressing tumour cells can only be found in 18 to 39% of SCLC cells.",
      "text": "The importance of the PD-L expression as a predictive marker in the SCLC is controversially discussed. A metaanalysis [1457] concluded a prog-",
      "start_page": 422,
      "end_page": 422
    },
    {
      "heading": "nostic role of the PD-L1 expression for survival.",
      "text": "Patients were not treated with checkpoint inhibitors, so no indication of predictive value could be made.",
      "start_page": 422,
      "end_page": 422
    },
    {
      "heading": "Correlation between PD-L1 status and clinical parameters.",
      "text": "Tumor mutation load (TMB) The SCLC is characterized by a high tumor mutation load, apparently due to association with cigarette smoking. TMB could be a predictive factor for immunotherapy. This is discussed with NSCLC and melanoma. To date, however, only contradictory results for TMB are available with the SCLC as predictive or prognostic factor. Summary Immunotherapy with SCLC in the first line of therapy 6 Beha and ng of the stage M1 (Extensive Disease) 423 • The combined chemo-immunotherapy with atezolizumab, carboplatin and etoposid has been approved as standard therapie in the first line of the advanced SCLC since autumn 2019, with Durvalumab, cis or car boplatin and etoposid since 10/2020, when used with durvalumab, cis or carboposide as standard therapie in the first line of treatment of the advanced SCLC. • When used with platinum/etoposid, however, the overall survival was significantly improved in terms of progression.",
      "start_page": 422,
      "end_page": 431
    },
    {
      "heading": "1b",
      "text": "handlu helation g f Evidenung des Stadiums M1 (Extensive Disease) 431 Radiation therapeutic indication in remote metastatic patient prophylactic cranial radiation PCI Evidence-based recommendation tested 2025 degrees SCLC patients with response to first-line chemotherapy should be offered prophylactic cranial radiation or active surveillance with 3-month MRI control of the brain in the first year, then every 6 months. If the PCI is performed, for example, at 30 Gy in single doses of 2 Gy or 25 Gy in single doses of 2.5 Gy. nce [1491] Consensus background In patients with partial or full remission after chemotherapy, the additional cranial radiation in the EORTC study by Slotman is to be extended in the survival period and increases the 1-year survival rate also in the patient group with primary remote metastasis. 283 evaluable patients who were clinically controlled after completion of the chemotherapy study were in the same group.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "1b). This survival advantage was explained by the fact that the prophylactic",
      "text": "However, there were no CT or MRI controls prior to randomization. The implementation of se- cond line chemotherapy was significantly reduced in the non-irradiated group. A later randomized phase 3 study [1491] from Japan also tested prophylactic cranial radiation (PCI) in 224 metastatic patients. An MRI study of the brain to exclude existing brain metastases was in contrast to the above study inclusion criterion. Also in the further course of every 3 months MRI skull investigations took place. The rate of second line chemotherapy was also 90% in the non-irradiated group. In the result, however, there was no effect of prophylactic brain radiation on the overall survival of the PCI on a relevant reduction in the incidence of brain metastases of 45% vs. 69%. Therefore, both options appear possible, the implementation of a PCI eliminates further MRT control on the PCI skull.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "9.27 Consensus-based recommendation reviewed 2025",
      "text": "EK SCLC patients with brain metastasis should be offered brain monitoring during therapy.",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "9.28 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In SCLC patients with multilocular symptomatic brain metastasis, B should be irradiation of the whole brain, e.g. with 30 Gy in single doses of 3 Gy, promptly after diagnosis. Level of Evidence [1492], [1493], [1494], [1495], [1496]",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "3a",
      "text": "Strong consensus",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "9.29 Evidence-based recommendation reviewed 2025",
      "text": "Degree of recommendation In SCLC patients with asymptomatic brain metastases and progression control 0 of cerebral metastasis, cranial irradiation can also occur after completion of chemotherapy. Level of Evidence [1492], [1493], [1494], [1495], [1496]",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "2a",
      "text": "Strong consensus",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "9.30 Consensus-based statement reviewed 2025",
      "text": "EK A stereotactic radiation of individual brain metastases (up to 3) can be offered at SCLC, but is associated with high relapse probability. Stereotactic radiation can simultaneously be combined with chemo-immunotherapy. Strong consensus on detectable cerebral metastasis: 9 T Therap pie of the s small cell lung cancer 433 In patients with primary brain metastasis, extracerebral emission rates are significantly higher than intracerebral emission rates by chemotherapy alone [1492] (Evidence level 2b). In the EORTC study of Postmus et al. 2000 [1494], a primarily asymptomatic patients with cerebral metastasis are mostly treated with chemotherapy alone in the course of treatment with symptomatic [1493] (Evidence level 2b).",
      "start_page": 432,
      "end_page": 437
    },
    {
      "heading": "1b",
      "text": "Empfeh pie des hlungsg f Eviden hungsg s small cell lung carcinoma 437 133 trial were 46% of patients older than 65 years. Surprisingly, the effect of the combined chemo-immunthearpie was more pronounced in this group of elderly patients than in the group of younger patients under 65 years of age. The median survival time for elderly patients was 12.5 vs. 9.6 months (HR 0.53) and for younger patients 12.1. vs. 11.6 months (HR In the CASPIAN study 41% of patients over 65 years of age. Here, the effect of the combined chemo-immun therapy in elderly patients (HR 0.92) was somewhat less pronounced than in younger patients (HR 0.76). For second line therapy with topotecan or amrubicin, analyses are available for patients over 70 years of age. Here, comparable efficacy is reported as in the younger comparative population. Especially in the use of topotecan, the increased mylotoxicity is reported.",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "A simultaneous approach should therefore be considered (evidence level 1b).",
      "text": "nce Consensus Evidence-based recommendation 2010 grade At the age of 75 years, there are no data available for simultaneous chemo-ray therapy in SCLC. Due to the increased toxicity, a simultaneous procedure should be avoided in these patients. Consolidative primary tumour irradiation can be considered in case of good general condition and lack of comorbidities (evidence level 3b). 2010: Recommendation level C (weak recommendation) 9 Level of evidence therapy",
      "start_page": 437,
      "end_page": 438
    },
    {
      "heading": "3b",
      "text": "Recommendationg Level of Eviden",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "3b",
      "text": "c small cell lung cancer 438 evidence-based recommendation 2010 nce consensus evidence-based recommendation 2010 grad The indications for prophylactic cranial irradiation in SCLC",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "(degree of evidence 3b, degree of recommendation)",
      "text": "C). Patients with cerebrovascular risk should be adequately monitored.",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "(degree of evidence 3b).",
      "text": "2010: Degree of recommendation C (weak recommendation) nce Consensus Background In the patient group limited disease, no gain in survival from primary tumour radiation at the age of 70 years could be detected in the metaanalysis for radiation therapy [1423] (evidence level 1a). Therefore, the indication for radiation therapy must be critically checked in the elderly patient. However, in the case of appropriate patient selection, the conduct of simultaneous chemo-ray therapy in the elderly patient group is generally similar to the treatment protocol of the younger patients with limited disease.The study of Schild et al. 2005 [1503] has included a subgroup analysis for the elderly patient group in the NCCTG study regarding hyperfractional versus conventional fractional simultaneous chemo-ray therapy. In this study, a total of 209 younger and 54 older patients > 70 years.",
      "start_page": 438,
      "end_page": 440
    },
    {
      "heading": "Treatment of lung carcinoma",
      "text": "10.1 Evidenceb Level of Evidence Consensus 10.2 Evidenceb Degree of recommendation Optimum A symptom with Talku * A pleu or Weigh Level of Evidence",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "1a",
      "text": "Consensus 10.3 Evidenceb Degree of recommendation",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "B",
      "text": "Level of Evidence",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "1a",
      "text": "Konsens",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "10.4 Evidenceb",
      "text": "Level of recommendation",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "B. Level",
      "text": "Level of Evidence",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "2a",
      "text": "© Guide pro zinoms with interventional procedures (capite-based recommendation based recommendation male procedures in patients with lungmatic, malignant pleural effusion* provides",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "5 to 10g (evidence level 1a).",
      "text": "urate effusion will then be proven as malignant term webe. based recommendation can be applied in anaesthesia or local anaesthesia based recommendation talc should be applied to a particle size",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "d 2a).",
      "text": "ogram oncology - lung cancer - langve el currently due to run ncarcinoma and reciting thoracoscopic hnet when in it thesia occurs (evidence bumps > 10 μm",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "nder 441",
      "text": "poudrage-like cells",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "1a).",
      "text": "(Evi-",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "10 Treatment of lung cancer with interventional procedures (chapter currently due to ongoing 442",
      "text": "Review suspended)",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "10.4 Evidence-based Recommendation 2010",
      "text": "Konsens",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "10.5 Evidence-based Recommendation 2010",
      "text": "A more complicated but less effective alternative is treatment B via thorax drainage with talc suspension or a tetracycline derivative (doxycycline 500 mg). A pleurodosis with local cytostatic agents is not recommended.",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "(degree of evidence 1a).",
      "text": "Level of Evidence",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "1a",
      "text": "Konsens",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "10.6 Evidence-based Recommendation 2010",
      "text": "In the case of a trapped lung, thoracic permanent drainage or pleu-",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "0 roperitoneal shunt (degree of evidence 4).",
      "text": "Level of Evidence Consensus",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "10.2 Haemoptysen",
      "text": "Haemoptysen is a common complication of lung carcinoma (20%), especially in central lung carcinoma. Approximately 3% of patients die from blood collapse. Potential life-threateningness results from the transfer of central respiratory pathways through blood and/or coagula, not from the hemodynamic consequence of",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "Bleeding [1523], [1524], [1525] (evidence level 2b).",
      "text": "Bleeding sources are mostly bronchial or intercostal arteries. Bleeding causes are fragile vessels of neovascularization of the tumor, which have been damaged by necrosis, traumatisation by coughing or after iatrogen irritation.",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "is subject to a high lethality of about 40 % [1525], (evidence level 2c).",
      "text": "Haemoptysis often do not require intervention, but patients with more severe haemoptysis should be treated with palliative or curative target set- ing. 10 treatment of lung carcinoma with interventional procedures (chapter currently suspended due to ongoing 443 g) Emergency measures and diagnostics Curative therapy by resection of the bleeding lung area is usually not possible due to the interoperability of the tumour. Consequently, in the case of haemoptoe, the primary focus is on the central respiratory tract and the oxidation. Intubation and blocking of a contralateral main bronchus is effective in order to protect the non-bleed lung. In this case, large-scale tubes facilitate the bronchial toilette and bronchoscopy intervention. The most important diagnostic measure is bronchoscopy. In addition, a CT of the thorax may be necessary for the bleeding site or for staging [1526] (Evidenztischgrad 1c) and bronchoscopy therapy is used for the identification of the bronchopia.",
      "start_page": 442,
      "end_page": 444
    },
    {
      "heading": "2a",
      "text": "Recommendation B Level of Evidence",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "2a",
      "text": "g of lung carcinoma with interventional procedures (chapter currently suspended due to ongoing 444 g) Evidence-based recommendation 2010 grade In hemoptysis, bronchoscopy is used to identify the source of bleeding and",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Blood distillation indicated by local measures (evidence level 2a).",
      "text": "nce Consensus Evidence-based recommendation 2010 grade Bronchial artery embolization is an effective and safe method for the rapie of massive or moderate relapsed hemoptyses.",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "it should be repeated (evidence level 2a).",
      "text": "nce Consensus Vena-cava-superior syndrome Up to 40% of Vena-cava-superior syndromes (VCSS) are caused by SCLC [1536]. The diagnosis is based on symptoms with increased neck and/or arm circumference, headache, dyspnoea, hoarseness, swallowing disorders and the computer tomogram. The clinical drama with asphyxiation risk in Glottisoedema requires rapid, effective treatment [1537], [1536]. For the efficacy and safety of different treatment options, there are 5 studies with 103 patients, 93 of them lung carcinomas and two systematic reviews, a historical and a cochrane review of the most effective acute method is the percutaneous, endovasal implantation of a self-expanding wallstents in the Vena cava superior, mostly after balloon angioplasia of the V. cava or bragiocephalica. The procedure remains predominantly the same for the 90 years.",
      "start_page": 444,
      "end_page": 445
    },
    {
      "heading": "2a",
      "text": "The anticoagulation effect of the pulmonary carcinoma with interventional procedures (currently suspended due to ongoing 445 g) [1540]. Anticoagulation is not required. In the case of the detection of thrombosis no stentthrombosis was observed during therapy with low-molecular heparins. After chemotherapy or radiatio or the combination of both, a symptom regression is achieved in 60-77% of patients treated [1542]. For the small cell carcinoma, an effective palliation of the vena-cava-superior syndrome was achieved in 76.9% of cases, for combined radiochemotherapy in 83% of cases. The improvement occurs only after an average of 7 to 14 days in contrast to the stentimplantation. In the case of non-small cell lung carcinoma, the success rates are significantly lower, a symptom reduction was achieved by chemotherapy in 59% of patients, achieved by irradiation in 63% [1542].",
      "start_page": 445,
      "end_page": 445
    },
    {
      "heading": "(degree of evidence 2a)",
      "text": "nce Consensus Tracheobronchial Tumor Obstruction In symptomatic stenoses of the central respiratory tract, endoscopic measures can lead to immediate relief of symptoms (air distress, cough, secretion) and to the dissolution of poststenotic pneumonia [1545] (evidence level 2c). The primary aim is to improve the quality of life, a lifetime extension can be achieved by improving the overall clinical situation and symptom control (evidence level 4). Measurable functional improvements can only be achieved if functional, perfused parenchyma can be recruited by tumour deobliteration. Small, early tumours could be corrected in functionally inoperable patients, in individual cases technical operability could be achieved. 10 Treatment of lung carcinoma with interventional procedures (chapter currently suspended due to ongoing 446 revision)",
      "start_page": 445,
      "end_page": 446
    },
    {
      "heading": "10.10 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation The palliative, endoscopic methods for the treatment of tracheobronchia- 0 l tumour obstruction should be accessible to all cancer patients, even if the primary treatment department does not keep them in-house",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "(degree of evidence 5). There are various methods of desobliteration and lo-",
      "text": "kalen Tumorbehandlung zur Verfügung.\nLevel of Evidence",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "10.4.1 Mechanical processes, removal",
      "text": "Exophytic tumour components can be removed with the edge of the rigid bronchoscope, with tanning agents or balloons. Since there is primarily no bleeding, the risk is higher than with other methods.",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "Suistically described [1546], [1547]. Working with the flexible bronchoscope and",
      "text": "Balloons is possible to support the breathing facilitated by jet ventilation",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "10.11 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation The mechanical methods of removal of exophytic tumor components with the 0 edge of the rigid bronchoscope, with pliers or balloons have immediate effect, but can only be recommended for emergency situations if no other procedures are available (evidence level 4). Balloon dilatation with the flexible bronchoscope is possible (evidence level 3b). Level of Evidence",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "4 (Oxford 2009): Mechanical removal procedures",
      "text": "3b 3b (Oxford 2009): Balloon dilatation",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "10.4.2 Laser therapy",
      "text": "The most established, non-mechanical method for the removal of intraluminal",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "Foreign tissue is laser coagulation [1549], [1550]. Infrared light from diodes",
      "text": "or Nd-YAG lasers are transmitted via fibers through the working channel to the tumor tissue. Depending on the energy, the penetration depth is coagulated or vaporized.",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "The effect is obtained in more than 80 % of cases [1550], [1551] (evidence level 3b).",
      "text": "10 Behan Over-arbe Empfeh Level of 3b Empfeh B ndlung erung hungsg f Eviden hungsg g of lung carcinoma with interventional procedures (chapter currently suspended due to ongoing 447 g) occurs immediately. In case of lappenbronchien the clinical success is about 40 %. Without local differentiation, lung function improves at 70 – 80 % of patients, peak flow increases by 25 %, perfusion and oxygen saturation improve in 30 % of cases [1552], [1553] (evidence grade 4). The procedure is sure that the complication rates (blooding, perforation, asphyxia, fire, pneumothorax) are below 2 % [1545], [1554], [1555] (evidence grade 4). The procedure can also lead to relevant respiratory tract irritations [1556]. Working with the flexible bronchoscope is possible [1557], [1558], which is considered to be rigid bronchops, is preferred [15], and has been proven to be safe in cases [15].",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "10 Treatment of lung cancer with interventional procedures (chapter currently due to ongoing 448",
      "text": "Review suspended)",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "10.13 Evidence-based Recommendation 2010",
      "text": "Level of Evidence",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "10.14 Evidence-based Recommendation 2010",
      "text": "In isolated cases, small mucosa tumours may be induced, provided that they are limited to 0 of the intraluminal surface. This should only be done in case of inoperable pati-",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "(degree of evidence 4).",
      "text": "Level of Evidence",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "10.4.3 Electrical processes",
      "text": "Various methods for endobronchial desobliteration are available,",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "which can be used according to the expertise of the treating physician [1545],",
      "text": "With all high frequency current devices as well as with the laser application, an immediate desobliteration can be achieved in the case of central tumor infestation. The penetration depth of the APC is about 2 – 3 mm lower than that of the laser. The increasing spread indicates that the processes are not only cheaper but also with regard to the",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "The clinical applicability of the laser is equal [1570], [1563] (degree of evidence 4).",
      "text": "There is no comparable study yet. In addition to the cutting effect, the coagulation capabilities of the APC are particularly used. The argon plasma coagulator is used to stop blood from central tumour tissue.",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "superior to all other procedures [1564], [1535] (evidence level 3b).",
      "text": "For removal, the electrical methods are combined with mechanical removal. This is particularly efficient in rigid technology with larger pliers. Improvements in function and quality of life depend on how much rechanneling can be done, as in the application of the laser.",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "10 Treatment of lung cancer with interventional procedures (chapter currently due to ongoing 449",
      "text": "The argon plasma coagulator is designed for non-contact mode. It is necessary to point out the possibility that argon gas embolisms with cardiac and cerebral consequences can be formed if the APC probe is accidentally activated with high gas flow inside tumors [1572]. Recent investigations indicate that endobrochial intervention procedures improve the quality of life of patients and possibly also their lifetime. Various methods for endobronchial desobliteration are available, which can be used depending on the expertise of the treating physician.",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "10.15 Consensus-based Recommendation 2018",
      "text": "EK Endobronchial electro-methods such as the argon-plasma coagulator, electrocauther and cryoprobes can be used as alternatives to the ND-YAG laser for deobliteration in case of infestation of the central respiratory tract. The quality of life is improved.",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "10.16 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation The APC is superior to all other local procedures (evidence-",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "0 grade 3b).",
      "text": "Level of Evidence",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "10.17 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation Small tumours of the mucous membrane can be adjusted in individual cases.",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "0 should only be considered in inoperable patients (degree of evidence 4).",
      "text": "Level of Evidence",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "10 Treatment of lung cancer with interventional procedures (chapter currently due to ongoing 450",
      "text": "Review suspended)",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "10.4.4 Cryotherapy",
      "text": "As with high frequency ablation probes, flexible cold probes can be used by the",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "[1573], [1574].",
      "text": "Since cartilage tissue has a high cold tolerance, the process is considered to be somewhat safer with comparable efficiency than electro- and laser therapy [1573] (degree of evidence 4).",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "in 70 – 80 % of cases [1575], [1576] (degree of evidence 3b).",
      "text": "Radiofrequency ablation is possible and can be achieved both before and after radiation",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "(degree of evidence 3b). As with the laser, a",
      "text": "previous, complete tumor removal with the cryoprobe the outcome of the road therapy [1578] (degree of evidence 4). A possible radiation sensitization and sensitization against chemotherapeutics is postulated after experimental studies [1578], [1579], clinical data that would confirm this is not available.",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "For early tumours less than 2 cm of longitudinal extension limited to the mucous membrane",
      "text": "Within 4 years, there was a marked increase in the number of patients receiving treatment.",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "10.18 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation The endobronchial cryotherapy with rigid or flexible probe is gentle, similar to laser and APC. However, the effect occurs later. For tumour removal in patients who are not acutely threatened, it can be recommended that the patient",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "(degree of evidence 3b).",
      "text": "Level of Evidence",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "10.19 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation For the curation of small mucous membrane tumors, cryotherapy can be tried.",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "B",
      "text": "Level of Evidence\n10 Behan\nÜberarbe\nEmpfeh\nLevel of",
      "start_page": 450,
      "end_page": 451
    },
    {
      "heading": "3b",
      "text": "In the case of patients currently exposed to interventional procedures (chapter currently due to ongoing exposure to 451 g), evidence-based recommendation 2010 grade Due to the high recurrence rate, this should only be considered in inoperable patients.",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "(degree of evidence 3b).",
      "text": "nce Photodynamic therapy In photodynamic therapy (PDT), a sensitizer is applied hours to days before endoscopic surgery (mostly intravenous). The selectivity of tumor tissue is based on a lack of competitive inhibition of a final product, an active metabolic power or a decreased clearance of the sensitizer from cancer cells. When irradiation with red light from a laser source results in cytotoxic products that lead to direct tumour decay or tumor infarction by closing its vessels. There are many publications with small falls, especially from Japan. The design of the studies is mostly of limited quality. Many reviews and meta-analysis with data from more than 1200 patients emphasize the importance of the method [1581], [1574](Evidence level 2c). There are still technical problems to illuminate the tumor region completely and equally. If an invasive tumor exceeds the wall, the significance of the method [1574] (Evidenzgrade 2c) is not excluded.",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "3b).",
      "text": "There is evidence of superiority of the PDT to the YAG laser with regard to symptom control and life-long extension, but the studies show that the",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "[1585], [1582] (degree of evidence 3b).",
      "text": "The main side effect of the now available sensitizers is the general sensitivity to light (sunburn in normal daylight). Therefore, the method has been largely abandoned in palliative situa tion. Clinically convincing evidence that the unapproved sensitizers are superior is currently not available (evidence level 5). For the eradication of small tumors, limited to the mucous membranes, good data are available. Curation rates of 92% were achieved in tumours < 1 cm in diameter. In tumour diameters > 2 cm, the curation rate decreases below 50% [1583], [1586], [1586]",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "over 80 % [1587] (evidence level 3b).",
      "text": "10 Treatment of lung carcinoma with interventional procedures (chapter currently suspended due to ongoing 452 revision) A PDT can be repeated, combined with other methods and used in pre-operated patients. In individual cases, a prior PDT can achieve local operability [1588], [1589], [1590] (degree of evidence 4).",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "10.21 Evidence-based Recommendation 2010",
      "text": "For the control of symptoms in palliation, photodynamic therapy is only slightly superior to the 0 conventional laser. The quality of life is disproportionately impaired due to skin sensitization. With the sensitizers currently available, a PDT for palliation can hardly be recommended, this can change if new sensitizers are approved (evidence level).",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "3b).",
      "text": "Level of Evidence",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "10.22 Evidence-based Recommendation 2010",
      "text": "For the eradication of early tumours below 1 cm diameter, which are limited to the mucous membrane, the PDT is the most effective method. A prior examination with the endobronchial ultrasound should be carried out to achieve a deeper in-",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "to exclude vasion (evidence level 3b).",
      "text": "Level of Evidence",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "10.23 Evidence-based Recommendation 2010",
      "text": "Recommendation level For tumour lengths between 1 cm and 2 cm without deeper invasion, a com-",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "O to be treated with brachytherapy (evidence level 3b).",
      "text": "Level of Evidence",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "Treatment",
      "text": "Revision Recommendationg Level of Evidence Recommendationg Level of Evidence g of Lung Carcinoma with Interventional Procedures (chapter currently suspended due to ongoing 453 g)",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "Evidence-based Recommendation 2010",
      "text": "The procedures can currently only be recommended in studies, surgery, also with bronchoplastic procedures, remains standard at first. A PDT can be justified in inoperable patients. nce",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "Evidence-based Recommendation 2010",
      "text": "In isolated cases, local operability can be achieved by the PDT. nce bronchial and tracheal stents stents are used in endobronchial and endotracheal stenoses for the local palliatial treatment of dyspnoea and retention symptoms. Silicone and self-expanding metal stents are available, which are inserted into the trachea and central bronchials. Indications are generally symptomatic endoluminal tumor growth and/or extrinsic compression. 33 studies were selected, which consist of case reports or retrospective/ pros- pective case series with 1-162 patients. All studies corresponded to evidence grade 4 [1591], [1592], [436], [1593], [1594], [1596], [1597], [1598], randomized studies did not exist.",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "In many cases, local control could be achieved through a",
      "text": "A life extension is to be concluded, but is not identifiable in the absence of randomised comparisons. Typical complications are the growth of tumour tissue in the",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "Stent, the stent migration and the secretion with a frequency of 10",
      "text": "10 Obtainability Recommendation Level of qualification",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "g of lung carcinoma with interventional procedures (chapter currently due to ongoing 454",
      "text": "g) Evidence-based recommendation 2010 grade The implantation of bronchial, tracheal and tracheobronchial stents is suitable for palliative treatment of symptomatic central respiratory stenosis. The therapeutic effect occurs immediately. It can and should be combined with other methods (e.g. la sertherapy, brachytherapy) and should not be used as the last method available in principle. In the case of tumour remediation, stents can be removed in principle.",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "or are accessible (degree of evidence 4).",
      "text": "nce Endobronchial brachytherapy In endoluminal brachytherapy, a radioactive radiation is temporarily introduced into the lung tumor via an exhaust catheter, which can be bronchoscopically placed and controlled. The tumor-infected area of the bronchus is treated in addition to a small safety catheter. The periods of stay at the various stop points of the radiator, which is now remotely controlled without the burden of personnel, are calculated prior to therapy according to the prescribed dose. Randomized studies on the use of brachytherapy in the palliative therapy of the stenosing-growing lung carcinoma have demonstrated their effectiveness. However, after laser debulking of central stenosing lung tumors is extended by the endolumi- nal brachytherapy the relapse-free time compared to the sole laser intervention [1621] (evidence level 2b) was after the study of Stout et al.",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "production in stenosing central lung tumours [1623], [1624], but",
      "text": "A similar increase in palliative effect can also be achieved by higher dose percutaneous radiotherapy (evidence level 2b). Ung et al. found in a systematic review of randomised and non-randomised prospective studies of palliation of symptoms with the",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "% and pain of 43-88% [1625] (degree of evidence 2a).",
      "text": "10 Treatment of lung carcinoma with interventional procedures (chapter currently suspended due to ongoing 455 revision) Even after radiotherapy pre-treatment, longer-lasting tumour regressions can be achieved with endobronchial brachytherapy [1626] (Evi- denzgrade 3b). Risks of brachytherapy are the formation of fistulas and blood vessels. Dosage of endobronchial brachytherapy: The macroscopically visible tumor portion should be safely recorded in bronchus lengthwise direction. The afterloading catheter should be centered in bronchus centre. Usual doses per fraction range from 5-10 Gy, applied with high dose performance (HDR). The dosage is usually calculated at 10 mm axis distance. In addition to percutaneous radiation therapy, brachytherapy is used at a dose of 2 x 4.8 to 2 x 7.5 Gy with a time interval of at least one week. [1623] As a sole measure wur- the dose of the American Endocetherapy 1 x single dose of gytherapy 4 Society was also used.",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "10.27 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation In patients without radiation therapeutic preload, the use of B Brachytherapy in palliative intention is suitable in individual cases for centrally stenosing tumors. If no radiation therapeutic preload exists, brachytherapy should be combined with percutaneous radiotherapy. Level of Evidence",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "10.28 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation In a tumor with stenosis of the central airways and radiation therapeutic",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "The endoluminal brachytherapy may be appropriate in individual cases.",
      "text": "Level of Evidence 10 Treatment of lung cancer with interventional procedures (chapter currently suspended due to ongoing revision)",
      "start_page": 455,
      "end_page": 456
    },
    {
      "heading": "10.29 Evidence-based Recommendation 2010",
      "text": "Degree of recommendation Brachytherapy as a boost to percutaneous radiotherapy in treatment centres in a curative situation is controversial and should only be carried out within the study. Level of Evidence concept of Psych Hooncological care for patients with lung cancer Psychooncological care for patients with lung cancer For psychooncological care there is also a S3 leit program oncology, which is also available for patients with lung cancer In the S3 guideline for the diagnosis, counselling and treatment of e patients, detailed guidance is given on the topics listed below, including specific stress of patien chial carcinoma after lung resection (see Markieru • Definition and basic principles of psychooncology o Definition o Aims o Task areas and measures o Needs for information and psychosocial treatment • Structural prerequisites of psychooncological verso • Stationary care facilities • Ambulant psychooncological care facilities • Facilities of palliative care • Self-help groups • Cross-sector coordination of psychooncologis • Psychosocial stress and quality of life • Psychosocial stress",
      "start_page": 456,
      "end_page": 471
    },
    {
      "heading": "2a",
      "text": "ativmedlungsg f Eviden dizinische Behandlung im Lungkarzinoma 471 For the care of lung carcinoma patients in the terminal stage, the key recommendations or statements of the S3 guideline Palliative Medicine should be observed [514]. Due to the high mortality of lung carcinoma, relevant key errors in the adaptation process of the S3 guideline Pulmonary Carcinoma to the S3 guideline Palliative Medicine have been adopted: Consensus-based recommendation tested 2025 The death of a patient with lung carcinoma is to be recognised by those involved in the treatment as a natural part of life. The death process should neither be accelerated nor delayed. Strong consensus-based recommendation tested 2025 In patients with lung carcinoma, decisions and measures for treatment in the death phase are to be documented and continuously re-evaluated. Strong consensus-based recommendation 2025 All measures in the death phase of a patient with lung carcinoma are to be socially adapted to the needs of the lung carcinoma.",
      "start_page": 471,
      "end_page": 476
    },
    {
      "heading": "1a",
      "text": "bilitati hungsg f Eviden ion 476 \"Interventions by nurses/care\" air emergency can improve. This is mainly about behavioral therapeutic approaches, which lead the patient to self-employment through consultation and support during or after an oncological therapy [1630], [1733], [1734]. However, such interventions are hardly transferable due to the health system in the USA, which is differently designed in comparison to Germany. Complex interdisciplinary rehabilitation programs, such as those offered in the German-speaking area, have not been investigated. During oncological therapy (also in high-dose therapy) can be performed with good efficiency (e.g. in relation to bone marrow regeneration) aerobic endurance sports activities [1735], [1736]. It is not established whether this is also true for multimorbid patients with lung cancer. This working group could show at any time in operated patients (n = 27 lung-operated patients), that a aerobic endurance and relaxation training has a positive effect on ermorbide performance17.",
      "start_page": 476,
      "end_page": 476
    },
    {
      "heading": "(degree of evidence 1a).",
      "text": "nce\n15 Rehabilitati\nEmpfehlungsg\nB\nLevel of Eviden",
      "start_page": 476,
      "end_page": 477
    },
    {
      "heading": "1b",
      "text": "Recommendationg C Level of Evidence Recommendationg D ion 477 Evidence-based Recommendation 2010 Consensus Evidence-based Recommendation 2010 grade During oncological therapy (also in high-dose therapy) aerobic endurance training programs (e.g. interval training with lactate determination, heart frequency analysis) for a faster recovery of performance",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "It is therefore recommended (evidence level 1b).",
      "text": "nce Consensus Evidence-based Recommendation 2010 grade Oncological rehabilitation procedures carried out in a stationary manner are recommended to improve quality of life and aerobic endurance after primary therapy, if certain quality requirements are met. These include the structural, process and outcome characteristics set out in BAR guidelines, and a sufficient experience in the rehabilitation of lung cancer patients to docu-men- tation and the cost promoters and instructors to docu- ment. The rehabilitation period should be flexible and related to the individual case and should be based on the therapeutic objectives discussed with the patient together (reintegration into everyday life, rehabilitation before retirement, rehabilitation before nursing). 2010: Recommendation level C (weak recommendation) nce Consensus Evidence-based Recommendation 2010 grade Ambulant rehabilitation procedures are to be discussed with the patient if these institutions meet comparable high requirements as they need to meet state-based facilities. Oncological rehabilitation facilities that take part in ambulatory or gen-patient rehabilitation measures, patients should also be able to take part in lung cancer or gen-",
      "start_page": 477,
      "end_page": 481
    },
    {
      "heading": "2b",
      "text": "ed ucides/history/follow-up 481 Second tumours in those patients who continue after successful therapy",
      "start_page": 481,
      "end_page": 481
    },
    {
      "heading": "[85]; [83] (evidence level 2b).",
      "text": "the continued tobacco smoking has a negative effect on pulmonary function. Evidence-based recommendation tested 2025 grade patients with lung carcinoma should be permanently motivated to stop smoking with ta- bak. To support the patients, effective help for smoking cessation should be obtained. nce [63], [85], [83] Strong consensus Aftercare following a local ablative therapy The question of optimal aftercare for integration of a local ablative therapy into the multimodal therapy concept is the subject of few studies. Except for a single prospective examination and as a result the propectively-raandomized phase III study [1742] all other investigations are retrospective cohort studies. In addition, there are a number of individual follow-up plans at the individual tumor centres and lung cancer centres, which were usually not prospectively vali- dieted.",
      "start_page": 481,
      "end_page": 485
    },
    {
      "heading": "1a",
      "text": "Recommendation A Level of Evidence",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "1a",
      "text": "In patients after ablative local therapy (stage I-II and III surgery, radiotherapy/radiochemotherapy in stage I and II) postthrapeutic complications that can occur after surgery or radiotherapy should be recorded and treated. Typically, this is done within 8 weeks after completion of local therapy. Strong consensus evidence-based recommendation tested 2025 degrees In patients with NSCLC in stage III after ablative local therapy (radiation therapy/radiation chemotherapy) posttherapeutic complication that can occur after radiotherapy should be recorded and treated. The first clinical idea after completion of radiation therapy should be carried out within 8 weeks. nce [1757], [795] consensus evidence-based recommendation tested 2025 degrees After locally ablative therapy of the NSCLC in stage III, a CT-thorax should be performed to exclude a progression after completion of radiation therapy (initiation of durvalumab). nce [794] consensus evidence-based recommendation tested 2025 degrees After locally ablative therapy of the NSCLC in stage III.",
      "start_page": 485,
      "end_page": 491
    },
    {
      "heading": "18 Quality indicators",
      "text": "Quality indicators are measures whose purpose is to assess the quality of the underlying structures, processes and results. Quality indicators are an important instrument of quality management. The aim of their use is to continuously improve the supply by presenting, critically reflecting and, if necessary, improving the results of the supply. The present selection of quality indicators has been prepared in accordance with the methodology of the Oncology guidance programme [1763]. For the derivation process, a \"Quality Indicators Working Group\" (AG QI) was formed, which produced the final set of quality indicators on the basis of the existing quality indicators of the 2018 Lung Carcinoma Guideline, the new strong recommendations ('should') of the updated guideline, the results of the existing quality indicators from the certified lung cancer centres of the German Cancer Society and the results of the research according to existing national and international quality indicators. The precise approach and composition of AG QI are set out in the guidelines report (see below). After two online meetings of this AG, 8 new quality indicators (QI) have been defined.",
      "start_page": 492,
      "end_page": 500
    },
    {
      "heading": "ICD-O-3",
      "text": "The results of the molecular pathological studies: Therapeutic objectives (as far as at least: from all NSCLC stage IV before applicable, i.e. as first-line therapy: EGFR mutations in the supplementary report) Exonene 18-21, BRAF V600 mutations, ALK fusions, ROS1 fusions, RET fusions and NTRK1-3 fusions Immunohistochemical examination: NSCLC stage II and III before neoadjuvant induction therapy or stage III prior to definititic radiation chemotherapy: PD-L1 expression After determination of a therapeutically reliable TPS value, a test on EGFR mutations (Exone 18-21 and ALK fusions) is to be performed in these tumours.",
      "start_page": 500,
      "end_page": 503
    },
    {
      "heading": "19.3 Übersicht der Änderungen in Version 4",
      "text": "19.3 Overview of Ä Table 46: Overview of changes in version 3.0 For each patient with lung carcinoma, anamnestically the risk factors (smoking, occupational noxies) are to be asked (smoking, occupational noxies). The survey of a comprehensive work history is required. 2010: Degree of recommendation D (lack of or inconsistent studies, recommendation based on expert opinion) Compliance with the statutory working safety regulations and regulations in cooperation with a permanent scientific review and risk assessment of hazardous substances ensures a broad minimisation of the risk of carcinogenic noxes at the workplace. A test on EGFR mutations in exon 19 and 21 is to be carried out on the basis of the available tumour strain after tumour resection also in early tumour stadia (IB – IIIA). © Oncological guidance programme Changes in version 4 n of version 4.01 For each patient with lung carcinoma, anamnestically the risk factors should be performed in early tumour stadia (IB – IIIA) as well.",
      "start_page": 504,
      "end_page": 515
    },
    {
      "heading": "*Cave: no approval yet",
      "text": "In the case of NSCLC stage IV with L858R-Mu onen, the survival and/or efficacy data should be used to determine the initial line TKI of effectivit and toxicity of the approved TKI (afatinib, dacomitinib, erlotinib, gef nib, osimertinib, erlotinib in combination with bevacizumab, erlotinib in combination with ramucirumab). Patients with NSCLC stage IV and common mutations in the EGFR should be offered treatment with the EGF TKI osimertinib or afatinib-in combination.",
      "start_page": 515,
      "end_page": 516
    },
    {
      "heading": "*Cave: no approval yet",
      "text": "Patients with NSCLC stage IV and uncommon mutations in EGFR in group 1 should be offered treatment with EGFR-TKI afatinib or alternatively osimertinib. NSCLC stage IV with exon-20 insertion mutations should be tested in a molecular tumor board. In the first-line therapy, chemotherapy should be offered in combination with avivantamab. In case of failure of a platinum-containing gy",
      "start_page": 516,
      "end_page": 523
    },
    {
      "heading": "20 List of tables",
      "text": "Table 7: Age-standardised new disease rates by gender in international comparison, ICD-10 C33 – C34, 2017 – 2018 or last available year per Table 8: Age-standardised death rates by gender in international comparison, ICD-10 Table 10: Composition of noxes according to German occupational disease law as Table 11: Legislative requirements in the Lung Cancer Early Detection Regulation (LuKrErkV) for medical treatment in Table 12: Characteristics of randomised-controlled studies for early detection of Table 13: Vulnerabilities and sources of error in unstructured lung cancer screening Table 14: Core elements of an organized early detection program according to § 25 SGB V (points 1–6) and scientifically meaningful minimum requirements for the transition phase after entry into force of the transition phase after entry into force of the BMUV lung cancer early detection regulation or the G-BA early detection guideline according to § 25 SGB V (points 2–5), as well as scientifically meaningful minimum requirements for the transition phase after entry into force of the transition phase after entry into the BMUV lung cancer early detection regulation or the G-BA early detection regulation in Table modified in the LABR.",
      "start_page": 524,
      "end_page": 524
    },
    {
      "heading": "19.3 Übersicht der Änderungen in Version 4 525",
      "text": "Table 18: Frequency of initial symptoms in lung carcinoma (modified according to Spiro et al., Table 24: Anatomical definition of thoracic and supraclavicular lymph nodes according to Table 27: Histopathological typing of lung tumours according to WHO classification of Table 29: Clinical predictors of an increased perioperative cardiovascular risk. Table 32: 5-year survival rates depending on stage III subclassification according to Table 33: 5-year survival as a function of mediastinal ipsilateral Table 38: Overview of chemotherapy studies in combination with PD-1 and PD-L1 Table 42: Indications of diagnostic measures in post-care of lung carcinoma .... 488 19.3 Overview of changes in version 4 Table 43: Quality indicators ........................................................................................................... Table 44: Pathology report Lung carcinoma – Biopsy (Status: 05/2023) ............ Table 45: Pathology report Pulmonary carcinoma Resectional image (Abbilt.u)",
      "start_page": 525,
      "end_page": 528
    },
    {
      "heading": "22 Bibliography",
      "text": "1. Barta-JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 31. Repace JL, Lowrey AH. An enable indoor air quality standard for environmental tobacco smoke in the workplace. Risk Anal. 1993;13:463-75. URL: med/8234955 32. Kolb S, Bruckner U, Nowak D, Radon K. Quantification of ETS exposure in hospitality workers who have never smoked. Environment Health. 2010;9:49. URL: med.ncbi.nlm.nih.gov/20704719/ 33. Repace JL. Ventilation Control Second hand Smoke in the Hospitality Industry? Analysis of the Document",
      "start_page": 529,
      "end_page": 661
    },
    {
      "heading": "table under heading <11 Psychooncological care of patients with> (from previous page)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved>",
      "text": "In addition, it is possible to: Tod. Tod. Tod. Tod. Tod. Tod. Dr. Dr. med. Torsten Gerriet Blum Blum Row 5: (ADT) Tod. Tod. Todsten Gerriet Blum Blum Row 5: (ADT) Tod. Tod. Tod. Tod. Tod. Tod. Tod. Todsten Gerriet Blum Blum Row 5: (ADT) Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod. Tod.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (column 2)",
      "text": "Row 1: Row 2: Row 3: m Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 23:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Participating Professional Societies and Organisms Row 2: One (Alphabetic) Row 3: - Row 4: -PD Dr. Robert Scheubel Row 5: -Prof. Dr. Erich Stoelben Row 6: Working Group Prevention and Integrative Prof. Dr. Ralph Mücke Row 7: Medicine in Oncology in the DKG (PRiO)- Row 8: - Row 9: Working Group Radiological Oncology Prof. Dr. Eleni Gkika Row 10: in the DKG (ARO)-Prof. Dr. Ursula Nestle Row 11: Working Group Social Work in the Onco-----Dipl. Soz. Päd. Marie Rösler Row 12: Psychology (ASO) in DKG-Row 13: - Row 14: Working Group Supportive Measures in the Onco---Dipl. Soz. Päd. Päd. Marie Rösler Row 12: Psychology (ASO) Row 16: Working Group of the Dinkow 13: Working Group of the Row 14.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Participating Professional Societies and Organisms Row 2: One (Alphabetic) Row 3: - Row 4: -PD Dr. Robert Scheubel Row 5: -Prof. Dr. Erich Stoelben Row 6: Working Group Prevention and Integrative Prof. Dr. Ralph Mücke Row 7: Medicine in Oncology in the DKG (PRiO)- Row 8: - Row 9: Working Group Radiological Oncology Prof. Dr. Eleni Gkika Row 10: in the DKG (ARO)-Prof. Dr. Ursula Nestle Row 11: Working Group Social Work in the Onko-----Dipl. Soz. Päd. Marie Rösl Row 12: Psychology (ASO) in DKG-Row 13: - Row 14: Working Group Supportive Measures in the Onko----Dipl. Soz. Päd. Päd. Marie Rösl Row 12: Psychology (ASO) Row 16: Working Group of the Tow.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: ler Row 10: Row 11: Row 12: Row 13: el Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: your Row 28: Row 29: r Row 30:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Participating Professional Societies and Organisms Row 2: One (Alphabetisch) Row 3: 的 Row 4: German Society for Medical Informatics Prof. Dr. Tim Friede Row 5: tik, Biometrie und Epidemiologie (GMDS)-Prof. Dr. Peter Schlattmann Row 6: German Society for Nuclear Medicine-Prof. Dr. Dipl. Phys. Dirk Hellwig Row 7: (DGN)- Row 8: 的 Row 9: German Society for Palliative Medicine (DGP)-Dr. Sandra Delis Row 10: Dr. Wiebke Row 14: (DGP/BDP)-Row 15: German Society for Pathology/Berufsver----Prof. Dr. Reinhard Büttner Row 13: band of German Pathologists-Prof. Dr. Klaus Junker Row 14: (DGP/BDP)-Row 16: German Society for Pneumology and Dr. Karl-Math.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Part Row 2: one Row 3: Deutsc Row 4: tik, Bio Row 5: Deutsc Row 6: (DGN) Row 7: Deutsc Row 8: Row 9: Deutsc Row 10: band D Row 11: (DGP/ Row 12: Deutsc Row 13: atmun Row 14: Row 15: Deutsc Row 16: (DEGR Row 17: Row 18: Deutsc Row 19: Row 20: Deutsc Row 21: Row 22: Eingel Row 23: Row 24: Metho Row 25:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: chem Gesellschaft für Nuclearme Row 6: ) Row 7: che Gesellschaft für Palliativme Row 8: Row 9: che Gesellschaft für Pathologie Row 10: Deutscher Pathologinnen und P Row 11: /BDP) Row 12: che Gesellschaft für Pneumolog Row 13: ngsmedizin (DGP) Row 14: Row 15: che Gesellschaft für Radioonko Row 16: RO) Row 17: Row 18: che Gesellschaft für Zytologie ( Row 19: Row 20: che Röntgengesellschaft (DRG) Row 21: Row 22: invited experts (excluding Stim Row 23: Row 24: odik, Coordination Row 25:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Organisat Row 2: Row 3: che Inform Row 4: MDS) Row 5: edizin Row 6: Row 7: edizin (DGP Row 8: Row 9: e/Profession Row 10: Pathologists Row 11: Row 12: gie and Be Row 13: Row 14: Row 15: ologie Row 16: Row 17: Row 18: (DGZ) Row 19: Row 20: ) Row 21: Row 22: mmrecht) Row 23: Row 24: Row 25:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: TI---Perpersons Row 2:  to to Row 22: to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:wig Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: n Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: he Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: opeit Row 28: Row 29: Row 30: Row 31: Row 32: Row 33: eat Row 34: Row 35: Row 36: Row 37:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31: Row 32: Row 33: Row 34: Row 35: Row 36: Row 37:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Participating societies and organisati---People Row 2: one (alphabetic)-- Row 3: - Row 4: Pneumological-oncological working group---Prof. Dr. Wolfgang Brückl Row 5: schaft in der Deutschen Krebsgesellschaft (POA)--Prof. Dr. Christian Grohé Row 6: -Dr. Cornelia Kropf-Sanchen Row 7: -- Row 8: -Prof. Dr. Bernd Schmidt Row 9: -Prof. Dr. Michael Thomas Row 10: Austrian Society for Pneumology--Dr. Maximilian Hochmair Row 11: (ÖGP)--- Row 12: ---",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Working Group Row 2: Occupational Exposure and Lung Cancer Prof. Dr. Dennis Nowak Row 1: Prof. Dr. Thomas Kraus, Prof. Dr. Dennis Nowak Row 4: Prof. Dr. Hans-Ulrich Kauczor Row 6: Prof. Dr. med. Torsten Gerriet Blum, Prof. Dr. Hans Hoff- Row 7: Epidemiology Prof. Dr. Hans-Ulrich Kauczor, Dr. Christian Kug- Row 9: Prof. Dr. Erich Stoelben, Prof. Dr. Dag Wormanns Row 10: Epidemiology Prof. Dr. med. Torsten Gerriet Blum Row 11: Prof. Dr. med. Torsten Gerriet Blum, Prof. Dr. Nina Buttmann- Row 12: Prof. Dr. Dr. 13: Schweiger, Prof. Dr. Thomas Kraus, Dr. 14. Krawin Fr. Klaus. Dr.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Part Row 2: one Row 3: Pneum Row 4: schaft Row 5: Row 6: Österr Row 7: (ÖGP)",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Work Row 2: Job Row 3: Row 4: Diagn Row 5: Row 6: Epidem Row 7: Row 8: Former Row 9: Row 10: Panco Row 11:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: Ligente Fachgesellschaften and Organisati---Personen Row 2: (alphabetisch)-- Row 3: -- Row 4: mologisch-onkologische Arbeitsgemeinschaft----Prof. Dr. Wolfgang Brückl Row 5: t in der Deutschen Krebsgesellschaft (POA)---Prof. Dr. Christian Grohé Row 6: -Dr. Cornelia Kropf-Sanchen Row 7: -- Row 8: -Prof. Dr. Bernd Schmidt Row 9: -Prof. Dr. Michael Thomas Row 10: rich society for pneumology--Dr. Maximilian Hochmair Row 11: --- Row 12: ----",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 1: Drow 2: Drow 1: Drow 2: Drow 1: Drow: Dr. Hans-Ulrich Kauczor Row 6: Drw: Dr. Dr. med. Torsten Gerriet Blum, Prof. Dr. Dag Worma Row 7: Drow 8: Drw: Drw: Dr. Hans-Ulrich Kauczor, Dr. Christia Row 9: Drw: Prof. Dr. Erich Stoelben, Prof. Dr. Dag Worma Row 12: Prof. Dag Worma Row 13: Prof. Dr. Thomas Kraus, Prof. Dr. Thomas Kraus, Dr. Klaus Kra Row 14: Drw: Dr. med. Torsten Gerriet Blum, Dr. Nina But Row 12: Prof. Dag Worma Row 13: Prof. Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw: Drw",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: ns Hoff- Row 6: to Kug- Row 7: anns Row 8: Row 9: ttmann- Row 10: aywin- Row 11: Row 12: Row 13: ns Hoff- Row 14: ch Row 15: Row 16: Row 17: eling, Row 18:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Dr. Klaus Junker, Prof. Dr. Klaus Junker, Prof. Dr. Klaus Junker, Prof. Wiebke Nehls, Row 6: Dr. Sandra Delis, Dr. Wiebke Nehls, Row 7, Dr. Wiebke Nehls, Dr. Sandra Delis, Dr. Wiebke Nehls, Row 7:          Row 8: Control group        Row 8: Control group     to Row 9, Dr. Wiebke Nehls, Row 6: Dr. Wiebke Nehls, Row 6: Dr. Sandra Delis, Dr. Wiebke Nehls, Row 7, Dr. Wiebke Nehls, Row 7, Dr. Wiebke Nehls, Row 7, Dr. Wiebke Nehls, Row 7:",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Work Row 2: Pathol Row 3: Row 4: Patien Row 5: Row 6: Steuer Row 7: Row 8: Therap Row 9: Row 10: Therap Row 11: Row 12: Therap Row 13: mutat Row 14: Row 15: Therap Row 16: tenepi Row 17: Row 18: Therap Row 19: stasier Row 20: Row 21: Therap Row 22: tenepi Row 23: Row 24: Therap Row 25: Row 26: Therap Row 27:",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: group Row 2: logy Row 3: Row 4: ntenaufklärung/ Row 5: Row 6: rgruppe Row 7: Row 8: pie NSCLC Stadi Row 9: Row 10: pie NSCLC Stadi Row 11: Row 12: pie NSCLC Stadi Row 13: nations Row 14: Row 15: pie NSCLC Stadi Row 16: ithel Row 17: Row 18: pie NSCLC Stadi Row 19: rt Row 20: Row 21: pie NSCLC Stadi Row 22: ithel Row 23: Row 24: pie SCLC Stadiu Row 25: Row 26: pie SCLC Stadiu Row 27:",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: /Palliativeme Row 5: Row 6: Row 7: Row 8: ium I and I Row 9: Row 10: ium III Row 11: Row 12: ium IV with Row 13: Row 14: Row 15: ium IV Nich Row 16: Row 17: Row 18: ium IV olig Row 19: Row 20: Row 21: ium IV Plat Row 22: Row 23: Row 24: around I and II Row 25: Row 26: around III Row 27:",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: edizin Row 5: Row 6: Row 7: Row 8: II Row 9: Row 10: Row 11: Row 12: t Drift Row 13: Row 14: Row 15: ht-Pla Row 16: Row 17: Row 18: Gomet Row 19: Row 20: Row 21: t- Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27:",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Members of the Working Group Row 2: Row 2: Row: Prof. Dr. Klaus Junker Row 3: Row: Prof. Dr. Reinhard Büttner, Prof. Dr. Klaus Junker Row 4: Row 5: Row 5: Row: Row 6: Row: Dr. Sandra Delis, Dr. Wiebke Nehls Row 7: Row 8: Row 8: Row 9: Row 9: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row 11: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: he, Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: he, Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31: Row 32: Row 33: r. Row 34: Row 35: Row 36:",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Working Group, members of the Working Group Row 2: Therapy SCLC Stadium IV, Dr. Cornelia Kropf-Sanchen Row 3:, Dr. Cornelia Kropf-Sanchen, Prof. Dr. Bernd Schmidt Row 4:, Row 5: Working Group leaders are marked in bold.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Abbreviation Row 2: zung: Row 3: 13cRA:13-cis-retinoic-acid Row 5: 4-HPR:-(4-hydrophenyl)-retinamide Row 6: ACCP:American College of Chest Physicians Row 7: ACP: Advance Care Planning Row 8: AE:Adverse Events Row 9: AG: AIS:Adenocarcinoma in situ Row 11: AJCC:American Joint Committee on Cancer",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Work Row 2: Therap Row 3: Row 4: Work",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: 13cRA Row 4: 4-HPR Row 5: ACCP Row 6: ACP Row 7: AE Row 8: AG Row 9: AIS Row 10: AJCC",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: tsgruppe-members of the working group Row 2: pie SCLC Stadium IV-Dr. Cornelia Kropf-Sanchen Row 3:-Dr. Cornelia Kropf-Sanchen, Prof. Dr. Bernd Schm Row 4:-- Row 5: group leaders are marked in bold.--",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r---Explanation Row 2: -- Row 3: -- Row 4: A--13-cis-retinoic-acid Row 5: ---(4-hydrophenyl)-retinamide Row 6: --American College of Chest Physicians Row 7: --Advanced Care Planning Row 8: -Adverse Events Row 9: --Working Group Row 10: --Adenocarcinoma in situ Row 11: --American Joint Committee on Cancer",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: midt Row 4:",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "In addition: In addition: In addition: In addition: In addition: In addition: In addition: In addition: In addition: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to: In to to: In to: In to: In to: In to: In To: In to: In to: In to: In To: In To: In To: In To: In To: In To: In To To: In To: In To: In To To: In To: In To: In To: In To To To To To To To To To",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: ALARA Row 4: APC Row 5: ARDS Row 6: ASCO Row 7: ATS Row 8: AUC Row 9: AWMF Row 10: BAE Row 11: BAR Row 12: BED Row 13: BGB Row 14: BK Row 15: BRSK Row 16: BSC Row 17: BTS Row 18: CG Row 19: CGA Row 20: CI Row 21: COPD Row 22: CR Row 23: CT Row 24: CT Row 25: DEGRO",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: A Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: F-IMWi Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: E Row 25: O",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: 24-Erklärung Row 2: -- Row 3: -- Row 4: --As low as normal achievable Row 5: --Argon-Plasma Laser Coagulation Row 6: --Acute Respiratory Distress Syndrome Row 7: --American Society of Clinical Oncology Row 8: --American Thoracic Society Row 9: --Area Under the Curve Row 10: i---AWMF Institute for Medical Wiss Row 11: ---Bronchial Arterial Embolisation Row 12: -----Federal Working Group for Rehab Row 13: ----Biological Effective Dose Row 14:----Civilian Law Book Row 15: ----Profession Row 16: ---Bronchial Arterial Embolization Row 17:----Best Supportive Care Row 18: ----British Thoracic Society Row 19------ControlControl Row 20",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: y Row 7: Row 8: Row 9: sensm Row 10: Row 11: bilitat Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: kung Row 22: Row 23: Row 24: dverse Row 25: logy",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: manag Row 10: Row 11: nation Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: e Even Row 25:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: gemen Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: nts Row 25:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Nt Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "In the case of the following cases, it is not possible to determine whether or not the risk of a disease is due to the fact that the risk of a disease is greater than the risk associated with the risk of a disease.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: DFS Row 4: DLP Row 5: DME Row 6: DNA Row 7: DRW Row 8: EBUS Row 9: ECOG Row 10: ED Row 11: EGFR Row 12: EGFR Row 13: EKG Row 14: EMA Row 15: EORTC Row 16: EQ-5D Row 17: ERS Row 18: ESMO Row 19: EGFR Row 20: FDG-PE Row 21: FEV Row 22: FGFR Row 23: FM Row 24: HCV Row 25: HE-Fär",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: C Row 16: D Row 17: Row 18: Row 19: Row 20: ET Row 21: Row 22: Row 23: Row 24: Row 25: row",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: 的Explanation Row 2: 的 Row 3: 的 Row 4: 的Krankh Row 5: 的Doszelä Row 6: 的Dieselm Row 7: 的Desoxy Row 8: 的Diagno Row 9: 的Endobr Row 10: 的Eastern Row 11: 的Extens Row 12: 的Epiderm Row 13: 的Expert Row 14: 的Electro Row 15: 的Europe Row 16: 的Europe Row 17: 的Europe Row 18: 的Europe Row 19: 的Europe Row 20: 的Endosk Row 21: 的18F-Flu Row 22: 的Forcier Row 23: 的Fibrobl Row 24: 的Fernme Row 25: 的Hepatit Row 26: g",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: erung Row 2: Row 3: non-hazardous survival Row 8: ronchial ultrasonic Row 9: n Cooperative Oncology Group Row 10: sive disease Row 11: male growth factor (E Row 12: enkonsens Row 13: ocardiogram Row 14: ean Medicines Agency Row 15: ean Organisation for Research a Row 16: ean Quality of Life 5 Dimension Row 17: ean Respiratory Society Row 18: ean Society of Medical Oncology Row 19: cubic ultrasound Row 20: uordeoxyglucose Positronem Row 21: rtes expiratory volume Row 22: last growth factor Row 23:etastasen Row 24: uordeoxyglucose Positronem Row 21: rtes expiratory volume Row 22: last growth factor Row 23: uordeoxyglucose",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: ease-f Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Epide Row 12: Row 13: Row 14: Row 15: and T Row 16: ns Row 17: Row 18: and Row 19: Row 20: missio Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: free surviv Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Ermal Grow Row 12: Row 13: Row 14: Row 15: Treatment o Row 16: Row 17: Row 18: Row 19: Row 20: onstomogra Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: val) Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: wth Factor Recep Row 12: Row 13: Row 14: Row 15: of Cancer Row 16: Row 17: Row 18: Row 19: Row 20: aphie Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: ptor) Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down: Down:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: HER2 Row 4: HIV Row 5: HLM Row 6: HPV Row 7: HR Row 8: HRQoL Row 9: IARC Row 10: Row 11: IASLC Row 12: IC Row 13: ICD Row 14: ICD Row 15: IMRT Row 16: IO Row 17: IP Row 18: IP Row 19: IQWiG Row 20: ITT Row 21: KHK Row 22: LD Row 23: LDCT Row 24: LDH Row 25: LK Row 26: LL",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: G Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row 4: Human Epidermal Growth Factor Rece Row 5: Human Immunodeficiency Virus Row 6: Row 7: Humanes Papillomavirus Row 8: Hazard ratio Row 9: Health-related quality of life Row 10: International Agency for Research on Row 11: Shung Row 12: Row 13: International Association for the Stud Row 14: Immune Cells Row 15: Immune Cells Row 15: Implanted Cardioverter Defibrillator Row 17: Row 17: Intensity Modulated Radiotherapy Row 18: Immun Checkpoint Inhibitors Row 19:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: eptor Type 2 Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Cancer, interna Row 10: Row 11: dy of Lung Cance Row 12: Row 13: it Row 14: ren Row 15: Row 16: Row 17: Row 18: Row 19: ren Row 20: Row 21: Row 22: Row 23: y Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: nationa Row 10: Row 11: he Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: dheits Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: ales Institu Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: being Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: ut for Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Cancer Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: sfor- Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "In the case of the following cases, it is not possible to determine whether or not it is possible to determine whether the aid is compatible with the common market or whether the aid is compatible with the common market.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: LoE Row 4: LR Row 5: LUSI Row 6: MASCC Row 7: MIA Row 8: MRT Row 9: Nab Row 10: NCCN Row 11: NCCTG Row 12: NELSO Row 13: NGS Row 14: NICE Row 15: NIH Row 16: NPV Row 17: NSCLC Row 18: NSE Row 19: NSLT Row 20: NTRK Row 21: OMD Row 22: OP Row 23: OR Row 24: ORR Row 25: OS",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: Row 4: Row 5: Row 6: C Row 7: Row 8: Row 9: Row 10: Row 11: G Row 12: ON Row 13: Row 14: Row 15: Row 16: Row 17: C Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: on trial Row 6: ve Care in Canc Row 7: Row 8: Row 9: Row 10: work Row 11: up Row 12: cer Screening T Row 13: Row 14: e Excellence Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: ival)",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: cer Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Trial Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Row 2: Row 2: Row 2: Row 3: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: p.a. Row 4: PAK Row 5: PCI Row 6: pCR Row 7: PCR Row 8: PDT Row 9: PET Row 10: PFS Row 11: PLCO Row 12: PPV Row 13: PS Row 14: pTNM Row 15: QI Row 16: QLQ Row 17: QoL Row 18: RCT Row 19: REACH Row 20: RECIST Row 21: RG Row 22: RKI Row 23: RöV Row 24: RR Row 25:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: H Row 20: T Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "22-Row: 22-Row: 22-Row: 22-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: 23-Row: , 13-Row: 7-Row: 7-Row: 8-Row: 8-Row: 9-Row: 9-Row: 9-Row: 9-Row: 9-Row: 9-Row: 9-Row: 9-Row: 10-Row: 10-Row: 14-Row: 14-Row: 15-Row: 16-Row: 16-Row: 16-Row: 23-Row: 24-Row: 24-Row: 23-Row: 24-Row: 24-Row: 24-Row: 24-Row",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: toffe Row 5: table Schä Row 6: Row 7: Row 8: Row 9: Row 10: resolution-fre Row 11: ncer Screen Row 12: Row 13: Row 14: ymphknote Row 15: Row 16: Row 17: Row 18: Row 19: in chronic Row 20: ors Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Adel irradiation Row 6: Row 7: Row 8: Row 9: Row 10: ee survival) Row 11: ning Row 12: Row 13: Row 14: en and Metastas Row 15: Row 16: Row 17: Row 18: Row 19: c hepatitis B Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: g) Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Sen Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "In addition, it should be noted that, in the absence of a decision by the Court of Justice of the European Union, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of First Instance of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of First Instance of the European Communities, the Court of Justice of the European Communities, the Court of Justice of the European Communities, the Court of First Instance of the European Communities, the Court of First Instance of the European Communities, the Court of First Instance of the European Communities, the Court of Justice of the European Communities, the Court of First Instance of the European Union, the Court of Justice of Justice of the European Union, the European Communities, the Court of Justice of Justice of Justice of the European Union, the European Communities, the European Communities, the European Communities, the European Court of Justice, the European Court of Justice, the European Court of Justice, the Court of Justice, the European Court of First Instance, the European Court of First Instance, of",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: SBRT Row 4: SCLC Row 5: SEER Row 6: SRS Row 7: SSK Row 8: ST Row 9: SUV Row 10: SWOG Row 11: Row 12: TC Row 13: TIA Row 14: TKI Row 15: TLCO Row 16: TMB Row 17: TNM Row 18: TPS Row 19: TTLB Row 20: TTNA Row 21: TTUS Row 22: UAW Row 23: UICC Row 24: VAMLA Row 25: VAT Row 26: VDT",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: A Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Result Row 6: Row 7: Row 8: Row 9: Row 10: Niche Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: utatio Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: n Row 23: Row 24: adene Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: ts (USA) Row 6: Row 7: Row 8: Row 9: Row 10: e Studyer Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Onal Burde Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Ectomy Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: rgani Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: en) Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: ization Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: n Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Abbreviation Row 2: zung: Row 3: 的 Row 4: VEGF:Vascular endeothelial growth factor Row 5: VLD:Very limited disease Row 6: VO2max: Maximum oxygen intake Row 7: VRB:Vinorelbine Row 8: WHO:World Health Organization Row 9: WT:Wild type Row 10: CNS: Central nervous system",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Abbreviation Row 2:zung Row 3: VEGF Row 4: VLD Row 5: VO2m Row 6: VRB Row 7: WHO Row 8: WT Row 9: CNS",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: r- Row 2: Row 3: Row 4: Row 5: max Row 6: Row 7: Row 8: Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "Row 1: 的Explanation Row 2:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: helial Row 4: ase Row 5: fabricau Row 6: Row 7: ganiza Row 8: Row 9: stem",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: growth factor Row 4: Row 5: ufnahm Row 6: Row 7: nation (World Gesu Row 8: Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: undhe Row 8: Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: egg organis Row 8: Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: satation) Row 8: Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Eviden Row 2: 1a (Ox Row 3: Row 4: 1b (Ox Row 5: Row 6: 2a (Ox Row 7: Row 8: 2b (Ox Row 9: Row 10: 3a (Ox Row 11: Row 12: 3b (Ox Row 13: 4 (Oxf Row 14:",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: nzgrad-Description Row 2: xford 2009)--Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogenity) Row 3: RCTs Row 4: Row 5: xford 2009)--Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogenousity) Row 9: Row 10: Row 11: xford 2009---Therapy/Prevention, Aetiology, Harm: Systematic Review (with homogenousity) Row 9: Row 10: Row 11: xford 2009------Therapy/Prevention, Aetiology, Harm: Individual cohort study (including low Row 12: Row quality; e.g.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page)",
      "text": "Row 1: Evidence grade Description Row 2: 5 (Oxford 2009): Thickness/Prevention, Aetiology, Harm: Expert opinion without explicit critical Row 3: -appraisal, or based on physiology, bench research or first principals: Row 4: , Row 5: 1 (Oxford 2011)--Categorie - Does this intervention help? (Treatment Benefits): Randomized Row 9: ,trial or observational study withdramatic effect Row 10: 2 (Oxford 2011)--Categorie - Does this intervention help? (Treatment Benefits): Randomized Row 9: ,-trial or observational study with drag 10:,- Row 11: 3 (Oxford 2011)-Txford 2011)-Benefits?",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 1)",
      "text": "Row 1: Eviden Row 2: 5 (Oxf Row 3: Row 4: 1 (Oxf Row 5: Row 6: 2 (Oxf Row 7: Row 8: 3 (Oxf Row 9: Row 10: 4 (Oxf Row 11: Row 12: 5 (Oxf Row 13: Row 14:",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 2)",
      "text": "Row 1: nzgrad Row 2: ford 2009) Row 3: Row 4: ford 2011) Row 5: Row 6: ford 2011) Row 7: Row 8: ford 2011) Row 9: Row 10: ford 2011) Row 11: Row 12: ford 2011) Row 13: Row 14:",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Table under heading <1.9.2 Professional societies and organisations involved> (from previous page, column 3)",
      "text": "In this case, it is possible to use the following methods of analysis to determine whether or not the results of the study are consistent with the results of the study, and to determine whether the results of the study are consistent with the results of the study carried out in the Member States.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading < 2.2.3 Statements>",
      "text": "Row 1: Degree of recommendation--Description Row 2: A--Strong recommendation for or against a measure--used expression-- Row 3:--wise = shall/should not Row 4: -- Row 5: B--Recommendation for or against a measure--used expression = Row 6: --should/should not Row 7: -- Row 8: 0--open recommendation (option) regarding a measure--used expression- Row 9: --wise = can Row 10: --",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table under heading < 2.2.3 Statements>",
      "text": "Row 1: Strength of Consensus-Description Row 2: Consensus-> 75-95% Voter's approval Row 3: Majority vote-> 50-75% Voter's approval Row 4: Strong Consensus-> 95% Voter's approval Row 5: No majority vote-< 50% Voter's approval",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table under heading < 2.2.3 Statements> (from previous page)",
      "text": "Row 1: Age-standardised new disease rate 2017-2018--- Row 2: Country--Women--Men Row 3: Switzerland--31,4--48,3 Row 4: Austria--30,4-49,1 Row 5: Germany--31,6-56,7 Row 6: 1 Switzerland: Data on incidence only for 2017--- Row 7: Source: Center for Cancer Registry Data at the Robert Koch Institute---",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table under heading < 2.2.3 Statements> (from previous page, column 1)",
      "text": "Row 1: Age Row 2: Country Row 3: Schwe Row 4: Österr Row 5: Deutsc Row 6: 1 Schw Row 7: Source",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table under heading < 2.2.3 Statements> (from previous page, column 2)",
      "text": "Row 1: Standardized New Disease Rate 2017-2018---- Row 2: Women----Men Row 3: Eiz 1--31,4--48,3 Row 4: rich---30,4-49,1 Row 5: chland--31,6-56,7 Row 6: white: incidence data only for 2017--- Row 7: e: Center for Cancer Registry Data at the Robert Koch Institute---",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table under heading <3.3 Trend>",
      "text": "Row 1: Age Standardized Mortality Rate 2017-2018---- Row 2: Women---Men Row 3: Switzerland--19,0-33,3 Row 4: Austria--21,2--40,1 Row 5: Germany--22,1-43,4 Row 6: Source: Center for Cancer Registry Data at the Robert Koch Institute---",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Table under heading <3.3 Trend> (column 1)",
      "text": "Row 1: Age Row 2: Row 3: Schwe Row 4: Österr Row 5: Deutsc Row 6: Source:",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "table under heading <3.3 Trend> (column 2)",
      "text": "Row 1: stood Row 2: Row 3: eiz Row 4: rich Row 5: chlan Row 6: : centr",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "table under heading <3.3 Trend> (column 3)",
      "text": "Row 1: ndardized death rate in 2017-2018---- Row 2: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page)",
      "text": "Row 1: 3.1.3Consensus-based recommendation--modified 2025 Row 2: EC--In every patient with lung carcinoma the risk factors-- Row 3: (smoking, occupational noxies and family anamnesis regarding malignant crane-- Row 4: -kungen) are to be asked. The survey of a comprehensive work anamnesis is Row 5: ---- Row 6: --necessary.- Row 7: --Starker Konsent--- Row 8: ----",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page)",
      "text": "Row 1: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page, column 1)",
      "text": "Row 1: 3.1 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page, column 1)",
      "text": "Row 1: Row 2: Row 3: Beispi Row 4:",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: iel Row 4:",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--modified 2025 Row 2:--In every patient with lung carcinoma, anaesthetically, the risk factors-- Row 3:-- (smoking, occupational noxies and family anamnesis regarding malignant crane-- Row 4:--kungen) are to be asked. The survey of a comprehensive work anamnesis is Row 5:---- Row 6:--necessary.-- Row 7:--Starker Konsensenz--- Row 8:------",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <3.3 Trend> (from previous page, column 3)",
      "text": "Row 1: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Rounding-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row: Round-Row",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Row 1: Harmful work substance (occupational/typical occurrence/remarks Row 2: disease number) Row 3: Row 4: \"Siliotic scar carcinoma\"- Such a tumor is only to be discussed if a Row 5: (4101)-Siliconosis, i.e. a quartz dusting disease is present. Row 6: Row 10: Row 10: Row 10: Row 11: Row 8: Row 8: Row 8: Row 8: Row 9: Row 9: Row 9: Row 12: Row 12: Row 13: Row 13: Row 13: Row 14: Row 14: Row 14: Row 14: Row 16: Row 16: Row 12: Row 12: Row 12: Row 12: Row 13: Row 13: Row 13: Row 13: Row 14: Row 14: Row 16: Row 16: Row 16: Row 12: Row 12: Row 12: Row 13: Row 13: Row 13: Row 13: Row 13: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 13: Row 13: Row 13: Row",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: \"Siliko Row 4: (4101 Row 5: Row 6: Kristal Row 7:",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dlich Arb Row 2: kiemenum Row 3: otish Na Row 4: 1) Row 5: Row 6: llines Silizi Row 7:",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: beitss Row 2: mmer Row 3: arbenk Row 4: Row 5: Row 6: iumdi Row 7:",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: substance Row 2: r) Row 3: carcinogen Row 4: Row 5: Row 6: ioxid Row 7:",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "Row 1: (Beru Row 2: Row 3: nom\" Row 4: Row 5: Row 6: (4112 Row 7:",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 6)",
      "text": "Row 1: ufs---Typical occurrence/Notes Row 2: -- Row 3: - Row 4: -- Such a tumor can only be discussed if a Row 5: -Siliconosis, i.e. a quartz dusting disease, is present. Row 6: This is recognized by the doctor on the X-ray image or in the Compu- Row 7: - Row 8: -tertomogram, possibly in the fine-woven examination. Row 9: --This is an already reportable Be- Row 10: --Running disease. The Quartz dusting disease (silicosis) Row 11: ----is formed by inhalation of dust particles, the Quartz, Row 12: --Cristobalite or Tridymite. Row 13: Danger, processing or processing of sandstone, Row 14: -Quarzit, Grauwacke, Kieselerde (Kieselkreide), Kieschifer, Row 15: 16-Quarzichfier, Granite, Rowb.",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Row 1: Harmful work substance (occupational/typical occurrence/remarks Row 2: disease number) Row 3: Row 4: Row 4: Emaille and ceramic industry (glazes and frits, Row 5: Row 5: Row 6: Row 6: Row 6: Row 6: Row 6: Row 6: Row 4: Row 4: Row: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 9: Row 9: Row 9: Row 9: Row 12: Row 12: Row 13: Row 13: Row 13: Row 13: Row 13: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 15: Row 16: Row 16: Row 13: Row 13: Row 17: Row 17: Row 17: Row 17: Row 14: Row 14: Row 14: Row 14: Row 14: Row 15: Row 15: Row 15: Row 15: Row 15: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 13: R",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Ionisie Row 11: Row 12: Arsen, Row 13:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dliche Row 2: kheite Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: erend Row 11: Row 12: , -verb Row 13:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: he Arb Row 2: ennum Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: de Stra Row 11: Row 12: bindu Row 13:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: beitss Row 2: mmer Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: ahlun Row 11: Row 12: ungen Row 13:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "Row 1: fabric Row 2: r) Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: ng (24 Row 11: Row 12: n (110 Row 13:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 6)",
      "text": "Row 1: (Beru Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: 402) Row 11: Row 12: 08) Row 13:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 7)",
      "text": "Row 1: ufs--Typical occurrence/Notes Row 2: -- Row 3: - Row 4: -Email and ceramic industries (glazes and frits, Row 5: -Feinkeramik) Row 6: -Production of refractory stones as well as the jewellery stoneverar- Row 7: -Betung Row 8: -Quarz sand or quartz flour as fillers (pebble resins, rubber, Row 9: -Colours, decorative plaster, washing pastes), as filter material (water Row 10: -processing) and as raw material, e.g. for the production of Row 11: -Schweringquarts, silicon carbide, silica gels, silicones and at Row 12: --the crystall breeding Row 13: - Use as abrasives and abrasives (polishing and Row 14:-shear pastes) or as ray mediums Row 15: -Cristobalit and Tridy: zow.",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "In the case of the following products, the following conditions shall be met:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Dichlo Row 10: Row 11: Chrome Row 12:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dliche Row 2: kheite Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: ormet Row 10: Row 11: m, -ve Row 12:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: he Arb Row 2: ennum Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: thyleth Row 10: Row 11:bind Row 12:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: beitss Row 2: mmer Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "Row 1: fabric Row 2: r) Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: 1310) Row 10: Row 11: en (11 Row 12:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 6)",
      "text": "Row 1: (Beru Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: ) Row 10: Row 11: 103) Row 12:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 7)",
      "text": "In addition, it is important to note that it is not possible to determine whether or not the content of the active substance should be taken into account in the determination of the content of the active substance, i.e. the content of the active substance.",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Dried: Dried: Dried: Dried: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: Ded: D",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Dichlo Row 15:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dliche Row 2: kheite Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: ordiet Row 15:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: he Arb Row 2: ennum Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: thylsu Row 15:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: beitss Row 2: mmer Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:ulfide (L Row 15:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "Row 1: fabric Row 2: r) Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: LOST) Row 15:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 6)",
      "text": "Row 1: (Beru Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: ) (131 Row 15:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 7)",
      "text": "Row 1: ufs---Typical occurrence/Notes Row 2: -- Row 3: - Row 4: --Cutting, welding and grinding of plates with Row 5: --chromium-containing coatings Row 6: --Production and use of chromium(VI) pigments, ins- Row 7: special zinc and lead chromatography, in the paint, paint and Row 8: --plastic industry Row 9: ---use of chromium(VI) oxide and alkali chromatography, in particular Row 10: --in the lithography, the photographic industry, the textile Row 11: --and carpet industry, the glass and ceramic industry, Row 12: ---used in the manufacture of fireworks and zünhölzern Row 13: - as well as of plant glues Row 14: --wood imprevention Row 15: ---production and use of cutting oils Row 16:---breaths and Zünhöls Row 13: - production and production:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 23-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-Row: 22-R",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Nickel Row 4: Row 5: Coke Row 6: Armoa Row 7: (4110)",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dlicher Arbeits Row 2: kheitennummer Row 3: l, kombinden Row 4: Row 5: eirohgase, poly Row 6: atiken Kolhenw Row 7: 0, 4113, also 41",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: fabric Row 2: r) Row 3: n (410 Row 4: Row 5: ycyclis Row 6: water Row 7: 114)",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: (Beru Row 2: Row 3: 09) Row 4: Row 5: row 6: row cloth Row 7:",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "22-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 25-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 25-Row: 25-Row: 25-Row: 25-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 8-Row: 8-Row: 8-Row: 8-Row: 8-Row: 8-Row: 13-Row: 13: 13-Row: 19-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24-Row: 24",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Row 1: Harmful work material (occupational--typical occurrence/remarks Row 2: disease number)- Row 3: - Row 4: -Roller driver Row 5: -Einfeger (Deckenmann) Row 6: -Steigohrreiniger Row 7: -Teerschlager Row 8: -Pressurized machine driver Row 9: -Kokskuchenführungswagenfahrer resp. Koksüberleitungsma- Row 10: -Schinist Row 11: -Löschwagenfahrer Row 12: -Türmann Row 13: -Rampenmann Row 14: - Regular maintenance of raw gas lines when the Mög- Row 15: -Lischinist Row 11: --Lischinist Row 11: -Lisherwagenfahrer Row 12: -Türmann Row 17: --Teerrafinärien Row 18: --Electrgraphite industry Row 19: -Aluminium production Row 20: -Ironium production Row 21- and radiation Row 21: Row:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 21:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: he Arb Row 2: ennum Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: beitss Row 2: mmer Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 21:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "Row 1: fabric Row 2: r) Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 6)",
      "text": "Row 1: (Beru Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 7)",
      "text": "Row 1: ufs---Ty Row 2: -- Row 3: -- Row 4: --Fül Row 5: --A Row 6: --Ste Row 7: --Tee Row 8: --Dru Row 9: ---Ko Row 10: ---Row 11: --Lös Row 12: --Tü Row 13: --Ram Row 14: --Reg Row 15: ---Row 16: ---Auß Row 17: ----Tee Row 18: ----Ele Row 19: ----Alu Row 20: --Eis Row 21: ---Gie Row 22: --Str Row 23: -----Da Row 24: -----Sch",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 8)",
      "text": "Row 1: ypisches Vorkom Row 2: Row 3: llwagenfahrer Row 4: nfeger (Deckenm Row 5: eigohrreiniger Row 6: erschlauber Row 7: uckmaschinenfa Row 8: okskuchenführun Row 9: hinist Row 10: scherwagenfahrer Row 11: rmann Row 12: mpenmann Row 13: gelmäßige Wartu Row 14: higkeit des Freiwe Row 15: ßerdem: Row 16: erreffinerien Row 17: ektrographitindu Row 18: uminiumherstell Row 19: sent and beam Row 20: eßereien Row 21: rassenbau Row 22: achdecker Row 23: hornstone sweeper",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 9)",
      "text": "Row 1: mmen/An Row 2: Row 3: Row 4: mann) Row 5: Row 6: Row 7: ahrer Row 8: ngswagenf Row 9: Row 10: r Row 11: Row 12: Row 13: ungen von Row 14: earthenware of Row 15: Row 16: Row 17: ustrie Row 18: lung Row 19: enerzeugun Row 20: Row 21: Row 22: Row 23:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 10)",
      "text": "Row 1: comments Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: driver and coke Row 9: Row 10: Row 11: Row 12: Row 13: n Rohgas pipelines Row 14: n Gases exist Row 15: Row 16: Row 17: Row 18: Row 19: ng Row 20: Row 21: Row 22: Row 23:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 11)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: ksüber Row 9: Row 10: Row 11: Row 12: Row 13: en, w Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: reitu Row 9: Row 10: Row 11: Row 12: Row 13: if d Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 13)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: ungsm Row 9: Row 10: Row 11: Row 12: Row 13: Mö Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 14)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: ma- Row 9: Row 10: Row 11: Row 12: Row 13: Og- Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Row 1: Harmful working material (occupational--typical occurrence/remarks Row 2: disease number)-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Passive Row 4: Row 5: Berylli Row 6: Row 7: Cadmi Row 8:",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dlicher Arbeits Row 2: kheitennummer Row 3: vuse am Arb Row 4: Row 5: ium, -verbindun Row 6: Row 7: ium, -verbindun Row 8:",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: fabric (Beru Row 2: r) Row 3: beitsplatz Row 4: Row 5: ngen (1110 Row 6: Row 7: ngen (1104 Row 8:",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "22 Row 1: ufs---Typical occurrence/Notes Row 2: -- Row 3: - Row 4: -- Practically only relevant to life-long non-smokers: Row 5: hazard especially in the catering industry, e.g. as a tank-- Row 6: - Row 7: -kellner Row 8: 0)--Production of high refractory equipment and materials as well as Row 9: keramic colours Row 10: -- Row 11: --Production of aluminium welding powder Row 12: -Production of sepial porzellan Row 13: -Production of incandescent substances Row 14:--Processing of dry, dusty beryllium compounds, Row 15:--mainly the grinding and unloading process, in slightly low- Row 16:-rem measurements of the beryllium from its ore Row 17:---and intermediate products Row 18:----To-be-thream also applicable to workstations in the field of manufacture or of production of: Rowling or of: Rowling",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "22- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to-- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to- to to to to- to- to- to- to- to to to- to to to to to to to to to to",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Lung Row 4: Row 5: Asbes Row 6:",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dliche Row 2: kheite Row 3: ennarb Row 4: Row 5: st (410 Row 6:",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 3)",
      "text": "Row 1: he Arb Row 2: ennum Row 3: ben Row 4: Row 5: 04, 41 Row 6:",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 4)",
      "text": "Row 1: beitss Row 2: mmer Row 3: Row 4: Row 5: 105, Row 6:",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 5)",
      "text": "Row 1: fabric Row 2: r) Row 3: Row 4: Row 5: 4114 Row 6:",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 6)",
      "text": "Row 1: (Beru Row 2: Row 3: Row 4: Row 5: 4) Row 6:",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 7)",
      "text": "22-Typical Occurrence/Notes Row 2: - Row 3: - Row 4: - after tuberculosis as an occupational disease (BK 3101) Row 5: - after thoracic perforation dreams (if necessary as an abatement accident- Row 6: - order) Row 7: - Asbestos preparation. Herein either mother rock containing asbestos is broken down by Row 9: - Row 10: - and/or raw asbestos to become more open-up Fa- Row 11: - loosely in collieries, - Row 12: - to produce and process asbestos textil products such as Row 13: - yarn, tow, tow, ribbons, hoses, tow, tow, tow, tow, tow, tow, tow, tow, tow, etc. There are activities such as Down 15: - Fill, tow, tow, tow,w, tow, tow, tow, tow, tow, tow, tow, tow, tow, tow, tow.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "table under heading <BK 4114> (from previous page)",
      "text": "Row 1: Harmful agent (occupational/typical occurrence/remarks Row 2: disease number)- Row 3:-- Row 4:--Production, processing and processing of rubber asbestos (IT)-Pro- Row 5:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 1)",
      "text": "Row 1: Shame Row 2: Sick Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "table under heading <BK 4114> (from previous page, column 2)",
      "text": "Row 1: dlicher Arbeitsstoff (Vocational---Typische Erbies/Notes Row 2: kheitennummer)- Row 3: -- Row 4: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease>",
      "text": "Row 1: 4.1-Evidence-based recommendation-tested 2025 Row 2: Recommendation level-to-use should be consistently avoided and/or terminated.- Row 3: A-to-row Row 4: -- Row 5: Level of Evidence--- Row 6: -Konsens-Row 7: ---",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease>",
      "text": "Row 1: 4.2-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "Table under heading <to reduce the negative effects of an already occurring disease> (column 1)",
      "text": "Row 1: 4.1 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: Row 6:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "Table under heading <to reduce the negative effects of an already occurring disease> (column 1)",
      "text": "Row 1: 4.2 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: Row 6:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "Table under heading <to reduce the negative effects of an already occurring disease> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-tobacco smoke is to be consistently avoided or terminated.- Row 3: -- Row 4: -- Row 5: nce--- Row 6: -Konsens- Row 7: ---",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "Table under heading <to reduce the negative effects of an already occurring disease> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: degree-testedPassive smoke exposure should be avoided in every way.- Row 3: level-based Row 4: level-based Row 5: level-based Row 6: level-based Row 7: level-based Row 7: level-based",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page)",
      "text": "Row 1: 4.3-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In patients with lung cancer tobacco consumption is to be regularly asked and Row 3: A-documented.- Row 4: -- Row 5: Level of Evidence--- Row 6: -Konsens-- Row 7: ---",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page)",
      "text": "Row 1: 4.4-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-level of lung cancer patients who still smoke are to be motivated to stop Row 3: Tobacco use. They are to be offered a qualified smoking cessation-level of Row 4:-level of Evidence-level of Row 6:",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 1)",
      "text": "Row 1: 4.3 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: Row 6:",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 1)",
      "text": "Row 1: 4.4 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: Row 6:",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn patients with lung cancer, tobacco consumption is to be regularly questioned and Row 3: documented.- Row 4: level-down Row 5: level-down Row 6: level-down Row 7: level-down Row 7: level-down",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients with lung carcinoma who are still smoking are to be motivated to stop smoking Row 3: graded tobacco consumption. They are to be offered a qualified tobacco cessation-- Row 4: graded Row 5: nce",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page)",
      "text": "Row 1: 4.5--Consensus-based statement--modifies 2025 Row 2: EC-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 1)",
      "text": "Row 1: 4.5 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 3)",
      "text": "Row 1: Consensus-based statement-modified 2025 Row 2:--The compliance with statutory health and safety regulations guarantees with a Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page)",
      "text": "Row 1: 4.6-Evidence-based recommendation-2010 Row 2: Degree of recommendation-To reduce the risk of lung cancer by radon, exposure in-row 3: apartments must be consistently reduced by constructional measures. Row 4: Indication position for the medical application of ionizing radiation- Row 5: Applies to critically weigh the benefit of radiation application against the risk of-row 6: --- Row 7: --Ray exposure.- Row 8: Level of Evidence--- Row 9: --Consensens- Row 10: -----",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page)",
      "text": "Row 1: 4.7的Evidence-based Statement-2010 Row 2: Level of Evidence-The lung cancer risk from air pollutants can most effectively be reduced by reduk-",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 1)",
      "text": "Row 1: 4.6 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 1)",
      "text": "Row 1: 4.7 Row 2: Level of Eviden Row 3: 2a Row 4: Row 5: Row 6:",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-2010 Row 2: grade-To reduce the risk of lung cancer by radon, exposure in-row 3: graded apartments must be reduced by construction measures. Row 4: indication position for the medical application of ionizing radiation- Row 5: applies it to critically weigh the benefit of radiation application against the risk of-row 6:",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 2)",
      "text": "Row 1: evidence-based statement-2010 Row 2: nce:The lung cancer risk from air pollutants can most effectively be reduced by reduk-e: Row 3: emission of diesel soot.- Row 4: -- Row 5: -- Row 6: --Konsens: Row 7: ---",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page)",
      "text": "Row 1: 4.8-Evidence-based recommendation--2010 Row 2: Recommendation level--Nutrition rich in fruits, fresh vegetables and tomatoes--Row 3: 0--reduced the risk of lung cancer and is therefore recommended.-- Row 4: -2010: Recommendation level C (weak recommendation)-- Row 5: --- Row 6: Level of Evidence--- Row 7: --Konsens-- Row 8: ---",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 1)",
      "text": "Row 1: 4.8 Row 2: Recommend Row 3: 0 Row 4: Row 5: Level of Row 6: Row 7:",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7:",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "table under heading <to reduce the negative effects of an already occurring disease> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--food rich in fruits, fresh vegetables and tomatoes,----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "In addition, β-carotene administration was so->",
      "text": "Row 1: 4.9-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-A drug-related primary or secondary prevention can so far not be recommended outside Row 3: A-by-study.- Row 4: -- Row 5: Level of Evidence--[123], [124], [125], [126], [127], [128], [129], [130], [131], [132]-- Row 6: 1b---- Row 7: ---- Row 8: ---Konsens-- Row 9: -----",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "In addition, β-carotene administration was so-> (column 1) in two studies.",
      "text": "Row 1: 4.9 Row 2: Recommend Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "In addition, β-carotene administration was so-> (column 2) in two studies.",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "In addition, β-carotene administration was so-> (column 3) in two studies.",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedA drug-related primary or secondary prevention can not be recommended outside Row 3: level of studies so far.- Row 4: level-based Row 5: level-based [123], [124], [125], [126], [127], [128], [129], [130], [131], [132]-level-based Row 6: level-based Row 7: level-based Row 8: level-based Row 9: level-based",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 5.1的evidence-based recommendation-tested 2025 Row 2: recommendation-level-level-of-recommendation-level-of-recommendation-level-of-recommendation-level-of-recommendation-level-of-recommendation-of-recommendation-of-recommendation-of-asymptomatic subjects for lung carcinoma.- Row 5: level of evidence-grade-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-relevance-of-reduction-relev-of-reduction-relevance-of-reduction-relev-of-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-reduction-",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 5.1 Row 2: Recommend Row 3: A Row 4: Level of Row 5: 1a Row 6: Row 7:",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn case of asymptomatic risk persons for a lung cancer, an early-checked Row 3: identification using chest overview images alone or in combination with cyto-checked Row 4:",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73>",
      "text": "Row 1: Legal requirements in the Lung Cancer Early Detection Ordinance-Paragraph in the Row 2: (LuKrFrühErkV)-LuKrFrühErkV Row 3: Admissibility of lung cancer early detection investigations based on § 2 Row 4: of age, tobacco smoke exposure, duration of nicotincarenz and the medizini--- Row 5: Row 6: Aptitude profiles as well as the need for a report on the aptitude test--- Row 7: Fung and information of participants-- Row 8: Examination of the admissibility requirement and position of justifying § 3 Row 9: Indication by radiologists on the basis of the report on the aptitude test--- Row 10: Row 11: According to § 2-- Row 12: Requirements for CT scanners, diagnostic workstation, execution of sub-----§ 4 Row 13: Suche and software for computer-assisted detection- Row 14: Row 15: Determination of the examination with first and second findings Principle, respectively 16----- ter Test Areas: Row 13: Dection",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.2-Evidence-based statement--modified 2025 Row 2: Level of Evidence--Asymptomatic risk persons for lung cancer, defined by:-- Row 3: 1-- Row 4:--• an age between 50 and a maximum of 75 years-- Row 5:---• a smoking history of ≥ 15 cigarettes/day for a minimum of 25-- Row 6:-- Row 7:---years or ≥ 10 cigarettes per day for a minimum of 30 years--- and-- Row 8:------- missing or less than 10 years------ Row 9:------ generally profit from a structured lung cancer early----- Row 10:-----nung program using annual low-dose CT studies.--- Row 11:-----*In the legally binding admissibility requirements of lung cancer early-------Row 12:---Row was used in NELSON and LUSI the criteria of tobacco smoke exposure to at least 13-----------------------------------------------------------------",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.3-\"Consensus-based recommendation\"new 2025 Row 2: EC-\"Benefits and risks of lung cancer screening depend primarily on the two-\" Row 3:\"factors of lung cancer risk and residual life expectancy. This is the case, he-\" Row 4:\" appear the current in the lung cancer early detection regulation to be-\" Row 5:\" Row 6:\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.2 Row 2: Level of Row 3: 1 Row 4: Row 5: Row 6: Row 7:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.3 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: f Eviden Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: Evidence-based statement-modified 2025 Row 2: ncetereAsymptomatic risk persons for lung cancer, defined by:-- Row 3: -- Row 4:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation: New 2025 Row 2: Benefits and risks of lung cancer screening depend primarily on the two Row 3: Factors of lung cancer risk and remaining life expectancy. This includes Row 4: The current provisions in the Lung Cancer Early Detection Regulation appear to be Row 5: --- Row 6: called inclusion criteria, although feasible but not optimal. Therefore, Row 7: Validity of inclusion criteria in the Lung Cancer Early Detection Ordnance--- Row 8: Nung on the basis of new evidence (including risk models, subgroup analyses) should be tested in Row 9: At least three years and adjusted with sufficient evidence----- Row 10: ------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: 5 Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: rd- Row 10: en- Row 11: - Row 12: Row 13: ig- Row 14: Row 15: Row 16:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: Row 2: en Row 3: er- Row 4: Row 5: Row 6: Row 7: Row 8: - Row 9: Row 10:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.4-Consensus-based recommendation: New 2025 Row 2: EC-EIn accordance with § 2 and § 6 para. 3 of the Lung Cancer Early Detection Regulation: Row 3:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.5-Consensus-based recommendation-neu 2025 Row 2: EK-the main objective of the assessment of the medical fitness profile according to § 2-row 3: -Abs. 1 sentence 3 of the Lung Cancer Early Detection Regulation by qualified-row 4: -doctors from the fields of General Medicine, Internal Medicine and Occupational Medicine is- Row 5: -- Row 6: -the inclusion of participants in a low-dose CT lung cancer early-erkens--- Row 7: -nung measure that is suitable for curatively intended lung cancer treatment--- Row 8: --net.- Row 9: --At the same time, inappropriate persons should not be excluded from participation---- Row 10:--- who are qualified for low remaining life----- Row 11: - maintenance and therefore a high individual risk for overdiagnosis and - Row 12: - overtherapy is not a positive benefit-risk ratio 14.",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.4 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.5 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation: New 2025 Row 2 : Further studies in lung cancer 13: New 14: New 2025 Row 2 : New 2025 Row 2 : New 2025 Row 2 : New 2025 Row 2 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 11 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 12 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025 Row 9 : New 2025",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation: New 2025 Row 2 : The main objective of recording the medical fitness profile according to § 2 : Row 3 : Abs. 1 sentence 3 of the Lung Cancer Early Detection Regulation by qualified : Row 4 : Doctors from the fields of General Medicine, Internal Medicine and Occupational Medicine is : Row 5:  : Row 6: The inclusion of participants in a low-dose CT lung cancer early-erkens - Row 7 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.6-Consensus-based recommendation: New 2025 Row 2: EC-CQualified physicians from the fields of general medicine, internal medicine and Ar--- Row 3: -Beitsmedizin should carry out early detection measures up to the age of 70-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.7-Evidence-based recommendation: New 2025 Row 2: Recommended level of smoking Patients who undergo screening on lung cancer Row 3: A-Zinoma should be offered a tobacco cessation with psychosocial and medicka Row 4: mentous support. In the medical, nursing Row 5: and psychosocial health care should be offered short advice for smokers Row 6: --- Row 7: -- and smokers to achieve the smoke stop.- Row 8: --A short advice on smoke stop doubling according to international studies Row 9: ---Effectiveness of the screening program and is cost effective.--- Row 10: Level of Evidence [145], [146], [148], [148] Row 11: 1-------row 12: ----1 (Oxford 2011): Adaptation Row 10: Level of Evidence [145], [147], [148] Row 11: 1------row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-row-",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.6 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.7 Row 2: Recommend Row 3: A Row 4: Row 5: Level of Row 6: 1 Row 7: Row 8: Row 9:",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8: Row 9:",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-new 2025 Row 2: --Qualified physicians from the fields of general medicine, internal medicine and Ar--- Row 3: --Beitsmedizin should carry out early detection measures up to 70----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: New evidence-based recommendation 2025 Row 2: new smoking, diagnosis and treatment: Row 1: New evidence-based recommendation 2025 Row 2: new smoking patients who undergo a screening on lung cancer Row 3: new smoking treatment should be offered with psychosocial and medicka Row 4: mental support. In the medical, nursing Row 5: and psychosocial health care, short advice for smokers is to be offered Row 6: --- Row 7: -- and smokers to achieve the smoke stop. Row 8: ---A short consultation on smoking stop doubles according to international studies the Row 9: -----Effectiveness of the screening program and is cost-effective. Row 10: nce----[145], [146], [148], [148] Row 11: ------ Row 12: ------1 (Oxford 2011): Adaptation S3-Leitline Smoking and Tobacco Dependent: Sce------ Row 13: -----Rowing, Diagnosis 14----",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: d- Row 4: Row 5: Row 6: Row 7: o- Row 8: Row 9: re- Row 10: Row 11: ra- Row 12: Row 13:",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: Row 2: r- Row 3: - Row 4: n Row 5: Row 6: Row 7: e Row 8: Row 9: Row 10: e Row 11: Row 12:",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.8-Consensus-based recommendation: new 2025 Row 2: EC-EIn accordance with § 1, § 5 and § 6 of the Lung Cancer Early Detection Ordinance, the Row 3:",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "RAW 1 and RAW 1 • RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1 • RAW 1 and RAW 1",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.8 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.9 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.10, \"Consensus-based recommendation\", \"New 2025 Row 2: EK\"A radiology specialist who works at an institution specializing in the treatment and treatment of lung cancer, and as a qualified Row 4: \"Second finder\" according to § 5 para. 2 and § 6 para. 1 and 2 of the lung cancer-earlier Row 5: \"\" Row 6: \"Denomination-Regulation CT-investigations\", should also carry out first-\" Row 7: \"Premium-recognition-measure\" by means of Row 8: \"Low-dose-CT.\"",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.11, \"Consensus-based recommendation\"2025 Row 2: EK, \"The further diagnosis and therapy of findings requiring clarification in the Row 3: \"The framework of a low-dose CT lung cancer early detection measure is to be carried out in a timely manner in Row 4: \"A one specializing in the investigation and treatment of lung cancer\" Row 5: \"\" Row 6: \" Direction\" (according to the requirement criteria in Table 15).\" Row 7: \"The cooperation between first and second investigators and the transition to the Row 8: \"Clinical care at an institution specializing in the examination and treatment of lung-\" Row 9: \"Cancer\" should be settled in a cooperation agreement.\" Row 11: \"\"Starker Konsentenz\" Row 12: \"\"",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: 5.12:Consensus-based recommendation: New 2025 Row 2: EK:In analogy to the infectious pulmonary round herds (Chapter 6.4), Row 3: should use screening-detected pulmonary round herds (according to Sections 4 to 1 of the Lung Cancer Early Detection Ordinance) for further imaging--- Row 5: --- Row 6: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.10 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.11 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.12 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation: New 2025 Row 2 : A specialist in radiology who works at an institution specializing in the treatment and treatment of lung cancer, and as a qualified Row 4 : Second finder according to § 5 para. 2 and § 6 para. 1 and 2 of the lung cancer-early Row 5 : Red 6: ID-regulation CT-investigations, should at the same time also carry out first- and second finders according to § 5 para. 1 and § 6 para. 1 and 2 of the lung cancer-early Row 5 : Red 8: Low-dose CT.",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation: 2025 Row 2 : The further diagnosis and therapy of findings requiring clarification in the Row 3 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: 的Consensus-based recommendation--new 2025 Row 2: 的In analogy to the infectious pulmonary round herds (Chapter 6.4), Row 3: should use screening-detected pulmonary round herds (according to section--- Row 4: 的1 of the Lung Cancer Early Detection Ordinance) for further imaging--- Row 5: --- Row 6: Bending diagnostics (e.g., FDG-PET/CT-investigation) and the method--- Row 7: to be chosen for pathological diagnosis (bronchoscopy with transbronchialer---- Row 8: ----Biopsy, CT-controlled transthoracal biopsy or minimally invasive surgical----- Row 9:---Resection) in a thorax-oncological tumor board of one of the Untersu--------- Row 10:",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "The number of people to be taken into account in the evaluation of the results and results should be the consent of the participants to be given Row 7: • a central storage of the data collected in the context of lung cancer screening. • Row 8: and subsequent treatments. • Row 9: • Matching with population registration offices and cancer registers. • Row 10: • For research purposes to optimize lung cancer screeningpro-",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: 5.13 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Number of people: Row 1: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row 1: Row: Row: Row: Row: Row: Row: Row:R: Row: Row: Row: Row: Row: Row: Row: R: Row: R: R:R:R:",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: o- Row 10: Row 11: Row 12: Row 13: Row 14: er- Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: i Row 27: Row 28: Row 29: Row 30: Row 31: Row 32: Row 33: Row 34: Row 35: - Row 36: Row 37: Row 38: Row 39: Row 40: Row 41: Row 42: Row 43: Row 44: Row 45:",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "In order to get to 13: LDCT to 13: LDCT: 1.246.RR 13: LDCT to 1.01 [95%-KI 0.70-Row 10: time to go] Row 8: time to go] Row 9: RK Ratio, mediane Row 5: RK Ratio, mediane Row 5: RK Ratio, mediane Row 5: RKT-Design to to go] Follow-up time to Row 6: RKT-Design to go] Follow-up time to Row 6: Row 6: RK Ratio, mediane Row 5: RKT-Row 9: DANTE [1665] [165] To go to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 2 : Row 1 : Row 1 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 : Row 2 - Row 2 : Row 2 : Row 2 : Row 2",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Row 1: Row 1: Row 2: Row 2: Row 3: Row 4: Row 4: Row: Row 5: Row 6: Row 6: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 1: Row 1: Row 2: Row 2: Row: Row 3: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row 1: Row: Row: Row: Row: Row: Row: Row: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Three: Row: Row: Row: Row: Three: Row: Row: Row: Row: Row: Row: Row: Row: Row: Three: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: fi- Row 2: Row 3: e Row 4: Row 5: Row 6: 0- Row 7: Row 8: Row 9: Row 10: un- Row 11: he Row 12: Row 13: Row 14: 6- Row 15: Row 16: Row 17: Row 18: 8- Row 19: Row 20: Row 21: Row 22: p Row 23: Row 24: 5- Row 25: Row 26: Row 27:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "In addition, it takes a year to: 95%-ki4 0.73 [95%-ki 0.44c7-Row 11: centric.int 12: int.int.int 13: MILD [175], [176], [176], [176], [176], [276], [276], [276], [276], [276], [276], [276], [276], [276], [276], [276], [276], [276], [276], [276], [295%-ki 0.47-R 0.73 [295%-ki 0.44ccc7-Row all 14: 14: intint.int_11int_11_14] Row 15: Italien 15: ItiIII 15: ItI 15: ItI 15: Years, [275] 49 years annually annually: annual: to 0.73 [95%-R 0.73 [214141414141414 14 14 14 14 14 14 14: 14: 14 14: 14 14: 14 14: 1414 14: int int int int int 14 14 14 14 14 14 14 14 14 14 14 int #1 #1 #1 #1",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: RCT acronym Row 2: Country Row 3: RCT design Row 4: Row 5: LDCT vs. no Row 6: Screening, mono Row 7: centric Row 8: MILD [175], [176 Row 9: Italy Row 10: LDCT annually vs Row 11: LDCT every 2 year Row 12: vs. no Screenin Row 13: centric Row 14: NELSON [159], Row 15: [160][161], Row 16: [162][178], Row 17: Netherlands Row 18: Belgium Row 19: LDCT vs. no Row 20: Screening, multi Row 21: centric Row 22: NLST [158], Row 23: USA Row 24: LDCT vs. Röntge Row 25: Thorax, multizen Row 26: Ric Row 27: UKLS [179] Row 28: Row 22: Row: Row 23: Row 24: LDCT vs. Röntge Row 31: Row.",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "In addition, there are 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 24: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 24: 25: 25: 25: 25: 24: 25: 24: 25: 25: 24: 25: 25: 24: 25: 24: 25: 25: 24: 25: 24: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 24: 30: 30: 30: 40: 40: 40: 40: 40: 40: 40: 40: 50: 50: 50: 50: 50: 75: 25: 50: 25: 50: 25: 50: 50: 50: 50: 75: 75: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 25: 24: 24: 24: 24: 24: 24: 24: 25",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: number of T Row 2: hmer in de Row 3: low level Row 4: Row 5: Row 6: CT annually Row 7: 190 Row 8: CT all 2 Yes Row 9: 186 Row 10: in Screenin Row 11: 723 Row 12: Row 13: CT: 7.900 Row 14: in Screenin Row 15: 892 Row 16: Row 17: CT: 26.723 Row 18: ntgen Thor Row 19: .733 Row 20: Row 21: CT: 2.028 Row 22: in Screenin Row 23: 027 Row 24:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "Row 1: Part- Row 2: en Row 3: en Row 4: Row 5: Row 6: h: Row 7: Row 8: ahre: Row 9: Row 10: ng: Row 11: Row 12: Row 13: Row 14: ng: Row 15: Row 16: Row 17: 3 Row 18: rax: Row 19: Row 20: Row 21: Row 22: ng: Row 23: Row 24:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 5)",
      "text": "Row 1: Lung cancer-specific Row 2: Lung mortality Row 3: Lung mortality Row 3: Lung mortality Row 1: Lung mortality Row 1: Lung mortality Row 1: Lung mortality Row 2: Lung mortality Row 2: Lung mortality Row 1: Lung mortality Row 1: Lung mortality Row 5: Lung mortality Row 7: Lang mortality Row 8: RR 0.73 [95% CI 0.47 Row 9: Lung mortality Row 5: Lung mortality Row 5: Lang mortality Row 5: Lang mortality Row 7: Lang mortality Row 8: Lang mortality RR 0.73 [95% CI 0.47 Row 9: Lung death Row 10: Lung death Row 11: Lang death Row 12: Lung mortality Row 12: Lang mortality Row 13: Lung mortality Row 14: Lung mortality Row 15: Lung mortality Row 16: Lung mortality RR 0.75 [95% CI 0.70 Row 23: Low death Row 18: Low death Row 19: Low death Row death Row 20: Low death Row 21: Low 22: Low 22: Low death Row 22: Low death Row death Row death Row death Row death Row death Row death Row death Row death Row death R",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 6)",
      "text": "Row 1: fi- Row 2: Row 3: e Row 4: Row 5: Row 6: Row 7: 7- Row 8: Row 9: Row 10: Row 11: 2- Row 12: Row 13: Row 14: Row 15: 0- Row 16: Row 17: Row 18: Row 19: 1- Row 20: Row 21: Row 22:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "Row 1: RCT-Acronym-Risk Criteria-Risk Ratio, mediane Row 5: RCT-Design-Roow: Follow-up-Time after Row 6: the-row Row 7: the-rundomization) Row 8: the-row 9: the-own-anamnesis, former-row 10: the-cancer disease with the-row 11: the-age in the family-the-row 12: the-nese of relatives-the-row 13: the-row1. Grades, asbestosexpo-the-row 14: the-sition)-the-row",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: RCT-A Row 2: Country Row 3: RCT-D Row 4: Row 5:",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: Akron Row 2: Row 3: Desig Row 4: Row 5:",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: nym:Risk Ratio, mediane Row 5: gn:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page)",
      "text": "22 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 25 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 25 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 -",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 1)",
      "text": "Row 1: Vulnerabilities/Fehl Row 2: nes unstructured Row 3: process Row 4: insufficient Identi Row 5: risk persons Row 6: Row 7: missing/insufficient Row 8: inclusion of risk Row 9: Row 10: non-standardised Row 11: detection and evaluation Row 12: Row 13: insufficiently coordinated Row 14: continuation of the Screw Row 15:",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 2)",
      "text": "Row 1: lerspringen im R Row 2: n Pulmonary cancer Row 3: Row 4: ification and a Row 5: Row 6: Row 7: nd Aptitude limit Row 8: Opersonen Row 9: Row 10: , Technically unzure Row 11: rtung der Niedr Row 12: Row 13: niede and stand Row 14: enings Row 15:",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 3)",
      "text": "Row 1: Rahm Row 2: sscree Row 3: Row 4: nladun Row 5: Row 6: Row 7: Refug Row 8: Row 9: Row 10: Eiche Row 11: rigdos Row 12: Row 13: dardis Row 14: Row 15:",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading <5.1 Imaging methods 73> (from previous page, column 4)",
      "text": "22 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 25 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 8 - 24 - 8 - 24 - 24 - 24 - 8 - 8 - 24 - 24 - 24 - 9 - 9 - 9 - 9 - 9 - 9 - 19 - 19 - 19 - 19 - 19 - 19 - 19 - 24 - 24 - 24 - 24 - 24 -",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading <5.1 Imaging methods 93>",
      "text": "22- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24- 24-",
      "start_page": 93,
      "end_page": 93
    },
    {
      "heading": "table under heading <5.1 Imaging methods 95>",
      "text": "24-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row",
      "start_page": 95,
      "end_page": 95
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96>",
      "text": "Row 1: Recommended requirement criteria for a lung cancer centre Row 2: Meeting minimum levels at Centre Row 3: ▪ Initial diagnosis of at least 200 primary cases per year with the ICD-10 diagnosis C34 Row 4: ▪ At least 75 anatomical resections per year (OPS 5-323 to 5-328) for ICD-10 diagnoses Row 5: C34 or C78.0 Row 6: Expertise at Centre (Z) level and at Specialist (FA) level: Row 7: ▪ ≥ 500 bronchoscopy per year (Z) Row 8: ▪ ≥ 10 interventional bronchoscopic interventions in closure or stenoses (independent of Row 9: indication) per year (Z) Row 10: ▪ ≥ 200 (Z) and ≥ 100 (FA) histopathological assessments of malignant lung tumours per Row 11: Year Row 12: ▪ ≥ 100 anatomical lung resections for the qualification of Thoraxypheral Diseases in 12: ▪",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: Recommended requirement criteria for a lung cancer centre Row 2: ▪ ≥ 150 drug tumour therapies in lung cancer patients (alternatively: ≥ 50 primary cases Row 3: or ≥ 200 entity independent per year (Z) Row 4: ▪ Offering clinical studies with ethics vote with a study inclusion rate of ≥ 5% of the Row 5: primary case number per year (Z) Row 6: ▪ ≥ 100 pain therapies, of which ≥ 50 in lung cancer per year at the Centre (Z) Row 7: structural requirements at the centre level: Row 8: ▪ at least 1 times weekly interdisciplinary case conference: Row 9: – for the assessment of LDCT screening findings requiring clarification Radiologist participation, Row 10: Pneumologist and thoracic surgeon required Row 11: ▪ Interdisciplinary team: Row 12: – Department of Pneumology (or area with focus) with at least 2 pneumatic Row 13: Specialists Pneumology in full-time, at least 2 full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-, full-, full- and-, full-time, full- and-, full-, full-time, full-, full-, full-, full-, full- and-, full-, full-,",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Recommended requirement criteria for a lung cancer centre Row 2: ▪ ≥ 150 drug-related tumour therapies in lung cancer patients (alternatively: ≥ 50 Prim Row 3: or ≥ 200 Entity independent per year (Z) Row 4: ▪ Offering clinical studies with ethics vote with a study inclusion rate of ≥ 5% Row 5: Primary case number per year (Z) Row 6: ▪ ≥ 100 Pain therapies, of which ≥ 50 in lung cancer per year at the centre (Z) Row 7: Structural requirements at the centre level: Row 8: ▪ At least 1-time weekly interdisciplinary case conference: Row 9: – to assess LDCT screening findings requiring clarification Radio Row 10: Pneumologist and thoracic surgeon required Row 11: ▪ Interdisciplinary team: Row 12: – Department of Pneumology (or area with focus) with at least 2 pneumologist Row 13: Specialists Pneumology in full-time, at least 14 full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-time, full-time, full- and full-time, full-time, full-time, full-, full-time, full-, full-, full-, full-, full-, full-, full-, full-, full-, full-, full-, full-,",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: rurgi- Row 15: Row 16: Eration Row 17: Row 18: Row 19: Row 20: Row 21: and Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31:",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: , Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31:",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: Step--Process Row 2: 1.--Identification and Invitation Process Row 3: 2.--Consulting and Enlightenment Discussion, Aptitude Examination and inclusion in the Early Row 4:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Schrit Row 2: 1. Row 3: 2. Row 4: Row 5: 3. Row 6: 4. Row 7: 5. Row 8: 6. Row 9: 7. Row 10: Row 11: 8.",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Tt-Process Row 2: Identification and Invitation Process Row 3: 的Consultancy and Enlightenment Discussion, Aptitude Examination and Integration into the Early Row 4: Identification Program as well as Information on Benefits and Risks of the LDCT Early-Earth Row 5: 的 Row 6: Immediate Investigation, Consulting and Motivation of Active Smokers to the Tobacco Detector Row 7: Immediate Position Row 8: Immediate Indication Row 9: Immediate Implementation of the LDCT Early-Edication Investigation Row 10: Immediate Assessment of the LDCT and Assessment of Findings by the Qualified Radiologist Row 11: Immediate continuation, leaving and ending of the Early-Edication Process Row 12: Immediate Management of Detection Findings in Centers Specialized for Lung Cancer Row 13: Immediate Row 14: Immediate Row 15: Immediate Entry into the Early-Edication Process",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "In addition, it can not be evaluated by a part or the whole of the lung. . .Renewed LDCT imaging required. . .Row 6: Prevalence: ~ 1%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Lung--Category Row 2: RADS--Description Row 3: 0--Incomplete Row 4: --Estimated Row 5: --Prevalence: ~ 1% Row 6: -- Row 7: 1--Negative Row 8: --Estimated Row 9: --Prevalence: 39 % Row 10: -- Row 11: 2--Gutartig Row 12: --Based on imaged Row 13: --Featured or good Row 14: ---Behavior; Estimated P Row 15: ----Valence: 45 % Row 16: -----",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "RID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: DID: D",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: T Row 4: erlich Row 5: Row 6: ndli- Row 7: Row 8: Row 9:",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row-Dow-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-R",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Lung--Kategor Row 2: RADS--Schreiber Row 3: - Row 4: - Row 5: - Row 6: - Row 7: - Row 8: 3-Truch",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: domestic",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: benign",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 4)",
      "text": "Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Rd: Row: R",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 5)",
      "text": "Row 1: found M Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: month fo",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 6)",
      "text": "Row 1: Managem Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: ollow-up",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 7)",
      "text": "Row 1: ment Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: p LDCT",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: Lung--Category:Found management Row 2: RADS-----————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Lung---Kategor Row 2: RADS--Schreiber Row 3: -Basieren Row 4: -Merma Row 5: -Shape Row 6: - Row 7: - Row 8: - Row 9: - Row 10: - Row 11: 4A--Verdächt Row 12: -Shape Row 13: --",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 3: Row 4: Row 4: Row 4: Row 5: Row: Row: Row 7: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row 2: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 1: Row 1: Row 2: Row 3: Row 4: Row: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: Round: R",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 4)",
      "text": "Row 1: Row: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 20: Row 20: Row 21: Row 22: Row 21: Row 22: Row 23: Row 23: Row 23: Row 23: Row 24: Row 24: Row 25: Row 25: Row 25: Row 25: Row 25: Row 24: Row 5: Row 7: Row 8: Row 9: Row 10: Row 11: Row 11: Row 12: Row 13: Row 13: Row 13: Row 14: Row 14: Row 15: Row 15: Row 16: Row 16: Row 17: Row 17: Row 17: Row 18: Row 18: Row 19: Row 19: Row 13: Row 19: Row 20: Row 20: Row 20: Row 3 month: Row 20: Row 25: Row 25: Row 25",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: ll Auswer- Row 11: s in the Row 12: Row 13:",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "The following are the following examples of the following: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw: Rw:",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Lung--Kategor Row 2: RADS--Schreiber Row 3: - Row 4: - Row 5: - Row 6: - Row 7: 4B--Very good Row 8: --Shadow Row 9: --",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Präv Row 9:",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: g Row 8: value:2 Row 9:",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 5)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "{To be completed, please check the box below.}}} {To be completed, please check the box below.}} {To be completed, please check the box below.}} {To be completed, please check the box below.} {To be completed, please check the box below.} {To be completed, please check the box below.}} {To be completed, please check the box below.} {To be completed, please check the box below.} {To be completed, please check the box.}} {To be completed, please check the box.} {To be completed, please check the box.}} {To be completed, please check the box.} {To be completed, please check the box.}} {To be completed, please check the box.} {To be completed, please check the box.} {To be completed, please check the box.} {To be completed, please check the box.} {To be completed, please check the box.}",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "In the following cases, the following additional information is provided in the form of an e-mail address: http://europa.eu.int/comm/dgl/index_en.htm",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: RHmm3 (≥ 8 mm) is present; Wedge Row 4: RHAbsorption (biopsy or resection) Row 5: RH Row 6: RH Row 7: RH Row 8: RH Row 9: RH Row 10: RH Row 11: RH Row 12: RH Row 13: RH Row 14: RH Row 15: RH Row 16: RH Row 17: RH Row 18: RH Row 19: RHAccording to findings Row 20: RH Row 21: RH Row 22: RH Row 23: RH",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: 5.14-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn case of asymptomatic risk persons for a lung carcinoma, a screening-based Row 3: is to be performed by means of:- Row 4:-• Sputum cytology and/or Row 5:--• Bronchoscopy and/or Row 6:--• Biomarkers (e.g., classic tumor markers, liquid biopsies, ex-breath gas-ex----row 7:-halate analyses)-- Row 8:---not done.- Row 9:---Strong Consensus-Row 10:-----",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: 5.14 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : In case of asymptomatic risk persons for a lung carcinoma, a screening-based Row 3 : means:-- Row 4 :--• Sputum cytology and/- Row 5:--• Bronchoscopy and/or-- Row 6:--• Biomarkers (e.g. classic tumor markers, liquid biopsies, gas ex---- Row 7 :---halate analyses)-- Row 8 :---not done.- Row 9:---Starker Consensus- Row 10:------",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: Symptom or clinical sign--frequency Row 2: cough--8-75% Row 3: weight loss--0-68% Row 4: air pressure---60% Row 5: brood pain--20-49% Row 6: hemoptyse--6-35% Row 7: bone pain--6-25% Row 8: clubbing---0-20% Row 9: fever---0-20% Row 10: weakness---0-10% Row 11: source: [271]--",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: Symptt Row 2: Cough Row 3: Dig Row 4: Luftno Row 5: Brutsc Row 6: Hemop Row 7: Knoch Row 8: Finger Row 9: Fever Row 10: Schwä Row 11: Source:",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: tom and/or clinical sign--frequency Row 2: n:8-75% Row 3: bad luck---0-68% Row 4: ot:3-60% Row 5: chmerzen--20-49% Row 6: ptyse---6-35% Row 7: hen pain--6-25% Row 8: rendpartial changes (clubbing)---0-20% Row 9: r:0-20% Row 10: avenger---0-10% Row 11: [271]--",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: 6.1--Consensus-based recommendation--tested 2025 Row 2: EC---In patients with suspected or detected lung cancer, a Row 3:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page)",
      "text": "Row 1: 6.2-Consensus-based recommendation--tested 2025 Row 2: EK--A patient with lung cancer and paraneoplastic syndrome should not be excluded from a potentially curative approach to therapy-- Row 4:---to be excluded from the symptoms---Row 3:-----Row 5:----Roow 6:--Starker Consensus--Roow 7:-----",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: 6.1 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 1)",
      "text": "Row 1: 6.2 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : In patients with suspected or detected lung cancer, a Row 3 : Careful clinical evaluation including anamnesis/work history and body fluid-based Row 4 : Investigation should be carried out.- Row 5 : --- Row 6: -Starker Konsensenz- Row 7: ---",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "table under heading <5.1 Imaging methods 96> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--A patient with lung carcinoma and paraneoplastic syndrome is to be closed on--- Row 3:-- because of symptoms not from a potentially curative approach to therapy-- Row 4:----Row 5:--- Row 6:--Starker Consensus-- Row 7:----",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory tests 114>",
      "text": "Read more Previous Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next Next",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory tests 114> (from previous page)",
      "text": "In addition, the following are: • Thrombocomastia • Thrombocomastia • Thrombocytosis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytitis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytitis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytosis, -penie Row 9: • Hypoglycocytosis, - penie Row 9: • Hypoglycocytitis, - Microangiopathic haemolytic hamolyttic Row 9: • Hyperthyroidoidism, - Subacute sensoro 15: • Subacute sensoro 15: • Subacute sensororeireireireireirei 24 11: • ERE14:  • Erebebebe 16:  to to to to to to tore: • Ro 13 13: • R 13 13 13 13: • To 13: • To 13 13 13 13 13 13 13 13 13 13 13 13 13 13:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 1)",
      "text": "Row 1: Row 2: Endocrine Syndrome Row 3: • Syndrome of inad Row 4: tion (SIADH) Row 5: • Cushing Syndrome Row 6: • Hypercalcaemia Row 7: • Hypercalcionine Row 8: • Gynecomastia Row 9: • Hypoglycaemia Row 10: • Hyperthyroidism Row 11: Row 12: Neurological symptoms Row 13: • Subacute sensor Row 14: • Mononeuritis mu Row 15: • Intestinal Pseud Row 16: • Lambert-Eaton-m Row 17: drom (LENS) Row 18: • Myasthenia gravi Row 19: • Enzephalomyeliti Row 20: • Necrotizing Row 21: • Tumor-associated Row 22: • Guillain-Barré Syndrome Row 23: • Limbische Enzep Row 24: • Opsoclonus-Myo Row 25: • Subacute Skeletonary Row 21:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: däqua Row 4: Row 5: m Row 6: Row 7:emia Row 8: Row 9: Row 10: mus Row 11: Row 12: e Row 13: ric Row 14: ultiple Row 15: doobs Row 16: myasth Row 17: Row 18: is Row 19: is Row 20: Myelo Row 21: e Reti Row 22: ndrom Row 23: phalop Row 24: oclonu Row 25: pathie Row 26: Row 27: teoart Row 28: r-Synd Row 29: elevening Row 30: Row 31: Row 32: Row 33: Row 34:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: aten A Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: e Neur Row 14: ex Row 15: strutt Row 16: henisc Row 17: Row 18: Row 19: Row 20: opath Row 21: inopa Row 22: m Row 23: pathie Row 24: us Row 25: e Row 26: Row 27: thropa Row 28: drom) Row 29: he Row 30: Row 31: Row 32: Row 33: Row 34:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: ADH-Produ Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 15: nation Row 16: Che Syn- Row 17: Row 18: Row 19: Row 20: here Row 21: athe Row 22: Row 23: e Row 24: Row 25: Row 26: Row 27: Athe (Pierre Row 28: ) Row 29: Row 30: Row 31: Row 32: Row 33: Row 34:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 6)",
      "text": "Row 1: Row 2: Che Syndrome Row 3: Onenic Anemia Row 4: Ocytosis with Eosinop Row 5: Emoide Reaction Row 6: Immunohaemolytic Row 7:hrocytosis Row 8: mbocytosis, -penie Row 9: oangiopathic hem Row 10: mie Row 11: gulopathy Row 12: mbophlebitis Row 13: sche Symptoms Row 14: heme gyratum repens Row 15: hema multiforme Row 16: sis Row 17: hrodema Row 18: et Syndrome Row 19: nthos nigricans Row 20: olytic migrating Row 21: liative dermatitis Row 22: us and Urtikara Row 23: Row 24: ome Row 25: merulonephritis Row 26: hrotic syndrome Row 27: Row 28: vasculitatom Row: 32",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Philie Row 5: Row 6: e Anäm Row 7: Row 8: Row 9: molyti Row 10: Row 11: Row 12: Row 13: Row 14: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Er Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: ome Row 29: Row 30: Row 31: Row 32: hemat Row 33: Row 34:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: mie Row 7: Row 8: Row 9: sche Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Rythem Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31: Row 32: dead Row 33: Row 34:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "Table under heading <6.2 History, clinical examination, laboratory examination 114> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: m Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31: Row 32: s Row 33: Row 34:",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.3-evidence-based recommendation-tested 2025 Row 2: recommendation-level-the X-ray examination of the thoracic organs (radiation of posterior-anterior and-row 3: 0-side) can be used as initial radiological procedure.- Row 4: -- Row 5: Level of Evidence-[284], [285], [286]- Row 6: 2a--- Row 7: --- Row 8: --Starker Konsent-Row 9: ----",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.4: Consensus-based recommendation-tested 2025 Row 2: EC-testedIn patients suspected of lung cancer and foreseeable therapy-op-ed Row 3: action a CT examination of the thoracic organs is to be performed.- Row 4: Starker Konsent-ed Row 5:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.3 Row 2: Empfeh Row 3: 0 Row 4: Level of Row 5: 2a Row 6: Row 7:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.4 Row 2: EC Row 3: Row 4:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, X-ray examination of thoracic organs (radiation of posterior-anterior and Row 3: grade, side) can be used as initial radiological procedure., Row 4: grade, Row 5: nce,[284], [285], [286], Row 6: --- Row 7: --- Row 8: --Strong Consensus, Row 9: ----",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In patients suspected of lung carcinoma and foreseeable therapy-- Row 3:-- a CT examination of the thoracic organs should be performed.-- Row 4:--Stark Consensus-- Row 5:---",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6,5,0Evidence-based recommendation,025 Row 2:Recommendation level,0In the case of suspected or proven lung cancer and existing Thera-,0 Row 3: A,0pieoption, the following imaging studies are to be carried out with contrast agents, possibly in the context of a PET-CT,0 Row 7: ,0• MRI of the brain skull, in contraindications against MRI, CT,0 Row 8: ,0 of the brain skull with contrast agent,0 Row 9: Level of Evidence,0 Row 10: 2a,0 Row 11: ,0 Row 12: ,0Starker Konsentenz,0 Row 13: ,0,0",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.5 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--In case of suspected or detected lung cancer and existing Thera--- Row 3:--pieoption, the following imaging examinations are to be carried out:-- Row 5:--• Full diagnostic CT of thorax and abdomen (upper and be--- Row 6:---) with contrast agents, if necessary in the context of a PET-CT--- Row 7:-----MRI of the brain skull, in case of contraindication against MRI replacement CT--- Row 8:---the brain skull with contrast agent---- Row 9:--nce[302]---row 10:------- Row 11:----- Row 12:----Starker Consensus---- Row 13:------",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.6-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In case of suspected or proven non-small cell lung cancer and Row 3: An existing therapy option in clinical stage IB-IIIB and oligometasta-- Row 4: a full-body FDG-PET/CT should be performed for staging.- Row 5: If, for medical reasons (e.g. diabetic metabolic situation), an FDG--- Row 6: PET examination cannot be performed, an examination on Row 7: Extrathoracal metastases is performed either by means of whole-body MRT or bone scinti---- Row 8: 的graphie plus CT Abdomen or bone scintigrafie plus sonography Abdomen indi-",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.7/\"Consensus-based recommendation\"tested 2025 Row 2: EK\"In suspected or proven non-small cell lung cancer and\" Row 3:\"existing therapeutic option in clinical stage IA\", the full-body FDG-\" Row 4:\"PET/CT can be used for mediastinal and extrathoracic staging.\" Row 5:\"\" Row 6:\"Starker Konsent\" Row 7:\"\"\"",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.6 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.7 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -In case of suspected or proven non-small cell lung cancer and Row 3: existing therapy option in clinical stage IA, the full-body FDG--- Row 4: -PET/CT can be used for mediastinal and extrathoracic staging.- Row 5: -- Row 6: -Starker Konsent--- Row 7: ---",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a respectively. Both me->",
      "text": "Row 1: 6.8-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In case of detected small cell lung carcinoma an FDG-PET/CT should be used to determine the tumor stage including the detection of remote metastases-Row 4: unless an M1 stage (extensive disease-) was previously established-- Row 5:--secured-- Row 6: --- Row 7: Level of Evidence--[312], [313] Row 8: 2a---- Row 9: ---- Row 10: ---Starker Konsens- Row 11: ------",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a respectively. Both me->",
      "text": "Row 1: 6.9-Consensus-based recommendation-tested 2025 Row 2: EK-EIn case of small cell lung carcinoma in the M-1 stage (extensive-row 3: -disease-), an FDG-PET/CT can be used to determine the tumour spread--- Row 4: - including the detection of further remote metastases, also Row 5: --- Row 6: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a. Both me-> (column 1)",
      "text": "Row 1: 6.8 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a. Both me-> (column 1)",
      "text": "Row 1: 6.9 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a. Both me-> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a. Both me-> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a. Both me-> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn case of small cell lung carcinoma, an FDG-PET/CT should be used to determine the tumor stage including the detection of remote metastases-Row 4: if not previously an M1 stage (extensive disease-),- Row 5: level-secured.- Row 6: level-down Row 7: level-down[312], [313]- Row 8: level-down Row 9: level-down Row 10: level-down Row 11: level-down Row 11: level-down",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were evaluated with evidence level 1a and 2a. Both me-> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--In case of detectable small cell lung carcinoma in the M-1 stage (extensive-row 3:--disease--), an FDG-PET/CT can be used to determine the tumour spread--- Row 4:--including the detection of further remote metastases, also-- Row 5:--- Row 6:--if individual remote metastases have been previously secured.-- Row 7:--*CAVE: In this indication, the PET study is not the subject of the performance catalog of the--- Row 8: statutory health insurance (cost assumption not secured)--- Row 9:---Consensence-Row 10:---------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page)",
      "text": "Row 1: 6.10-Consensus-based recommendation--tested 2025 Row 2: EC--In a sulcus-superior tumor (pancoast tumor) and curative treatment-- Row 3:--the MRI should be used to assess the local tumour spread---row 4:---.- Row 5: --- Row 6: --Starker Consensus-- Row 7: ----",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page)",
      "text": "Row 1: 6.11-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn a proven well-differentiated neuroendocrine tumor of the Row 3: Lunge, a nuclear medicine so-called Row 4: receptor diagnosis can be performed in order to clarify treatment options.-Row 5:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 1)",
      "text": "Row 1: 6.10 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 1)",
      "text": "Row 1: 6.11 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In a sulcus-superior tumor (pancoast tumor) and curative treatment---row 3:--the MRI should be used to assess the local tumor spread---row 4:---.- Row 5: --- Row 6: --Strong consensus-- Row 7: ----",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --In a proven well differentiated neuroendocrine tumor of the Row 3: --Lunge, a nuclear medicine so--- Row 4: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page)",
      "text": "Row 1: 6.12-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn the case of a conspicuous clinical examination without correlate in the Row 3: routine staging imaging, this should be clarified with a suitable method-tested Row 4: further.",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page)",
      "text": "Row 1: 6.13-Consensus-based recommendation--tested 2025 Row 2: EK--In the case of a metastasis-suspicious finding in an imaging trial-- Row 3:-- this is to be histologically secured and the staging completes who--- Row 4:-- before patients are excluded from a potentially curative treatment-- Row 5:---- Row 6:------Row 7:--Stark Consensus--- Row 8:-----",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 1)",
      "text": "Row 1: 6.12 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 1)",
      "text": "Row 1: 6.13 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -In the case of a conspicuous clinical examination without correlation in the Row 3: Routine Staging Imaging, this should be clarified with a suitable method-checked Row 4: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <([313]; [312]). These were rated with evidence level 1a and 2a respectively. Both me-> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In the case of a metastasis-suspicious finding in an imaging trial-- Row 3:-- this is to be confirmed histologically and the staging completes who--- Row 4:-- before patients are excluded from a potentially curative treatment-- Row 5:---- Row 6:----Row 7:---Starker Konsent-- Row 8:-----",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.14-Consensus-based recommendation--tested 2025 Row 2: EK---The bronchoscopy (BRSK) represents the most important method of diagnosis-- Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.15-Evidence-based recommendation--tested 2025 Row 2: Recommendation level--In a central tumor the BRSK is to be performed using various methods of sample-- Row 3: A-- withdrawal as primary method of diagnostic protection.- Row 4: -- Row 5: Level of Evidence--[326]-- Row 6: 2a---- Row 7: --- Row 8: --Starker Consensus-- Row 9: ----",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.16-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In a peripheral lung tumor ≥ 2 cm diameter, the TTLB or the Row 3: B-BRSK should be performed using different methods of sampling under radiological con--- Row 4: troll, such as X-ray illumination.- Row 5: Level of Evidence--[327], [328], [329]-- Row 6: 2a---- Row 7: ----- Row 8: --Starker Konsentenz-- Row 9: ------",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.17, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"If a curative treatment intension exists, a pathological Row 5: \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.14 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.15 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.16 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.17 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--The bronchoscopy (BRSK) represents the most important method of diagnosis-- Row 3:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--In a central tumor, the BRSK is to be performed using various methods of sample-- Row 3: sampling as the primary diagnostic method.-- Row 4: -- Row 5: nce--[326]-- Row 6: -- Row 7: -- Row 8: --Strong Consensus-- Row 9: ----",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn a peripheral lung tumor ≥ 2 cm in diameter, the TTLB or the Row 3:--BRSK should be performed using different methods of sampling under radiological con--- Row 4:--troll, such as X-ray illumination.-- Row 5: nce--[327], [328], [329]-- Row 6: ---- Row 7: ---- Row 8: ---Strong Consensus- Row 9: -----",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--If a curative treatment intension exists, a pathological Row 5:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 6.18, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"For the pathological evaluation of the mediastinal lymph node status, endoscopic examination methods with ultra-\" Row 4: \"Sonic-controlled sampling\" (bronchoscopy with endobronchial ultra-\" Row 5: \"Sonic\" and with needle biopsy/aspiration [EBUS-TBNA]; oesophagoscopy with oeso-\" Row 6: \"\" Row 7: \"Phageal ultrasound\" and needle biopsy/aspiration [EUS-FNA]; combination of \"Row 8: \"\" EBUS/EUS procedure) should be used.",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 6.19:Consensus-based recommendation--tested 2025 Row 2: EC-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 6.18 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 6.19 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: 的Evidence-based recommendation--tested 2025 Row 2: grad--For the pathological evaluation of the mediastinal lymph node status, endoscopic examination methods with ultra----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1 : Consensus-based recommendation--tested 2025 Row 2: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.20-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-Cytological diagnosis of a non-small cell lung carcinoma (e.g. Bron--- Row 3: 0-choscopy, needle puncture method) can be accepted for therapeutic management-Row 4: provided a required full molecular Ana--- Row 5: -lytics can be performed.- Row 6: --- Row 7: Level of Evidence--[351], [330], [352]- Row 8: 2a----- Row 9: ---- Row 10: ---Starker Konsens- Row 11: -----",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 6.21, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"If, in the cytological diagnosis of a small cell lung carcinoma, the clinical appearance or course is more likely to speak against a small cell\" Row 4: \"Lung carcinoma\", a bioptic method for the histological\" Row 5: \"\"\" Row 6: \"\"and immunohistochemical diagnostic assurance\" should be performed.\" Row 7: \"Starker Konsent\" Row 8: \"\"\"",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.20 Row 2: Recommend Row 3: 0 Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 6.21 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, the cytological diagnosis of a non-small cell lung carcinoma (e.g. bron-, Row 3: echocopy, needle puncture method) can be accepted for therapeutic management, Row 4: provided a required full molecular Ana-, Row 5:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : If in the cytological diagnosis of a small cell lung carcinoma the clinical appearance or the clinical course is more likely to speak against a small cell-based Row 4 : lung carcinoma, a bioptic procedure for the histological Row 5: --- Row 6: and immunohistochemical diagnosis should be performed.- Row 7: --Stark Consensus- Row 8: ----",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.22, \"Consensus-based recommendation\" tested 2025 Row 2: \"EC\"In a peripheral lung tumor <2 cm and indication for non-surgical Row 3: \"Biopsy\" the CT-controlled TTLB or the BRSK can be used with navigational procedures\" Row 4: \"Roow 4: \"Roow 5: \"\" Row 6: \"Starker Consensus\" Row 7: \"\"\"",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.23, \"Consensus-based recommendation\" tested 2025 Row 2: EK\"In a non pleural peripheral lung tumor, CT-controlled TTLB should be performed in the case of a nega-, \"Row 3:\" activity bronchoscopic biopsy.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.24-Consensus-based recommendation-tested 2025 Row 2: EC-controlledIn a pleural tumor, the transthoracic lung biopsy (TTLB)-based Row 3: Ultrasound or CT-controlled should be performed.- Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.25-Consensus-based recommendation-tested 2025 Row 2: EK-testedIf a pleural effusion is present, a thoracocentesis (pleurapuncture) for the Row 3: etiological examination is to be carried out.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.26, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"In case of a no more than twice negative cytological examination of the Row 3: \"Pleurapunktat\" a thoracic copy should be performed, provided the etiolo-\" Row 4: \"Egic clarification of therapeutic decisive meaning or a palliative in-\" Row 5: \"\" Row 6: \"\"tervention\" is indicated.\" Row 7: \"\"Starker Konsent\"\" Row 8: \"\"\"",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.22 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.23 Row 2: EC Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.24 Row 2: EC Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.25 Row 2: EC Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.26 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--previous Row 2:--In a non-pleural peripheral lung tumor, CT-controlled TTLB should be performed in the case of Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--Prüv Row 2:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 4)",
      "text": "Row 1: air 2025 Row 2: surgical Row 3: process Row 4: Row 5:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 4)",
      "text": "Row 1: air 2025 Row 2: le ein nega- Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 4)",
      "text": "Row 1: air 2025 Row 2: opsie (TTLB) Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 4)",
      "text": "Row 1: air 2025 Row 2: puncture) to Row 3: Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page, column 4)",
      "text": "Row 1: air 2025 Row 2: search of Row 3: rn the etiolo- Row 4: palliative In- Row 5: Row 6:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.27, \"Consensus-based recommendation\" tested 2025 Row 2: \"EC\" If a lung carcinoma is suspected, a surgical biopsy should only be performed if less invasive methods of sampling have not yielded or could not be performed.\" Row 5: \"\" Row 6: \"Starker Konsent\"\" Row 7: \"\"\"",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.27 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.28, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"In each patient with one or more newly occurred, isolated Lun- to Row 3: \"A\" round herd(s) a comparison with previously performed X-ray and CT- to Row 4: \"Recommendation level\" is to be performed.\" Row 5: \"Level of Evidence\"[378], [379], [380], [381], [382], [383], [384], [385], [386], [387]\" Row 6: 2, 1a\", \"Row 7: \"2\" (Oxford 2011): (taken from LL 2010)\"\" Row 8: \"381a\" (Oxford 2009): (Fleischner Society Guideline, 2017)\" Row 9: \"\"\" Row 10: \"\"Starker Konsent\" Row 11: \"\"",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.29-Evidence-based recommendation-tested 2025 Row 2: Recommendation-level--In each patient with newly occurred, isolated lung ring < 3cm--row 3: A-diameter, the probability for malignancy of the lung ring---row 4:-- should be estimated. To this end, the following parameters should be taken into account: Age,- Row 5: Smoke status, known malignancies disease, as well as size, localization and-- Row 6: --- Row 7: --Radiomorphology of the round ring herd.-- Row 8: Level of Evidence----[378], [379], [380], [382], [383], [385], [386], [387] Row 9: 2, 2-----------------row 10: -2 (Oxford 2011): [382], [382], [384], [387], [387] Row 9: 2-----------------------------------------------------------",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.30-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-To estimate the malignancy of a newly occurred lung ring herd, Row 3: 0- can be used on a validated online probability calculation model (e.g.Mayo-Clinic, Her-Er-Er-Der, Brock).- Row 5: Level of Evidence-[378], [379], [380], [381], [382], [383], [384], [385], [386], [387]- Row 6: 3-",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.28 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 2, 1a Row 6: Row 7: Row 8:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.29 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: 2, 2+ Row 7: Row 8: Row 9:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.30 Row 2: Recommendationg Row 3: 0 Row 4: Level of Eviden Row 5: 3 Row 6: Row 7:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation, Row 2: grade, is to be estimated for each patient with newly occurred, isolated lung ring, Row 3: diameter, the probability of malignancy of the lung ring, Row 4: grade. To this end, the following parameters are to be taken into account: Row 5: smoker status, known malignancy disease, as well as size, Localis, Row 6: ,, Row 7: , Radiomorphology of the round herd., Row 8: nce,[378], [379], [380], [382], [38383], [384], [385], [386], [387], [387], Row 9: , ,, Row 10: ,2 (Oxford 2011): (adopted from LL 2010), Row 11: ,,2+: (British Thoracic Society, 2015), Row 12: , , to, Row 13: 14, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: \"Evidence-based recommendation\"Pray Row 2: \"grad\"To estimate the malignancy of a newly occurred lung round\" Row 3: \"on a validated online probability calculation model (e.g.May\" Row 4: \"der, Brock\").\" Row 5: \"nce\"[378], [379], [380], [381], [382], [383], [384], [385], [386], [387]\" Row 6: \"\" Row 7: \"3\" (Oxford 2011): (British Thoracic Society, 2015)\" Row 8: \"\" Row 9: \"\"Starker Consensus\" Row 10: \"\"",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: air 2025 Row 2: oiled Lun Row 3: en- and CT Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: air 2025 Row 2: earth < 3cm Row 3: earth off- Row 4: en: age, Row 5: satation and Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: aft 2025 Row 2: dherdes can Row 3: yo-Clinic, Her- Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.31-Consensus-based recommendation-tested 2025 Row 2: EC-checkedA lung ring herd diagnosed by chance should in principle only then-check Row 3: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.32-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In patients without malignancies (pre-)disease and low risk of lung--- Row 3: B-carcinoma with a lung ring <5 mm (or <80 mm3) or in patients,- Row 4: whose general condition does not allow further clarification or therapy-- Row 5: --no CT-control should be performed-- Row 6: --- Row 7: Level of Evidence--[379], [381], [388], [390]-- Row 8: 2------ Row 9:---2+: (British Thoracic Society, 2015)-- Row 10: ---- Row 11: ---Starker Consensus---- Row 12: ------",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.33, \"evidence-based recommendation\" tested 2025 Row 2: \"recommendation level\" In patients with a lung ring area ≥ 5 mm to < 8 mm (≥ 80 mm3 to <3, \"Row 3: \"B\", \"300 mm3), CT history checks should be carried out.\" Row 4: \"\"\" Row 5: Level of Evidence\"[379], [381], [388], [389], [390]\" Row 6: 2+\"\" Row 7: \"\"2+: (British Thoracic Society, 2015)\" Row 8: \"\" Row 9: \"\"Strong Consensus\" Row 10: \"\"\"",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.34/Evidence-based recommendation--tested 2025 Row 2: Recommendation level--CT-course controls – preferably with volumetric size determination-- should be carried out--- Row 3: sheets after 3, 6-12 and 18-24 months.-- Row 4: --- Row 5: Level of Evidence--[379], [381], [388], [389], [390]-- Row 6: 2, 3--- Row 7: -2 (Oxford 2011): (British Thoracic Society, 2015)-- Row 8: 3 (Oxford 2011): (Fleischner Society Guideline, 2017)--- Row 9: ---- Row 10: ---Starker Konsent---Roow 11: ------",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.31 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.32 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 2+ Row 7: Row 8:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.33 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2+ Row 6: Row 7:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.34 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2, 3 Row 6: Row 7: Row 8:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation Row 2: grade--In patients without malignant (pre-)E Row 3:--carcinoma with a lung round Row 4:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation Row 2: grade--In patients with a lung run Row 3: ,300 mm3), CT history code Row 4: , Row 5: nce[379], [381], [388], [389], [390] Row 6: , Row 7: ,2+: (British Thoracic Society, 2015 Row 8: , Row 9: , Stark Consensus Row 10: ,",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation Row 2: grade-CT history controls – preferred Row 3: , after 3, 6-12 and 18-24 month Row 4: , Row 5: nce-[379], [381], [388], [389], [390] Row 6: , Row 7: ,2 (Oxford 2011): (British Thoracic Row 8: ,3 (Oxford 2011): (Fleischner Socie Row 9: , , Row 10: , Starker Konsent Row 11: ,",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: tested 2025 Row 2: erter Lungrundherd should in principle only be Row 3: stik, if the general condition of the Pati-check Row 4: che therapy also allows.",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: 2025 Row 2: Disease and low risk for a lung--- Row 3: herd <5 mm (or <80 mm3) or in patients,-- Row 4: allows for more effusion or therapy,-- Row 5: should be led-- Row 6: - Row 7: 5)-- Row 8: -- Row 9: --",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: 2025 Row 2: ndherd ≥ 5 mm to < 8 mm (≥ 80 mm3 to <",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: 2025 Row 2: t with volumetric size determination - should be carried out--- Row 3: ten.-- Row 4: - Row 5: - Row 6: Society, 2015)-- Row 7: ety Guideline, 2017)-- Row 8: --",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.35-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-edited patients can be released from the CT-continuation control if the volume increase of the round herd is <25% in one year, or the volume increase is > 600 days (VDT) or the general state of the patien-",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.36, \"evidence-based recommendation\" tested 2025 Row 2: recommendation level\"In the case of a radiologically documented size progression (VDT < 400 days)\" Row 3: \"B\" of an isolated lung ring herd should be aimed for a definitive pathological clarification at-\" Row 4: \"\" .\" Row 5: Level of Evidence\"[379], [381], [388], [389], [390]\" Row 6: 2, \"\" Row 7: \"2\" (Oxford 2011): (British Thoracic Society, 2015)\" Row 8: \"\" Row 9: \"\" Stark Consens\" Row 10: \"\"",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.37, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"On the method to be chosen for the pathological diagnosis of a\" Row 3: \"Pulmonary round herd\" (bronchoscopy with transbronchial biopsy or CT-ge-\" Row 4: \"transthoracal biopsy controlled or minimally invasive surgical resection)\" Row 5: \"\" Row 6: \"should be interdisciplinary\" (pneumology, radiology, thoracic surgery) decided.\" Row 7: \"\"\" Row 8: \"Strong consensus\" Row 9: \"\"",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.35 Row 2: Recommendationg Row 3: 0 Row 4: Row 5: Level of Eviden Row 6: 2 Row 7: Row 8:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.36 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2 Row 6: Row 7:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.37 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients can be released from the CT history control if the volume increase of the round herd is <25% in a year, or the volume increase is > 600 days (VDT) or the general state of the patie-row 5: did not allow further clarification or therapy.- Row 6:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-in case of radiologically documented scale progression (VDT < 400 Tag-in case of an isolated lung ring herd-in case a definitive pathological clarification-in case of Row 4: grade-in case of a radiologically documented size progression-in case of Row 5: nce-[379], [381], [388], [389], [390]-in case of Row 6:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2: --On the method to be chosen for the pathological diagnosis of a Row 3 : Pulmonary round herd (bronchoscopy with transbronchial biopsy or CT-g--row 4: controlled transthoracic biopsy or minimally invasive surgical resection)-- Row 5: -- Row 6: should be decided interdisciplinary (pneumology, radiology, thoracic surgery)-- Row 7: --becoming.- Row 8: --Strong consensus-- Row 9: -----",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Row 2: u- Row 3: Ver- Row 4: en- Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Row 2: ge) Row 3: an- Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Ge- Row 4: Row 5: Row 6: Row 7:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.38/Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In patients with a subsolide that persists in the 3-month CT control-- Row 3: A--Lungenrundherd ≥ 5 mm or ≥ 80 mm3), depending on the age of the Pati--- Row 4:---enter, of smoking status, peripheral eosinophilia, lung carcinoma precursor--- Row 5:---layers as well as the radiomorphology of the round herd, in particular the Row 6:------- Row 7:------size of the solid component, the probability of lung malignancy------ Row 8:----herdes is estimated.-- Row 9: Level of Evidence----[379], [381], [392]-----row 10: 2------- Row Row 11:-------2 (Oxford 2011): (British Thoracic Society, 2015)-----row 12----------row 13-------------------------------------",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.39-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-indicated In patients with a persistent subsolid lung ring area ≥ 5 mm-indicative Row 3: B-(or ≥ 80 mm3) and low malignancy risk-indicative CT-indicative Row 4:-indicative Row 5: Level of Evidence-indicative[379], [381], [391], [392]-indicative Row 6: 3, 3-indicative Row 7: 的3 (Oxford 2011): (British Thoracic Society, 2015)-indicating Row 8: 的3 (Oxford 2011): (Fleischner Society Guideline, 2017)-indicating Row 9:",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.40-Evidence-based recommendation--tested 2025 Row 2: Degree of recommendation--In patients with a subsolid lung ring herd and significant size--- Row 3: Assumption (≥ 2 mm) - especially the solid component - or in case of addition--- Row 4:-- a solid proportion in the follow-up observation should be aimed at a definitive pathological clarification depending on the Row 5:--General condition of the patient--- Row 6:---- Row 7:------- Row 8: Level of Evidence--[379], [381], [391], [392]-- Row 9: 3----- Row 10:---3 (Oxford 2011): (British Thoracic Society, 2015)---- Row 11:----- Row 12:----Starker Consens------ Row 13: -----------------------------------------------------------------------------------------",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.38 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: 2 Row 7: Row 8:",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.39 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 3, 3 Row 6: Row 7: Row 8:",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.40 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 3 Row 7: Row 8:",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, tested In patients with a subssolidary, persistent in 3-month CT control, Row 3: lung ring herd ≥ 5 mm or ≥ 80 mm3), depending on the age of the pati-, Row 4: grade, smoking status, peripheral eosinophilia, lung carcinoma precursor, Row 5: layer, and radiomorphology of the round herd, in particular Row 6:",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn patients with a persistent subsolid lung ring area ≥ 5 mm-sound Row 3: -(or ≥ 80 mm3) and low malignancy risk, CT history controls should be performed Row 4: -over a duration of 3-5 years.- Row 5: nce-[379], [381], [391], [392]- Row 6: ---- Row 7: --3 (Oxford 2011): (British Thoracic Society, 2015)- Row 8: --3 (Oxford 2011): (Fleischner Society Guideline, 2017)- Row 9: ------ Row 10: ---Starker Consensus- Row 11: -----------------------------------------------------------------------------------------------------------------------------",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--In patients with a subsolid lung ring herd and significant size--- Row 3: intake (≥ 2 mm) - especially the solid component - or in case of add---- Row 4: a solid proportion in the course observation should be aimed at a definitive pathological clarification depending on the Row 5: general condition of the patient-- Row 6: --- Row 7: ------ Row 8: nce--[379], [381], [391], [392]-- Row 9: ----- Row 10: -----3 (Oxford 2011): (British Thoracic Society, 2015)--- Row 11: ----- Row 12: --Starker Consensus----- Row 13: --------",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.41,Evidence-based recommendation, checked 2025 Row 2:Recommendation level, patients with a solid lung ring herd with an initial malignancy--- Row 3: B-risk >10% (brock model) should be offered the execution of a PET-CT--- Row 4: , if the round herd size is above the local PET-CT detection threshold, Row 5: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.42, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"For patients with a solid lung ring >8 mm diameter (≥ 250, \"Row 3: \"B\"mm3) and after carrying out a PET/CT further, \"Malig,\" \"Row 4: \"Probability\" ≥ 10%, a definitive pathological clarification should be aimed at.\" Row 6: \"\"\" Row 7: Level of Evidence\"[379], [393], [395], [396], [397], [398], [399]\" Row 8: \"\"\" Row 9: \"\"3\" (Oxford 2011): (British Thoracic Society, 2015)\" Row 10: \"\"\" Row 11: \"\"Starker Consens\" Row 12: \"\"",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.43-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn operable patients with a solid lung ring herd >8 mm in diameter- Row 3: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.41 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 2 Row 7: Row 8:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.42 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 3 Row 7: Row 8:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.43 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: 的evidence-based recommendation-checked 2025 Row 2: grademPatients with a solid lung ring herd with an initial Malignitä-Row 3: -risk >10% (brock model) should be offered the execution of a PET-CT-Row 4: -den if the round herd size is above the local PET-CT detection threshold Row 5: - liet.",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, tested In patients with a solid lung ring area >8 mm diameter (≥ 250\" Row 3: \"mm3) and after a PET/CT further existence, a definitive pathological clarification should be aspired to by Row 5: \" Row 6: \"\" Row 7: \"nce\"[379], [393], [395], [396], [397], [399], [399]\" Row 8: \"\" Row 9: \"3\" (Oxford 2011): (British Thoracic Society, 2015)\" Row 10: \"\" Row 11: \"\" Starker Konsent\" Row 12: \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Row 2: äts- Row 3: r- Row 4: le Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: alig- Row 4: ge- Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Row 2: Ser Row 3: äts- Row 4: rgi- Row 5: chi- Row 6: Row 7:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.44, Consensus-based recommendation--tested 2025 Row 2: EC--In non-operable patients with a solid lung ring herd >8 mm Through--- Row 3: Knife (≥ 250 mm3) and Row 4: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.44 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In non-operable patients with a solid lung ring >8 mm Through-- Row 3:--meter (≥ 250 mm3) and-- Row 4:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 6.45-Consensus-based recommendation-tested 2025 Row 2: EC-testedThe diagnosis of lung carcinoma should always be accompanied by an exact TNM classification- Row 3: .",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 6.45 Row 2: EC Row 3: Row 4:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--The diagnosis of lung cancer should always be accompanied by an exact TNM classification--Row 3:---Row 4:--Starker Consensus--Row 5:----",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: T-Category-Explanation Row 2: Tx-EPrimary Tumor Cannot Be Evaluated or Detection of Malignant Cells in Row 3: T-Sputum or Bronchial Flush, However Tumor Radiological or Bronchosco- Row 4: T-Row 5: T-Einein Anhalt für Primary Tumor Row 7: Tis-ECarcinoma in situ with pure lepidic growth up to 3 cm for adenocarcinoma and Row 8: T-Platenepithel carcinoma in situ. [402], Row 9: T-E Row 10: T1mi-Minimal invasive adenocarcinoma Solitary adenocarcinoma No more than 3 cm in Row 11:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: T-Kate Row 2: Tx Row 3: Row 4: T0 Row 5: Tis Row 6: Row 7: T1mi Row 8: Row 9: T1 Row 10: Row 11: T1a",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: egori Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: he/she explains Row 2: \"Primary tumor cannot be assessed or evidence of malignant cells in Row 3: \"Sputum\" or bronchial flushes, but tumor radiologically or bronchosco- Row 4: \"Row 5: \"not visible in a manner. Row 6: \"kein Anhalt\" for primary tumor Row 7: \"Carcinoma in situ with pure lepidic growth up to 3 cm for adenocarcinoma and Row 8: \"Plattenepithelcarcinoma in situ.\" [402] Row 9: \"Row 10: \"minimal invasive adenocarcinoma\" Solitary adenocarcinoma no more than 3 cm in Row 11: \"the largest extent, with a predominantly lepidic growth pattern Row 12: \"Row 13: \"and no more than 5 mm invasive portion. Row 14: \"Tumore 3cm or less in the largest extent 15 of lung tissue no more than 15 of a bronchion.",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "Table under heading <6.5 Staging 151>",
      "text": "Row 1: T-category-explanation Row 2: T1b-tumor more than 1cm and up to and including 2cm in largest extent Row 3: T1c-tumor more than 2cm and up to and including 3cm in largest extent Row 4: T2-tumor more than 3cm, but not more than 5cm in largest extent or Tumor Row 5: with at least one of the following characteristics: Row 6: - Row 7: -Tumor infects main bronchus, 2 cm or further distal of the carina without infestation of the Row 8: -Carina Row 9: -Tumor infiltrates visceral Pleura Row 10:-associated atelectase or obstructive inflammation up to Hilus, either parts Row 11: -row or the whole lung absorbing Row 12: T2a-Tumor up to and including 4cm Row 13: T2b-Tumor more than 4cm and up to and including 5cm Row 14: T3-Tumor more than 5 cm, but not including the whole lung absorbing Row 12: T2a-Tumor up to and including 4cm Row 13: T2b-Tumor more than 4cm.",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "Table under heading <6.5 Stage classification (staging) 152>",
      "text": "The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following: The following are the following: The following are the following: The following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following:",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "Table under heading <6.5 Staging 153>",
      "text": "Row 1: Subset of Row 2: III Row 2: III Row 5: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page)",
      "text": "The upper limit of the upper limit of the upper limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the lower limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper limit of the upper",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 1)",
      "text": "Row 1: Lymph node station Row 2: # 1 (left and right) Row 3: Row 4: # 2 (left and right) Row 5: Row 6: #3 (a: prevascular, p: Row 7: retrotracheal, left Row 8: and right) Row 9: Row 10: # 4 (left/right) Row 11:",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 2)",
      "text": "Row 1: noDescribe Row 2: no Lower Row 3: no Supraclavic Row 4: no Row 5: no Row 6: no Upper Para Row 7: no Row 8: no Prevascula Row 9: noRotracheal Row 10: no Row 11: no Row 12: no Row 13: no Lower Par Row 14: no",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row: Row 2: Rvikale and Upper Border: Lower Border of the Krikoidknorpel Row 3: Cular LK: Lower Border: Row 7: Trachea Row 8: Atracheale LK:2R Upper Border: Lap of Lung and Row 9:",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page)",
      "text": "In addition, it is possible to use the following links: http://www.europarl.eu.int/comm/index_en/index_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.php_en.hp_en.php_en.hp_en.hp_en.hp_en.hp_en.hp_en.php_en.hp_en.hp_en.hp_en.hp_en.hp_en.hp_en.hp_en.hp_en.hp_en.hp_en.hpnhp_en.hp_en.hp_en.h_en.hpnh_nhpnhp_nhpnh_",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 1)",
      "text": "Row 1: Lymph node station Row 2: # 5 Row 3: Row 4: # 6 Row 5: Row 6: # 7 Row 7: Row 8: #8 (left and right) Row 9: Row 10: #9 (left and right) Row 11: Row 12: #10 (left and right) Row 13: Row 14: #11 (left and right) Row 15:",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 2)",
      "text": "Row 1: No Description Row 2: NoSubaortals LK (aorto Row 3: No Monal window) Row 4: No Row 5: No Row 6: No Row 6: No Row 11: No Row 12: No Row 13: No Row 14: No Row 9: No Row 15: No Row 16: No Row 17: No Row 11: No Row 11: No Row 13: No Row 13: No Row 19: No Row 19: No Row 20: No Row 21: No Row 21: No Row 22: No Row 22: No 22 22: No 22: No 22: No 22: No 22: No 22:",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 3)",
      "text": "In addition, the following provisions apply:",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page)",
      "text": "Row 1: Lymphatic Node Station-Description-Definition Row 2: #12 (left and right)-Lobäre LK-In the Environment of the Lappenbronchien Row 3: #13 (left and right)-Segmental LK-In the Environment of the Segmentbronchien Row 4: #14 (left and right)-Subsegmental LK-In the Environment of the Subsegmentbronchien Row 5: according to IASLC [406]--",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 1)",
      "text": "Row 1: Lymph node station Row 2: #12 (left and right Row 3: #13 (left and right Row 4: #14 (left and right Row 5: according to IASLC [406]",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 2)",
      "text": "Row 1: n-Description-Definition Row 2: s)--Lobäre LK--In der Umgeb Row 3: s)--Segmental LK--In der Umgeb Row 4: s)--Subsegmental LK--In der Umgeb Row 5:----",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 3)",
      "text": "Row 1: Row 2: Bend of Lappenbro Row 3: Bend of Segmentbr Row 4: Bend of Subsegmen Row 5:",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 4)",
      "text": "Row 1: Row 2: onchie Row 3: ronch Row 4: ntbro Row 5:",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "table under heading <6.5 Staging 153> (from previous page, column 5)",
      "text": "Row 1: Row 2: en Row 3: here Row 4: onchien Row 5:",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "Table under heading <6.5 Stage classification (staging) 158>",
      "text": "Row 1: M-Category-Explanation Row 2: M0-No remote metastases Row 3: M1-Fernmetastases Row 4: M1a-Explanation Row 2: M0-No remote metastases Row 3: M1-Fernmetastases Row 4: M1a-Explanation Row 5: M1-Or tumor with pleura- or pericardial metastases or with malignant pleura- Row 6: Row 7: Row 7: Row 8: M1b-A extrathoracal metastases in one organ (this includes also Row 9: Row 9: Row 9: Row 11: M1c-Multiple extrathoracal metastases in one or more organs Row 12: [407] Row 13: A second maligne-conducting lung herd (spiculated, further magnitude increase, PET-poisitv) may be assigned to a time tumor, a remote-Row 14: Tastase or good (Granowom) in the procedure.",
      "start_page": 158,
      "end_page": 158
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page)",
      "text": "In addition to: IIA2:T2a0M0M0M0M0Row 9: IIA2:T2a00M0Row 7: IIA3:T2a000M0Row 8: IIAA:T2a00M0Row 8: IIA:T2a00M0Row 8: IIA:T3T2M0M0Row 8: IIA:T2a0M0Row 8: IIA:T3T2a0M0Row 8: IIA:T3T2a0M0M0Row 8: IIA:T3T2M0M0Row 8: IIA:T3T0M0M0M0M0M0M0M0Row 9: IIB:T1T1a0M0M0Row 9: IIB: IB:T1T1a0M0Row 10: IB: IB: TT2aa'T1M0M0M0Row1aaaaaa, bb2aaaa, b b2b2b2lllllllllllllllllllllllllllllllll",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 1)",
      "text": "Row 1: Stadiu Row 2: 0 Row 3: IA1 Row 4: Row 5: IA2 Row 6: IA3 Row 7: IB Row 8: IIA Row 9: IIB Row 10: Row 11: IIIA Row 12: Row 13: IIIB Row 14: Row 15: IIIC Row 16: Row 17: IVA Row 18: Row 19: IVB Row 20: after [40",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 2)",
      "text": "Row 1: around Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: 08]",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 3)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 4)",
      "text": "Row 1: r Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 5)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 6)",
      "text": "Row 1: n Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 7)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 8)",
      "text": "Row 1: metas Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 9)",
      "text": "Row 1: stasen Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26:",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page)",
      "text": "Row 1: 6.46,0Consensus-based recommendation--tested 2025 Row 2: EK---In the macroscopic description and preparation of lung resection--- Row 3:--the following parameters are to be recorded:-- Row 4:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 1)",
      "text": "Row 1: 6.46 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In the macroscopic description and preparation of lung resection--- Row 3:--the following parameters shall be recorded:-- Row 4:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page)",
      "text": "Row 1: 6.47,Consensus-based recommendation, tested 2025 Row 2: EK, To histopathological assessment of the tumor tissue, a paraffin block of tumour tissue should be fed to the histo-, Row 4: or a central tumor disc should be combined with Row 5: ,,, Row 6: , plett embedded in paraffin blocks and histologically examined., Row 7: , depending on the question (e.g., Adenocarcinoma in situ, AIS), should be carried out, Row 8: , if necessary, further histological investigations., Row 9: , , All in the resectional preparation, macroscopically for the representation of the coming lymph-, Row 10: , nodes should be prepared and the histological examination should be performed., Row 11: , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 1)",
      "text": "Row 1: 6 Row 2: E Row 3: Row 4: Row 5:",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 2)",
      "text": "Row 1: 6.47 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 4)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page)",
      "text": "Row 1: 6.48, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"All lymph nodes taken in the context of preoperative staging, a mediastino-\" Row 3: \"Scopy\", a video-assisted mediastinal lymphadenectomy (VAMLA) or \"Row 4:\" in the context of tumor resection are to be fully investigated in Paraffin-\" Row 5: \"\"\" Row 6: \"Embedded\" and histologically examined in step sections (at least 2\" Row 7: \"Cutting levels, HE staining\").\" Row 8: \"Stark Consens\" Row 9: \"\"\"",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page)",
      "text": "Row 1: 6.49-Consensus-based statement-tested 2025 Row 2: EK-tested Pathological assessment of regional lymph nodes within the scope of the Row 3: Preoperative Staging is also possible using material from a fine needle biopsy Row 4: .",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 1)",
      "text": "Row 1: 6.48 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 1)",
      "text": "Row 1: 6.49 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--All lymph nodes taken in the context of preoperative staging, a mediastino-- Row 3:--scopy, a video-assisted mediastinal lymphadenectomy (VAMLA) or--Row 4:---are to be fully embedded in Paraffin--Row 5:----Row 6:--and examined in step sections histologically (at least 2---Row 7:---cut steps, HE staining).-- Row 8:---Strong consensus---Row 9:--------",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.5 Staging 158> (from previous page, column 3)",
      "text": "Row 1: Consensus-based statement-tested 2025 Row 2:--The pathological assessment of the regional lymph nodes within the scope of the Row 3:--preoperative staging is also possible using material from a fine needle biopsy--row 4:--.- Row 5:--- Row 6:--Consensus-- Row 7:---",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025>",
      "text": "Row 1: 6.50-Consensus-based recommendation-tested 2025 Row 2: EK-testedHistological typing of lung tumors in resection preparations such as Row 3:- also based on small biopsies and cytological preparations is to be performed according to criteria-- Row 4:--the respective WHO classification.- Row 5:--- Row 6:--Starker Consensus-- Row 7:---",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025>",
      "text": "Row 1: Epithelial tumors Row 2: • Papillome Row 3: • Adenome Row 4: • Glandular precursor lesions Row 5: o Atypical adenomatous hyperplasia Row 6: o Adenocarcinoma in situ Row 7: ▪ Adenocarcinoma in situ, non-muzinous Row 8: ▪ Adenocarcinoma in situ, muzinous Row 9: • Adenocarcinoma Row 10: o Minimally invasive adenocarcinoma Row 11: ▪ Minimally invasive adenocarcinoma, non-muzinous",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: ▪ Minimal Invasive Adenocarcinoma Row: ▪ Solid Adenocarcinoma Row: ▪ Solid Adenocarcinoma Row: ▪ Solid Adenocarcinoma Row: ▪ Invasives Adenocarcinoma Row: ▪ Mixed Invasive Adenocarcinoma Row: ▪ Mixed Invasive Adenocarcinoma Row: ▪ Adenocarcinoma Adenocarcinoma Row: ▪ Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adeno carcinoma Adenocarcinoma Adeno carcinoma Adeno carcinoma Adeno carcinoma Adeno carcinoma Adeno Carcinoma Adeno Carcinoma Adeno Carcinoma Adeno Carcinoma Adeno Adeno Carcinoma Adeno Carcinoma Adeno Carcinoma Adeno",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Invasive Adenocarcinoma Row 7: ▪ Solid Adenocarcinoma Row 8: o Invasive Adenocarcinoma Row 9: ▪ Mixed Invasive Adenocarcinoma Row 10: o Colloid Adenocarcinoma Row 11: o Fetal Adenocarcinoma Row 12: o Adenocarcinoma, enteral Type Row 13: o Adenocarcinoma, NOS Row 14:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: m, mu Row 2: zinom Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: and n Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Lasie Row 17: Lasie Row 18: plasie Row 19: Row 20: Row 21: nom Row 22: lkarzi Row 23: m Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 4)",
      "text": "Row 1: uzinous Row 2: m Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: non-Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: e Row 19: Row 20: Row 21: Row 22: inom Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 5)",
      "text": "Row 1: s Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: -muzin Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Nose Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: s Ade Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: enoka Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: arzino Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: om Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "12: o Pleomorphic adenoma Row 12: o Adenoidcystic carcinoma Row 13: o Epithelias-myepithitheliales carcinoma Row 14: o Mukoepidermoides Carcinoma Row 15: o Hyalinizing clear cell carcinoma Row 16: o Myoepithelioma Row 17: o Myoepitheliales Carcinoma Row 18: Neuroendocrine Neoplasia Row 15: o Hyalinizing clear cell carcinoma Row 19: o Myoepithelioma Row 17: o Myoepitheliales Row 18: Neuroendocrine Row 15: o Hyalinizing clear cell carcinoma Row 19:",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: • Sarcomatoide Carcinoma Row 2: o Pleomorphic Carcinoma Row 3: ▪ Giant Cell Carcinoma Row 4: ▪ Spindle Cell Carcinoma Row 5: o Pulmonary Blastom Row 6: o Carcinoma Row 7: • Other Epithelial Tumors Row 8: o NUT Carcinoma Row 9: o Thoracal SMARCA4-d Row 10: • Tumors from the Speicherrod Row 11: o Pleomorphic Adenom Row 12: o Adenoid Cystic Carcinoma Row 13: o Epithelial-myoepithe Row 14: o Mukoepidermoides Row 15: o Hyalinizing Clearness Row 16: o Myoepithelioma Row 17: o Myoepitheliales Carcinoma Row 18: Neuroendocrine Neoplasms Row 19: • Precursor-Läsion Row 20: o Diff idioids Row 21 Types: o Myoowioid Row 21:",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: m Row 3: Zinom Row 4: rzinom Row 5: Row 6: Row 7: n Row 8: Row 9: deficient andi Row 10: sentyp Row 11: Row 12: rzinom Row 13: eliales Carcinoma Row 14: rzinom Row 15: uliges Carcinoma Row 16: Row 17: nom Row 18: Row 19: Row 20: Hyperplasia pulm Row 21: Row 22: oendocrine Tum Row 23: id / neuroendoc Row 24: oid / neuroendo Row 25: e Row 26: m Row 27: nenzell carcinoma Row 28: dokrine Carcinoma",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Confected Tumor Row 10: Row 11: Row 12: Row 13: m Row 14: Row 15: m Row 16: Row 17: Row 18: Row 19: Row 20: Monal neuroendocrine cell Row 21: Row 22: mor, NOS Row 23: Cran Tumor, Grade 1 Row 24: Ocrine Tumor, Grade 2 Row 25: Row 26: Row 27: nom Row 28: om",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: en (DI Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: IPNEC Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: CH) Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28:",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: ▪ Combined large cell neuroendocrine carcinoma Row 2: Tumors ectopic tissue Row 3: Mesenchymal tumors Row 4: Haematolymphoid tumors Row 5: (modified according to WHO Classification of Tumours Editorial Board 2021 [410],",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.51,Consensus-based recommendation, tested 2025 Row 2: EC, tested In the case of a histological assessment of a non-small cell carcinoma, Row 3: should histological typing be carried out on the basis of the strategy recommended by the WHO classification, Row 4: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: Row 2: Tumo Row 3: Mesen Row 4: Häma Row 5: (modifiz",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.51 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: oren e Row 3: nchym Row 4: atlomym Row 5: decorated na",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: ▪ Combined large cell neuroendocrine carcinoma Row 2: ectopic tissue Row 3: male tumors Row 4: mphoide tumors Row 5: ach nach WHO Classification of Tumours Editorial Board 2021 [410],",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation, tested 2025 Row 2 : In the case of a histological assessment of a non-small cell carcinoma, Row 3 : should histological typing be carried out on the basis of the strategy recommended by the WHO classification, Row 4 : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.52-Consensus-based recommendation-tested 2025 Row 2: EK-tested Pathological-anatomical staging is to be performed according to the definitions of the respective gül-",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.53-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn multiple lung tumors, an analysis of clonality should be carried out to clarify the question of a curative local Row 3: .",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.52 Row 2: EC Row 3: Row 4:",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.53 Row 2: EC Row 3: Row 4:",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : The pathological-anatomical staging is to be carried out according to the definitions of the respective gül-- Row 3 : TNM classification.",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : In multiple lung tumors, an analysis of clonality should be carried out to clarify the question of a curative local Row 3 : Therapy.",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.54, Consensus-based recommendation, tested 2025 Row 2: EK, should be examined by default in the assessment of resection preparations, the resecti-, Row 3: ,onsränder histologically. In particular, the bron-, Row 4: ,chus and vascular resection margins, in locally advanced tumors, or er-, Row 5: ,-, Row 6: ,-, extended resections e.g. also the resection margins of the pericardium, the medias-, Row 7: tinum or the thorax wall should be considered.",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.54 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --In the evaluation of resection preparations the resecti--- Row 3: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.55-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn the assessment of resection preparations of pulmonary adenocarcinomas, Row 3: Grading is to be specified according to the recommendations of the current WHO-的 Row 4: classification (5th edition, 2021).",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.56,6-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn some lung tumors, the degree of differentiation is derived from histolo- such as the sarcomatoid carcinoma (pleomorphic carcinoids, carcinosarcoma, and pulmonary blastoma) or neuroendocrines, Row 5: --- Row 6: --tumors (typical carcinoids, atypical carcinoids, large cell neuroendocrines, Row 7: ---carcinomas, small cell carcinomas). Therefore, a histopa----- Row 8: --thological grading should not be specified separately.-- Row 9: ---Consensus-based recommendation-tested Row 10: -------------------------------------------------------------------------------------------------------------------------",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.55 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.56 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : When evaluating resection preparations of pulmonary adenocarcinomas, Row 3 : Grading is to be specified according to the recommendations of the current WHO--- Row 4 : Classification (5th edition, 2021).- Row 5 : --- Row 6: --Starker Consensus-- Row 7: ----",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation, tested 2025 Row 2 : In some lung tumors, the degree of differentiation is derived from histolo-- Row 3 : Agic typing, e.g. sarcomatoid carcinomas (pleomorphic carcinoids, carcinosarcoma, and pulmonary blastoma) or neuroendocrines, Row 5: --- Row 6: --Tumors (typical carcinoids, atypical carcinoids, large cell neuroendocrines, Row 7 : ---Carcinomas, small cell carcinomas). In these tumors, therefore, a histopa----- Row 8: thological grading should not be specified separately.",
      "start_page": 169,
      "end_page": 169
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page)",
      "text": "Row 1: 6.57, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"According to previous radio- and/or chemotherapy, in the resectate the Row 3: \"Extent of the treatment-induced tumor regression should be determined microscopically and Row 4: \"according to the regression-grading according to Junker\".\" Row 5: \"\" Row 6: \"Starker Consensus\" Row 7: \"\"\"",
      "start_page": 170,
      "end_page": 170
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 6.57 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 170,
      "end_page": 170
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 170,
      "end_page": 170
    },
    {
      "heading": "table under heading <6.50 Consensus-based recommendation reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -According to previous radio and/or chemotherapy, the resectate should determine the Row 3: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 170,
      "end_page": 170
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025>",
      "text": "Row 1: RG I: no tumor regression or only spontaneous tumor regression in the range Row 2:",
      "start_page": 171,
      "end_page": 171
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025>",
      "text": "Row 1: 6.58-Consensus-based recommendation-modified 2025 Row 2: EC-modifiedA test on EGFR mutations in Exonenen 19 and 21 and ALK fusions-row 3: should be performed on the available tumor tissue/cells at Row 4: NSCLC in early tumour stages (IB-IIIA, for ALK in tumors ≥ 4 cm)- Row 5:",
      "start_page": 171,
      "end_page": 171
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025>",
      "text": "Row 1: 6.59-Consensus-based recommendation: New 2025 Row 2: EK: All non-resectable NSCLC in stage III are to be performed using the tumor tissue/tumour cells available for distribution: Row 3: molecular pathological subdivisions: Row 4: investigations regarding the EGFR mutations in exons 19 and 21 as well as ALK-",
      "start_page": 171,
      "end_page": 171
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.60:Consensus-based recommendation: New 2025 Row 2: EC: In patients with non-small cell lung carcinoma in stage IB-III, parallel: Row 3: should be performed to the molecular pathological investigations an immunohistochemical low-row 4: investigation on PD-L1 expression.: Row 5: -- Row 6: --The result should be stated as a percentage of membraneous positive tumour cells (Tumour Pro--- Row 7: -portion Score, TPS). An external quality assurance within the framework of Row 8: -Ring trials should be demonstrated.: Row 9: ---Starker Konsensung: Row 10: -------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.61, Consensus-based recommendation--modified 2025 Row 2: EC---based on the available tumor tissue/tumour cells of al---- Row 3: NSCLC in stage IV, molecular pathological studies should be considered--- Row 4:---based on all therapeutically relevant molecular changes (according to the current Row 5: ROS1 fusions, RET fusions,-- Row 8: R & D 1-3 fusions, KRAS mutations (in particular KRAS-G12C mutations), MET------row 9: ROS1 fusions, RET fusions,---Row 8: RG1 fusions, and HER2 (ERBB 2) mutations (especially KRAS-G12C mutations), MET--------row 9: R & D 14-skipping mutations, NRG1 fusions,-Row 8: R & D 1-3 fusions, KRAS mutations, KRAS mutations (in particular KRAS-G12C mutations), MET--------Row 9: Row 9: R & D 14---Exon 14-Fusions, ROS-Fusions, RET 14-Fusions, RET-Fusions, R & R & R & R",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.62*Consensus-based recommendation\"tested 2025 Row 2: EK\"in the tissue samples of therapy-naïve patients in stage IV, parallel Row 3: \"to the molecular pathological investigations an immunohistochemical Row 4: \"search for PD-L1 expression\" is to be performed.*\" Row 5: \"Row 6: \"To the extent that only cytological preparations with tumour cells are available,\" Row 7: \"corresponding patients should undergo treatment in cell block technology with follow-up Row 8: \"immunzytochemical test for PD-L1 expression\" (TPS, s.u.) and as a percentage of positive immune cells (Immun Cell Score, 14] Row 10: \"The result is as a percentage of membrane-nally positive tumour cells (tumour pro- to-) Row 11: \"portion score\" (TPS, s.u.)",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.60 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.61 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.62 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation: New 2025 Row 2 : In patients with non-small cell lung carcinoma in stage IB-III, parallel: Row 3 : To the molecular pathological investigations, an immunohistochemical test on PD-L1 expression is to be performed.The result is to be given as a percentage of membraneous positive tumour cells (Tumour Pro---- Row 7:",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--modified 2025 Row 2:--based on the available tumor tissue/tumour cells of al--- Row 3:--n NSCLC in stage IV, molecular pathological investigations are to be looked at--- Row 4:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 172,
      "end_page": 172
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.63-Consensus-based recommendation-tested 2025 Row 2: EK-EIn molecular pathological studies, a method is to be used-- Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.64-Consensus-based recommendation-tested 2025 Row 2: EK-testedIn case of insufficient tissue for a molecular diagnosis, and if a Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.65-Consensus-based recommendation-tested 2025 Row 2: EC-EGFR-TKI resistance as well as acquired resistance according to ALK-, ROS1-- Row 3: or RET-inhibitor therapy should be performed a recovery of tumor cell material to the um--- Row 4: --comprehensive testing for resistance mechanisms.- Row 5: --- Row 6: --Starker Consensus-Row 7: ----",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.66-Consensus-based recommendation--tested 2025 Row 2: EC--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.63 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.64 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.65 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.66 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : In case of insufficient tissue for a molecular diagnosis, and if a Row 3 : Renewed biopsy cannot be performed at reasonable risk, e : Row 4 : Liquid Biopsy should be performed, provided a histological/cytologist-- Row 5 :",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 4)",
      "text": "Row 1: Row 2: zt Row 3: mt, Row 4: or- Row 5: Row 6: d Row 7: un- Row 8: Row 9: e- Row 10: Row 11: sen Row 12: Row 13: Row 14:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 4)",
      "text": "Row 1: Row 2: a Row 3: a Row 4: Row 5: Row 6:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 4)",
      "text": "Row 1: Row 2: S1- Row 3: um- Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 4)",
      "text": "Row 1: Row 2: ba- Row 3: uid Row 4: Row 5:",
      "start_page": 173,
      "end_page": 173
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.67-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In patients of higher age (>70 years) a particularly careful Row 3: B-Diagnosis and clinical evaluation of comorbidities should be carried out.- Row 4: -- Row 5: Level of Evidence--- Row 6: --Konsens-Row 7: ----",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.67 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: Row 6:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--In patients of higher age (>70 years), a particularly careful Row 3: diagnosis and clinical evaluation of comorbidities should be carried out.-- Row 4: -- Row 5: nce--- Row 6: --Konsens-- Row 7: ----",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.68-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In the evaluation of lung function a close interdisciplinary agreement should be made between pneumologists,- Row 4: -Thorax surgeons and radiation therapists in borderline cases and complex-row 3: B-Clinical image.- Row 5: Level of Evidence--- Row 6: -Konsens-- Row 7: ----",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.69-Evidence-based recommendation-2010 Row 2: Degree of recommendation--In a planned lobectomy, a postbronchodilator FEV1--row 3: B->1.5 l and a diffusion capacity (TLCO) should be >60 % of the target value, and at a Row 4: planned pneumonectomy at a postbronchodilator FEV1 >2.0 l---row 5: and a TLCO >60 % of the target value should not be followed by further lung function testing--- Row 6: ----- Row 7: -------- Row 8: Level of Evidence---- Row 9: ---Consensing Row 10: -------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: 6.70-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In patients who are not clearly operable based on FEV1 and TLCO values Row 3: B-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In patients who are not clearly operable based on FEV1 and TLCO values, a full-body plethysmography, a blood gas analysis at rest, a Row 4: quantitative lung perfusion scintigraphy and a spiroergometry should be carried out Row 5: .",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.68 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: Row 6:",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.69 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: 6.70 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--In a planned lobectomy, a post-bronchodilator FEV1-- Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: \"Evidence-based recommendation\"2010 Row 2: \"grad\"In patients who are not clearly operable based on FEV1 and TLCO values Row 3: \"Row 3:\" a full-body plethysmography, a blood gas analysis at rest, a Row 4: \"Quantitative Pulmonary Perfusion Scintigraphy\" and a spiroergometry should be performed.\" Row 5: \"\"\"\" Row 6: \"\"\"\" Row 7: \"nce\"\"\" Row 8: \"\"Konsens\" Row 9: \"\"\"\"",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page)",
      "text": "Row 1: (a)--a complete lung function test with spirometry - better still full-body Row 2:--plethysmography - and CO-transfer factor ([439], [451]) (evidence level 2b), Row 3:-- Row 4: (b)---the determination of arterial blood gases at rest ([452], [453], [454]) (evidence level Row 5: --3b), Row 6: -- Row 7: (c)---a lung perfusion scintigraphy with quantification of the regional Radionuc- Row 8: ---lid occupation ([455], [456], [458], [449], [459] (evidence level 2b) and a Row 9: -- Row 10: (d)---Spiroergometry [453], [446, [4] [4] Row 1:",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 1)",
      "text": "Row 1: (a) Row 2: Row 3: (b) Row 4: Row 5: (c) Row 6: Row 7: (d) Row 8:",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "table under heading <6.59 Consensus-based recommendation new 2025> (from previous page, column 3)",
      "text": "Row 1: a complete lung function test with spirometry - better still whole-body Row 2: plethysmography - and CO-transfer factor ([439], [451]) (evidence level 2b), Row 3:",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "Table under heading <6.7 Evaluation of clinical and functional operability 180>",
      "text": "Row 1: Postoperative FEV1 Row 2: Measurements: Row 3: preoperative post-bronchodilator FEV1 (1) (so-called Preop. FEV1) Row 4: quatitative lung perfussion scintigraphy Row 5: Calculation of post-operative FEV1 (ppo FEV1): Row 6: Post-op. FEV1 = preop. FEV1 x (100% proportion of lung perfusion of the resicant Row 7: range of total perfusion). Row 8: The calculated post-operative FEV1 is expressed in litres. Row 9: Transfer factor: Row 10: The post-operative transfer factor (ppoT(LCO)) is calculated analogously to the calculation of the post-operative FEV1 Row 11:.",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "table under heading <6.7 Evaluation of clinical and functional operability 180> (from previous page)",
      "text": "Row 1: Postoperative FEV1 Row 2: PBD = post-bronchodilator measurement of FEV1 after inhalation of bronchodilators Row 3: (400microgr salbutamol plus/minus 0 microgr ipratropium bromide)",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "table under heading <6.7 Evaluation of clinical and functional operability 180> (from previous page)",
      "text": "Row 1: 6.71-Evidence-based recommendation--2010 Row 2: Degree of recommendation--To assess the surgical risk associated with a lung resek--- Row 3: B--The spiroergometry should be used as a standardized load test--- Row 4: ------ Row 5: Level of Evidence---- Row 6: --Konsens-- Row 7: ----",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "table under heading <6.7 Evaluation of clinical and functional operability 180> (from previous page, column 1)",
      "text": "Row 1: Postoperat Row 2: PBD = post Row 3: (400microg)",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "table under heading <6.7 Evaluation of clinical and functional operability 180> (from previous page, column 1)",
      "text": "Row 1: 6.71 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: Row 6:",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "table under heading <6.7 Evaluation of clinical and functional operability 180> (from previous page, column 2)",
      "text": "Row 1: active FEV1 Row 2: tbronchodilator measurement of FEV1 after inhalation of bronchodilators Row 3: gr salbutamol plus/minus 0 microgr ipratropium bromide)",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "table under heading <6.7 Evaluation of clinical and functional operability 180> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--To assess the surgical risk associated with a lung resek--- Row 3:--ion, the spiroergometry should be used as a standardized load test--- Row 4:----Row 5: nce--- Row 6: --Konsens-- Row 7: ----",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "Table under heading < brain-providing arteries should be an interventional or > before lung resection",
      "text": "Row 1: 6.72-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Before a planned lung resection an ECG should be recorded.- Row 3: A的 Row 4:--In a conspicuous cardiac auscultation finding or in clinical signs-- Row 5: Heart failure should be performed an echocardiography.- Row 6:",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under heading < brain-providing arteries should be an interventional or > before lung resection",
      "text": "Row 1: 6.73-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In the first 6 weeks after a myocardial infarction, no lung resection-row 3: B- should be performed.- Row 4: -In patients with myocardial infarction in the past 6 months before a ge- and Row 5: Planned lung resection should be performed a cardiological examination.- Row 6: Level of Evidence- and Row 7: , and Consens- Row 8: , and",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under heading < brain-providing arteries should be an interventional or > before lung resection",
      "text": "Row 1: 6.74-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Before planned lung resection should be performed in patients with stroke or TIA in-row 3: B-nose history or flow noise over the carotids a carotid dopp--- Row 4: -ler and a duplex sonography. In case of symptomatic Row 5: high-grade but asymptomatic stenosis (>70%) of extracranial Row 6: --- Row 7: brain-providing arteries should be considered before lung resection an interventional or--- Row 8: surgical treatment of stenosis.-- Row 9: Level of Evidence---- Row 10: ---Konsens-row 11: -----------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under headed arteries should include an interventional or (column 1) prior to lung resection.",
      "text": "Row 1: 6.72 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under headed arteries should include an interventional or (column 1) prior to lung resection.",
      "text": "Row 1: 6.73 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under headed arteries should include an interventional or (column 1) prior to lung resection.",
      "text": "Row 1: 6.74 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under headed arteries should be interventional or (column 2) prior to lung resection.",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--An ECG should be recorded before a planned lung resection.-- Row 3: -- Row 4: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under headed arteries should be interventional or (column 2) prior to lung resection.",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--In the first 6 weeks after myocardial infarction, no lung resection-- Row 3:-- should be performed.-- Row 4:--In patients with myocardial infarction in the previous 6 months before a ge--- Row 5: planned lung resection should be performed a cardiological examination.-- Row 6:nce--- Row 7: --Konsens-- Row 8: ----",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "Table under headed arteries should be interventional or (column 2) prior to lung resection.",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--Before planned lung resection, a carotid dopp---row 4: -ler and a duplex sonography should be performed in patients with stroke or TIA in-- Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 183,
      "end_page": 183
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page) before lung resection.",
      "text": "Row 1: High risk of instable or severe angina pectoris: Row 2: • Recent myocardial infarction with reference Row 3: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 1) before lung resection",
      "text": "Row 1: High Row 2: Row 3: Middle Row 4:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 2) before lung resection",
      "text": "Row 1: s Risk-Instable or severe Angina pectoris: Row 2: -• Recent myocardial infarction with reference Row 3: -On a significant ischaemic Ri- Row 4: -siko based on clinical Sympto- Row 5: -men Row 6: --• Unstable or severe Angina Row 7: --Decompensated heart failure Row 8: --Significant arrhythmias: Row 9: --• AV-Block II and III Grades Row 10: --• Symptomatic ventricular arrhythmia Row 11: -----mmies in the presence of a heart failure-fizi- Row 12: --enz Row 13: ---• Supraventicular arrhythmias with non-row 14:---controlled heart rate Row 15:---• Severe heart valve failure Row 16: res Risk---Leichte Angina pectoris Row 17-----Presence",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page) before lung resection.",
      "text": "25 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 -",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page) before lung resection.",
      "text": "Row 1: Risk factors--• High surgical risk (including Row 2: Intrathoracal) Row 3:--• Ischaemic heart disease Row 4:--• Heart failure Row 5:--• Diabetes mellitus with existing Com-Row 6:--plications (arteriosclerosis with neuro-Row 7:-- and microangiopathy) Row 8:---• Creatinine > 1.7mg% Row 9: Number of risk factors---Cardial main complications* Row 10: 1---1.1.1% Row 11: 2--4.6% Row 12: ≥3-9.7%",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 1) before lung resection",
      "text": "Row 1: High Row 2: Row 3: Row 4: Low Row 5: Row 6: [489]",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 1) before lung resection",
      "text": "Row 1: Risk Row 2: Row 3: Anzah Row 4: 1 Row 5: 2 Row 6: ≥3",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 2) before lung resection",
      "text": "Row 1: s Risk Row 2: Row 3: Row 4: Row 5: ges Risk Row 6: Row 7: Row 8:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 2) before lung resection",
      "text": "Row 1: ofactor Row 2: Row 3: hl Risi Row 4: Row 5: Row 6:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 3) before lung resection",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 3) before lung resection",
      "text": "Row 1: Row 2: Row 3: ikofak Row 4: Row 5: Row 6:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 4) before lung resection",
      "text": "Row 1: Row 2: Row 3: ktore Row 4: Row 5: Row 6:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 5) before lung resection.",
      "text": "Row 1: Row 2: Row 3: and Row 4: Row 5: Row 6:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 9)",
      "text": "{Injection}} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Injection} {Inject} {Inject} {Inject {Inject} {Inject} {Inject} {(Inject} {Inject} {in (Inject} {in (Inject} {Inject} {in (Inject} (Inject} (Inject} {in (Inject} (Inject}",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 9)",
      "text": "Row 1: • High risk of surgery (including Row 2: Intrathoracic) Row 3: • Ischaemic heart disease Row 4: • Heart failure Row 5: • Diabetes mellitus with existing Com-Row 6: • Symptoms (arteriosclerosis with neuro-Row 7: • and microangiopathy) Row 8: • Creatinine > 1.7mg% Row 9: • Cardiac main complications* Row 10:",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page) before lung resection.",
      "text": "Row 1: Risk factors--• High surgical risk (including Row 2: Intrathoracic) Row 3:--• Ischaemic heart disease Row 4:--• Heart failure Row 5:--• Diabetes mellitus with existing com- Row 6:--plications (arteriosclerosis with neuro- Row 7:-- and microangiopathy) Row 8:--• Creatinine > 1.7mg% Row 9: modified after [431]-- Row 10: *Myocardial infarction, pulmonary oedema, atrial fibrillation, first cardiac syncope, total AV block or---Row 11: AV block III-----",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 1) before lung resection",
      "text": "Row 1: Risk Row 2: Row 3: modif Row 4: *Myok Row 5: AV-Blo",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 2) before lung resection",
      "text": "Row 1: ofakt Row 2: Row 3: infected Row 4: cardinal Row 5: ock III",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "table under heading < brain-providing arteries should be an interventional or> (from previous page, column 3) before lung resection",
      "text": "Row 1: oren,• High risk of surgery (including Row 2: intrathoracic) Row 3: • Ischaemic heart disease Row 4: • Heart failure Row 5: • Diabetes mellitus with existing Com- Row 6:",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 7.17.Evidence-based recommendation, tested 2025 Row 2: Degree of recommendation, the type of information and the patient's education is to be given by Row 3: A: the following basic principles of patient-centered communication, which enables Row 4: a participative decision-making: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 7.2-'Consensus-based statement-tested 2025 Row 2: EK-'The communicative competencies of the educating doctors can be improved by the Row 3:-'participation in a structured communication training.- Row 4:-'Konsens-' Row 5:-'",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 7.1 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 7.2 Row 2: EC Row 3: Row 4:",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: 2025 Row 2: grade: 163Leitatur: 153Leitatur: There are: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2050 Row: 2025 Row: 2050 Row: 2050 Row: 2025 Row: 2025 Row: 2050 Row: 2050 Row: 2025 Row: 2025 Row: 2025 Row: grade: 2050 Row: 2050 Row: 2025 Row: 2025 Row: 2025 Row: 2025 Row: 50 Row: 2025 Row: 50 Row: 2025 Row: 2025 Row: 2025 Row: 2025 Row: 2025: 2025 Row: 50 Row: 50 Row: 2025: 50 Row: 2025: 2025: 2025: 2025: 50 Row: 50 Row: 50 Row: 50 Row: 50 Row: 50 Row",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based statement-tested 2025 Row 2:--The communicative competencies of the educating doctors can be improved by the-- Row 3:--participation in a structured communication training.-- Row 4:--Consensus-- Row 5:----",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7.3- and consensus-based recommendation--tested 2025 Row 2: EC-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7,4 such a consensus-based recommendation, tested 2025 Row 2: EK, before transmitting information, is to be asked with what knowledge, with the Row 3: which ideas, hopes and fears in connection with the Row 4: his illness of the patient goes into the conversation.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7.5-Essence-based recommendation-tested 2025 Row 2: EK-Essential information should be transmitted step by step with regular reversing Row 3: to determine whether and to what extent the patient has understood it.- Row 4:-Essentially, the patient should be encouraged to ask questions.- Row 5: -Essense Row 6: -Essence-based recommendation-tested Row 2: EK-Essential information should be transmitted step by step with regular reversing Row 3:-Essence on whether and to what extent the patient has understood it.-Roow 4:-Essence on this basis should be explicitly encouraged to ask questions.- Row 5: -Essense Row 6: -Essense Row 6: -Essense Row 6: -Essence",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.3 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.4 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.5 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--The information about the disease and its course is to be provided primarily by the doctor who deals with the Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -Information shall be transmitted step by step with regular feedback-- Row 3: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7.6-Consensus-based recommendation--tested 2025 Row 2: EK--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.6 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--Members are to be asked about their needs and encouraged, if necessary, to accept Un---- Row 5:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7,7--Consensus-based recommendation--tested 2025 Row 2: EK--patients with non-healable lung cancer should receive the offer of predictive care plan--- Row 3:-----row 4:--Konsens-- Row 5:----",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7.8-Consensus-based recommendation--tested 2025 Row 2: EC--The subject of discussions on predictive care planning should be:-- Row 3:--• Scope and limits of treatment in the case of (illness)typical so--- Row 4:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.7 Row 2: EC Row 3: Row 4:",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.8 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--patients with a non-healable lung carcinoma should receive the addition-- Row 3:--bot of a predictive care plan.-- Row 4:--Consensus-- Row 5:----",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--The subject of discussions on predictive care planning should be:-- Row 3:--• Scope and limits of treatment in case of (illness)typical so--- Row 4:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 195,
      "end_page": 195
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7.9-Consensus-based recommendation--tested 2025 Row 2: EK--patients with a non-healable lung carcinoma should be given early-- Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 7.10 aConsensus-based recommendation-tested 2025 Row 2: EK-testedThe statement of a death wish of a patient with a non-healing Row 3: a cancer is to be met with empathy and willingness to talk Row 4: .",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.9 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 7.10 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--patients with a non-healable lung carcinoma should be given early--- Row 3:--and, in the case of disease progress, the explicit willingness to speak about Row 4:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--The statement of a death wish of a patient with a non-healing Row 3: cancer is to be met with empathy and willingness to talk-- Row 4:----Row 5: ---- Row 6: --Konsens-- Row 7: ----",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.1, Consensus-based recommendation, tested 2025 Row 2: EK, higher age should not be a sole reason for exclusion from treatment, Row 3: , with a treatment modality (chemotherapy, radiotherapy, surgery).",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.1 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--A higher age should not be a sole reason for exclusion from treatment-- Row 3:--with a treatment modality (chemotherapy, radiotherapy, surgery).-- Row 4:--The spectrum of comorbidities is of greater relevance.-- Row 5:--Starker Konsent-- Row 6:---",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8,2 such evidence-based recommendation is tested 2025 Row 2: Recommendation level, patients with non-healable lung cancer should receive early on the offer of an integration of palliative counselling and --- Row 4: care according to Diag-- Row 3: Anosis position, Row 5: Level of Evidence, [607], [568], [597], [564]",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.3-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-The offer for the integration of palliative counselling and care in patients- Row 3: B-with non-healable lung cancer should be made early (within the first 2 months of the first 2 months) after diagnosis.- Row 5: Level of Evidence--[568]- Row 6: 2b--- Row 7: --- Row 8: --Konsens- Row 9: -----",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.4-Evidence-based recommendation--tested 2025 Row 2: Degree of recommendation--Palliative care should be done and documented by palliative medical qualified specialists-- Row 3: Forces in all palliative medically relevant dimensions (physical, psychiatric-- Row 4: -sche, social and spiritual needs).-- Row 5: Level of Evidence--[607], [568], [597], [564]-- Row 6: 2b---- Row 7: ---- Row 8: --Konsens-- Row 9: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.5-Evidence-based recommendation--tested 2025 Row 2: Degree of recommendation--In the context of palliative counselling and care of patients with non-heilba--- Row 3: Blood lung cancer, the following tasks should be accomplished:-- Row 4:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.6-'Consensus-based statement-tested 2025 Row 2: EK-'In studies, the positive effects of early palliative consultation and-' Row 3: supply were achieved when: (a) the contacts were performed at least in monthly intervals-' Row 4: and (b) after a primary contact 3 follow-up contacts.- Row 5: \"\" Row 6: \"\"Konsens\" Row 7: \"\"\"",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.7-Essence-based recommendation-tested 2025 Row 2: EC-Structured palliative care should be integrated into decision-making processes in patients- Row 3: --with non-healable lung cancer (e.g., Row 4:--by participation in interdisciplinary tumor conferences or by a pallia--- Row 5: --- Row 6: -Tivmedical Consil Service). Row 7: --Konsens- Row 8: ----",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.5 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.6 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.7 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: Consensus-based statement-tested 2025 Row 2:--In studies, the positive effects of early palliative consultation and--- Row 3:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: Structured palliative care should be integrated into decision-making processes in patients-- Row 3:--with non-healable lung cancer (e.g.-- Row 4:--by participation in interdisciplinary tumor conferences or by a pallia--- Row 5:--- Row 6: Tivmedical Consil Service).-- Row 7: --Konsens- Row 8:----",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "table under heading <2b> (from previous page)",
      "text": "In addition, it is time to get it to: to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 203,
      "end_page": 203
    },
    {
      "heading": "table under heading <2b> (from previous page, column 1)",
      "text": "Row 1: Study Row 2: Badr, Row 3: al., 20 Row 4: [607], Row 5: Row 6: Bakita Row 7: et al., Row 8: [568], Row 9:",
      "start_page": 203,
      "end_page": 203
    },
    {
      "heading": "table under heading <2b> (from previous page, column 2)",
      "text": "In addition, it is time to get back to: to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 203,
      "end_page": 203
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204>",
      "text": "In addition, it is important to consider the following criteria: how to improve the quality of the products and services in order to improve the quality of the products and services in order to improve the quality of the products and services in order to improve the quality of the products and services in order to improve the quality of the products and services.",
      "start_page": 204,
      "end_page": 204
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page)",
      "text": "[2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2 [2] [2] [2] [2] [2] [2 [2] [2] [2] [2 [2 [2 [2] [2 [2 [2] [2] [2 [2 [2] [2] [",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page)",
      "text": "Row 1: 8.9-Evidence-based recommendation-tested 2025 Row 2: degree of recommendation-If, in patients with NSCLC in clinical stage II, a lobectomy is not possible due to Row 3: A, of comorbidities or pulmonary function limitation, a Row 4: , anatomical segment resection should be sought.- Row 5: Level of Evidence-[619], [620], [621], [622], [623], [624], [625], [475], [592], [626], [627], [628], [629], [630], [631], [632], [643], [643], [64] [635], [636], [636], [637], [638], [639], [640], [641], [642], [643, [643] [4] [4] [6 [6] [6] [6, [6] [6 [6] [6 [6, [6] [6",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page)",
      "text": "Row 1: 8.10-Consensus-based recommendation-tested 2025 Row 2: EK-tested In order to avoid pneumonectomy, a parenchyme-saving cuff-edged Row 4:",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page, column 1)",
      "text": "Row 1: 8.8 Row 2: Recommendationg Row 3: A/0 Row 4: Row 5: Level of Eviden Row 6: 2a Row 7: Row 8:",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page, column 1)",
      "text": "Row 1: 8.9 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page, column 1)",
      "text": "Row 1: 8.10 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page, column 2)",
      "text": "[6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6 [6 [6] [6] [6] [6] [4] [4] [6] [4] [4] Row 4: [6 [6 [6 [6 [4] Row 4: [8 [8 [8 [8 [8",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, if a lobectomy is not possible in patients with NSCLC in clinical stage II due to the Row 3: , of comorbidities or pulmonary function limitation, a Row 4: anatomical segment resection should be sought.",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <8.2 Concept of early integration of palliative care 204> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -To avoid pneumonectomy, a parenchyme-saving cuff-edged Row 4: -section should be performed in central tumors, if the Row 3: -technical operability is available.- Row 5: -- Row 6: --Starker Konsent-ed Row 7: ----",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.11-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In general or functionally inoperable patients with a NSCLC stage I-Row 3: A- and IIA should be offered a stereotactic radiotherapy.- Row 4: -- Row 5: Level of Evidence--[650], [644], [652], [653], [654]- Row 6: 1b--- Row 7: --- Row 8: --Starker Konsensenz-- Row 9: -----",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.12-Consensus-based recommendation-tested 2025 Row 2: EK-EIn the dose prescription for lung sterotaxia, the tumor localization is to be considered Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.13-Consensus-based recommendation-tested 2025 Row 2: EC-testedIf there is no pathological diagnosis due to high risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related risk-related",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.11 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.12 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.13 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn general or functionally inoperable patients with a NSCLC stage I-level Row 3: and IIA is to be offered a stereotactic radiation therapy.- Row 4:-level Row 5: nce[650], [644], [652], [653], [654]-level Row 6:",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--In the dose prescription for lung stereotaxia, the tumor localization-- Row 3:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.14-Evidence-based recommendation-tested 2025 Row 2: Recommended level-of-residence patients with NSCLC in stage I / II are to be offered a radical resection with adequate lung function and feh--- Row 3: Aelenden contraindications, whose goal is the R0 tumor removal.- Row 5: Level of Evidence--[592], [659], [660], [661], [662], [663], [664], [665], [666], [667], [667], [668], [668]- Row 6: 2a",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.15-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In the NSCLC in stage I/II, the Row 3: A-radical resection as lobectomy should be performed with sufficient cardiopulmonary function.- In the case of tumors ≤ 2cm in the outer third of the parenchyme mantle and cytologically-controlled Row 5: or histologically-secured N0 status, an anatomical segmental resection is equal to Row 6: -the lobectomy with respect to curation, provided that a resection distance can be achieved at the lung parenchyme-row 7: -a resection distance greater than the tumor-by-step Row 8: -the-meter.- Row 9: Level of Evidence-[659], [660], [592], [662], [665], [670], [671, [672] [67] [660]",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.16, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"For the NSCLC in stage I and II, minimally invasive VATS or RATS-, \"Row 3: \"Lobectomy\" compared to conventional open lobectomy - at the same-, \"Row 4:\" results in less postoperative complications and weni-, \"Row 5:\" postoperative pain, resulting in an improved quality of life\" Row 6: \"\"\"Row 7:\" and a shorter hospital stay. Therefore, the minimal-, \"Row 8:\" invasive lobectomy of conventional open lobectomy at the NSCLC in the Sta-, \"Row 9:\" and \"II\" should be preferred. \"Row 10: Level of Evidence\" [674,] [675], [677], [677,] [680] Row 11: 2, \"\"\"\"\" Row 10: \"Level of Evidence\" [674]",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.14 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.15 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: 1b Row 7: Row 8:",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.16 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 2a Row 7: Row 8:",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients with NSCLC in stage I / II are to be offered a radical resection with adequate lung function and feh-- Row 3: false contraindications, whose goal is the R0 tumor removal.- Row 5: nce[592], [659], [660], [661], [662], [663], [664], [665], [666], [657], [667], [668], [668]- Row 6:",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: \"Evidence-based recommendation\" tested 2025 Row 2: \"grade\" At NSCLC in stage I and II, according to minimal-invasive VATS or RATS Row 3: \"Lobectomy\" compared to conventional open lobectomy - at equal-\" Row 4: \"one-oncological result\" - less postoperative complications and weni-\" Row 5: \"ger postoperative pain\" observed, resulting in an improved quality of life\" Row 6: \"\"\" Row 7: \"\" and a shorter hospital stay. Therefore, the minimal-\" Row 8: \"invasive lobectomy\" of conventional open lobectomy at NSCLC in the Sta-\" Row 9: \"\" Row I and II should be preferred.\" Row 10: \"nce\"[674], [675], [677], [678], [680]\" Row 11: \"\"\" Row 12: \"\"\" Row 12: \"\"\"\" Row 10: \"nce\"[674], [676]",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "table under heading <8.20 Consensus-based recommendation reviewed 2025>",
      "text": "Row 1: 8.17-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In patients who are fed a curative resection, a systemati-- Row 3: Awesome lymph node dissection is to be performed to enable accurate staging-- Row 4:--and to possibly improve the prognosis.-- Row 5: Level of Evidence--[681], [682], [683], [684], [685], [686], [687]-- Row 6: 1b---- Row 7:",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "table under heading <8.20 Consensus-based recommendation reviewed 2025>",
      "text": "Row 1: 8.18, \"Evidence-based recommendation\" tested 2025 Row 2: Recommendation level\"In patients with chest wall infiltration, an R0 situation is crucial and there is to be an en bloc resection aimed at.\" Row 4: \"\" Row 5: Level of Evidence\"[592], [688], [689], [690], [691], [692], [693]\" Row 6: \"\"\" Row 7: \"\"\" Row 8: \"\"Starker Consensus\"\" Row 9: \"\"\"",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "table under heading <8.20 Consensus-based recommendation reviewed 2025>",
      "text": "Row 1: 8.19-Consensus-based recommendation-tested 2025 Row 2: EK-testedIn pleurainvasion without deeper chest wall infiltration, an extrapleural Row 3:-Lyse can be performed.- Row 4:-Strong Consensus-Row 5:--",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "table under heading <8.20 Consensus-based recommendation reviewed 2025>",
      "text": "Row 1: 8.20:Consensus-based recommendation, tested 2025 Row 2: EK:In case of deeper chest wall infiltration, a full wall resection is to be carried out.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.21-evidence-based recommendation-tested 2025 Row 2: recommendation level-after R1-resection, the other Row 3: B-therapy options (e.g. re-resection or radiation therapy) should be discussed in the Thoracic Oncological Tumor Board.-Roow 5: level of evidence-[694]-Roow 6: 3b",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.21 Row 2: Recommend Row 3: B Row 4: Level of Row 5: 3b Row 6: Row 7:",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "table under heading <3b> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: degree-testedAccording to R1-resection, the Thoracic Oncological Tumor Board should discuss the further Row 3: therapy options (e.g. re-resection or radiation therapy)- Row 4: level.- Row 5: level-[694]- Row 6: level-down Row 7: level-down Row 8: level-down Row 9: level-down Row 9: level-down",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]>",
      "text": "Row 1: 8.22-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-led NSCLC in stage I did not lead to an extension of the relapse-free or Ge--- Row 4: post-mortem survival and is therefore not recommended outside of studies.- Row 5: Level of Evidence--[714], [715], [717], [718]-- Row 6: 1---- Row 7: --- Row 8: --Starker Konsensenz--- Row 9: -----",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]>",
      "text": "Row 1: 8.23, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\" At NSCLC in stage II, it should be discussed in an interdisciplinary manner whether a syste- and Row 3: \"B\" mixed, anti-neoplastic induction therapy, followed by resection, is performed as alterna- and Row 4: \"active therapy option\". Decision criteria are Expression- and Row 5: \"PD-L1\" risk, R1/R2 resection, comorbidities, compliance assessment\" Row 6: \"\" Row 7: \"and Patient's request\". \"Row 8: Level of Evidence\"[714], [715], [719], [716], [717], [720],\" [720] Row 9: 3, \"\" Row 10: \"\" Row 11: \"\"Consens\" Row 12: \"\" Row 12: \"\"",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]>",
      "text": "Row 1: 8.24-Evidence-based recommendation-modified 2025 Row 2: Recommendation level--NSCLC patients with resectable tumours in stage II (without EGFR and ALK--- Row 3: Ageing) and recommendation of an induction therapy should be offered a combined Im--- Row 4:munchemotherapy. Checkpoint inhibitor therapy can be continued postoperatively, starting from--- Row 5: Depending on the admission status.- Row 6: ---- Row 7: Level of Evidence--[720], [721], [722], [723]- Row 8: 1b----- Row 9: ----- Row 10: ----Starker Consensus- Row 11: ------",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]> (column 1)",
      "text": "Row 1: 8.22 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 1 Row 6: Row 7:",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]> (column 1)",
      "text": "Row 1: 8.23 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 3 Row 7: Row 8:",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]> (column 1)",
      "text": "Row 1: 8.24 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 1b Row 7: Row 8:",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: degree-tested At NSCLC in stage I, preoperative chemotherapy in randomized Row 3: so far has not led to an extension of the relapse-free or Ge-\" Row 4: survival time and is therefore not recommended outside of studies.- Row 5: nce\"[714], [715], [716], [717], [718]- Row 6: \"\"\" Row 7: \"\" Row 8: \"\"Strong Consensus\" Row 9: \"\"",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]> (column 2)",
      "text": "Row 1: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <nce [720], [721], [722], [723]> (column 2)",
      "text": "Row 1: evidence-based recommendation modifies 2025 Row 2: grade-NSCLC patients with resectable tumours in stage II (without EGFR and ALK--- Row 3: age) and recommendation of an induction therapy, a combined induction therapy is to be offered Row 4: munchemotherapy. Checkpoint inhibitor therapy can be continued postoperatively, starting from--- Row 5: dependent on approval status.",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.25-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-According to R0-resection and systematic lymph node dissection, patients should be offered an adjuvant Che- and Row 4: if no neoadjuvant therapy was carried out- Row 5: , in good general condition (ECOG 0/1).- Row 6: -- Row 7: Level of Evidence--[726], [727], [729], [730]- Row 8: 1a",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.26, \"evidence-based recommendation\" audited 2025 Row 2: recommendation level\"Adjuvant chemotherapy should begin after completion of wound healing within the Row 3: \"b\" of 60 days after resection.\" Row 4: \"g\" Row 5: Level of Evidence\"[731], [732], [733]\" Row 6: 2b\" Row 7: \"g\" Row 8: \"g\" Row 9: \"g\" Row 9: \"g\"",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.27, \"Proof-based recommendation\" tested 2025 Row 2: \"Recommendation level\" In adjuvant chemotherapy patients with NSCLC in stage II, \"Row 3: \"Good general condition\" (ECOG 0/1) the administration of a cisplatin-containing combina-\" Row 4: \"4 cycles\" should take place.\" Row 5: \"Level of Evidence\"[734], [729], [730], [726]\" Row 6: \"1\"\" Row 7: \"\"\" Row 8: \"Starker Consensus\" Row 9: \"\"\"",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "table under heading up to the top: see evidence report>",
      "text": "Row 1: 8.28-Evidence-based recommendation-new 2025 Row 2: Recommendation level-patients with NSCLC in stage IB and an activating EGFR mutation (only: Row 3: B-Exon 19 Deletion, Exon 21 L858R), should be offered an ad-: Row 4: Ajuvant therapy with osimertinib over 3 years after primary R0-resection.- Row 5: Level of Evidence-[735], [736]-row 6:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report>",
      "text": "Row 1: 8.29-Evidence-based recommendation-tested 2025 Row 2: Recommended level of NSCLC patients in stage II and an activating EGFR mutation (only) Row 3: A-Exon 19 Deletion, Exon 21 L858R) is expected to receive an adjuvant therapy with osimertinib over 3 years after primary R0-resection and adjuvant-- Row 4: Adjuvant chemotherapy.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report>",
      "text": "Row 1: 8.30 a.m.Evidence-based recommendation: New 2025 Row 2: Degree of recommendation: Patients with NSCLC in stage II and an activating EGFR mutation (only: Row 3: B-Exon 19 Deletion, Exon 21 L858R), in which no Row 4: Adjuvant chemotherapy can be performed after primary R0 resection, an adjuvant therapy: Row 5: with osimertinib over 3 years is to be offered.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 1)",
      "text": "Row 1: 8.28 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: ----- Row 6: to Row 7: ----- Row 8: Row 9:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 1)",
      "text": "Row 1: 8.29 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 1)",
      "text": "Row 1: 8.30 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: ----- Row 7: to Row 8: ----- Row 9: Row 10:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 2)",
      "text": "Row 1: New 2025 Row 2: new, new 2025 Row 2: new NSCLC patients in stage IB and an activating EGFR mutation (only) Row 3: new 2025 Row 2: new 19 Deletion, Exon 21 L858R), is to be offered an ad- and ajuvant therapy with osimertinib over 3 years after primary R0 resection.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedPatients with NSCLC in stage II and an activating EGFR mutation (only-low 3: exon 19 deletion, exon 21 L858R) is expected to receive adjuvant therapy with osimertinib over 3 years after primary R0-resection and adjuvant Row 4: chemotherapy. Row 6:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 2)",
      "text": "Row 1: New 2025 Row 2: new, evidence-based recommendation, with NSCLC in stage II and an activating EGFR mutation (only) Row 3: Exon 19 Deletion, Exon 21 L858R), in which no Row 4: Adjuvant chemotherapy can be performed after primary R0 resection, an adjuvant Thera: Row 5: will be offered with osimertinib over 3 years.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 3)",
      "text": "Row 1: Row 2: r Row 3: Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 3)",
      "text": "Row 1: Row 2: Row 3: n- Row 4: bo- Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report> (column 3)",
      "text": "Row 1: Row 2: Row 3: e Row 4: apie Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "table under heading up to the top: see evidence report>",
      "text": "Row 1: 8.31,Evidence-based recommendation: New 2025 Row 2: Degree of recommendation: Patients with NSCLC in stage II and an ALK translocation should be offered an adjuvant therapy with alectinib over 2 years according to primä-- Row 3: Harder R0-Resection: Row 4: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading up to the top: see evidence report>",
      "text": "Row 1: 8.32-Evidence-based recommendation-tested 2025 Row 2: Recommended level of NSCLC patients in stage II with PD-L1 expression ≥ 50% (without EGFR-Evidence Row 3: or ALK alteration) is to be offered, according to primary R0-resection and performed ad-",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading up to the top: see evidence report>",
      "text": "Row 1: 8.33-Consensus-based recommendation--tested 2025 Row 2: EC--patients with NSCLC in stage II (without EGFR or ALK alteration) should, according to Row 3: primary R0-resection and conducted adjuvant chemotherapy, independent--- Row 4: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: 8.31 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: ---- Row 6: to Row 7: --- Row 8: Row 9:",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: 8.32 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: ----- Row 7: to Row 8: ---- Row 9: Row 10:",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: 8.33 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: evidence-based recommendation: New 2025 Row 2: gradedPatients with NSCLC in stage II and an ALK translocation should be offered an adjuvant therapy with alectinib over 2 years according to primä-",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: graded patients with NSCLC in stage II with PD-L1 expression ≥ 50 % (without EGFR-E Row 3: or ALK alteration) is to be offered, according to primary R0-resection and performed ad-\" Row 4: \"juvant chemotherapy\", an adjuvant therapy with atezolizumab over 1 year.\" Row 5: \"\"\"\" Row 6: \"\"\" Row 7: \"\"\"[740], [741]\" Row 8: \"\"\"\" Row 9: \"\"\"\"\"\" to \"\"\"\"\": see evidence report-\" Row 10: \"\"\"\" Row 11: \"\"\"\" Row 12: \"\"\"\"\" Row 13: \"\"\" Starker Konsensung\" Row 14: \"\"\"\"",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: Patients with NSCLC in stage II (without EGFR or ALK alteration) should, according to Row 3: primary R0-resection and conducted adjuvant chemotherapy, independent Row 4: depending on PD-L1 status, receive adjuvant therapy with pembrolizumab over 1 year--- Row 5:",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.34/Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with NSCLC in stage I and II shall not be offered an adjuvant-based Row 3: A-ray therapy according to R0-resection.- Row 4: -- Row 5: Level of Evidence--[758], [748], [759], [760], [761], [762], [763], [764]- Row 6: 1a--",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 8.34 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1a Row 6: Row 7:",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients with NSCLC in stage I and II are not to be offered an adjuvante-based Row 3: radiation therapy according to R0-resection.- Row 4: leveled Row 5: leveled[758], [748], [759], [760], [761], [762], [763], [764]- Row 6: leveled Row 7: leveled Row 8: leveled",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.354Consensus-based recommendation, tested 2025 Row 2: EC-Patients with non-small cell lung carcinoma (NSCLC) in the form of the Pancoast- and Row 3: Sulcus-superior tumors of the stages T3-4 N0-1 M0 should be evaluated in the Thorax-On- and Row 4: Cological tumor board (pneumologists, oncologists, thoracic surgeons, radiation- and Row 5:",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.36, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"In patients with non-small cell lung cancer (NSCLC) in the form of the Pan- and Row 3: \"B\"coast tumor (sulcus-superior tumor) of the stadiums T3 N0-1 M0, \"Row 4:\" should differ from the general procedures for this stage group in existing Row 5: \"Technical and functional operability\" an induction therapy based on \"Row 6:\" \"Row 7: \"a simultaneous radiochemotherapy followed by a resection\" Row 8: \"\"\"\"\" Row 9: Level of Evidence\" [765], [766]\" Row 10: 3b\"\" Row 11: \"\"\" Row 12: \"\"Starker Consens\"\" Row 13: \"\"",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.37/Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-level-indicating for patients with non-small cell lung cancer (NSCLC) in the form of the Pan-/ Row 3: B-coast tumor (sulcus-superior tumor) of the stadiums T4 N0-1 M0 should deviate-level-indicating Row 4:---from the general procedures for this stage group in potentially er-/ Row 5: Achievable technical and functional operability induction therapy ba-/- Row 6: ---- Row 7: A simultaneous radiochemotherapy, an immediate re-evaluation in terms of operability, and then either resection, or immediate completion of radiochemotherapy in the case of Inope-/-- Row 9:--------------------------------------------------------------------------------------------------------------------------",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.35 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.36 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 3b Row 7: Row 8:",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.37 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 3b Row 7: Row 8:",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: Patients with non-small cell lung carcinoma (NSCLC) in the form of the Pancoast-, Row 3: Tumor (Sulcus-superior tumor) of the stages T3-4 N0-1 M0 should be evaluated in the Thorax-On-, Row 4: Cological tumor board (pneumologist, oncologist, thoracic surgeon, radiation-, Row 5: -, Row 6: Therapists, pathologists, radiologists and nuclear physicians) regarding the Row 7: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn patients with non-small cell lung carcinoma (NSCLC) in the form of the Pan- and Row 3: coast tumor (sulcus-superior tumor) of the stadiums T3 N0-1 M0, deviating Row 4: should be performed from the general procedures for this stage group in existing Row 5: technical and functional operability an induction therapy based on Row 6: --- Row 7: a simultaneous radiochemotherapy followed by a resection--- Row 8: ------- Row 9: nce[765], [766]-- Row 10: ------ Row 11: ---- Row 12: ----Starker Konsentenz- Row 13: ----------------------------------------------------------------------------------------------------------------",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, in patients with non-small cell lung carcinoma (NSCLC) in the form of the Pan- and Row 3: coast tumor (sulcus-superior tumor) of the stadiums T4 N0-1 M0 should deviate from the general procedures for this stage group at potentially er- and Row 5: attainable technical and functional operability an induction therapy ba- and Row 6: , and Row 7: acting on simultaneous radiochemotherapy, an immediate reevalu- and Row 8: action regarding operability and then either the resection or in the case of Inope- and Row 9: ability to directly complete radiochemotherapy.",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.38, \"Evidence-based recommendation\" tested 2025 Row 2: Degree of recommendation\"In patients with non-small cell lung carcinoma (NSCLC) in the form of the Pan- and Row 3: \"B\"coast tumor (sulcus-superior tumor) of the stages T3-4 N0-1 M0 and not available- Row 4: \"hand\" and also not potentially attainable technical and functional Row 5: \"Operability should be the therapy as with tumors of this stage group at other\" Row 6: \"\" Row 7: \"Lokalization\" (Chapter 8.5.6). Row 8: Level of Evidence\"[767]\" Row 9: 2b\"\"\" Row 10: \"\"\" Row 11: \"\"Starker Konsentenz Row 12: \"\"",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.38 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "table under heading <2b> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn patients with non-small cell lung carcinoma (NSCLC) in the form of the Pan-",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "Table under heading <III C 13 12>",
      "text": "Row 1: 8.39-Evidence-based statement--tested 2025 Row 2: Level of Evidence--The distinction between subgroups is of great importance for the NSCLC in stage III for therapy-- Row 3: 1-- choice and prognosis. To this end, the clinical TNM –classifica---- Row 4:--tion (version 8) and the subdivision of the N2 stage according to Robinson are to be used--- Row 5:------ Row 6: ---- Row 7: -[775], [77], [404], [405], [401]-- Row 8: --Starker Konsensung--- Row 9: --------",
      "start_page": 238,
      "end_page": 238
    },
    {
      "heading": "Table under heading <III C 13 12>",
      "text": "Row 1: TNM 8:Clinical Stadium:Pathological Stadium Row 2: III A:36:41 Row 3: III B:26:24 Row 4: III C:13:12 Row 5: Modified according to [775], data from [401]:",
      "start_page": 238,
      "end_page": 238
    },
    {
      "heading": "table under heading <cN2L2+ 3>",
      "text": "Row 1: Type of N2 infestation-five-year survival (%) Row 2: mN2L1-34 Row 3: mN2L2+-11 Row 4: cN2L1-8 Row 5: cN2L2+-3 Row 6: Source: [776]- Row 7: mN2L1: microscopic infestation of a single lymph node level, mN2L2+: microscopic infestation of multiple lymph nodes-- Row 8: tions, cN2L1: preoperatively infestation of a single lymph node station already detected in the computer tomogram, cN2L2+:- Row 9: preoperatively infestation of multiple lymph node stations known in the computer tomogram",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page)",
      "text": "Row 1: 8.40, Consensus-based recommendation, tested 2025 Row 2: EC, the extent of a necessary additional diagnosis, the stage assignment, and op--- Row 3: Timal choice of treatment for the individual patient is to be determined prior to the start of therapy, Row 4: through a thoracic oncological tumor board (at least participation of Patho--- Row 5: ,-- Row 6: , psychology, pneumology, oncology, thoracic surgery, radiooncology and diagnostic Row 7: radiology, nuclear medicine).",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page)",
      "text": "Row 1: 8.41-Consensus-based recommendation-tested 2025 Row 2: EC-testedFor the loco-regional stage determination of the NSCLC in stage III, an actua-checked Row 3: pretherapeutic PET/CT is to be available.- Row 4: Stark Consensus-Row 5:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page)",
      "text": "Row 1: 8.42-Consensus-based recommendation-tested 2025 Row 2: EC-testedFor patients with NSCLC in clinical stage III, which are intended for a curatively intended Row 3: therapy, a mediastinal spread diagnosis is to be performed pre- to Row 4: ferentially by EBUS/EUS (in case of unclear findings supplementation by Mediastinosko- to Row 5:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 1)",
      "text": "Row 1: 8.40 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 1)",
      "text": "Row 1: 8.41 Row 2: EC Row 3: Row 4:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 1)",
      "text": "Row 1: 8.42 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --The extent of a necessary additional diagnostic, stage assignment and op--- Row 3: Timal choice of treatment for the individual patient is to be determined before the start of therapy-- Row 4: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--For the loco-regional stage determination of the NSCLC in stage III, an actua-- Row 3:--elles pretherapeutic PET/CT should be available.-- Row 4:--Strong consensus-- Row 5:----",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <cN2L2+ 3> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: --For patients with NSCLC in clinical stage III, which are intended for a curatively intended Row 3: --therapy, a mediastinal spread diagnosis should be pre---- Row 4: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.43, evidence-based recommendation, tested 2025 Row 2: recommendation level, tested The PD-L1 status is to be measured in patients with NSCLC in stage III in the framework of the pri--- Row 3: a---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.43 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation checked 2025 Row 2: gradedThe PD-L1 status is to be measured in patients with NSCLC in stage III in the framework of the Pri- and Row 3: märdiagnosis.",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "table under heading <nce [811], [812], [813], [737], [814], [815], [816], [817], [818]>",
      "text": "Row 1: 8.44, \"evidence-based recommendation\" tested 2025 Row 2: recommendation level\"In patients with NSCLC in stage III, molecular analyses on this Row 3: \"A\" stage of therapy-relevant driver mutations* should be performed.\" Row 4: \"EGFR\" and \"ALK\" Row 5: \"Evidence\"[811], [812], [813], [737], [814], [815], [816], [817], [818]\" Row 7: \"\" Row 8: \"\" Row 9: \"Konsens\" Row 10: \"\"",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "table under heading <nce [811], [812], [813], [737], [814], [815], [816], [817], [818], [818]> (column 1)",
      "text": "Row 1: 8.44 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 2 Row 7: Row 8:",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "table under heading <nce [811], [812], [813], [737], [814], [815], [816], [817], [818], [818]> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "table under heading <nce [811], [812], [813], [737], [814], [815], [816], [817], [818], [818]> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn patients with NSCLC in stage III, molecular analyses to be performed on this Row 3: stage of therapy-relevant driver mutations* are to be performed.- Row 4: --EGFR and ALK-- Row 5: --- Row 6: nce--[811], [812], [813], [737], [814], [815], [816], [817], [818]--- Row 7: ---- Row 8: ---- Row 9: ---Consensing Row 10: ------",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]>",
      "text": "Row 1: 8.45-Evidence-based recommendation-tested 2025 Row 2: Recommendation-level-the age should not be a sole exclusion criterion for a definitive multi-level Row 3: B-timodal therapy at NSCLC in stage III. This requires a special,-level Row 4: also internalistic/geriatric follow-up evaluation.- Row 5: Level of Evidence-[820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [832], [832]-Roow 6: 3-the-level Row 7:",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (column 1)",
      "text": "Row 1: 8.45 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: 3 Row 6: Row 7:",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-the age should not be a sole exclusion criterion for definitive multi-level Row 3: -timodal therapy at NSCLC in stage III. This requires a special,-- Row 4: also internalistic/geriatric follow-up evaluation.- Row 5: nce,[820], [821], [822], [824], [825], [826], [827], [828], [829], [831], [832], [832]",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (from previous page)",
      "text": "Row 1: 8.46, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"Relevant negative prognosis factors, such as weight loss, ECOG 2, LDH, sol, \"Row 3:\" are recorded especially in patients with NSCLC in stage III and taken into account in the Thera, \"Row 4:\" decision.\" Row 5: \"\"\" Row 6: \"\"Starker Consensus\" Row 7: \"\"\"",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (from previous page, column 1)",
      "text": "Row 1: 8 Row 2: E Row 3: Row 4: Row 5:",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (from previous page, column 2)",
      "text": "Row 1: 8.46 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "table under heading <nce [820], [821], [822], [823], [824], [825], [826], [827], [828], [829], [830], [831], [832]> (from previous page, column 4)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --Relevant negative prognosis factors, such as weight loss, ECOG 2, LDH, sol-- Row 3: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "table under heading <6. CALGB study>",
      "text": "Row 1: 8.47, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"For NSCLC in stage III with N2 status (IIIA1 or IIIA2), an adjuvant combination chemotherapy is to be performed according to Row 3: \"A\" complete resection (R0) and systematic lymph node dissection, at feh-\" Row 4: \"Ellender Kontraindication\", \"Adjuvant Kombinedschemotherapie\" [847], [848], [849], [850], [851], [729], [776], [745], [748], [749], [852], [849], [857], [851], [851], [851], [729], [776], [745]",
      "start_page": 245,
      "end_page": 245
    },
    {
      "heading": "Table under heading <6. CALGB study> (column 1)",
      "text": "Row 1: 8.47 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 245,
      "end_page": 245
    },
    {
      "heading": "Table under heading <6. CALGB study> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 245,
      "end_page": 245
    },
    {
      "heading": "Table under heading <6. CALGB study> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: degree-testedAt NSCLC in stage III with insecure N2 status (IIIA1 or IIIA2), an adjuvant combination chemotherapy is to be performed according to Row 3: complete resection (R0) and systematic lymph node dissection, at feh-",
      "start_page": 245,
      "end_page": 245
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page)",
      "text": "Row 1: 8.48-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-adjuvant chemotherapy at NSCLC in stage IIIA1 and IIIA2 is to be followed by a cisplatin-containing combination of four cycles-- Row 4: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 1)",
      "text": "Row 1: 8.48 Row 2: Recommend Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, adjuvant chemotherapy at NSCLC in stage IIIA1 and IIIA2 is to be followed in feh-, Row 3: ,lender contraindication as a cisplatin-containing combination over 4 cycles, Row 4: ,gen. Only in contraindication against cisplatin is the use of carboplatin er-, Row 5: , wogen., Row 6: , , , Row 7: , [771], [849], [850], [866], [858], [858], [859], [860], [861], [862], [863], [864], [865], [866], [867], [868] Row 8, [868] Row 8, [869] [748] [749], [732 [8] Row, [8]",
      "start_page": 246,
      "end_page": 246
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page)",
      "text": "Row 1: 8.49-Consensus-based recommendation--tested 2025 Row 2: EC---In patients with NSCLC in stage IIIA1 and IIIA2 with clinically relevant comor--- Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 248,
      "end_page": 248
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 1)",
      "text": "Row 1: 8.49 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 248,
      "end_page": 248
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 248,
      "end_page": 248
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In patients with NSCLC in stage IIIA1 and IIIA2 with clinically relevant comor--- Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 248,
      "end_page": 248
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page)",
      "text": "Row 1: 8.50-Evidence-based recommendation-modified 2025 Row 2: Recommended level of NSCLC patients in stage IIIA and an activating EGFR mutation (only) Row 3: An Exon 19 Deletion, Exon 21 L858R) is expected to receive adjuvant therapy with osimertinib for 3 years after primary R0-resection and adjuvant-- Row 4: An adjuvant therapy with osimertinib for 3 years Row 5:",
      "start_page": 249,
      "end_page": 249
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 1)",
      "text": "Row 1: 8.50 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: --- Row 7: to Row 8: --- Row 9: Row 10:",
      "start_page": 249,
      "end_page": 249
    },
    {
      "heading": "table under heading <6. CALGB study> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation-modified 2025 Row 2: degree of inhibition-patients with NSCLC in stage IIIA and an activating EGFR mutation (only--- Row 3: exon 19 deletion, exon 21 L858R) should receive adjuvant therapy with osimertinib for 3 years after primary R0-resection and adjuvant-- Row 4: adjuvant chemotherapy.-- Row 5:",
      "start_page": 249,
      "end_page": 249
    },
    {
      "heading": "table under heading <Level of Evidence [740], [741]>",
      "text": "Row 1: 8.51,Evidence-based recommendation: New 2025 Row 2: Degree of recommendation: Patients with NSCLC in stage IIIA and an activating EGFR mutation (only: Row 3: A-Exon 19 Deletion, Exon 21 L858R), in which no Row 4: Adjuvant chemotherapy can be performed after primary R0-resection, an adjuvant therapy: Row 5: with osimertinib over 3 years is to be offered.",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "table under heading <Level of Evidence [740], [741]>",
      "text": "Row 1: 8.52-Evidence-based recommendation: New 2025 Row 2: Degree of recommendation: Patients with NSCLC in stage IIIA and an ALK translocation should be offered an adjuvant therapy with alectinib over 2 years according to pri-",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "table under heading <Level of Evidence [740], [741]>",
      "text": "Row 1: 8.53/Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with NSCLC in stage IIIA with PD-L1 expression ≥ 50 % (without Row 3: A-EGFR or ALK alteration) is to be offered, after primary R0-resection and performed Row 4: Adjuvant chemotherapy, an adjuvant therapy with atezolizumab over 1 year-row 5: Row 5:",
      "start_page": 250,
      "end_page": 250
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.54-Consensus-based recommendation--tested 2025 Row 2: EC--patients with NSCLC in stage IIIA (without EGFR or ALK alteration) should, according to Row 3: primary R0-resection and conducted adjuvant chemotherapy, independent--- Row 4: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.55-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--For patients with incomplete resection, the primary goal is to test the possibility of post-reduction-- Row 3: A-section. Unless R0-resection can be achieved meaningfully, in--- Row 4: should become a multimodal overall concept after indication position in the Tho--- Row 5: Oncological Tumorboard offer post-operative radiotherapy--- Row 6: Oncology Row 6: Oncology Row 7: Oncology.--- Row 8: Level of Evidence---[771], [889], [891], [892], [893], [894], [895], [89], [897], [678], [416], [683], [761], [891], [892], [893], [894], [895], [895], [899], [895], [899], [89], [899], [897], [897], [897], [897], [897], [6, [678], [678], [678], [67], [678",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.54 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.55 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2: Patients with NSCLC in stage IIIA (without EGFR or ALK alteration) should, according to Row 3: primary R0-resection and conducted adjuvant chemotherapy, independent--- Row 4: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, tested For patients with incomplete resection, the primary goal is to test the possibility of post-reduction Row 3: section. If no R0-resection can be achieved meaningfully, in- the Row 4: should be provided with a multimodal overall concept according to indication position in the Tho- the Row 5: oncological tumor board, provided that a post-operative radiotherapy is offered, Row 6: oncology Row 7: oncology Row 8: oncology Row 7: oncology Row 5: oncology Row 6: oncology Row 6: oncology Row 7: oncology Row 8: oncology Row 8: oncology [771], [890], [891], [892], [893], [895], [895], [896], [678], [416], [683], [761], [875], [898] to Row 9: oncrow 10: oncrow 11: 12",
      "start_page": 251,
      "end_page": 251
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.56, \"evidence-based recommendation\" tested 2025 Row 2: \"recommendation level\"For patients with R0 resection and mediastinal lymph node infestation in the NSCLC-, \"Row 3: \"B\" stage IIIA1 or IIIA2 in addition to adjuvant chemotherapy, the Indi-, \"Row 4: \"kation for postoperative mediastinal irradiation\" should be individually tested but not \"Row 5: \"routine\" should be presented.\" Row 6: \"\"\" Row 7: Level of Evidence\"[900], [901], [902], [903], [904], [905],\" [906]\" Row 8: \"\"\"\" Row 9: \"\"\"\" Row 10: \"\"Starker Konsensung\" Row 11: \"\"",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 8.56 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, for patients with R0 resection and mediastinal lymph node infestation in the NSCLC-, Row 3: stage IIIA1 or IIIA2 should be individually tested in addition to adjuvant chemotherapy, the Indi-, Row 4: , cation for postoperative mediastinal irradiation, but not the Row 5: , routinely presented.",
      "start_page": 252,
      "end_page": 252
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 8.57-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-Patients with NSCLC in stage IIIA3 and technical and functional Operabi--- Row 3: Alleviation should be multimodally treated. Current multimodal options are: Row 4: the definitive radiochemotherapy +/- Durvalumab and the surgery after neoad--- Row 5:",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 8.57 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade-qualifiedPatients with NSCLC in stage IIIA3 and technical and functional Operabi--- Row 3: multimodality are to be treated. Current multimodal options are Row 4: the definitive radiochemotherapy +/- Durvalumab and the surgery after neoad--- Row 5:",
      "start_page": 254,
      "end_page": 254
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.58,3Evidence-based recommendation-tested 2025 Row 2: recommendation-level If a phase-level Row 3: all chemotherapy is used as part of an induction in patients with NSCLC stage IIIA3, a combination of Row 4: cisplatin and a taxan should preferably be used.- Row 5: Level of Evidence-level [771], [863], [872], [931], [932], [933], [933]- Row 6: 1b",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.59-Consensus-based recommendation modifies 2025 Row 2: EK:In NSCLC patients with resectable tumours in stage IIIA3 (without EGFR or Row 3: ALK alteration) and recommendation of a drug-related induction therapy should be offered Row 4: A combined immunochemotherapy.The Checkpointinhi-",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.58 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.59 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, used in patients with NSCLC stage IIIA3 as part of an induction, a phase, Row 3: all chemotherapy should preferably be used in a combination of Row 4: cisplatin and a taxane., Row 5: nce[771], [863], [872], [930], [931], [932], [933], [933], Row 6:",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based recommendation-modified 2025 Row 2: -In NSCLC patients with resectable tumours in stage IIIA3 (without EGFR or-- Row 3: ALK-alteration) and recommendation of drug induction therapy-- Row 4: --a combined immunochemotherapy is to be offered. Checkpointinhi-- Row 5: --- Row 6: -bitortherapy can be continued regardless of the approval status.- Row 7: --Consensions- Row 8: ----",
      "start_page": 258,
      "end_page": 258
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.60-Evidence-based recommendation-tested 2025 Row 2: Recommendation level--In the case of sole induction chemotherapy, after surgery and R0-resection-- Row 3: A NSCLC in stage IIIA3 should be evaluated in the thoracic oncological Tu--- Row 4: morboard and in the case of increased loco-regional relapse risk, a mediastinal Radi--- Row 5: -otherapy. The dose should be 50-54 Gy in 5-6 weeks.- Row 6: --- Row 7: Level of Evidence---[872], [936], [937], [938], [939], [904], [940], [941], [942], [943], [944], [945], [890], [977], [946], [946] Row 8: 2b-----------------------------------------------------------------------------------",
      "start_page": 260,
      "end_page": 260
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.60 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 260,
      "end_page": 260
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 260,
      "end_page": 260
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: R0-resection, Row 3: NSCLC at stage IIIA3 should be evaluated in the thoracic oncological Tu--- Row 4: morboard and in case of increased loco-regional relapse risk, a mediastinal Radi--- Row 5: otherapy. The dose should be 50-54 Gy in 5-6 weeks. Row 6: --- Row 7: nce[872], [936], [937], [938], [939], [904], [901], [941], [942], [943], [943], [944], [944], [944], [944], [890], [977], [946], [946], [946], [947] Row 8: [947] Row 9 ----- Row 10: 11 Rowker",
      "start_page": 260,
      "end_page": 260
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.61-Consensus-based statement-tested 2025 Row 2: EC-testedIn the subgroups NSCLC T4N0 and T4N1 (each stage IIIA), according to interdis-",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.61 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based statement-tested 2025 Row 2: -In the subgroups NSCLC T4N0 and T4N1 (each stage IIIA) the primary Opera---row 4:-- or the integration of the operation into the overall treatment concept is possible according to interdis--- Row 3:---ziplinary evaluation in the Thorax oncological tumor board at Row 5:--- Row 6:-- technical and functional operability. This should be weighed against the advantages of Row 7:--- a neoadjuvant procedure (see Recommendations 8.52 and 8.53)---- Row 8:-------- Row 9:----Strong consensus----Row 10:-------",
      "start_page": 262,
      "end_page": 262
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.62-Consensus-based recommendation-tested 2025 Row 2: EK-tested In primary melted tumors risks of a (radio)chemothera- such Row 3:--be weighed against those of a primary operation.- Row 4:--Stark Consensus-- Row 5:---",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.62 Row 2: EC Row 3: Row 4:",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--In primary molten tumors, risks of a (radio)chemothera--- Row 3:--pie should be weighed against those of a primary surgery.-- Row 4:--Stark Consensus-- Row 5:----",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.63-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-For selected patients with NSCLC in stage IIIA4/IIIB, a multimodal treatment-checking approach can be performed under integration of the operation, if an R0 resection-checking Row 5: is very probable in the thorax oncological tumor board.- Row 6:",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.64-Consensus-based recommendation-modified 2025 Row 2: EC-modifiedIn NSCLC patients with resectable tumours in stage IIIB, only T3N2, (without Row 3: EGFR or ALK alteration) and recommendation of a drug-related induction theorem- such as Row 4:",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.63 Row 2: Empfeh Row 3: 0 Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.64 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, for selected patients with NSCLC in stage IIIA4 / IIIB, a multimodal treatment-row 4: , can be performed under integration of the operation according to interdiscipli- , Row 3: , nary evaluation in the thoracic oncological tumor board, provided that an R0 resection, Row 5: , is very probable., Row 6: , , Row 7: nce[794], [965], [765], [966], [915], [916], [960], [864], [961], [922], [967], [771], [968], [872], [836], [969], [969], [890], [890] Row 9: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--modified 2025 Row 2:--In NSCLC patients with resectable tumours in stage IIIB, only T3N2, (without Row 3:---EGFR or ALK alteration) and recommendation of a drug---- Row 4:--rapie, a combined immunochemotherapy is to be offered. Check---- Row 5:---- Row 6:--point inhibitor therapy can be continued--- Row 7:---, depending on the status of approval.-- Row 8:----Consensive Row 9:-------",
      "start_page": 265,
      "end_page": 265
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.657 Consensus-based recommendation-tested 2025 Row 2: EC-Patients with NSCLC in stage IIIA4 / IIIB and IIIC should usually – if All-E Row 3: general condition and tumor expansion allow this – receive a combination of Row 4: radiation therapy and chemotherapy.- Row 5: -- Row 6: --Chemotherapy should be performed simultaneously with definitive radiochemotherapy and only at Row 7: medical contraindication alone sequentially.- Row 8: --Starker Versus-Row 9: -----",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.66, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"In patients with NSCLC in stage IIIA4, IIIB and IIIC and missing possibility\" Row 3: \"Simultaneous or sequential radiochemotherapy\" can be evaluated the radio-\" Row 4: \"therapy\" alone.\" Row 5: \"\" Row 6: \"Starker Consensus\" Row 7: \"\"\"",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.65 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.66 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: Patients with NSCLC in stage IIIA4 / IIIB and IIIC should usually – if all--- Row 3: general condition and tumor expansion allow this – receive a combination of Row 4: radiation therapy and chemotherapy.- Row 5: -- Row 6: --Chemotherapy should be performed simultaneously with definitive radiochemotherapy and only at Row 7: medical contraindication only sequentially.- Row 8:",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --In patients with NSCLC in stage IIIA4, IIIB and IIIC and missing possibility-- Row 3: Simultaneous or sequential radiochemotherapy, the sole radio--- Row 4: therapy can be evaluated.- Row 5: --- Row 6: -Starker Konsent-- Row 7: ---",
      "start_page": 268,
      "end_page": 268
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.67/Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In NSCLC stage IIIA4, IIIB and IIIC, two cycles of a fully-dosed cisplatin--- Row 4: combination chemotherapy (cycle interval 3-4 weeks) should be applied to both the simultaneous and the sequenced radiochemotherapy. Combination partners are usually Vinorelbine--- Row 6: --- Row 7: or Etoposid.-- Row 8: Level of Evidence--[976], [976], [978], [979], [981], [982], [983], [983], [984], [863], [771], [985], [724], [827], [828], [982], [982], [983], [983], [863], [863], [983] Row, [985, [985]",
      "start_page": 269,
      "end_page": 269
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.67 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1 Row 7: Row 8:",
      "start_page": 269,
      "end_page": 269
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 269,
      "end_page": 269
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: --evidence-based recommendation -- tested 2025 Row 2: grade --In NSCLC stage IIIA4, IIIB and IIIC, two cycles of a fully-dosed cisplatin--- Row 4: combination chemotherapy (cycle interval 3-4 weeks) should be applied to both simultaneous and random radiochemotherapy -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 269,
      "end_page": 269
    },
    {
      "heading": "table under heading <3a>",
      "text": "Row 1: 8.68-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-Radiotherapy should be based on the involved field principle on the basis of an ak-",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "table under heading <3a> (column 1)",
      "text": "Row 1: 8.68 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: 3a Row 6: Row 7:",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "table under heading <3a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "table under heading <3a> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedRadiotherapy should be based on the involved field principle on the basis of an ak- to-row 3: tissue pretherapeutic PET-CT and finely woven staging.- Row 4: heart and lung protection should be optimized according to the state of the art.- Row 5: nce-[974], [988], [989], [990], [655], [942], [991], [992], [993]- Row 6:",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "Table under heading <[994], [995]. The CHART study (without concomitant chemotherapy) suggested that>",
      "text": "Row 1: 8.69) Evidence-based recommendation-tested 2025 Row 2: Recommendation level--The dose of radiation therapy should biologically correspond to a total dose between the Row 3: A-60 and 70 Gy with conventional fractionation (1.8-2 Gy/die).- Row 4: -- Row 5: Level of Evidence--[771], [994], [995], [996], [997], [998]-- Row 6: 2a---- Row 7: --- Row 8: --Starker Consensus--- Row 9: -----",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "Table under heading <[994], [995]. The CHART study (without concomitant chemotherapy) suggested that>",
      "text": "Row 1: 8.70-Evidence-based recommendation-tested 2025 Row 2: Recommendation level--A prolongation of radiotherapy by interruptions is to be avoided-- Row 3: A---- Row 4: -- Row 5: Level of Evidence--[771], [994], [995], [996], [997], [998]-- Row 6: 4--- Row 7: --- Row 8: --Starker Konsent--- Row 9: ----",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "Table under heading <[994], [995]. The CHART study (without concomitant chemotherapy) suggested that> (column 1)",
      "text": "Row 1: 8.69 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "Table under heading <[994], [995]. The CHART study (without concomitant chemotherapy) suggested that> (column 1)",
      "text": "Row 1: 8.70 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 4 Row 6: Row 7:",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "Table under heading <[994], [995]. The CHART study (without concomitant chemotherapy) suggested that> (column 2)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, the dose of radiation therapy is to correspond biologically to a total dose between the Row 3: ,60 and 70 Gy with conventional fractionation (1,8-2 Gy/the)., Row 4: ,,, Row 5: nce[771], [994], [995], [996], [998], [998], Row 6: ,,, Row 7: ,, Row 8: ,, Starker Consensus, Row 9: ,,,",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "Table under heading <[994], [995]. The CHART study (without concomitant chemotherapy) suggested that> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-alongation of radiotherapy by interruptions is to be avoided- Row 3:--\" Row 4: \"\" Row 5: \"nce\"[771], [994], [995], [996], [997], [998]- Row 6: \"\" Row 7: \"\" Row 8: \"\"Strong Consensus\" Row 9: \"\"",
      "start_page": 271,
      "end_page": 271
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.71-Evidence-based recommendation-modified 2025 Row 2: Recommended level of NSCLC stage III patients after definitive radiochemotherapy without pro--- Row 3: Aggress that does not have a typical activating EGFR mutation (del 19, L858R)-- Row 4: In PD-L1 expression of ≥1% on tumour cells a consolidation with the Row 5:",
      "start_page": 272,
      "end_page": 272
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.71 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 272,
      "end_page": 272
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 272,
      "end_page": 272
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation-modified 2025 Row 2: graded patients with NSCLC stage III after definitive radiochemotherapy without pro--- Row 3: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 272,
      "end_page": 272
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.72-Consensus-based recommendation: New 2025 Row 2: EC-Patients with NSCLC stage III after definitive radiochemotherapy without Pro--- Row 3: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 273,
      "end_page": 273
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8 Row 2: E Row 3: Row 4: Row 5:",
      "start_page": 273,
      "end_page": 273
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 8.72 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 273,
      "end_page": 273
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 273,
      "end_page": 273
    },
    {
      "heading": "table under heading <1b> (from previous page, column 4)",
      "text": "Row 1 : Consensus-based recommendation: New 2025 Row 2 : Patients with NSCLC stage III after definitive radiochemotherapy without Pro--- Row 3 : Consensus-based recommendation: New 2025 Row 2 : Patients with NSCLC stage III after definitive radiochemotherapy without Pro--- Row 3 : Consensus-based recommendation: New 2025 Row 2 : Patients with NSCLC stage III after definitive radiochemotherapy without Pro--- Row 3 : Consensus with a typical activating EGFR mutation (del 19, L858R) ; Row 4 : Should be offered consolidation (up to disease progression) with the EGFR-TKI Osi----- Row 5 :",
      "start_page": 273,
      "end_page": 273
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.73/Evidence-based recommendation-tested 2025 Row 2: Recommendation level-based Following definitive radiochemotherapy at NSCLC stage III, no consensus-based Row 3: Binging chemotherapy should be performed.- Row 4: -- Row 5: Level of Evidence--[1005], [916], [915], [1006], [1007], [1008]-- Row 6: 1b--- Row 7: --- Row 8: --Starker Konsensenz--- Row 9: -----",
      "start_page": 274,
      "end_page": 274
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.73 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 274,
      "end_page": 274
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 274,
      "end_page": 274
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 274,
      "end_page": 274
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.74-Consensus-based recommendation-tested 2025 Row 2: EC-testedIn non-small cell lung cancer stage III, no prophylactic Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.754Evidence-based recommendation, tested 2025 Row 2: Degree of recommendation, palliative thoracic radiation therapy should not be used in patients with NSCLC Stadium, Row 3: B-IIIA4, IIIB, and IIIC, for which curative therapeutic concepts are not suitable despite local disease situations, Row 4:",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.74 Row 2: EC Row 3: Row 4:",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.75 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: In non-small cell lung carcinoma stage III no prophylactic Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Evidence-based recommendation, tested 2025 Row 2: grade, palliative thoracic radiation therapy should not be used in patients with NSCLC Stadium, Row 3: -IIIA4, IIIB and IIIC, for which curative therapeutic concepts are not suitable despite local disease situation--- Row 4: -tion, in existing or imminent thoracic sympto--- Row 5: -matics., Row 6: --- Row 7: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 275,
      "end_page": 275
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.76/Evidence-based recommendation--tested 2025 Row 2:Recommendation level--patients with NSCLC in stage III who are not suitable for surgery or radio-chemotherapy according to decision in the Thorax-Onkologi--- Row 3: 0-- can be offered, depending on PD-L1 status, a single immuno-monotherapy or Row 5:---one chemo-immunotherapy:-- Row 6:--- Row 7:----Cemiplimab + platinum-based chemotherapy (at PD-L1 expression ≥1%),-- Row 8:----every 3 weeks over 4 cycles, followed by Cemiplimab every 3 weeks----- Row 9:----- or-- Row 10:-------Cemiplimab (at PD-L1 expression ≥50%),---- every 3 weeks--- Row 11: Level of Evidence----[1022],----Row 9:------or--Row 10:--Row 10:------Row 12---------------------------------------",
      "start_page": 276,
      "end_page": 276
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 8.76 Row 2: Empfeh Row 3: 0 Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 276,
      "end_page": 276
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 276,
      "end_page": 276
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: graded Patients with NSCLC in stage III, who, according to decision in the Thorax oncologist Row 3: graded tumor board, are not suitable for surgery or radio-chemotherapy Row 4: graded, can be offered, depending on PD-L1 status, a single immuno-monotherapy or Row 5: graded a chemo-immunotherapy:- Row 6: graded Row 7: graded• Cemiplimab + platinum-based chemotherapy (at PD-L1 expression ≥1%),- Row 8:",
      "start_page": 276,
      "end_page": 276
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: 8.77-Consensus-based recommendation-tested 2025 Row 2: EK-EThe median survival time of patients with NSCLC in stage IV is 8-18 months at Row 3: unselected treatment and is significantly more favourable in the target-to-row 4: targeted therapy of selected, therapeutically approachable molecular-to-row 5: -- Row 6: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: 8.78的Consensus-based recommendation--tested 2025 Row 2: EK--Besides medical treatment, the possibilities for rehabilitation--- Row 3: -tion, psychooncological support, social counselling or support-- Row 4: should be addressed by self-help groups and early palliative therapy-- Row 5: --- Row 6: -- Row 7: --Starker Consensus-- Row 8: ----",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: 8.79-Consensus-based recommendation-tested 2025 Row 2: EC-tested Throughout the course of the disease, local measures are to be quickly initiated, e.g. for brain metastases, pleural effusion, threatening cross-sectional leprosy Row 4:",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: 8.77 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: 8.78 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: 8.79 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --The median survival time of patients with NSCLC in stage IV is 8-18 months at Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In addition to medical treatment, the possibilities for rehabilitation--- Row 3:--tion, psychooncological support, social counselling and support-- Row 4:--were addressed by self-help groups and early palliative therapy-- Row 5:---- Row 6:--- Row 7:--Starker Consensus-- Row 8:----",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--Over the entire course of the disease, local measures should be quickly initiated--- Row 3:--, e.g. for brain metastases, pleural effusion, threatening cross-sectional leprosy--- Row 4:--mung, bronchial lobstruktion.-- Row 5:--- Row 6:--Strong consensus-- Row 7:----",
      "start_page": 280,
      "end_page": 280
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: 8.80:Consensus-based recommendation-tested 2025 Row 2: EC-tested In the case of pretherapeutic presentation in an interdisciplinary center, a Row 3: time-based decision-making (possibly within 10 working days after Diag-",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: 8.81-Consensus-based recommendation-tested 2025 Row 2: EC-E Before initiating therapy the ECOG Performance Status is to be established.- Row 3: -- Row 4: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: 8.82-Consensus-based recommendation-tested 2025 Row 2: EK-tested Before initiating therapy, it should be checked whether there is an OMD (oligometastatic) Row 3:-disease situation with a potentially curative approach.- Row 4:-Strong Consensus-Row 5:--",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: 8.80 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: 8.81 Row 2: EC Row 3: Row 4:",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: 8.82 Row 2: EC Row 3: Row 4:",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 2)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : In an interdisciplinary centre, a Row 3 : Time-based decision-making (possibly within 10 working days after Diag--- Row 4 : Nosis position) and implementation (interdisciplinary tumor conference; documentation- Row 5: -- Row 6: -the recommended therapy) should be guaranteed.- Row 7 : --Starker Konsent-Row 8: ----",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--Before initiating therapy, the ECOG Performance Status is to be established.-- Row 3:--- Row 4:--Stark Consensus-- Row 5:---",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -Before initiating a therapy, it should be checked whether an OMD (oligometastatic) Row 3: -disease situation exists with a potentially curative approach.- Row 4: -Strong consensus- Row 5: ---",
      "start_page": 281,
      "end_page": 281
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page)",
      "text": "Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 4: Row 3: Row 4: Row 2: Row 5: ROW 5: RET first-line therapy as minimum requirement EGFR mutations in exonenes 18-21, BRAF Row 6: ROW 6: ROW 6 mutations, ALK fusions, ROS1 fusions, RET fusions, and NTRK1-3 fusions) Row 7: Row 7: Row 8: EK: Row 8: Row 8: Row 9: Row 9: Row 9: Row 13: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 13: Row 14: Row 12: Row 12: Row 12: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 12: Row 12: Row 12: Row 12: Row 12: R",
      "start_page": 282,
      "end_page": 282
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 1)",
      "text": "Row 1: EK Row 2: Row 3: EK Row 4: Row 5: EK Row 6: Row 7: EK Row 8: Row 9: Recommendation",
      "start_page": 282,
      "end_page": 282
    },
    {
      "heading": "table under heading <8.5.7 Flowcharts Stadium III> (from previous page, column 2)",
      "text": "Row 1: Based on the available tumor tissue/tumour cells from all Row 2: NSCLC in stage IV, molecular pathological studies are to be performed with respect to all Row 3: Row 4: Therapeuticly relevant molecular changes (according to the current state before Row 5: RET-Fusions and NTRK1-3 fusions) Row 7: Row 8: Row 8: Row 9: Row 9: Row 9: Row 9: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 10: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 12: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 12: Row 11: Row 11: Row 11: Row 12: Row 11: Row 11: Row 11: Row 9: Row 9: Row 9",
      "start_page": 282,
      "end_page": 282
    },
    {
      "heading": "table under heading <1b>",
      "text": "Rhow 1: 8.83-Evidence-based recommendation-tested 2025 Row 2: Recommendation-level of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24 hours of 24",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.83 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Rhow 1: 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 5 - 5 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.84-Evidence-based recommendation-tested 2025 Row 2: Recommendation level---In NSCLC patients in stage IV with squamous cell carcinoma, who do not have the--- Row 3: A-rapable mutations (e.g. EGFR, EML4-ALK, ROS1), and who have PD-L1 expression ≥ 50% of tumour cells or >10% on the Row 5: --immune cells in--- Row 6: --- Row 7: • Atezolizumab (≥ 50% of tumour cells or 10% of tumor infiltrators), Row 8: ----- Row 9: ----Cemiplimab (≥ 50% of tumor cells) or Row 10: ------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.854Consensus-based recommendation-tested 2025 Row 2: EC-testedIn general, NSCLC in stage IV after 2 cycles of therapy (6 weeks),- Row 3: but at the latest after 3 cycles (9 weeks) should follow a radiological follow-up check-up of the Row 4: .- Row 5: .-- Row 6: .-Starker Consensus- Row 7: .--",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.86-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In stage IV NSCLC patients with radiological response or Stabili-- Row 3: Maintenance therapy is to be performed after study-analogous cycle count--- Row 4: Platen-containing chemo/immunotherapy.- Row 5: Level of Evidence--[1033], [728], [1038], [1030], [882], [1039], [1040], [880], [1041], [1042], [1043], [1035], [1034]--- Row 6: 1a-------- Row 7: 1------ Row 8: -----------------------------------------------------------------------------------------------------------------------------",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 8.87,Consensus-based recommendation-tested 2025 Row 2: EK, The total duration of chemo-immune therapy or immuno-monotherapy at Row 3: NSCLC Stadium IV is not yet sufficiently clarified. Checkpointinhi--- Row 4: Bitors Pembrolizumab and Cemiplimab have been administered in the pivotal Stu--- Row 5: --- Row 6: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 8.88-Consensus-based recommendation--tested 2025 Row 2: EK--patients with NSCLC stage IV with special risk factors for an immune-- Row 3:--therapy-- Row 4:--patients with autoimmune diseases and good general condition (ECOG 0-1)--- Row 5:-- can be offered an immune (combination) therapy if the autoim--- Row 6:--mune disease is not life-threatening and not active. An intimate Mo----- Row 7:-----nitoring is particularly necessary in such cases.-- Row 8:---patients with controlled hepatitis B or C or a controlled HIV------ Row 9:------illness and good general condition (ECOG 0-1) can be offered an immune (combina------- Row 10:---) therapy. Close monitoring is especially necessary in such----- Row 11:-------------------------------------------------------------------------",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 8.87 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 8.88 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --The total duration of chemo-immune therapy or immuno-monotherapy at Row 3: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--patients with NSCLC stage IV with special risk factors for an immuno--- Row 3:--therapy-- Row 4:--patients with autoimmune diseases and good general condition (ECOG 0-1)--- Row 5:-- can be offered an immuno- (combination) therapy if the autoim--- Row 6:--mune disease is not life-threatening and not active. An intimate Mo----- Row 7:----nitoring is particularly necessary in such cases.-- Row 8:---patients with controlled hepatitis B or C or a controlled HIV------ Row 9:-----illness and good general condition (ECOG 0-1) can be offered an immuno- (combina------- Row 10:----) therapy. Close monitoring is particularly necessary in such---- Row 11:------Fallow.----row 12:-----starker consensus--row 13---row 13--",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.89-Evidence-based recommendation-tested 2025 Row 2: recommendation-level of NSCLC patients with squamous cell carcinoma at UICC stage IV and ECOG 0-1--- Row 3: no therapeutic mutations and not suitable for therapy with Row 4: checkpoint inhibitors should be offered 4-6 cycles of a platinum-based Row 5: combination chemotherapy.",
      "start_page": 287,
      "end_page": 287
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 8.89 Row 2: Recommend Row 3: A Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 287,
      "end_page": 287
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 287,
      "end_page": 287
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 287,
      "end_page": 287
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.90-Evidence-based recommendation-tested 2025 Row 2: Recommended level of NSCLC patients with squamous cell carcinoma in stage IV in good general--- Row 3: A-level (ECOG 0.1) with disease progression after primary combination--- Row 4: -Chemotherapy with immunocheckpoint inhibitor Therapy is to be offered a second-line thethe-- Row 5: -rapie to progression or occurrence of toxicity.- Row 6: --- Row 7: Level of Evidence--[1075], [1076], [1077], [1078], [1079], [1080]--- Row 8: 1b-------- Row 9: ----- Row 10: --Starker Konsensenz- Row 11: -------",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.91-Evidence-based recommendation-tested 2025 Row 2: Recommended level of NSCLC patients with squamous cell carcinoma in stage IV after first-line combination-- Row 3: Awesome chemotherapy in good general condition (ECOG 0.1) and without contra--- Row 4: Indications against an immunocheckpoint inhibitor therapy, a PD1--- Row 5: or PD-L1 antibody in second-line therapy is to be offered.- Row 6:",
      "start_page": 295,
      "end_page": 295
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.92-Consensus-based recommendation-tested 2025 Row 2: EK的NSCLC patients with stage IV squamous cell carcinoma with PD-L1 Ex-",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.93-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In NSCLC patients with squamous cell carcinoma in stage IV after first line--- Row 3: 0--Combination chemotherapy with ECOG 2 without contraindications against egg--- Row 4:--Immune checkpoint inhibitor therapy-- Row 5:--• Atezolizumab or nivolumab (independent of PD-L1 status or-- Row 6:------- Pembrolizumab (PD-L1 ≥1%)--- Row 7:-----in second line therapy.-- Row 8: Level of Evidence----- Row 9: 5----- Row 10:------ Row 11:----Starker consensus---- Row 12:-------",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.94-Evidence-based recommendation-checked 2025 Row 2: Recommended level of NSCLC patients with squamous cell carcinoma Stage IV after first-line combina--- Row 3: B'tions chemotherapy with/without immunocheckpoint inhibitor therapy in good all--- Row 4: general condition (ECOG 0.1) and without contraindications against an angioge--- Row 5: -nese inhibitor should be offered a second-line therapy with docetaxel +/- ramucirumab on--- Row 6:",
      "start_page": 296,
      "end_page": 296
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.95-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In NSCLC patients with stage IV squamous cell carcinoma who have received immunocheckpoint inhibitor therapy as second-line Row 3: 0--therapy and have no Row 4:---contraindications against third-line therapy, docetaxel +/--- Row 5:",
      "start_page": 297,
      "end_page": 297
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.95 Row 2: Empfeh Row 3: 0 Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 297,
      "end_page": 297
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 297,
      "end_page": 297
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn NSCLC patients with stage IV squamous cell carcinoma who have received immunocheckpoint inhibitor therapy as second-line Row 3: therapy and have no Row 4: contraindications against a third-line therapy, docetaxel +/-",
      "start_page": 297,
      "end_page": 297
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.96-Consensus-based recommendation-tested 2025 Row 2: EK-EIn NSCLC patients in stage IV with squamous cell carcinoma and ECOG 2, wel- such Row 3: in tissue samples a PD-L1 expression of ≥ 50 % of the tumour cells or Row 4: -10% on immune cells should have a monotherapy with Row 5: --- Row 6: -• atezolizumab (≥ 50% of the tumour cells or 10% of the tumor infiltrating Row 7: -Lymphocytes) or Row 8: - - Cemiplimab (≥ 50% of the tumour cells) or - Row 9: - - Pembrolizumab (≥ 50% of the tumour cells) - Row 10: - as first-line therapy.",
      "start_page": 299,
      "end_page": 299
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.96 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 299,
      "end_page": 299
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 299,
      "end_page": 299
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation tested 2025 Row 2 : In NSCLC patients in stage IV with squamous cell carcinoma and ECOG 2, which--- Row 3 : In tissue samples, PD-L1 expression of ≥ 50 % of tumour cells or Row 4 : > > 10% on immune cells should be monotherapy with Row 5: --- Row 6: • Atezolizumab (≥ 50% of tumour cells or 10% of tumour infiltrators) Row 7: --Lymphocytes) or Row 8: • Cemiplimab (≥ 50% of tumour cells) or Row 9: ------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 299,
      "end_page": 299
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.97-Consensus-based recommendation-tested 2025 Row 2: EK-NSCLC patients with stage IV squamous cell carcinoma and ECOG 2 with Row 3:--comorbidities that do not allow platinum-containing combination therapy-- Row 4:--can be offered mono-chemotherapy-- Row 5:--- Row 6:--Starker Consensus-- Row 7:----",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.98-Consensus-based recommendation tested 2025 Row 2: EK-NSCLC patients with stage IV squamous cell carcinoma and ECOG 2-3 or older Row 3: higher patients ≥ 70 years can be offered a monotherapy with atezolizumab in palliative first-line therapy independent Row 4: from PD-L1 status.",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.97 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.98 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: NSCLC patients with stage IV squamous cell carcinoma as well as ECOG 2 with Row 3: -comorbidities that do not allow platinum-containing combination therapy-- Row 4: -can be offered mono-chemotherapy.- Row 5: -- Row 6: -Starker Consensus- Row 7: ---",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation tested 2025 Row 2: NSCLC patients with stage IV squamous cell carcinoma and ECOG 2-3 or older Row 3: higher patients ≥ 70 years can be offered a monotherapy with atezolizumab in palliative first-line therapy independent Row 4: from PD-L1 status.",
      "start_page": 300,
      "end_page": 300
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "In NSCLC patients with non-plate epithelithelial histology at UICC Stadium IV/ Row 3: A and as well as ECOG 0-1, which have no therapeutic mutations and no contraindicika--- Row 4: ,tion against checkpoint inhibitors, should, regardless of the PD-L1/ Row 5, be provided with chemo-immuntherapy, independent of the PD-L1/ Row 5, as well as ECOG 0-1, which has no therapeutic mutations and no contraindicika----- Row 4: , regardless of the PD-L1/ Row 5, in the initial line therapy a chemo-immuntherapy should be provided.",
      "start_page": 303,
      "end_page": 303
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.99 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 303,
      "end_page": 303
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "In NSCLC patients with non-plate epithithelial histology at UICC Stadium IV/ Row 3: as well as ECOG 0-1, which have no therapeuticable mutations and no contraindicika--- Row 4: as opposed to checkpoint inhibitors, regardless of the PD-L1/ Row 5: is to be provided, regardless of the PD-L1/ Row 5: status, in the first line therapy a chemo immunotherapy is to be offered.",
      "start_page": 303,
      "end_page": 303
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.100-Evidence-based recommendation-tested 2025 Row 2: Recommendation level------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.101-Consensus-based recommendation--tested 2025 Row 2: EK-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 8.102-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In stage IV NSCLC patients with radiological response or Stabili-- Row 3: Maintenance therapy is to be performed according to study-analogous cycle count--- Row 4: platinum-containing chemo/immunotherapy.- Row 5: Level of Evidence--[1033], [728], [1038], [1030], [882], [1039], [1040], [880], [1041], [1042], [1043], [1035], [1034]--- Row 6: 1a-------- Row 7: 1------ Row 8: ,----------------------------------------------------------------------------------------------------------------------------",
      "start_page": 304,
      "end_page": 304
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 8.103-Consensus-based recommendation-tested 2025 Row 2: EC-EThe overall duration of chemo-immune therapy and/or immuno-monotherapy at Row 3: NSCLC Stadium IV is not yet sufficiently clarified. Checkpointinhi- to Row 4: bitors pembrolizumab and cemiplimab were administered in the regulatory-relevant Row 5: --- Row 6: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 305,
      "end_page": 305
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 8.104-Consensus-based recommendation--tested 2025 Row 2: EK--patients with NSCLC stage IV with special risk factors for an immune-- Row 3:--therapie-- Row 4:--patients with autoimmune diseases and good general condition (ECOG 0-1)--- Row 5:-- can be offered an immuno- (combination) therapy if the autoim--- Row 6:--mune disease is not life-threatening and not active. A close-meshed Mo----- Row 7:----nitoring is particularly necessary in such cases.-- Row 8:---patients with controlled hepatitis B or C or a controlled HIV----- Row 9:------illness and good general condition (ECOG 0-1) can be offered an immuno- (combina-------- Row 10:--) therapy. Close monitoring is especially necessary in such---- Row 11:---------------------------------------------------------------------",
      "start_page": 305,
      "end_page": 305
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 8,103 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 305,
      "end_page": 305
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 8,104 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 305,
      "end_page": 305
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: 3, \"Consensus-based recommendation\" tested 2025 Row 2: \"The total duration of chemo-immune therapy or immuno-monotherapy at Row 3: \"NSCLC Stadium IV\" is not yet sufficiently clarified. Checkpointinhi-\" Row 4: \"Bitors Pembrolizumab\" and \"Cemiplimab\" were administered in the pivotal Row 5: \"\"Row 6: \"\"Studies over two years. Continued therapy beyond this In-\" Row 7: \"Tervall\" can be offered in case of continued tumour control and tolerability\" Row 8: \"To the patient\". For atezolizumab, \"Row 9:\" was defined in the admission study that does not limit the duration of the therapy.",
      "start_page": 305,
      "end_page": 305
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: 4-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 305,
      "end_page": 305
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "In addition, it is necessary to: [1010,10,10,0Evidence-based recommendation] [10,10,10,0Evidence-based recommendation]. In addition, it is necessary to: [10,10,2Evidence-based recommendation] [10,2Evidence-based recommendation]. In addition, it is recommended that patients with a NSCLC in UICC stage IV and with a non-plate epithelitheliheller. In addition, it should be offered 4-6 cycles of a Row 5: Inflated platinum-based combination chemotherapy. In addition, the following schedules are recommended: - Row 8: In the following schedules: - Row 8: In the following schedules: • Cisplatin/ Carboplatin/ Carboplatin/ Carboplatin+ Bevacizumab over 4-6 cycles, followed by a: In the following cycle, followed by - Row 11: In the event of maintenance therapy with Bevacizumababab 9: In the appropriate patient, in the appropriate patient, in the appropriate patient, to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 306,
      "end_page": 306
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 8.105 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 306,
      "end_page": 306
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 306,
      "end_page": 306
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "In the case of patients who are eligible for treatment with checkpoint inhibitors, Row 4: and have a good general status (ECOG 0-1) will be offered 4-6 cycles of a Row 5: 的-based combination chemotherapy.",
      "start_page": 306,
      "end_page": 306
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.106-Evidence-based recommendation-tested 2025 Row 2: Recommended NSCLC patients with non-plate epithelial carcinoma in stage IV with ECOG 0-2-Evidence Row 3: Without contraindications, another therapy line should be offered.- Row 4: -This is based on first-line therapy.- Row 5: Level of Evidence-[1138], [1139], [1140], [1081], [1082], [1141], [1143]- Row 6: 1b-Evidence-Row 7:",
      "start_page": 321,
      "end_page": 321
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.107: Evidence-based recommendation, tested 2025 Row 2: Recommendation level, NSCLC patients with non-platten epithelium carcinoma in stage IV with a PD-L1: Row 3: B-Expression ≥50% and ECOG 0-2 without contraindications received in the first line ate-: Row 4: zolizumab or cemiplimab or pembrolizumab should be offered a platinum-based chemotherapy for the Row 5:",
      "start_page": 321,
      "end_page": 321
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.108-Evidence-based recommendation-tested 2025 Row 2: Recommended level of NSCLC patients with non-platten epithelial cancer in stage IV who received immunochemotherapy in the first-line Row 3: B-nie should be offered another therapy line-up Row 4: R-E. Therapeutic options are:-- Row 6: • Docetaxel ± Nintedanib or Ramucirumab Row 7:---• Pemetrexed-Row 8: Level of Evidence--[1145], [1080]- Row 9: 1b的 Row 10:-----Row 11:---Starker Consensus-Row 12:-----",
      "start_page": 322,
      "end_page": 322
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.108 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 322,
      "end_page": 322
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 8 Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 322,
      "end_page": 322
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-NSCLC patients with non-plate epithelial carcinoma in stage IV who received immunochemotherapy in the first-line Row 3: never should be offered another line of therapy Row 4: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 322,
      "end_page": 322
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.109, Consensus-based recommendation-tested 2025 Row 2: EC-EIn NSCLC patients with non-plate epithelial cancer in stage IV and ECOG 2, the Row 3: which in tissue samples exhibit PD-L1 expression of ≥ 50 % of tumour cells or Row 4: > > 10% on immune cells, a monotherapy with Row 5: ---- Row 6: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.110-Consensus-based recommendation-new 2025 Row 2: EK-NSCLC patients with non-plate epithelial carcinoma in stage IV and ECOG 2-row 3: with comorbidities, which do not give rise to platinum-containing combination therapy- Row 4: can be offered mono-chemotherapy.- Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.11\"Consensus-based recommendation\"tested 2025 Row 2: EK的NSCLC patients with non-plate epithelial cancer in stage IV and ECOG 2-3\" Row 3: or older patients ≥ 70 years can be offered monotherapy with atezolizumab in palliative first-line therapy unab-",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.109 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8,110 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.111 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 9 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 0 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 1 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--In NSCLC patients with non-platten epithelium cancer in stage IV and ECOG 2,-- Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation: New 2025 Row 2: NSCLC patients with non-plattenepithelial carcinoma in stage IV and ECOG 2: Row 3: with comorbidities that do not allow platinum-containing combination therapy: Row 4: can be offered mono-chemotherapy.",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: NSCLC patients with non-platten epithelial cancer in stage IV and ECOG 2-3-- Row 3: or elderly patients ≥ 70 years of age can be offered monotherapy with atezolizumab in palliative first-line therapy, unab--- Row 4: depending on PD-L1 status, Row 5:",
      "start_page": 326,
      "end_page": 326
    },
    {
      "heading": "table under heading up to and including: b) see evidence report>",
      "text": "Row 1: 8.112-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In NSCLC stage IV and the presence of a typical activating EGFR mutation-row 3: A-(del 19, L858R) patients with ECOG 0-2 in first-line therapy are to be offered an EGFR-TKI-row 4: -.- Row 5: Level of Evidence-[1170], [1171], [1172], [1173], [1174], [1175], [1176], [1177], [1178], [1179], [1180], [1181], [1182]-- Row 6: 1a-",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "table under heading up to and including: b) see evidence report>",
      "text": "Row 1: 8.113 to Evidence-Based Recommendation 2025 Row 2: Recommendation Level: 1 - 3b) At NSCLC Stadium IV, EGFR Exon 19 Deletion should be preferred for Osimertinib Row 3: B/0 to First Line Therapy.EgFR Exon 19 Deletion at NSCLC Stadium IV, especially in the group Row 5: with ZNS metastases, can be offered a combination of osimertinib and chemotherapy Row 6: (pemetrexed and platinum with Pemetrexed maintenance therapy).EgFR Exon 19 Deletion at NSCLC Stadium IV, with EGFR Exon 19 Deletion, can be offered a combination of osimertinib and chemotherapy Row 8:",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "Table under heading to ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: 8.112-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In NSCLC stage IV and the presence of a typical activating EGFR mutati-row 3: A-(del 19, L858R) patients with ECOG 0-2 should be offered an EGFR-T-row 4:-in first-line therapy.- Row 5: Level of Evidence-[1170], [1171], [1172], [1173], [1174], [1175], [1176], [1177], [1178], [1179], [1180], [1181], [1182]-- Row 6: 1a-",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "Table under heading to ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: 8.113 to Evidence-Based Recommendation 202 Row 2: Recommendation Level: 1 - 3b) At NSCLC Stadium IV, EGFR Exon 19 Deletion should be preferred for Osimertini Row 3: B/0 to First Line Therapy.Egfr Exon 19 Deletion at NSCLC Stadium IV, especially in the Grupp: Row 5: with ZNS metastases, a combination of osimertinib and Chemotherap: Row 6: (pemetrexed and platinum with Pemetrexed maintenance therapy) can be offered at NSCLC Stadium IV with EGFR Exon 19 Deletion can be offered as a combination The Row 8:",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "Table under heading to ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: Row 2: ion Row 3: TKI Row 4: Row 5: Row 6: Row 7:",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "Table under heading to ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "text": "Row 1: 25 Row 2: ib Row 3: Row 4: pe Row 5: pie Row 6: n. Row 7: era- Row 8: Row 9: Row 10: Row 11: Row 12: Row 13:",
      "start_page": 335,
      "end_page": 335
    },
    {
      "heading": "(b) see evidence report>",
      "text": "In addition, it is possible to use a combination of osimergib and chemotherapy: Row 9 at NSCLC Stadium IV with EGFR L858R mutations.",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report>",
      "text": "Row 1: 8.1154Consensus-based recommendation-tested 2025 Row 2: EK-tested At NSCLC stage IV and the presence of an activating EGFR mutation, an EGFR-TKI should be offered in the first-line therapy for Row 3: EGG-3 patients.- Row 4: EGFR-TKI should be offered in the first-line therapy.",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report>",
      "text": "Row 1: 8.8116, \"Consensus-based recommendation\" tested 2025 Row 2: EK\"In NSCLC stage IV and the presence of an activating EGFR mutation, an EGFR TKI can be offered at Row 3: \"patients with ECOG 4\" in the first-line therapy.",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report> (column 1)",
      "text": "Row 1: 8.114 Row 2: Empfeh Row 3: B/0 Row 4: Row 5: Level of Row 6: --- Row 7: to Row 8: --- Row 9: Row 10:",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report> (column 1)",
      "text": "Row 1: 8,115 Row 2: EC Row 3: Row 4:",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report> (column 1)",
      "text": "Row 1: 8.116 Row 2: EC Row 3: Row 4:",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report> (column 2)",
      "text": "Row 1: 4Evidence-based recommendation - modified 2025 Row 2: Hilungsgrad -a) At NSCLC Stadium IV, with EGFR L858R mutations, the selection of the first-hand Row 3: 0Eritinib TKI should be dependent on the effectiveness and toxicity of the approved TKI (Afatinib, Dacomiti--- Row 4: -nib, Erlotinib, Gefitinib, Osimertinib, Erlotinib in combination with Bevacizumab, - Row 5: - erlotinib in combination with Ramucirumab) - Row 6: -- Row 7: --b) At NSCLC Stadium IV, with EGFR L858R mutations, especially in the group - Row 8: - with ZNS metastases, can be offered a combination of osimertinib and chemotherapy - Row 9: - (Pemetred and platinum with Pemetred maintenance therapy)",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report> (column 2)",
      "text": "Row 1: 5-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "(b) see evidence report> (column 2)",
      "text": "Row 1: 6-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 336,
      "end_page": 336
    },
    {
      "heading": "table under heading <3a>",
      "text": "Row 1: 8.117/Evidence-based recommendation-modified 2025 Row 2: Degree of recommendation-type patients with NSCLC stage IV and uncommon mutations in EGFR group 1: Row 3: B-should be offered treatment with EGFR-TKI afatinib or alternatively osimertinib Row 4: .",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "table under heading <3a>",
      "text": "Row 1: 8.818/Evidence-based recommendation-tested 2025 Row 2: recommendation-level-level-of-recommendation-level-of-recommendation-level-of-recommendation for patients with NSCLC stage IV with EGFR T790M is to be offered the treatment with the Row 3: A-EGFR-TKI osimertinib.-level-of-evidence-level-level-of-evidence-[1189]-row 6: 1b-",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "table under heading <3a>",
      "text": "Row 1: 8.1119-Evidence-based recommendation--modified 2025 Row 2: Recommendation level--NSCLC stage IV with exon-20 insertion mutations should be discussed in a molecula--- Row 3: B-ren tumor board. In the first line therapy a chemo---- Row 4: therapy should be offered in combination with amivantamab. In case of failure of a Row 5: first line combination therapy containing platinum (without amivantamab) a Row 6: --- Row 7: targeted treatment with amivantamab should be offered.-- Row 8: Level of Evidence----[1190]-- Row 9: 3a----- Row 10: 3a----- Row 11: ----Starker Consensus----- Row 12: ------",
      "start_page": 337,
      "end_page": 337
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.120-Evidence-based recommendation-tested 2025 Row 2: Recommendation level--NSCLC Stage IV with evidence of acquired EGFR-TKI resistance by Row 3: A-Acquisition of an EGFR-T790M mutation and if osimertinib was not used in the first-line Row 4:--never, a therapy with osimertinib is to be offered.- Row 5: Level of Evidence--[1195], [1214]- Row 6: 1b-",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.121--Consensus-based recommendation--tested 2025 Row 2: EC------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.122/\"Consensus-based recommendation\" tested 2025 Row 2: EK\"In oligoprogressive cases, adequate imaging and CNS-MRI should be followed up Row 3: and the possibility of local therapy should be tested interdisciplinary.\" Row 4: \"Because of the possibilities of local therapy in CNS metastases, an adä-\" Row 5: \"quate imaging of CNS metastases should be performed at regular intervals, e.g. every 6\" Row 6: \" or 12 months also in asymptomatic patients.\"",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.123-Consensus-based recommendation-tested 2025 Row 2: EC-testedIf there is no evidence of an acquired EGFR-T790M mutation and missing Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8,120 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.121 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.122 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8,123 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 0 Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 1 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 2 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 3 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, tested At NSCLC Stadium IV with evidence of EGFR-TKI resistance acquired by Row 3: acquisition of an EGFR-T790M mutation, and if osimertinib was not used in the first-line Row 4: grade, a therapy with osimertinib is to be offered.",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1 : Consensus-based recommendation--tested 2025 Row 2:--In oligoprogressive cases, adequate imaging and CNS-MRI should be followed--- Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 345,
      "end_page": 345
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8,124, \"Consensus-based recommendation\" modifies 2025 Row 2: EK\"After failure of osimertinib therapy in patients with EGFR mutated Row 3: NSCLC Stadium IV and ECOG 0-1, \" Row 4: \"• a chemotherapy combination with amivantamab or \" Row 5: \"• a combination therapy with paclitaxel, carboplatin, bevacizumab and \" Row 6: \"Atezolizumab or \" Row 7: \"• a chemotherapy combination (without immune checkpoint inhibitor)\"\" Row 8: \"offers.\"",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.125-Consensus-based recommendation--tested 2025 Row 2: EC--In the case of SCLC transformation, platinum-etoposid therapy should be erwo--- Row 3:-- tested.-- Row 4: Stark Consensus-- Row 5: ---",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: Recommendations on biopsy and rebiopsia in EGFR-TKI-acquired resistance (see Ka--- Row 2: pitel 6.6.10)- Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.124 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8,125 Row 2: EC Row 3: Row 4:",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: Empfe Row 2: pitel 6 Row 3: Row 4: Row 5: Row 6:",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 4-Consensus-based recommendation-modified 2025 Row 2: -After failure of osimertinib therapy in patients with EGFR mutated-row 3: NSCLC stage IV and ECOG 0-1, Row 4: -• a chemotherapy combination with avivantamab or Row 5:--• a combination therapy with paclitaxel, carboplatin, bevacizumab and Row 6: Atezolizumab or Row 7:--• a chemotherapy combination (without immune checkpoint inhibitor)-- Row 8: to be offered.- Row 9: -Starker Konsent- Row 10: ------",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 5-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Rejection of biopsy and rebiopsia in EGFR-TKI acquired resistance (see Ka--- Row 2: 6.6.10)- Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 346,
      "end_page": 346
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.1267Evidence-based recommendation-modified 2025 Row 2: Degree of recommendation-type patients with NSCLC in stage IV with an ALK translocation are to be offered in the first-line Row 3: Anenia therapy the therapy with an approved CNS-effective ALK-inhibitor-row 4:",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 8.127/\"Consensus-based recommendation\"modified 2025 Row 2: EK\"In case of acquired resistance to an ALK inhibitor, a comprehensive Resis-\" Row 3: \"Tenztestung\" should be carried out. The result of the resistance test should be taken into account in the selection of Row 4: \"Follow-up therapy\".",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.126 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 8.127 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 6 Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: 7 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation--modifies 2025 Row 2: grade--patients with NSCLC in stage IV with an ALK translocation in the first---- Row 3: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--modified 2025 Row 2:--In case of acquired resistance to an ALK inhibitor, a comprehensive resistance-- Row 3:--tenztestung should be carried out. The result of resistance testing should be taken into account in the selection of Row 4:--the follow-up therapy.-- Row 5:--- Row 6:--Starker Consensus-- Row 7:----",
      "start_page": 350,
      "end_page": 350
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.128-Evidence-based recommendation-tested 2025 Row 2: Recommended level of ALK positive NSCLC patients Stage IV with Progress according to platinum-based Stan-- Row 3: A-dardchemotherapy, which did not receive an ALK inhibitor in the first line, is to be offered Row 4: ALK-inhibitor analogous to recommended first line therapy.- Row 5: - (see chapter 8.6.5.1)- Row 6: Level of Evidence--[1244], [1169], [1245]- Row 7: 1b",
      "start_page": 355,
      "end_page": 355
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.128 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 355,
      "end_page": 355
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 8 Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 355,
      "end_page": 355
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, ALK positive NSCLC patients Stage IV with progress according to platinum-based Stan-, Row 3: ,dardchemotherapy, which did not receive an ALK inhibitor in the first line, should be offered Row 4: , an ALK inhibitor analogous to recommended first line therapy.",
      "start_page": 355,
      "end_page": 355
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.129-Evidence-based recommendation-tested 2025 Row 2: Recommended level of ALK inhibitors of the second or third generation are to be offered ALK-positive NSCLC-",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.130-Consensus-based recommendation-tested 2025 Row 2: EC-tested At NSCLC stage IV with acquired ALK-TKI resistance, a tissue biopsy and/or a liquid biopsy should be performed prior to changing the Row 3: system therapy to determine Row 4: resistance mechanisms.",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8,131-Consensus-based recommendation-tested 2025 Row 2: EK-testedIf \"off-target\", ALK-independent resistance mechanisms are detected, which can be used as po- such Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.129 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8,130 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.131 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 9 Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 0 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 1 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade ALK inhibitors of the second or third generation are to be offered ALK-positive NSCLC-",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: - At NSCLC stage IV with acquired ALK-TKI resistance, a tissue biopsy and/or a liquid biopsy should be performed before changing the Row 3: System therapy to determine Row 4: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: ALK-independent resistance mechanisms that are po--- Row 3: ALK-positive NSCLC patients should be included in Stu--- Row 4: . If this is not possible, the use of Row 5: -- Row 6: potentially active substances should be considered, if necessary after discussion in a Thorax-Onkolo--- Row 7: ALK-independent tumor board, regardless of the regulatory status.",
      "start_page": 356,
      "end_page": 356
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.132/Consensus-based recommendation-tested 2025 Row 2: EK-tested In oligoprogressive cases, the possibility of a local therapy interdiszipli-",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8,133-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-testedIn ALK+ NSCLC patients stage IV with failure of a second generation TKI (Ce- such Row 3: A-ritinib, Alectinib, Brigatinib) the treatment with the third generation ALK-In-row 4 is to be offered.- Row 5: Level of Evidence-[1255]-Roow 6: 1b such Row 7:",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 8.134/Consensus-based recommendation-tested 2025 Row 2: EK-testedIf \"off-target\", ALK-independent resistance mechanisms, which are po--- Row 3: are potentially therapeutic, ALK+ NSCLC patients stage IV should be included in studies--- Row 4:--. If this is not possible, the use of potential-- Row 5: --- Row 6: active substances, possibly after discussion in a thoracic oncological Tu---- Row 7: -morboard, independently of the approval status should be considered.- Row 8: ---Konsens-- Row 9: ------",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.132 Row 2: EC Row 3: Row 4:",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.133 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 8.134 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 2--Consensus-based recommendation--tested 2025 Row 2: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 3-evidence-based recommendation-tested 2025 Row 2: degree of elevation-testedIn ALK+ NSCLC patients stage IV with failure of a second generation TKI (Ce-的 Row 3: -ritinib, Alectinib, Brigatinib), treatment with the third generation ALK-in---- Row 4: -hibitor Lorlatinib is to be offered.- Row 5: f Evidence--[1255]-- Row 6: ---- Row 7: ----- Row 8: --Starker Konsentenz- Row 9: -------Roow 9: -------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: 4-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 358,
      "end_page": 358
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.135--Consensus-based recommendation--tested 2025 Row 2: EC-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.136-Consensus-based recommendation-tested 2025 Row 2: EK-EIn case of detection of \"off-target\", ALK-independent resistance mechanisms, which are po- to Row 3: tentatively therapeutically, ALK+ NSCLC patients stage IV should be included in studies- to Row 4: . If this is not possible, the use of potentially- to Row 5: --- Row 6: effective substances, possibly after discussion in a thorax-oncological Tu--- Row 7: -morboard, independently of the approval status should be considered.- Row 8: --Starker Konsent- Row 9: ------",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.137, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"After exploiting the molecularly targeted treatment options, Row 3: B/0, \"ALK+ NSCLC patients stage IV should be introduced in line-to-line mode Wild type Row 4: \"Row 4: \".\" Row 5: \"As chemotherapy, Pemetrexed has the highest intrinsic effectiveness in ALK+, \"Row 6: \"Tumors.\" As chemoimmun therapy, a combination therapy with Paclit-, \"Row 7: \"axel\", \"carboplatin\", \"bevacizumab\" and \"atezolizumab\" (IMpower150) can be offered. \"Row 8: \"\"den. \"Row 9: Level of Evidence\"[1244], [1042], [1106]\" Row 10: 2b, \"\" Row 11: \"\" Row 12: \"\" Starker Consensus\" tested 13: \"\"",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.135 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8,136 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.137 Row 2: Empfeh Row 3: B/0 Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 5 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 6 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 7 Row 2: Hlungsg Row 3: 0 Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 3)",
      "text": "Row 1 : Consensus-based recommendation tested 2025 Row 2 : In oligoprogressive cases, the possibility of a local therapy interdiszipli-- Row 3 : is to be examined by the eye.The possibility of a local therapy in CNS metastases should be examined by ALK-- Row 5:   -+ tumors a regular imaging of the CNS, also in asymptomatic Pa--- Row 6: -tients, every 3-9 months.",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 3)",
      "text": "Row 1: ALK-independent resistance mechanisms that are po--- Row 3: ALK+ NSCLC patients should be included in studies for the detection of \"off-target\", ALK-independent resistance mechanisms that are po--- Row 3: ALK+ NSCLC patients should be included in studies for the inclusion of stage IV. If this is not possible, the use of potential-- Row 5: --- Row 6: active substances, possibly after discussion in a thoracic oncological Tu---- Row 7: -morboard, regardless of the regulatory status should be considered.",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <2b> (column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 360,
      "end_page": 360
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.138,Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with NSCLC stage IV with ROS1 fusion genes (ROS1 + NSCLC) are to be offered as Row 3: A-first line therapy crizotinib or entrectinib. ZNS metasta-",
      "start_page": 361,
      "end_page": 361
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.138 Row 2: Recommend Row 3: A Row 4: Level of Row 5: 3b Row 6: Row 7:",
      "start_page": 361,
      "end_page": 361
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 361,
      "end_page": 361
    },
    {
      "heading": "table under heading <3b> (column 3)",
      "text": "Row 1: evidence-based recommendation being tested 2025 Row 2: gradedPatients with NSCLC stage IV with ROS1 fusion genes (ROS1 + NSCLC) are to be offered as Row 3: first line therapy crizotinib or entrectinib. ZNS metasta-",
      "start_page": 361,
      "end_page": 361
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.139--Consensus-based recommendation--tested 2025 Row 2: EC--At NSCLC stage IV with acquired ROS1-TKI resistance, a tissue bioop--- Row 3: and/or a liquid biopsy should be performed to determine resistance mechanisms-- Row 4: --------- Row 5: --- Row 6: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.140-Consensus-based recommendation--modified 2025 Row 2: EC--In case of systemic progress (with and without CNS metastases) under treatment with Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.1414*Consensus-based recommendation-modified 2025 Row 2: EC-modifiedIn case of detection of \"off-target\", ROS1-independent resistance mechanisms, which are potentially systemically therapeutical Row 3: (e.g. activating KIT mutation, high-level Row 4: MET amplification), the use of potentially effective substances should be offered, according to Row 5: --- Row 6: --Discussion in a molecular tumor board, independent of the approval status-- Row 7: .",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.142,Consensus-based recommendation, tested 2025 Row 2: EC, tested In oligoprogressive cases, the possibility of a local therapy is to be examined interdiszipli-, Row 3: när., tested Row 4: Because of the possibilities of local therapy in CNS metastases, regular imaging of the CNS should be performed at Row 5: ROS1+ tumors, also in asymptomatia-, Row 6: in patients every 3-9 months.",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8.139 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8,140 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8.141 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8.142 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 9 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 0 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 1 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 2 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation tested 2025 Row 2 : At NSCLC stage IV with acquired ROS1-TKI resistance, a tissue test should be performed Row 3 : and/or a liquid biopsy for the determination of resistance mechanisms called Row 4 : .",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation, which modifies 202 Row 2: -In systemic progress (with and without CNS metastases) under treatment with Row 3: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-modified 202 Row 2:--In case of detection of \"off-target\", ROS1-independent resistance mechanisms, which are Row 3:--potentially systemically therapeutic (e.g., activating KIT mutation, high-lev--row 4:--MET amplification), the use of potentially effective substances should be offered.Row 8:--Starker Konsent-Row 9:----Row 6:--Discussion in a molecular tumor board, independent of the approval stage--Row 7:----",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--In oligoprogressive cases the possibility of a local therapy interdiszi-Row 3:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 4)",
      "text": "Row 1: Row 2: iop- Row 3: Row 4: Row 5:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 4)",
      "text": "Row 1: 25 Row 2: Row 3: Row 4: Row 5: mo- Row 6: u- Row 7: cti- Row 8: i- Row 9: Row 10:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 4)",
      "text": "Row 1: 25 Row 2: Row 3: vel Row 4: ach Row 5: atus Row 6: Row 7:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page, column 4)",
      "text": "Row 1: Row 2: ipli- Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 363,
      "end_page": 363
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.1434*Consensus-based recommendation: New 2025 Row 2: EK-NSCLC patients with ROS1+ fusion should be advised of an increased risk of venous and",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8 Row 2: E Row 3: Row 4: Row 5:",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 8.143 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1: 3 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "table under heading <3b> (from previous page, column 4)",
      "text": "Row 1: Consensus-based recommendation: New 2025 Row 2: NSCLC patients with ROS1+ fusion should be pointed out to an increased risk for venous and Row 3: arterial thromboembolic events. In the absence of Row 4: contraindications you can be offered a prophylactic anticoagulation with a Row 5: --- Row 6: low molecular heparin or a direct oral anticoagulant Row 7: ---- Row 8: --Starker Konsent: Row 9: -----",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8,144-Evidence-based recommendation-modified 2025 Row 2: Recommended level-of-recommendation-patients with NSCLC stage IV with proven BRAF-V600 mutation- should be offered Row 3: A combination of dabrafenib and trametinib or encorafenib and binimeti-h Row 4: ,nib.- Row 5: Alternatively, combined immunochemotherapy can be offered. Row 6: , failure of this, should be offered a combination of dabrafenib and trametinib or En-, Row 7: ,corafenib and binimetinib.- Row 8: , not-V600 Mutations+ NSCLC patients should be discussed in a molecular Tu-, Row 9: , , morboard.- Row 10: Level of Evidence-[1281], [1282], [1283]",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.144 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 4 Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "table under heading <2b> (column 3)",
      "text": "Row 1: evidence-based recommendation--modified 2025 Row 2: grade--patients with NSCLC stage IV with proven BRAF V600 mutation-- Row 3:--a combination of dabrafenib and trametinib or encorafenib and binimeti--- Row 4:-----Row 5:---Alternatively, combined immunochemotherapy can be offered. Row 6:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.1457Evidence-based recommendation-tested 2025 Row 2: Recommended level of NSCLC stage IV patients with proven NTRK 1-3 fusion should be offered a Row 3: A-therapy with larotrectinib or entrectinib.- Row 4: -- Row 5: Level of Evidence--[1260]- Row 6: 3b--- Row 7: --- Row 8: --Strong Consensus-- Row 9: ----",
      "start_page": 368,
      "end_page": 368
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 8.146, \"Consensus-based recommendation\" tested 2025 Row 2: EK: In oligoprogressive cases, the possibility of a local therapy interdiszipli-- Row 3: \"narrow\" should be examined. Due to the possibilities of local therapy at CNS-meta--- Row 4: \"stasen\" should be a regular imaging of the CNS, also in asymptomatic Row 5: \"\"\" Row 6:\"Patients, every 3-9 months.\" Row 7: \"Starker Konsent\" Row 8: \"\"",
      "start_page": 368,
      "end_page": 368
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.145 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 3b Row 6: Row 7:",
      "start_page": 368,
      "end_page": 368
    },
    {
      "heading": "table under heading <3b> (column 1)",
      "text": "Row 1: 8.146 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 368,
      "end_page": 368
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: 5-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 368,
      "end_page": 368
    },
    {
      "heading": "table under heading <3b> (column 2)",
      "text": "Row 1: 6--Consensus-based recommendation--tested 2025 Row 2: --In oligoprogressive cases, the possibility of a local therapy interdiszipli--- Row 3:-- is to be tested. Due to the possibilities of local therapy at CNS-Meta---- Row 4:---stasen, a regular imaging of the CNS, even in asymptomatic-- Row 5:---- Row 6:--patients, every 3-9 months.-- Row 7:--Starker Konsent--- Row 8:-----",
      "start_page": 368,
      "end_page": 368
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.147, \"Consensus-based recommendation\" modifies 2025 Row 2: \"EK\" patients with NSCLC stage IV and proven RET fusion should be offered a first-line Row 3: \"Row\" therapy with a specific RET inhibitor (selpercatinib) who are offered Row 4: \"Roow 4: \"\" Row 5: \"\" Row 6: \"Starker Consensus\" Row 7: \"\"",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page)",
      "text": "Row 1: 8.148, \"Consensus-based recommendation\" tested 2025 Row 2: EK\"In oligoprogressive cases, the possibility of a local therapy interdiszipli-\" Row 3: \"nary\" should be examined.\" Row 4: \"Because of the possibilities of local therapy in CNS metastases, a re-\" Row 5: \"gelmliche Bildgebildung des CNS\", also in asymptomatic patients, should take place all 3-9\" Row 6: \"\"Months\".\" Row 7: \"Stark Consens\" Row 8: \"\"",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8.147 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page, column 1)",
      "text": "Row 1: 8.148 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 7 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page, column 2)",
      "text": "Row 1: 8 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--modified 2025 Row 2:--patients with NSCLC stage IV and proven RET fusion should be offered a first li--- Row 3:--nie therapy with a specific RET inhibitor (selpercatinib)--- Row 4:--en.-- Row 5:--- Row 6:--Starker Consensus-- Row 7:---",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3b> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --In oligoprogressive cases, the possibility of a local therapy interdiszipli--- Row 3: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 370,
      "end_page": 370
    },
    {
      "heading": "table under heading <3a>",
      "text": "Row 1: 8.149/Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-level of patients with NSCLC stage IV with proven MET exon 14 skipping Muta--- Row 3: At the latest after failure of the first line therapy, a therapy with a Row 4: -MET inhibitor (capmatinib*, tepotinib or crizotinib) is to be offered.- Row 5: -* currently not available on the market in DE--Row 6: Level of Evidence--[1297], [1298] Row 7: 3a",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a>",
      "text": "Row 1: 8.150:Consensus-based recommendation-tested 2025 Row 2: EK-tested In oligoprogressive cases, the possibility of a local therapy interdiszipli-",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a> (column 1)",
      "text": "Row 1: 8.149 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 3a Row 7: Row 8:",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a> (column 1)",
      "text": "Row 1: 8,150 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a> (column 2)",
      "text": "Row 1: 9 Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a> (column 2)",
      "text": "Row 1: 0 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedPatients with NSCLC stage IV with proven MET exon 14 skipping Muta--- Row 3: action is to be offered a therapy with a Row 4: measure inhibitor (capmatinib*, tepotinib or crizotinib) at the latest after failure of the first line therapy.- Row 5:",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "table under heading <3a> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --In oligoprogressive cases, the possibility of a local therapy interdiszipli--- Row 3: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 371,
      "end_page": 371
    },
    {
      "heading": "Table under heading <chen was significantly better at 80.4 vs 62.8%, ORR was higher at 28.1 vs 13.2>",
      "text": "Row 1: 8.151-Evidence-based recommendation-modified 2025 Row 2: Recommended level of NSCLC stage IV and KRAS-G12C mutation to be offered according to Versa-- Row 3: a combination chemotherapy and immunocheckpoint inhibitor therapy-- Row 4: a targeted therapy with the KRAS inhibitor Sotorasib.- Row 5: Level of Evidence--[1301], [1302]-- Row 6: 1--- Row 7: ---- Row 8: --Starker Konsent- Row 9: -----",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table under heading <chen was significantly better at 80.4 vs 62.8%, ORR was higher at 28.1 vs 13.2>",
      "text": "Row 1: 8.152-Consensus-based recommendation: New 2025 Row 2: EC-Patients with NSCLC stage IV and a KRAS-G12C mutation should be offered according to Versa-: Row 3: A combination chemotherapy and immunocheckpoint inhibitor therapy: Row 4: A targeted therapy with the KRAS inhibitor: Adagrasib* who-: Row 5:",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table-under-heading <chen was significantly better at 80.4 vs. 62.8%, the ORR was 13.2> (28.1 vs. 13.2> (column 1)",
      "text": "Row 1: 8.151 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1 Row 6: Row 7:",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table-under-heading <chen was significantly better at 80.4 vs. 62.8%, the ORR was 13.2> (28.1 vs. 13.2> (column 1)",
      "text": "Row 1: 8,152 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table-under-heading <chen was significantly better at 80.4 vs 62.8%, the ORR was 13.2> (column 2) at 28.1 vs 13.2>.",
      "text": "Row 1: 1 Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table-under-heading <chen was significantly better at 80.4 vs 62.8%, the ORR was 13.2> (column 2) at 28.1 vs 13.2>.",
      "text": "Row 1: 2 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table-under-heading <chen was significantly better at 80.4 vs. 62.8%, the ORR was 13.2> (28.1 vs. 13.2> (column 3)",
      "text": "Row 1: evidence-based recommendation-modified 2025 Row 2: gradedPatients with NSCLC stage IV and a KRAS G12C mutation are to be offered according to Versa Row 3: a combination chemotherapy and immunocheckpoint inhibitor therapy-row 4: a targeted therapy with the KRAS inhibitor Sotorasib.- Row 5:nce[1301], [1302]- Row 6:",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "Table-under-heading <chen was significantly better at 80.4 vs. 62.8%, the ORR was 13.2> (28.1 vs. 13.2> (column 3)",
      "text": "Row 1: Consensus-based recommendation: New 2025 Row 2: NSCLC stage IV patients and a KRAS G12C mutation should be offered according to Versa Row 3: a combination chemotherapy and immunocheckpoint inhibitor therapy: Row 4: a targeted therapy with the KRAS inhibitor: Adagrasib* who--- Row 5: ,,,, Row 6: ,,,,,,, Row 7: ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,",
      "start_page": 373,
      "end_page": 373
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY->",
      "text": "Row 1: 8,153 such evidence-based recommendation, new 2025 Row 2: recommendation level, patients with NSCLC stage IV with a HER2 mutation, should be offered after failure, Row 3: At least one system therapy should offer a targeted therapy with the anticoagulant, Row 4: per-drug conjugate trastuzumab deruxtecan., Row 5: Level of Evidence, [1303], [1304], [1305], Row 6: 1",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (column 1)",
      "text": "Row 1: 8,153 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1 Row 6: Row 7:",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (column 2)",
      "text": "Row 1: 3 Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (column 3)",
      "text": "Row 1: new 2025 Row 2: graded patients with NSCLC stage IV with a HER2 mutation should be offered after failure of Row 3: minimum of a system therapy a targeted therapy with the anti-cooking Row 4: serum drug Konjugat Trastuzumab deruxtecan.",
      "start_page": 375,
      "end_page": 375
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page)",
      "text": "Row 1: 8,154-Consensus-based recommendation-modified 2025 Row 2: EK: Given the dynamics of the development of new personalized therapy-based Row 3: , the aim should be to ensure that each patient with NSCLC stage IV receives a comprehensive NGS-based molecular diagnosis-based Row 5: -- Row 6: ----In patients with wild type configuration for EGFR, ALK, ROS1, BRAF V600 , NTRK,--- Row 8: -RET, METex14, KRAS, HER2 (ERBB2) a comprehensive genotyping should take place on Row 9: -------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 376,
      "end_page": 376
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 1)",
      "text": "Row 1: 8.154 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 376,
      "end_page": 376
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 376,
      "end_page": 376
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 3)",
      "text": "In view of the dynamics of the development of new personalized therapy approaches, it should be pursued that every patient with NSCLC stage IV should receive a comprehensive NGS-based molecular diagnosis approach prior to the Row 4: first-line therapy decision.In view of the dynamics of the development of new personalized therapy approaches, the goal should be to ensure that every patient with NSCLC stage IV receives a comprehensive NGS-based molecular diagnosis approach prior to the Row 4: first-line therapy decision.In patients with wild type configuration for EGFR, ALK, ROS1, BRAF V600 , NTRK,- Row 8: RET, METex14, KRAS, HER2 (ERBB2), comprehensive genotyping should take place at the Row 9: further known driver mutations, in order to detect a sol-te Row 10: DYDYDYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTYTY",
      "start_page": 376,
      "end_page": 376
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page)",
      "text": "Row 1: 8.155 to Row 3: A local ablative therapy of all tumor herds in addition to Row 4: System therapy is characterized by a curative therapy goal. A limited number of Row 5: A solitary remote metastasis according to M1b stage is used as a surrogate for a limited metastasis Row 7: A maximum of 3-5 remote metastases may vary Row 8: A maximum of 3-5 remote metastases may vary Row 8: A maximum of two Row 9: A maximum of 2 Row 9: A maximum of 2 Row 9: A maximum of 2 Row 9: A maximum of 2 Row 9: A maximum of 2 Row 10: A maximum of 2 Row 10: A maximum of 2 Row 10: A maximum of 2 Row 9: A maximum of 2 Row 9: A maximum of 2 Row 9: A maximum of 3 Row 13 Row 10: Row 10: A maximum of 4 Row 10: A maximum of 2 Row 9: A maximum of 2 Row 9: A maximum of 4 Row 13 Row 10 is an indication",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page)",
      "text": "Row 1: 8.156/Consensus-based statement-tested 2025 Row 2: EK: A synchronous oligometastasis of the NSCLC is defined by the simultaneous Row 3: diagnosis of the locoregional primary tumor and oligometastasis, while Row 4: an interval of at least 6: Row 5: Row 6: Row 6: Row 6: Row 6: Row: Row 7: Row 7: Row 7: Row 7: Row 8: Row 8: Row 8: Row 8: Row 9: Row 9: Row 9: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 9: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 7: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8: Row 8",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 1)",
      "text": "Row 1: 8.155 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 1)",
      "text": "Row 1: 8.156 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 2)",
      "text": "Row 1: 5 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 2)",
      "text": "Row 1: 6 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 3)",
      "text": "Row 1: 14Konsensbasiertes Statement--tested 2025 Row 2:--The stage of oligometastasation is characterized by a limited me--- Row 3:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <The pooled results of exploratory analyses of the DESTINY-Lung01 and DESTINY-> (from previous page, column 3)",
      "text": "Row 1: Consensus-based statement-tested 2025 Row 2: --Synchronous oligometastasis of the NSCLC is defined by the simultaneous Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 377,
      "end_page": 377
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.177%Consensus-based recommendation-tested 2025 Row 2: EK: To confirm the diagnosis of an oligometastasis a whole body-tested Row 3: FDG-PET CT examination as well as a cranial MRI should be performed. At Ver-",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.188, \"Consensus-based recommendation\" tested 2025 Row 2: EK\"In oligometase-based NSCLC a system therapy is to be offered. Row 3: \"Indication for system therapy and criteria for the choice of system therapy\" was to be directed to Row 4: \"Row 4:\" according to the current approval and guidelines in metastatic stage IV\" Row 5: \"\" Row 6: \"\"NSCLC\".\" Row 7: \"\"Starker Konsent\"\" Row 8: \"\"\"",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.1594Evidence-based recommendation-tested 2025 Row 2: Recommendation level---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 8.160-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation- locally ablative therapy in the oligomestatic NSCLC is to be integrated into a multimodal treatment concept with a syste- to Row 3: Aemic therapy,- Row 4: which is defined in the thorax oncological tumor board.- Row 5: Level of Evidence-[1308], [1307], [884]- Row 6: 2a- to Row 7:",
      "start_page": 378,
      "end_page": 378
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.161/Evidence-based recommendation-tested 2025 Row 2: Recommendation level--An optimal sequence of system therapy and locally ablative therapy is not established at the Row 3: B. Oligometastase NSCLC. An induction therapy over 3-4 Mo- and Row 4: -nate should be performed before a local ablative therapy of locoregional primaryius as well as Row 5: Oligometastases in case of missing progress.- Row 6: --- Row 7: Level of Evidence[1307], [884] Row 8: 2b---- Row 9: ---- Row 10: ---Starker Consensus- Row 11: ------",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8,162 such a consensus-based recommendation is tested 2025 Row 2: EK: In oligometastated NSCLC, depending on the tumor load, presence of Row 3: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.163/Consensus-based recommendation--tested 2025 Row 2: EC---As a modality for the local ablative therapy of the loco-regional primary tumor so--- Row 3: like the cerebral and extracerebral oligometastases should be evaluated in an interdisciplinary way radithera---- Row 4: Peutian and surgical procedures. The off---- Row 5: --- Row 6: choice of the appropriate local procedure should be decided in the thoracic oncological Tu----- Row 7: morboard and is based on the localization of the Row 8: ----metastases, the surgical resectability and the feasibility of a local ab------ Row 9: ------lative radiotherapy, the necessity of a histological backup, the To------- Row 10: ---xicity profile, the possibility of combining with system therapy and the All------- Row 11: general condition of the patient.",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.161 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8,162 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.163 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 1-Evidence-based recommendation-tested 2025 Row 2: Hilence-level-An optimal sequence of system therapy and locally ablative therapy is not established at the Row 3: Oligometastasis NSCLC. An induction therapy over 3-4 Mo-E Row 4: should be performed before a local ablative therapy of locoregional primaryius and Row 5: Oligometastasis in the absence of progress.- Row 6: Oligometastasis in the absence of progress.- Row 6: Oligometastasis in the absence of progress.- Row 6: Oligometastasis in the absence of progress.- Row 6: Oligometastasis in the absence of progress.- Row 7: f Evidence-[1307], [884]- Row 8: Oligotherapy-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level-level",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 2--Consensus-based recommendation--tested 2025 Row 2: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: 3, \"Consensus-based recommendation\" tested 2025 Row 2: \"As a modality for the local ablative therapy of the locoregional primary tumor so-\" Row 3: \"like cerebral and extracerebral oligometastases\" should be evaluated in an interdisciplinary way radithera-\" Row 4: \"peutical and surgical procedures\". The off-\" Row 5: \"\" Row 6: \"choice of the appropriate local procedure\" should be decided in the thoracic oncological Tu-\" Row 7: \"morboard\" and is based on the localization of the Row 8: \"Metastases\", the surgical resectability and the feasibility of a local ab-\" Row 9: \"\"lative radiotherapy\", the necessity of a histological assurance, the To-\" Row 10: \"xicity profile\", the possibility of combining with system therapy and the All-\" Row 11: \"common condition of the patient\".",
      "start_page": 379,
      "end_page": 379
    },
    {
      "heading": "table under heading <2b>",
      "text": "Row 1: 8.1647Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--A general advantage of (in particular) stereotactic radiation therapy in the Row 3: Uniform to oligometastic NSCLC surgery is not established, so that-- Row 4: low evidence regarding the importance of surgery in comparison-- Row 5: for radiotherapy in the oligometastic stage, both options should be considered as complementary-- Row 6: --- Row 7: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 380,
      "end_page": 380
    },
    {
      "heading": "table under heading <2b> (column 1)",
      "text": "Row 1: 8.164 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2b Row 7: Row 8:",
      "start_page": 380,
      "end_page": 380
    },
    {
      "heading": "table under heading <2b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 380,
      "end_page": 380
    },
    {
      "heading": "table under heading <2b> (column 3)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--A general advantage of (in particular) stereotactic radiation therapy in Ver--- Row 3: equal to surgery in oligometastase NSCLC is not established, so-- Row 4: compared to lower evidence regarding the importance of surgery-- Row 5: - to radiotherapy in oligometastase stage, both options should be considered as supplement--- Row 6: ---- Row 7: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 380,
      "end_page": 380
    },
    {
      "heading": "table under heading <2b> (from previous page)",
      "text": "In addition, it is time to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page, column 1)",
      "text": "Row 1: Study: #Pati Row 2: #Row 3: One-armed Phase II Studies: Row 4: De Ruysscher 2018]N=39 Row 5: [1308]]\" Row 6: \"Row 7: \"Row 8: Collen 2014\" [1312]]\"N=26 Row 9: \"Row 10: Petty 2018\" [1313]\"N=29 Row 11: \"Row 12: Arrieta 2019\" [1314]\"N=37 Row 13: \"Row 14: Bauml 2019\" [1315]\"N=51 Row 15: \"Row 16: Randomized Phase II Studies: Row 17: Iyengar 2018\" [884]\"N=29 Row 18: \"\"",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page, column 2)",
      "text": "Row 1: iente Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page, column 3)",
      "text": "The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the following: The following are the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the more the",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page, column 4)",
      "text": "Row 1: diane / ma Row 2: number of Fe Row 3: sen in Row 4: n patients Row 5: Row 6: dian n=1 Row 7: ximum n=3 Row 8: Row 9: dian n=1 Row 10: ximum n=5 Row 11: Row 12: dian n=2 Row 13: ximum n=4 Row 14: Row 15: dian n=2 Row 16: Row 17: dian n=1 Row 18: ximum n=4 Row 19: Row 20: Row 21: dian n=2 Row 22: ximum n=3 Row 23:",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page, column 5)",
      "text": "Row 1: maximum Row 2: first Row 3: nklud Row 4: n Row 5: Row 6: Row 7: 3 Row 8: Row 9: Row 10: 5 Row 11: Row 12: Row 13: 4 Row 14: Row 15: Row 16: Row 17: Row 18: 4 Row 19: Row 20: Row 21: Row 22: 3 Row 23:",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page, column 6)",
      "text": "Row 1: paint Row 2: eta- Row 3: dier- Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23:",
      "start_page": 382,
      "end_page": 382
    },
    {
      "heading": "table under heading <2b> (from previous page)",
      "text": "In addition, the number of cases to be to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To",
      "start_page": 383,
      "end_page": 383
    },
    {
      "heading": "table under heading <2b> (from previous page, column 1)",
      "text": "Row 1: Study Row 2: Row 3: Row 4: Goem Row 5: Row 6: Palma Row 7: Row 8: Rando Row 9: Wang Row 10:",
      "start_page": 383,
      "end_page": 383
    },
    {
      "heading": "table under heading <2b> (from previous page, column 2)",
      "text": "In addition, the number of cases to be to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 383,
      "end_page": 383
    },
    {
      "heading": "table under heading <2b> (from previous page)",
      "text": "In addition: SBRT with 50Gy in 104Median2Median 23 Row 9: [1308]]N=26.100% SBRT with 50Gy with 50Gy in 104Median2Median2Median2___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading <2b> (from previous page, column 1)",
      "text": "The Row 1: The Phase: Pa Row 2: One-armed Phase II Studies: Row 3: De Ruysscher: N=3 Thow 28:: De Ruysscher: N=3 Thow 28:: De Ruysscher: N=3 Thow 28:: De Ruysscher: N=3 Thow 28:: De Ruysscher: N=3 Thow 28::: De Ruysscher: N=3 Thow 28::: De Ruysscher: N=3 Th Thow: 2018 [1308]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]] []]]]]]] []]]]]]]] []]]]]]]]] [ [] [] [ [ []] [] [ [] [] [] [] [ [] [ [ [ [] [ [] [ [ [] [ [ [] [ [] [] [] [] [ [ [ [] [ [ [ [] [ [ [] [ [ [] [ [ [ [ [",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading <2b> (from previous page, column 2)",
      "text": "Row 1: atient Row 2: n Row 3: 39 Row 4: Row 5: 26 Row 6: Row 7: 29 Row 8: Row 9: 37 Row 10: Row 11: 51 Row 12: Row 13: andien Row 14: 29 Row 15: Row 16: 49 Row 17: Row 18: 99 Row 19: Row 20: andien Row 21: 133 Row 22:",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading <2b> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: n Row 21: Row 22: Row",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading <2b> (from previous page, column 4)",
      "text": "24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 24G: 25G: 24G: 25G: 24G: 25G: 24G: 24G: 25G: 24G: 25G: 24G: 24G: 25G: 24G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25G: 25",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading <2b> (from previous page, column 5)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading <2b> (from previous page, column 6)",
      "text": "Row 1: 的OS Row 2: 的 Row 3: 的Median 13.5 Row 4: 的Mo Row 5:",
      "start_page": 385,
      "end_page": 385
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page)",
      "text": "Row 1: 9.1-Consensus-based recommendation-tested 2025 Row 2: EK-testedThe classification of the SCLC tumor spread should be based on TNM features-based Row 3: and the current staging system of the UICC.",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page)",
      "text": "Row 1: 9.2的Development-based statement-tested 2025 Row 2: Level of Evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based evidence-based",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page, column 1)",
      "text": "Row 1: 9.1 Row 2: EC Row 3: Row 4:",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page, column 1)",
      "text": "Row 1: 9.2 Row 2: Level of Row 3: 3b Row 4: Row 5: Row 6:",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page, column 2)",
      "text": "Row 1: Row 2: f Eviden Row 3: Row 4: Row 5: Row 6:",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--The classification of the SCLC tumor spread should be based on TNM features-- Row 3:--and the current staging system of the UICC.-- Row 4:--Starker Consensus-- Row 5:----",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < 8.6.15 Flowcharts to NSCLC stage IV> (from previous page, column 3)",
      "text": "Row 1: evidence-based statement, checked 2025 Row 2: nce, because of particular prognostic significance in SCLC, ECOG Perfor-",
      "start_page": 397,
      "end_page": 397
    },
    {
      "heading": "table under heading < change in progress not superior (evidence level 1b) [1362], [1364], [1365], [1366],>",
      "text": "Row 1: 9.3-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In all patients with SCLC a combination system therapy is to be carried out- Row 3: A-. Patient- and stadia-dependent it should be combined with local measures, e.g.- Row 4: -Operation or radiation therapy.- Row 5: Level of Evidence--- Row 6: 1b-- Row 7: --- Row 8: --Strong Consensus-- Row 9: ----",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading < change in progress not superior (evidence level 1b) [1362], [1364], [1365], [1366],> (column 1)",
      "text": "Row 1: 9.3 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1b Row 6: Row 7:",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading < change in progress not superior (evidence level 1b) [1362], [1364], [1365], [1366],> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading < change in progress not superior (evidence level 1b) [1362], [1364], [1365], [1366],> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn all patients with SCLC, a combination system therapy is to be carried out- Row 3: . Patients and stadia-dependent should be combined with local measures, e.g.- Row 4: operation or radiation therapy.- Row 5: nce-",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 9.4-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In patients with SCLC in stage I/II without mediastinal lymph node infestation- Row 3: a multimodal therapy as a combination of a local treatment (Operation-Row 4: or, especially at high surgical risk, radiotherapy) with a systemi-",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 9.4 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, tested In patients with SCLC in stage I/II without mediastinal lymph node infestation, Row 3: should be performed as a multimodal therapy as a combination of a local treatment (operation, Row 4: or, especially at high surgical risk, radiation therapy) with a systemi-, Row 5: chemotherapy.",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "In patients with SCLC in stage I/II without mediastinal lymhp node infest infest I/II without mediastinal lymhp node infection, Row 3: A/0, a primary operation can be performed.Established 2025 Row 2: Recommendation Level: Recommendation Level: [1382] [1383], [1384], [1385], [1385], [1386], [1386], [1386], [1387], [1349], [1374], [1376], [1386], [1385], [1386] [1386], [1387], [1349], [1374], [1375] [1376], [1376], [1376] [1376] [1377] [1383], [1384] [1384], [1385], [1386], [1386] [1386] [1384] [1384] [1383] [1383] [1383] [1383], [1383] [1383] [1383] [1383] [ [ [131383] [ [131383 [1313] [] [131313 [ [ [13] [ [13131313] [ [1313131313",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 9.5 Row 2: Empfeh Row 3: A/0 Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: 0 Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 9.6的Consensus-based recommendation--tested 2025 Row 2: EK-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 402,
      "end_page": 402
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 9.6 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 402,
      "end_page": 402
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 402,
      "end_page": 402
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --If a resection has been performed in a patient with SCLC in stage I/II, Row 3: is to be offered adjuvant chemotherapy postoperatively. The protocol Cis--- Row 4: -platin/Etoposid over 4 cycles represents the therapy of the first choice. In contra--- Row 5: --- Row 6: --indications against cisplatin is to be offered the use of alternative protocols-- Row 7: -----row 8: ---Strong consensus--- Row 9: -------",
      "start_page": 402,
      "end_page": 402
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 9.7-Consensus-based recommendation-tested 2025 Row 2: EK-E After curative therapy of the SCLC in stage I/II, besides adjuvant-based Row 3: chemotherapy a prophylactic radiatio of the skull should be offered. One-row 4: frequently used procedure provides for the administration of 30 Gy in 15 fractions or from-row 5:",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 9.8的Consensus-based recommendation--tested 2025 Row 2: EK---If a resection has been performed in a patient with SCLC in stage I/II, Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 9.9-Consensus-based recommendation--tested 2025 Row 2: EK--If a resection-- Row 3:-- is achieved in a patient with SCLC in preoperative stage I/II, a mediastinal irradiation should be performed in N2 infestation.-- Row 4:---This should be carried out at a dose of 50-60 Gy in conventional fractionation--- Row 5:---- Row 6:------ Row 7:--Starker Konsensenz--- Row 8:-------",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 9.7 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 9.8 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 9.9 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--After curative therapy of SCLC in stage I/II, besides adjuvant-based Row 3:--Chemotherapy, a prophylactic radiatio of the skull should be offered. A-- Row 4:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --If a resection has been performed in a patient with SCLC in stage I/II, Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading <2a> (from previous page)",
      "text": "Row 1: 9.10-Consensus-based recommendation-tested 2025 Row 2: EC-testedIf a resection has been performed in a patient with SCLC in stage I/II, Row 3: should also be performed in the case of a R1/2 resection an additional mediastinal irradiation-Row 4: analogue of the primary chemo-radiation therapy.- Row 5:",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "table under heading <2a> (from previous page, column 1)",
      "text": "Row 1: 9.10 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "table under heading <2a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "table under heading <2a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--If a resection is performed in a patient with SCLC in stage I/II, Row 3:--in the case of a R1/2 resection, an additional mediastinal irradiation-- Row 4:--analog of primary chemo-radiation therapy is also to be performed.-- Row 5:-- Row 6:--Starker Consensus-- Row 7:----",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 9.11-Evidence-based recommendation-modified 2025 Row 2: Recommendation-level-level-of-recommendation-For patients with a SCLC in stage I/II, a primary definitive chemo-radiation therapy can be performed, especially at a high surgical level- of-row 3: A/0-Hazard, analogous to the procedure at SCLC stage III (chapter 9.5) and at Row 5: Achieving a remission by prophylactic cranial irradiation com- of- of- Row 6: Aplete.- Row 7: Inoperable patients without progression after chemo-radiation should be offered, analog-of-row 8: The procedure at SCLC stage III (chapter 9.5), a 24-month maintenance-of-row 9: Durvalumab therapy.- Row 10: Level of Evidence-of-radiation[1391], [1392]-h Row 11: 1b",
      "start_page": 405,
      "end_page": 405
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 9.11 Row 2: Empfeh Row 3: A/0 Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 405,
      "end_page": 405
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: 0 Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 405,
      "end_page": 405
    },
    {
      "heading": "table under heading <1b> (column 3)",
      "text": "Row 1: Evidence-based recommendation--modified 2025 Row 2: grad--In patients with a SCLC in stage I/II, especially at high surgical--- Row 3: -Risk, a primary definitive chemo-ray therapy can be performed-- Row 4: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 405,
      "end_page": 405
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 9.12-Evidence-based recommendation-tested 2025 Row 2: Recommendation level-Chemotherapy combination of the first choice, in the context of simultaneous radio--- Row 3: B-chemotherapy at SCLC stage III, is cisplatin and etoposid (PE). The therapy-- Row 4: should be performed over at least 4 cycles. Carboplatin-containing Proto--- Row 5: -colle are only insufficiently tested and should only be used for unambiguous contraindika---- Row 6: 1394, [1395], [1396], [1398], [1399], [1400], [1402], [1402], [14] [14] [14] [14] [14] [14] [14] [14] [14] Row: [14] [14] [14] Row:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 9.12 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 9.13-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with SCLC stage III with irradiable primary tumor expansion-level Row 3: should receive irradiation of the primary tumor region.- Row 4: -- Row 5: Level of Evidence-level[1417], [1418], [1419], [1420], [1421], [1422], [1423], [1424]-level Row 6: 1a---- Row 7:",
      "start_page": 411,
      "end_page": 411
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 9.13 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1a Row 6: Row 7:",
      "start_page": 411,
      "end_page": 411
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 411,
      "end_page": 411
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: graded SCLC stage III patients with irradiable primary tumor expansion-rated Row 3: should receive irradiation of the primary tumor region.- Row 4: graded Row 5: level[1417], [1418], [1419], [1420], [1421], [1422], [1423], [1424]-- Row 6: leveled Row 7: leveled Row 8: leveled",
      "start_page": 411,
      "end_page": 411
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 9.14-Evidence-based recommendation-tested 2025 Row 2:Recommendation degree-patients under simultaneous chemo-radiation should smoke one-stove Row 3: Bolen.- Row 4: -- Row 5: Level of Evidence--[80]- Row 6: 2b-- Row 7: -- Row 8: --Strong Consensus-- Row 9: ---",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 9.15-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-Application of radiotherapy to SCLC in tumour stages T3-4 N0-1-- Row 3: A- and T1-4N2-3M0 (Limited disease) is to be performed simultaneously for chemotherapy with cisplatin-- Row 4:-- and etoposide.- Row 5: Level of Evidence--[1425], [1426], [1427]- Row 6: 1b--- Row 7:---- Row 8:---Starker Consensus-- Row 9:------",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 9.14 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2b Row 6: Row 7:",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 9.15 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 1b Row 6: Row 7:",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedPatients under simultaneous chemo-radiation should smoke one-stower Row 3: grade.- Row 4: grade-down Row 5: level-down[80]- Row 6: level-down Row 7: level-down Row 8: level-down Row 9: level-down Row 9: level-down",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: degree-testedThe application of radiotherapy to SCLC in tumour stages T3-4 N0-1-Y Row 3: and T1-4N2-3M0 (Limited Disease) is to be carried out simultaneously for chemotherapy with cisplatin-Y Row 4: and etoposid.- Row 5:nce-[1425], [1426], [1427]- Row 6:",
      "start_page": 412,
      "end_page": 412
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: 9.16-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with irradiable primary tumor expansion of SCLC stage III-Row 3: B-should either receive hyperfractional accelerated radiation therapy with a Row 4: GD of at least 45 Gy or conventionally fractionated early radiation therapy-Row 5: , with 60-66 Gy.-Row 6: ,-- Row 7: Level of Evidence-[1437], [1438], [1439], [1440], [869], [1441], [1442], [1443], [1444], [1445]--Row 8: 1b,---- Row 9:,----- Row 10: ,---Konsenst-Row 11: ,-----",
      "start_page": 414,
      "end_page": 414
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: 9.16 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 414,
      "end_page": 414
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 414,
      "end_page": 414
    },
    {
      "heading": "table under heading <1b> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients with irradiable primary tumor expansion of SCLC stage III-leveled Row 3: should either receive hyperfractional accelerated radiation therapy with a Row 4: graded GD of at least 45 Gy or conventionally fractionated early radiotherapy-leveled Row 5: graded 60-66 Gy. Row 6: graded Row 7: leveled [1437], [1438], [1439], [1440], [1441], [1442], [1443], [1444], [1445] to Row 8: graded Row 9:",
      "start_page": 414,
      "end_page": 414
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 9.17, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"In all patients with SCLC stage III with remission after completion of chemo- and Row 3: \"Ray therapy\" a prophylactic cranial irradiation should be offered.\" Row 4: \"Preferred is a GHD to 25 Gy in single doses of 2.5 Gy or 30 Gy in single- and Row 5: \"doses of 2 Gy daily\".\" Row 6: \"\"\"\" Row 7: Level of Evidence\"[1446], [1447], [1449], [1450]\" Row 8: 1a\"\" Row 9: \"\"\" Row 10: \"\"Konsens\" Row 11: \"\"\"",
      "start_page": 415,
      "end_page": 415
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 9.17 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1a Row 7: Row 8:",
      "start_page": 415,
      "end_page": 415
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 415,
      "end_page": 415
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedAll patients with SCLC stage III with remission after completion of chemo- such Row 3: radiation therapy should be offered prophylactic cranial radiation.- Row 4: grade-preferred is a GHD up to 25 Gy in single doses of 2.5 Gy or 30 Gy in single- and Row 5: doses of 2 Gy daily.- Row 6: level-down Row 7: level-down Row 7: level-down [1446], [1448], [1449], [1450]- Row 8: level-down Row 9: level-down Row 10: level-down Row 11: level-down Row 11: level-down",
      "start_page": 415,
      "end_page": 415
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 9.18,Consensus-based recommendation: New 2025 Row 2: EK, All patients with SCLC stage III without progress after completion of chemo-, Row 3: radiation therapy should be offered a 24-month maintenance therapy with Durvalumab Row 4: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 416,
      "end_page": 416
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 9.18 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 416,
      "end_page": 416
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 416,
      "end_page": 416
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation: New 2025 Row 2: All patients with SCLC stage III without progress after completion of chemo-E Row 3: Radiation therapy is to be offered a 24-month maintenance therapy with Durvalumab Row 4: .",
      "start_page": 416,
      "end_page": 416
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 9.19-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with remote metastatic small cell lung carcinoma should, unless there are any Row 3: A-contraindications, be offered primarily a chemo-immunotherapy with platinum/Eto--- Row 4: posid and a PD-L1 antibody (atezolizumab or durvalumab)- Row 5: --become.- Row 6: --- Row 7: Level of Evidence--[1456], [1457], [1454]- Row 8: 1b---- Row 9:",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "table under heading <1b>",
      "text": "Row 1: 9.20-Evidence-based recommendation-tested 2025 Row 2: Recommendation-level-maintenance therapy with a checkpoint inhibitor according to the sole chemothe-- Row 3: A-rapie is not to be offered at SCLC stage IV.- Row 4: -- Row 5: Level of Evidence--[1456], [1457]- Row 6: 1b--- Row 7: --- Row 8: --Starker Consensus-- Row 9: ----",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 9.19 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: 1b Row 7: Row 8:",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "table under heading <1b> (column 1)",
      "text": "Row 1: 9.20 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 1b Row 6: Row 7:",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients with remote metastatic small cell lung carcinoma should be offered, unless there are any Row 3: contraindications, primarily a chemo-immunotherapy with platinum/Eto-: Row 4: ,posid and a PD-L1 antibody (atezolizumab or Durvalumab)- Row 5: ,-- Row 6: ,-- Row 7: nce-:[1456], [1457], [1454]- Row 8: ,--- Row 9: ,-- Row 10: ,---Strong Consensions- Row 11: ,----",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "table under heading <1b> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedMaintenance therapy with a checkpoint inhibitor according to the sole chemothe-- Row 3:-rapie is not to be offered at SCLC stage IV.- Row 4:--\" Row 5: nce\"[1456], [1457]- Row 6: \"-\" Row 7: \"-\" Row 8: \"Stark Consensus\" Row 9: \"-\"",
      "start_page": 418,
      "end_page": 418
    },
    {
      "heading": "table under heading <1b> (from previous page)",
      "text": "Row 1: Study of core results Row 2: IMPOWER 133的12 Mon. PFS rate 13 % vs. 5%, PFS 5.2 vs. 4.3 Mo, HR for PFS 0.77, Row 3: .med. OS: 12.3 vs. 10.3 Mon., OS after 18 months: 34 % vs. 21 %; HR for OS 0.70 Row 4: CASPIAN的12 Mon. PFS rate 17.5% vs. 5 % HR for PFS 0.78, Row 5: .med. OS 13.0 vs. 10.3 Mon., OS after 26 months 17.5 % vs. 5.8%; HR for OS 0.71 Row 6: Keynote 604",
      "start_page": 421,
      "end_page": 421
    },
    {
      "heading": "table under heading <1b> (from previous page, column 1)",
      "text": "Row 1: Study Row 2: IMPOW Row 3: Row 4: CASPIA Row 5: Row 6: Keynot Row 7: Row 8: ECOG-A Row 9: 5161 Row 10:",
      "start_page": 421,
      "end_page": 421
    },
    {
      "heading": "table under heading <1b> (from previous page, column 2)",
      "text": "Row 1: Core results Row 2: WER 1333-12 Mon. PFS rate 13 % vs. 5%, PFS 5.2 vs. 4.3 Mo, HR for PFS 0.77, Row 3: RPM: 12.3 vs. 10.3 Mon., OS after 18 months: 34 % vs. 21 %; HR for OS 0.70 Row 4: RPM: 17.52 Mon. PFS rate 17.5% vs. 5 % HR for PFS 0.78, Row 5: RPM: 13.0 vs. 10.3 Mon., OS after 26 months 17.5 % vs. 5.8 %; HR for OS 0.71 Row 6: RPM: 4.5 vs. 4.3 Mon., HR for PFS Row 7: RPM: 10.8 month, HR for OS 0.71 Row 6: RPM: 4.5 vs. 4.3 Mon.",
      "start_page": 421,
      "end_page": 421
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page)",
      "text": "Row 1: 9.21, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\" A second-line therapy is to be offered in patients with small cell lung cancer and Row 3: \"A\" depending on the time of occurrence of the recurrence.\" Row 4: \"\"\" Row 5: Level of Evidence\"[1472], [1473], [1474], [1475], [1476], [1477], [1478], [1479], [1480], [1481]\" Row 6: \"1a\" Row 7: \"1a\" (Oxford 2009): for topotecan monotherapy\" Row 8: \"\"\" Row 9: \"\"Starker Consens\" Row 10: \"\"\"",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page)",
      "text": "Row 1: 9.22, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"In case of local recurrence after primary therapy of an initial limited tumor stage\" Row 3: \"SCLC\" can, after exclusion of a remote metastasis, a local therapy\" Row 4: \"By means of resection or radiation therapy\" (if applicable stereotactic radiation therapy) be applied--\" Row 5: \"\" Row 6: \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page)",
      "text": "Row 1: 9.23, \"Consensus-based recommendation\" tested 2025 Row 2: EK, \"If there is a systemic progress of the SCLC, an immunotherapy up to this\" Row 3: \"Time point should be stopped.\" Row 4: \"Stark Consensus\" Row 5: \"\"",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 1)",
      "text": "Row 1: 9.21 Row 2: Empfeh Row 3: A Row 4: Level of Row 5: 1a Row 6: Row 7:",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 1)",
      "text": "Row 1: 9.22 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 1)",
      "text": "Row 1: 9.23 Row 2: EC Row 3: Row 4:",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-basedSecond-line therapy should be offered in patients with small cell lung carcinoma and-- Row 3: depending on the time of occurrence of the recurrence.- Row 4: level-based Row 5: level-based [1472], [1473], [1474], [1475], [1476], [1477], [1478], [1479], [1480], [1481]-based Row 6: level-based Row 7: level-based (Oxford 2009): for topotecan monotherapy Row 8: level-based Row 9: level-based consensus-based Row 10: level-based",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -In case of a systemic progress of the SCLC, an immunotherapy up to this Row 3: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 424,
      "end_page": 424
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page)",
      "text": "Row 1: 9.24-Evidence-based recommendation--tested 2025 Row 2: Recommendation level--As a systemic secondary-line therapy of the SCLC, the administration of topotecan should be offered to: Row 3: B/0--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page)",
      "text": "Row 1: 9.25-Consensus-based recommendation-tested 2025 Row 2: EC-E1. In case of sensitive progression of the SCLC with less than 6 months after Che-: Row 3: .motherapy and ECOG 0-1, the second-line therapy is to be offered.- Row 4: 2. In case of progression of the SCLC with more than 6 months after chemotherapy-- Row 5: . should a repetition of the first-line chemotherapy be offered-- Row 6: . .Stark Consensus-- Row 7: .",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 1)",
      "text": "Row 1: 9.24 Row 2: Empfeh Row 3: B/0 Row 4: Row 5: Level of Row 6: 1a Row 7: 2b Row 8: Row 9:",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 1)",
      "text": "Row 1: 9.25 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: 0 Row 4: Row 5: f Eviden Row 6: Row 7: Row 8: Row 9:",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--As a systemic secondary-line therapy of the SCLC, the administration of topotecan should be prescribed to Row 3:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <Correlations between PD-L1 status and clinical parameters.> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--1. In case of sensitive progression of SCLC with less than 6 months after Che--- Row 3:--motherapy and ECOG 0-1, second-line therapy is to be offered.-- Row 4:--2. In case of progression of SCLC with more than 6 months after Chemotherapy-- Row 5:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "Table under heading <1b). This survival advantage was explained by the fact that the prophylactic Schä->",
      "text": "Row 1: 9.26, \"Evidence-based recommendation\" tested 2025 Row 2: \"Recommendation level\"In SCLC patients with response to first-line chemotherapy, the pro-\" Row 3: \"A\"phylactic cranial radiation or an active surveillance with 3-monthly Row 4: \"MRI control of the brain in the 1st year, then every 6 months,\" Row 5: \"\" is to be offered.\" Row 6: \"\"\"\" Row 7: \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Table under heading <1b). This survival advantage was explained by the fact that the prophylactic sheep-> (column 1)",
      "text": "Row 1: 9.26 Row 2: Empfeh Row 3: A Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Table under heading <1b). This survival advantage was explained by the fact that the prophylactic sheep-> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Table under heading <1b). This survival advantage was explained by the fact that the prophylactic sheep-> (column 3)",
      "text": "Row 1: evidence-based recommendation, tested 2025 Row 2: grade, in SCLC patients with response to first-line chemotherapy, the pro--- Row 3: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025>",
      "text": "Row 1: 9.27, \"Consensus-based recommendation\" tested 2025 Row 2: EK-SCLC patients with brain metastasis should be offered a brain-derived line during therapy.\" Row 4: \"Stark Consensus\" Row 5: \"\"\"",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025>",
      "text": "Row 1: 9.28-Evidence-based recommendation-tested 2025 Row 2: Recommendation level--In SCLC patients with multi-locular symptomatic brain metastasis-- Row 3: All brain irradiation, e.g. with 30 Gy in single doses of 3 Gy, should take place promptly after Di--- Row 4: diagnosis position.- Row 5: Level of Evidence--[1492], [1493], [1494], [1495], [1496]-- Row 6: 3a--",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025>",
      "text": "Row 1: 9.29-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In SCLC patients with asymptomatic brain metastases and progression control-- Row 3: 0-Cerebral metastasis, cranial radiation can also occur after completion of Row 4: Chemotherapy.-- Row 5: Level of Evidence--[1492], [1493], [1494], [1495], [1496]-- Row 6: 2a",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025>",
      "text": "Row 1: 9.30-Consensus-based statement--tested 2025 Row 2: EC--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 432,
      "end_page": 432
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page)",
      "text": "Row 1: 9.31,Consensus-based recommendation, tested 2025 Row 2: EC, patients with SCLC stage IV in good general condition with remission according to the Row 3: ,,, first line system therapy can be offered a consolidating mediastinal and primary tube, Row 4: ,,, especially if a limited remote metas-, Row 5: ,,,, Row 6: ,,, or a high thoracic tumor load.",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page)",
      "text": "Row 1: 9.32, \"Consensus-based recommendation\", \"tested 2025 Row 2: EK\"The indications for palliative irradiation at \"places of need\", e.g. thorakal or \"row 3:\" are to be checked regularly during the course of the disease at SCLC stage IV symptom-\" Row 4: \"and based on findings.\" Row 5: \"\"\" Row 6: \"\"Stark Consensus\" Row 7: \"\"\"",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 9.31 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 9.32 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -Patients with SCLC stage IV in good general condition with remission according to Row 3:--First line system therapy can be offered a consolidating mediastinal and primary tube-- Row 4:--mor irradiation, especially if a limited remote metas--- Row 5:---- Row 6:--tasting and/or a high thoracic tumor load.-- Row 7:--Starker Consensus-- Row 8:-----",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -The indications for palliative irradiation on \"places of need-- such as thorakal or-- Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 434,
      "end_page": 434
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page)",
      "text": "Row 1: 9.33-Consensus-based recommendation--tested 2025 Row 2: EK--patients aged > 75 years have higher hematotoxicity and a Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page)",
      "text": "Row 1: 9.34/Consensus-based recommendation-tested 2025 Row 2: EC-testedIn patients > 85 years with SCLC, the indication for chemotherapy should be placed indivi-/ Row 3: double. Here, dose-reduced protocols or possibly also wö-/ Row 4: weekly and well controllable regimes should be used.- Row 5:",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 9.33 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 1)",
      "text": "Row 1: 9.34 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: Patients > 75 years of age have higher hematotoxicity and a Row 3: less metabolization rate of chemotherapy. Choosing chemothe-",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "table under heading <9.30 Consensus-based statement reviewed 2025> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2:--In patients > 85 years with SCLC, the indication for chemotherapy should be placed indivi--- Row 3:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 436,
      "end_page": 436
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).>",
      "text": "Row 1: 9.35-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Determining selection criteria for the use of radiotherapy in older-row 3: patients with SCLC seems to be the general condition of the patients rather than the ka--- Row 4:--Lendary age.- Row 5:-- At an age between 70 and 75 years also the execution of a simultaneous--- Row 6:--tan chemo-ray therapy with very good general status is possible, with Er---- Row 7:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).>",
      "text": "Row 1: 9.36, \"Proof-based recommendation\"2010 Row 2: \"Recommendation level\"There are no data available at the age of 75 for simultaneous chemo-radiation therapy in SCLC, \"Row 3: 0\", due to the increased toxicity of these patients, \"Row 4: \"a simultaneous procedure\" should be dispensed with. Here, a consolidating Pri-, \"Row 5: \"Märtumorbe irradiation\" with good general condition and missing comorbidite-, \"Row 6: \"\" Row 7: \"ten\" can be considered (evidence level 3b). \" Row 8: \"2010: \"Recommendation level C\" (weak recommendation) \"",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).> (column 1)",
      "text": "Row 1: 9.35 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1b Row 7: Row 8:",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).> (column 1)",
      "text": "Row 1: 9.36 Row 2: Empfeh Row 3: 0 Row 4:",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4:",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).> (column 3)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--Determining selection criteria for the use of radiotherapy in older-- Row 3:--patients with SCLC seems to be the general condition of the patients rather than the ka--- Row 4:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "Table under heading should therefore be considered for simultaneous action (evidence level 1b).> (column 3)",
      "text": "Row 1: evidence-based recommendation-2010 Row 2: grade- At the age of 75 years, there are no data available for simultaneous chemo-radiation therapy in SCLC-E Row 3: . Due to the increased toxicity in these patients, Row 4: should be dispensed with a simultaneous procedure. Here, a consolidating Pri-E Row 5: mary tumor irradiation with good general condition and lack of comorbidite-E Row 6:",
      "start_page": 437,
      "end_page": 437
    },
    {
      "heading": "(evidence level 3b).>",
      "text": "Row 1: 9.36, \"evidence-based recommendation\"2010 Row 2: Level of Evidence\" Row 3: 3b, \"row 4: \"\"\" Row 5: \"\"Konsens\" Row 6: \"\"\"\"",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "(evidence level 3b).>",
      "text": "Row 1: 9.37/Evidence-based recommendation-2010 Row 2: Degree of recommendation-Indications for prophylactic cranial irradiation in SCLC despre-: Row 3: 0---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "Table under heading (evidence level 3b).> (column 1)",
      "text": "Row 1: 9.36 Row 2: Level of Eviden Row 3: 3b Row 4: Row 5:",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "Table under heading (evidence level 3b).> (column 1)",
      "text": "Row 1: 9.37 Row 2: Recommendationg Row 3: 0 Row 4: Row 5: Level of Eviden Row 6: 3b Row 7: Row 8:",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "(evidence level 3b).> (column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: nce--- Row 3: ,,, Row 4: ,,, Row 5: ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "(evidence level 3b).> (column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--The indications for prophylactic cranial irradiation in SCLC despre--- Row 3:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 438,
      "end_page": 438
    },
    {
      "heading": "Table under heading <tung. (evidence level 3b).> (from previous page)",
      "text": "Row 1: 10.1-Evidence-based recommendation--2010 Row 2: Degree of recommendation--By appropriate investigations (bronchoscopy / CT-thorax) it should be safely-- Row 3: 0---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 440,
      "end_page": 440
    },
    {
      "heading": "Table under heading <tung. (evidence level 3b).> (from previous page, column 1)",
      "text": "Row 1: 10.1 Row 2: Empfeh Row 3: 0 Row 4:",
      "start_page": 440,
      "end_page": 440
    },
    {
      "heading": "Table under heading <tung. (evidence level 3b).> (from previous page, column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4:",
      "start_page": 440,
      "end_page": 440
    },
    {
      "heading": "Table under heading <tung. (evidence level 3b).> (from previous page, column 3)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 440,
      "end_page": 440
    },
    {
      "heading": "Table under heading <enzgrade 1a).>",
      "text": "Row 1: 10.1-evidence-based recommendation--2010 Row 2: Level of Evidence-- Row 3: 4--- Row 4: -- Row 5: --Konsens-- Row 6: ---",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).>",
      "text": "Row 1: 10.2-Evidence-based recommendation-2010 Row 2: Degree of recommendation-The optimal procedure for patients with lung carcinoma and recurrent,- Row 3: A-symptomatic, malignant pleural effusion* represents the thoracoscopic poudrage-row 4: with talc (5 – 10g) (Evidence level 1a).- Row 5: -* A pleural effusion is then called malignant if malignant cells-row 6: or tissue are detected in it.- Row 7: Level of Evidence-",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).>",
      "text": "Row 1: 10.3-Evidence-based recommendation-2010 Row 2: Recommendation level-The procedure can be performed in anaesthesia or local anaesthesia (evidence level 1a).- Row 3: Bow 3: Bow 4: -- Row 5: Level of Evidence--- Row 6: 1a--- Row 7: --- Row 8: --Konsens-- Row 9: ----",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).>",
      "text": "Row 1: 10.4:evidence-based recommendation-2010 Row 2: recommendation-level-the talc used should be set to a particle size > 10 μm (Evi-:row 3: degree 2a).- Row 4: level-the-row 5: level of evidence-the-row 6: level-two-the-row 7: level-the-row",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 1)",
      "text": "Row 1: 10.1的Evidenceb Row 2: Level of Evidence",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 1)",
      "text": "Row 1: 10.2-Evidenceb Row 2:Recommendation level--The optimal Row 3: A-symptom Row 4: -with Talku Row 5: -* A Pleu Row 6: -or Geh Row 7: Level of Evidence-- Row 8: 1a-- Row 9: -- Row 10: --Konsens Row 11: --",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 1)",
      "text": "Row 1: 10.3-Evidenceb Row 2: Recommendation level---Verfa Row 3: B--Row 4: -- Row 5: Level of Evidence-- Row 6: 1a-- Row 7: -- Row 8: --Konsens Row 9: --",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 1)",
      "text": "Row 1: 10.4-Evidenceb Row 2: Recommendation level--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 2)",
      "text": "Row 1: based recommendation Row 2: Row 3: Row 4:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 2)",
      "text": "Row 1: based recommendation Row 2: male procedures in patients with lungs Row 3:matic, malignant pleural effusion* represents Row 4: um (5 – 10g) (evidence level 1a). Row 5: ural effusion will then be identified as malignant Row 6: webe. Row 7: Row 8: Row 9:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 2)",
      "text": "Row 1: based recommendation Row 2: can be used in anesthesia or local anesthesia Row 3: Row 4: Row 5: Row 6:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 2)",
      "text": "Row 1: based recommendation Row 2: applied talc to a particle size Row 3: d 2a. Row 4: Row 5: Row 6:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 3)",
      "text": "Row 1: .2010 Row 2: . . Row 3: . Row 4: . .",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 3)",
      "text": "Row 1 : 2010 Row 2 : ncarcinoma and rezidis Row 3 : t the thoracoscopic Row 4 : . Row 5: hnet, if in it evil Row 6: . . Row 7 : . . Row 8 : . Row 9 : . .",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 3)",
      "text": "Row 1: .2010 Row 2: thesie occur (Evide . Row 3: . Row 4: . Row 5: . Row 6: .",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 3)",
      "text": "Row 1: 2010 Row 2: kicks > 10 μm enter Row 3: 2013 Row 4: 2013 Row 5: 2013 Row 6: 2013",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 4)",
      "text": "Row 1: Row 2: ivating, Row 3: he Poudrage Row 4: Row 5: s like cells Row 6: Row 7: Row 8: Row 9:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 4)",
      "text": "Row 1: Row 2: enzgrad 1a. Row 3: Row 4: Row 5: Row 6:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "Table under heading <enzgrade 1a).> (column 4)",
      "text": "Row 1: Row 2: Tells (Evi- Row 3: Row 4: Row 5: Row 6:",
      "start_page": 441,
      "end_page": 441
    },
    {
      "heading": "table under heading <is with a high lethality of about 40% [1525], (evidence level 2c).",
      "text": "Row 1: 10.4-Evidence-based recommendation-2010 Row 2: -Konsens-Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "table under heading <is with a high lethality of about 40% [1525], (evidence level 2c).",
      "text": "Row 1: 10.5-Evidence-based recommendation-2010 Row 2: Recommendation level--A more complication-deficient but less effective alternative is the treatment-- Row 3: About a thoracic drainage with talc suspension or a tetracyclin derivative-- Row 4: (doxycycline 500 mg). A pleurodosis with local cytostatics is not recommended--- Row 5: -- (evidence level 1a).-- Row 6: --- Row 7: Level of Evidence--- Row 8: 1a---- Row 9: ----- Row 10: ---Consensions-- Row 11: -----",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "table under heading <is with a high lethality of about 40% [1525], (evidence level 2c).",
      "text": "Row 1: 10.6-Evidence-based recommendation-2010 Row 2: Recommendation level-In the case of a trapped lung, a thorax duration drainage or a pleu--- Row 3: 0-roperitoneal shunt can be used (evidence level 4).- Row 4: -- Row 5: Level of Evidence--- Row 6: 4--- Row 7: -- Row 8: --Konsens-- Row 9: ---",
      "start_page": 442,
      "end_page": 442
    },
    {
      "heading": "Table under heading <should be repeated (evidence level 2a).>",
      "text": "Row 1: 10.7-Evidence-based recommendation-2010 Row 2: Recommendation level--In hemoptysen, a bronchoscopy is indicated for the identification of the bleeding source and Row 3: B-Blood-stillation by local measures (evidence level 2a).- Row 4: -- Row 5: Level of Evidence--- Row 6: 2a--- Row 7: --- Row 8: --Konsens- Row 9: ----",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Table under heading <should be repeated (evidence level 2a).>",
      "text": "Row 1: 10.8-Evidence-based recommendation-2010 Row 2: Degree of recommendation-The bronchial arterial embolization is an effective and safe method for the the--- Row 3: Rapidity of massive or moderate relapsed hemoptyses. When relapsed Row 4: should they be repeated (evidence level 2a).-- Row 5: Level of Evidence--- Row 6: 2a--- Row 7:",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Table under heading should be repeated (evidence level 2a).> (column 1)",
      "text": "Row 1: 10.7 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Table under heading should be repeated (evidence level 2a).> (column 1)",
      "text": "Row 1: 10.8 Row 2: Recommendationg Row 3: B Row 4: Level of Eviden Row 5: 2a Row 6: Row 7:",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Table under heading <should be repeated (evidence level 2a).> (column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--In hemoptysen, a bronchoscopy is indicated for the identification of the bleeding source and Row 3: blood--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Table under heading <should be repeated (evidence level 2a).> (column 2)",
      "text": "Row 1: \"Evidence-based recommendation\"2010 Row 2: \"grad\" Bronchial arterial embolization is an effective and safe method for the \"The-\" Row 3: \"rapie of massive or moderate relapsed hemoptyses. When relapsed Row 4: \"should be repeated\" (evidence level 2a).\" Row 5: \"nce\" Row 6: \"\" Row 7: \"\" Row 8: \"\"Konsens\" Row 9: \"\"\"",
      "start_page": 444,
      "end_page": 444
    },
    {
      "heading": "Table under heading <ten. (degree of evidence 2a)>",
      "text": "Row 1: 10.9-Evidence-based recommendation--2010 Row 2: Degree of recommendation--The method of choice for the palliation of Vena-cava-superior syndrome is the per--- Row 3: B-cutaneous intravasal stentimplantation, which allows a rapid and safe palliation of Vena-cava-superior syndrome. In the treatment-naive small cell lung cancer, primarily a Row 5: chemo- and/or radiotherapy is indicated, the stentimplantation is patients with-- Row 6: ---- Row 7: therapy-refractary or recurrent Vena-cava-superior syndrome pre------ Row 8: -----ten. (Evidence degree 2a)---- Row 9: Level of Evidence---- Row 10: 2a-------- Row 11: ------row 12:",
      "start_page": 445,
      "end_page": 445
    },
    {
      "heading": "Table under heading <ten. (degree of evidence 2a)> (column 1)",
      "text": "Row 1: 10.9 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 2a Row 7: Row 8:",
      "start_page": 445,
      "end_page": 445
    },
    {
      "heading": "Table under heading <ten. (evidence grade 2a)> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 445,
      "end_page": 445
    },
    {
      "heading": "Table under heading <ten. (evidence grade 2a)> (column 3)",
      "text": "Row 1: \"Evidence-based recommendation\"2010 Row 2: \"grad\"The method of choice for palliation of Vena-cava-superior syndrome is the per-\" Row 3: \"cutaneous intravasal stentim implantation\" which allows rapid and safe palliation of Vena-cava-superior syndrome. In the treatment-naive small cell lung cancer, primarily a Row 5: \"Chemo- and/or radiotherapy\" is indicated, the stentim implantation is patients with \" Row 6: \"\" Row 7: \"therapy-refractory or recurrent Vena-cava-superior syndrome\" is pre-behaled-\" Row 8: \"\" (evidence level 2a)\" Row 9: \"nce\" Row 10: \"\" Row 11: \"\" Row 12: \"\"Consens\"\" Row 13: \"\"",
      "start_page": 445,
      "end_page": 445
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect>",
      "text": "Row 1: 10.10: Evidence-based recommendation-2010 Row 2: Recommendation level--The palliative, endoscopic methods for the treatment of tracheobronchia--- Row 3: 0: Tumor obstruction should be accessible to any cancer patient, even if Row 4: The primary treatment-conducting department does not have these in its own home-- Row 5: --(Evidence level 5). There are various methods of desobliteration and lo--- Row 6: ---- Row 7: --cale tumor treatment available.- Row 8: Level of Evidence---- Row 9: 5----- Row 10: ---- Row 11: ------",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect>",
      "text": "Row 1: 10.11-Evidence-based recommendation-2010 Row 2: Degree of recommendation-The mechanical methods of removal of exophytic tumor components with the Row 3: 0-Kante of the rigid bronchoscope, with pliers or balloons have immediate effect, but Row 4:- can only be recommended for emergency situation, if no other Row 5:-Kante of the rigid bronchoscope are available (Evidence level 4).- Row 6: -- Row 7: --Ballon dilation with the flexible bronchoscope is possible (Evidence level 3b).-- Row 8: Level of Evidence---- Row 9: 4------ Row 10: -4 (Oxford 2009): Mechanical abduction procedures-- Row 11: 3b--3b (Oxford 2009): Ballon dilation- Row 12: ------ Row 13: -----------------------------------------------------------------------------------------------------",
      "start_page": 446,
      "end_page": 446
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page)",
      "text": "Row 1: 10.12-Evidence-based recommendation--2010 Row 2: Recommendation level---In case of central tumor infestation, especially in case of trachea and main bron--- Row 3: 0-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page)",
      "text": "Row 1: 10.13-evidence-based recommendation-2010 Row 2: degree of recommendation-combination with stent inlay and/or brachytherapy stabilizes the positive-row 3: B-effect (evidence level 3b).-row 4:",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page, column 1)",
      "text": "Row 1: 10.12 Row 2: Empfeh Row 3: 0 Row 4: Row 5: Level of Row 6: 3b Row 7: 4 Row 8:",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page, column 1)",
      "text": "Row 1: 10.13 Row 2: Empfeh Row 3: B",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page, column 2)",
      "text": "Row 1: 2 Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7: Row 8:",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page, column 2)",
      "text": "Row 1: 3 Row 2: Hlungsg Row 3:",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page, column 3)",
      "text": "Row 1 : ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under headed < lity) in over 80% of cases [1550], [1551] (evidence level 3b). The effect> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation-2010 Row 2: grade-combination with stent inlay and/or brachytherapy stabilizes the positive-level Row 3:--effect (evidence level 3b).-- Row 4:---",
      "start_page": 447,
      "end_page": 447
    },
    {
      "heading": "Table under heading <In isolated cases, early tumours can be induced [1570], [1571] (degree of evidence 3b).>",
      "text": "Row 1: 10.13的evidence-based recommendation--2010 Row 2: Level of Evidence--- Row 3: 3b--\" Row 4: \"--\" Row 5: \"--\"",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "Table under heading <In isolated cases, early tumours can be induced [1570], [1571] (degree of evidence 3b).>",
      "text": "Row 1: 10.14-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In individual cases small mucosa tumors can be induced, if they are limited to Row 3: 0-the intraluminal surface. This should only be considered in case of inoperable Pati-",
      "start_page": 448,
      "end_page": 448
    },
    {
      "heading": "Table under heading <0 should only be considered in inoperable patients (degree of evidence 4).>",
      "text": "Row 1: 10.15-Consensus-based recommendation--2018 Row 2: EK-Endobronchial electro-methods such as the Argon-Plasma-Coagulator, Electrokauther-Row 3: and Kryosonden can be used as alternatives to the ND-YAG laser for deobliteration--Row 4: ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Table under heading <0 should only be considered in inoperable patients (degree of evidence 4).>",
      "text": "Row 1: 10.16-Evidence-based recommendation-2010 Row 2: Degree of recommendation-The APC is superior to all other local procedures for the treatment of bleeding (evidence- such as Row 3: 0-grade 3b).- Row 4: -- Row 5: Level of Evidence--- Row 6: 3b--- Row 7: --- Row 8: ---",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Table under heading <0 should only be considered in inoperable patients (degree of evidence 4).>",
      "text": "Row 1: 10.17-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In individual cases, small tumors of the mucous membrane can be diagnosed. This Row 3: 0-should only be considered in inoperable patients (degree of evidence 4).- Row 4: --- Row 5: Level of Evidence--- Row 6: 4--- Row 7: -- Row 8: ---",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "table under heading <B>",
      "text": "Row 1: 10.18-Evidence-based recommendation-2010 Row 2: Degree of recommendation-The endobronchial cryotherapy with rigid or flexible probe is gentle, si--- Row 3: 0--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "table under heading <B>",
      "text": "Row 1: 10.19: Evidence-based recommendation: 2010 Row 2: Recommendation level:Cryotherapy can be tried to cure small mucosa tumors.: Row 3: B: Row 4: R: Level of Evidence: Row 6: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R: R:",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "Table under heading < 80 % [1587] (evidence level 3b).>",
      "text": "Row 1: 10.20-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Due to the high recurrence rate, this should only be considered in inoperable patients Row 3: 0- (evidence level 3b).- Row 4: -- Row 5: Level of Evidence--- Row 6: 3b--- Row 7: --- Row 8: ---",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "Table under heading < 80 % [1587] (evidence level 3b).> (column 1)",
      "text": "Row 1: 10.20 Row 2: Empfeh Row 3: 0 Row 4: Level of Row 5: 3b Row 6:",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "Table under heading < 80 % [1587] (evidence level 3b).> (column 2)",
      "text": "Row 1: 0 Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6:",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "Table under heading < 80 % [1587] (evidence level 3b).> (column 3)",
      "text": "Row 1: \"Evidence-based recommendation\"2010 Row 2: \"grad\" Because of the high recurrence rate, this should only be considered in inoperable patients.\" Row 3: \"Evidence-level 3b\".\" Row 4: \"\" Row 5: \"nce\"\" Row 6: \"\"\" Row 7: \"\"\" Row 8: \"\"\"",
      "start_page": 451,
      "end_page": 451
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 10.21-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Photodynamic therapy is only slightly superior to the Row 3: 0-Conventional laser for symptom control in palliation. The quality of life is disproportionately impaired due to the Row 4: -Hautsensitization. With the Sensitizers currently available for delivery- Row 5: - a PDT for palliation can hardly be recommended- Row 6: --- Row 7: --den, this can change if new Sensitizers are approved (Evidence-grade-Row 8: -3b).-- Row 9: Level of Evidence-",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 10.22-Evidence-based recommendation-2010 Row 2: Degree of recommendation--For the eradication of early tumors below 1 cm diameter, which are limited to the mucous-- Row 3: 0-skin, the PDT is the most effective method. A previous sub---- Row 4: search with the endobronchial ultrasound should be done to exclude a deeper in--- Row 5: --vasion (evidence level 3b).-- Row 6: --- Row 7: Level of Evidence---- Row 8: 3b---- Row 9: ---- Row 10: ------",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "table under heading <3b>",
      "text": "Row 1: 10.23-Evidence-based recommendation--2010 Row 2: Recommendation level---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "table under heading < stent, stent migration and secretion with a frequency of 10->",
      "text": "Row 1: 10.24: Evidence-based recommendation: 2010 Row 2: Recommendation level: Currently, the procedures can only be recommended in studies where surgery, Row 3: 0, also with bronchoplastic procedures, remains standard. A PDT can be justified by Row 4: In case of inoperable patients.: Row 5: Level of Evidence: Row 6:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading < stent, stent migration and secretion with a frequency of 10->",
      "text": "Row 1: 10.25-Evidence-based recommendation-2010 Row 2: Recommendation level-In individual cases, local operability can be achieved by the PDT.- Row 3: 0-\" Row 4: -\" Row 5: Level of Evidence-\" Row 6: -\"",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading < stent, stent migration and secretion with a frequency of 10> each (column 1)",
      "text": "Row 1: 10.24 Row 2: Recommendationg Row 3: 0 Row 4: Level of Eviden Row 5:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading < stent, stent migration and secretion with a frequency of 10> each (column 1)",
      "text": "Row 1: 10.25 Row 2: Recommendationg Row 3: 0 Row 4: Level of Eviden Row 5:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading < stent, stent migration and secretion with a frequency of 10> each (column 2)",
      "text": "Row 1: evidence-based recommendation-2010 Row 2: grade-The procedures can currently only be recommended in studies, the surgery, Row 3: also with bronchoplastic procedures, remains first standard. A PDT can be justified- Row 4: in case of inoperable patients.- Row 5: nce",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading < stent, stent migration and secretion with a frequency of 10> each (column 2)",
      "text": "Row 1: evidence-based recommendation-2010 Row 2: grade-In individual cases, local operability can be achieved by the PDT.- Row 3: -- Row 4: -- Row 5: nce--- Row 6: ---",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "Table under heading <% and pain of 43-88% [1625] (evidence level 2a).>",
      "text": "Row 1: 10.26-Evidence-based recommendation: 2010 Row 2: Degree of recommendation: The implantation of bronchial, tracheal and tracheobronchial stents is suitable for pal- and Row 3: 0-liative treatment of symptomatic central respiratory stenosis. The Row 4: Therapeutic effect occurs immediately. It can and should be combined with other methods (e.g. La- and Row 5:",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "Table under heading <% and pain of 43-88% [1625] (evidence level 2a).> (column 1)",
      "text": "Row 1: 10.26 Row 2: Recommend Row 3: 0 Row 4: Row 5: Level of Row 6: 4 Row 7:",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "Table under heading <% and pain of 43-88% [1625] (evidence level 2a).> (column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: Row 5: f Eviden Row 6: Row 7:",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "Table under heading <% and pain of 43-88% [1625] (evidence level 2a).> (column 3)",
      "text": "Row 1: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "Table under heading <0 Preload may be appropriate for endoluminal brachytherapy in individual cases.>",
      "text": "Row 1: 10.27-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In patients without radiation therapeutic pre-load, the use of the Row 3: Brachytherapy in palliative intention is suitable in individual cases for centrally stenosing Tu-the Row 4: -mor. If there is no radiation therapeutic pre-load, the Row 5: Brachytherapy should be combined with a percutaneous radiotherapy.- Row 6:",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "Table under heading <0 Preload may be appropriate for endoluminal brachytherapy in individual cases.>",
      "text": "Row 1: 10.28-Evidence-based recommendation-2010 Row 2: Degree of recommendation-In case of a tumor with stenosis of the central airways and radiation-therapeutic-row 3: 0-Preloading, endoluminal brachytherapy can be suitable in individual cases.- Row 4: -- Row 5: Level of Evidence--- Row 6: ---",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010>",
      "text": "Row 1: 10.29-Evidence-based recommendation--2010 Row 2: Degree of recommendation--Brachytherapy as a boost to percutaneous radiotherapy in therapy-- Row 3: 0----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 456,
      "end_page": 456
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (column 1)",
      "text": "Row 1: 10.29-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Brachytherapy as a boost to percutaneous radiotherapy in Therapeutic Row 3: 0-ten in curative situation is controversial and should only be carried out within Study-Row 4: .",
      "start_page": 456,
      "end_page": 456
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (column 2)",
      "text": "Row 1: Row 2: concept Row 3: en Row 4: Row 5: Row 6:",
      "start_page": 456,
      "end_page": 456
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "In addition, it is clear to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: sympt Row 2: festat Row 3: Trache Row 4: gestut Row 5: Row 6: Pleura Row 7: Row 8: Vena-c Row 9: Row 10: Perika Row 11: nade Row 12: Pneum Row 13: Row 14: Pulmo Row 15: Lymph Row 16: Row 17: Ascite Row 18: Obstip Row 19:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: tom/ disease ma Row 2: union Row 3: eobronchial tumoro Row 4: union Row 5: Row 6: eergus Row 7: Row 8: cava-superior-Syndro Row 9: Row 10: alderguss, Perikardta Row 11: Row 12: mothorax Row 13: Row 14: onal tumor manifest Row 15: hangiosis carcinoma Row 16: Row 17: it Row 18: pation Row 19:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 3)",
      "text": "Row 1: ani- Row 2: Row 3: ob- Row 4: Row 5: Row 6: Row 7: Row 8: om Row 9: Row 10: ampo- Row 11: Row 12: Row 13: Row 14: tation Row 15: atosa Row 16: Row 17: Row 18: Row 19: Row 19:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 4)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: e, Row 5: ie, Row 6: Row 7: Row 8: Row 9: ako- Row 10: Row 11: tion, Row 12: Row 13:dio- Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Che Row 22:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 6)",
      "text": "Row 1: 的Leitlinenkapitte Row 2:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 7)",
      "text": "Row 1: el Row 2: Row 3: ndlung des Row 4: ms mit inte Row 5: run Row 6: Row 7: Row 8: Row 9: ndlung des Row 10: ms mit inte Row 11: run Row 12: pie des nich Row 13: ngenkarzi- Row 14: Row 15: dlung des Row 16: ngenkarzi- Row 17: Row 18: Row 19: Row 20:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: s Row 4: he- Row 5: Row 6: Row 7: Row 8: Row 9: s Row 10: er- Row 11: Row 12: ht- Row 13: - Row 14: Row 15: Row 16: - Row 17: Row 18: Row 19: Row 20: Row 20:",
      "start_page": 463,
      "end_page": 463
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: 14.1-Consensus-based recommendation-tested 2025 Row 2: EK-testedIn patients with lung cancer, the symptom of shortness of breath is to be recorded by the subject- such as the patient's subjective assessment, e.g. in the context of a multiple-row 4: enclosing symptoms.- Row 5:",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: 14.2, Consensus-based recommendation, tested 2025 Row 2: EK, If a causal therapy of respiratory distress is possible, this should be carried out before or before or pa-, Row 3: ,rallel to a symptomatic therapy., Row 4: , the following should be taken into account:, Row 5: ,• Consideration of the medical indication, Row 6: ,• Stress and benefit for the patient, Row 7: ,• Patient's will, Row 8: ,,Konsens, Row 9: ,",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: 14.1 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: 14.2 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In patients with lung cancer, the symptom of shortness of breath should be recorded by the subject--- Row 3:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 464,
      "end_page": 464
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: Dimensional Outcomes Row 2: Sensory Experience of Intensity/ Heaviness Level/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////",
      "start_page": 465,
      "end_page": 465
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: Dimen Row 2: Senso Row 3: Breathing Row 4: Row 5: Emotio Row 6: The At Row 7: Row 8: Awn Row 9: Breathing Row 10: Row 11: (adapted)",
      "start_page": 465,
      "end_page": 465
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: nsionen-Outcomes-Development Row 2: Orical experience of the-Intensity/Grade/-Individual question, numerically or Row 3: not--Strength of breathlessness--Categorial (e.g. NRS 0-10, VAS, Row 4:",
      "start_page": 465,
      "end_page": 465
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: 14.3Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation--In patients with lung carcinoma and shortness of breath, oral or parenteral opi--- Row 3: Aeoids are to be used for symptomatic relief of shortness of breath.-- Row 4: Row 4: Row 5: Row 5: Rough: cave: causative therapy of shortness of breath to be considered (see Recommendation 14.2.)-- Row 6: Level of Evidence--[1639], [1641], [1642], [1643], [1644], [1645], [1646], [1647], [1648], [1649], [1650], [1651], [1652]--- Row 7: 1+--[1653], [1654], [1655], [1656]--- Row 8: ----------------------------------------------------------------------------------------",
      "start_page": 466,
      "end_page": 466
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: 14.4-Evidence-based statement-tested 2025 Row 2: Level of Evidence-There is no indication that a lay artis-led therapy of respiratory distress-row 3: 1+-in patients with lung carcinoma with opioids leads to clinically relevant Row 4: -Emdepression.- Row 5: -[1657], [1658], [1659], [1660], [1643], [1644], [1645], [1646], [1647], [1648], [1649], [1650], [1651], [1651], [1656]-- Row 7:",
      "start_page": 466,
      "end_page": 466
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: 14.3 Row 2: Recommendationg Row 3: A Row 4: Row 5: Level of Eviden Row 6: 1+ Row 7: Row 8:",
      "start_page": 466,
      "end_page": 466
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: 14.4 Row 2: Level of Eviden Row 3: 1+ Row 4: Row 5: Row 6: Row 7:",
      "start_page": 466,
      "end_page": 466
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--In patients with lung cancer and shortness of breath, oral or parenteral opi--- Row 3:--oids should be used for symptomatic relief of shortness of breath.-- Row 4:--- Row 5:--Cave: causative therapy of shortness of breath should be taken into account (see recommendation 14.2.)-- Row 6:-nce[1639], [1641], [1642], [1643], [1644], [1645], [1646], [1647], [1648], [1649], [1650], [1651], [1652],--- Row 7:--[1653], [1654], [1655], [1656]---- Row 8:-------Roow 9:------Consens 22 10:--------------------------------------------------------------------------------",
      "start_page": 466,
      "end_page": 466
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: evidence-based statement, tested 2025 Row 2: nce, there is no indication that a lay artis-based therapy of respiratory distress, Row 3: , in patients with lung cancer with opioids, leads to clinically relevant Row 4: ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,",
      "start_page": 466,
      "end_page": 466
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: 14.5-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In patients with lung cancer, benzodiazepines can be used to relieve Row 3: 0-Emnot if treatment with opioids is not effective.- Row 4: -- Row 5: Level of Evidence--[1671], [1672]- Row 6: 1+--- Row 7: --- Row 8: --Starker Consensus-- Row 9: ----",
      "start_page": 467,
      "end_page": 467
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: 14.5 Row 2: Recommend Row 3: 0 Row 4: Level of Row 5: 1+ Row 6: Row 7:",
      "start_page": 467,
      "end_page": 467
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: Row 2: lungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 467,
      "end_page": 467
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: degree-testedIn patients with lung cancer, benzodiazepines can be used to relieve Row 3: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 467,
      "end_page": 467
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page)",
      "text": "Row 1: benzodiazepine-dosing Row 2: lorazepam-0,5-1.0 mg every 6-8 hours p.o./s.l. Row 3: midazolam-0,5-5 mg /4 h s.c., 10-30 mg/24 h s.c.",
      "start_page": 468,
      "end_page": 468
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 1)",
      "text": "Row 1: Benzo Row 2: Loraze Row 3: Midaz",
      "start_page": 468,
      "end_page": 468
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 2)",
      "text": "Row 1: odizaz Row 2: epam Row 3: zolam",
      "start_page": 468,
      "end_page": 468
    },
    {
      "heading": "table under heading <10.29 Evidence-based recommendation 2010> (from previous page, column 3)",
      "text": "Row 1: Zepine-dosing Row 2: m:0.5-1.0 mg every 6-8 hours p.o./s.l. Row 3: m:2.5-5 mg /4 h s.c., 10-30 mg /24 h s.c.",
      "start_page": 468,
      "end_page": 468
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 14.6-Consensus-based recommendation--tested 2025 Row 2: EK--The death of a patient with lung cancer is to be recognized by those involved in treatment-- Row 3:--as a natural part of life.-- Row 4:--The death process is not to be accelerated or delayed.- Row 5:--- Row 6:--Starker Consensus-- Row 7:----",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 14.7-Consensus-based recommendation--tested 2025 Row 2: EC--In patients with lung cancer, decisions and measures on the Row 3: action in the death phase are to be documented and continuously re-evaluated.-- Row 4: --den.-- Row 5: --- Row 6: --Stark Consensus-- Row 7: ----",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 14.8-Consensus-based recommendation-tested 2025 Row 2: EC-testedAll measures in the death phase of a patient with lung cancer are to be adapted in Row 3: their frequency and manifestation to the needs of the dying one-down Row 4: ---- Row 5: --- Row 6: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a>",
      "text": "Row 1: 14.9-Evidence-based recommendation--tested 2025 Row 2: Recommendation level---After careful consideration in individual cases (e.g. breastfeeding of hunger and thirst)---- Row 3: Does not give artificial nutrition and hydration to dying people--- Row 4:----- Row 5: Level of Evidence--[1711], [1712], [1713]-- Row 6: 2a---- Row 7: ----- Row 8: --Starker Konsent--- Row 9: -----",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 14.6 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 14.7 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 14.8 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 1)",
      "text": "Row 1: 14.9 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: 2a Row 6: Row 7:",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -The death of a patient with lung carcinoma is to be recognized as a natural part of life by those involved in treatment-row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--For patients with lung cancer, decisions and measures on the Row 3: action in the death phase should be documented and continuously re-evaluated who--- Row 4:--en.-- Row 5:--- Row 6:--Stark Consensus-- Row 7:----",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: Consensus-Based Recommendation-tested 2025 Row 2:--All measures in the death phase of a patient with lung cancer should be adapted to the needs of the dying in-- Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "table under heading <2a> (column 3)",
      "text": "Row 1: evidence-based recommendation--tested 2025 Row 2: grade--After careful consideration in individual cases (e.g. breastfeeding of hunger and thirst), Row 3: should not be given artificial nutrition and hydration for dying people-- Row 4: grade--- Row 5: nce--[1711], [1712], [1713]-- Row 6: --- Row 7: --- Row 8: --Strong Consensus-- Row 9: ----",
      "start_page": 471,
      "end_page": 471
    },
    {
      "heading": "Table under heading < (evidence grade 1a)>",
      "text": "Row 1: 15.1-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Individual rehabilitation measures (non-medical and nursing) wei--- Row 3: These positive effects in terms of quality of life (including the psychiatric-- Row 4:) or lack of air in lung cancer patients are therefore recommended-- Row 5: In the context of rehabilitation procedures (ambulant or stationary)- Row 6: --- Row 7: --(Evidence level 1a).-- Row 8: Level of Evidence-- Row 9: 1a---- Row 10: ----",
      "start_page": 476,
      "end_page": 476
    },
    {
      "heading": "Table under heading < (evidence grade 1a).> (column 1)",
      "text": "Row 1: 15.1 Row 2: Empfeh Row 3: B Row 4: Row 5: Level of Row 6: 1a",
      "start_page": 476,
      "end_page": 476
    },
    {
      "heading": "Table under heading < (evidence grade 1a)> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: Row 5: f Eviden Row 6:",
      "start_page": 476,
      "end_page": 476
    },
    {
      "heading": "Table under heading < (evidence grade 1a)> (column 3)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--Individual rehabilitation measures (non-medical and nursing) wei--- Row 3:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 476,
      "end_page": 476
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true->",
      "text": "Row 1: 15.1-evidence-based recommendation--2010 Row 2: --Consensus-- Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true->",
      "text": "Row 1: 15.2:Evidence-based recommendation – 2010 Row 2:Recommendation level – During oncological therapy (also in high-dose therapy) – Row 3: Brow with good efficiency (e.g. in relation to bone marrow regeneration) – Aerobic Off-Row 4: --Duration training programs (e.g. interval training with lactate determination, heart fre--- Row 5: --Quenzanalyse) for faster recovery of performance – Row 6: ---- Row 7: to be performed and thus recommended (evidence level 1b). It is true---- Row 8:----like that comparable programs are also effective in lung cancer patients – Row 9: -------- Row 10: Level of Evidence – Row 11: 1b------- Row 12: ------- Row 13: ----Consens\" Row 14: -----Roow 14: -------Roow 10: Level of Evidence – Row 11: 1b-------Roow Row 12 Row 12: ----------------------------------------",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true->",
      "text": "Row 1: 15.3-Evidence-based recommendation--2010 Row 2: Recommendation level--Stationary oncological rehabilitation procedures are recommended to improve quality of life and aerobic endurance after primary therapy--- Row 4:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true->",
      "text": "Row 1: 15.4-Evidence-based recommendation-2010 Row 2: Degree of recommendation-Ambulant rehabilitation procedures are then to be discussed with the patient,- Row 3: D-If these institutions meet comparable high requirements as they have to fulfill sta- to Row 4: Tionary facilities. Oncological rehabilitation facilities- Row 5: Oncological rehabilitation facilities should also be involved in outpatient or inpatient rehabilitation measures at Lun- to Row 6:",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 1)",
      "text": "Row 1: 15.1 Row 2: Row 3:",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 1)",
      "text": "Row 1: 15.2 Row 2: Recommendationg Row 3: B Row 4: Row 5: Level of Eviden Row 6: 1b Row 7: Row 8:",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 1)",
      "text": "Row 1: 15.3 Row 2: Recommendationg Row 3: C Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 1)",
      "text": "Row 1: 15.4 Row 2: Recommendationg Row 3: D Row 4:",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 2)",
      "text": "Row 1: evidence-based recommendation-2010 Row 2: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 2)",
      "text": "Row 1:",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 2)",
      "text": "Row 1: Evidence-based recommendation--2010 Row 2: grade--Stationary oncological rehabilitation procedures are recommended for improving quality of life and aerobic endurance after primary therapy--- Row 4:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "Table under heading and therefore recommended (evidence level 1b). It is true-> (column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--Ambulant rehabilitation procedures are then to be discussed with the patient,-- Row 3:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 477,
      "end_page": 477
    },
    {
      "heading": "table under heading and therefore recommended (evidence level 1b). It is true-> (from previous page)",
      "text": "Row 1: 15.4, 2010 Row 2: possess and offer special programs for patients with lung cancer. Pri--- Row 3: drug-treated physicians should be involved in the selection of the appropriate clinic Row 4: ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and therefore recommended (evidence level 1b). It is true-> (from previous page)",
      "text": "Row 1: 15.5Evidence-based recommendation-2010 Row 2: Degree of recommendation-Operated patients and those after intervening other therapies (combined Row 3: D-Radiochemotherapy) and with pronounced consequential disorders should be given in relation to Row 4: contextal factors (occupational situation, home care, leisure-time valley-- Row 5: -tung) to a rehabilitation.- Row 6: -- Row 7: --2010: Degree of recommendation D (missing or inconsistent studies, recommendation due to Row 8: --expert opinion)- Row 9: Level of Evidence--- Row 10: --Konsens-Row 11: -----------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 1)",
      "text": "Row 1: 15.4 Row 2: Row 3: Level of Eviden Row 4: Row 5:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 1)",
      "text": "Row 1: 15.5 Row 2: Recommendationg Row 3: D Row 4: Row 5: Level of Eviden Row 6: Row 7:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: possess and offer special programs for patients with lung cancer-- Row 3: pharmaceutical doctors should be in the selection of the appropriate clinic bete-- Row 4: .- Row 5: -2010: recommendation level D (missing or inconsistent studies, recommendation level Row 6: --expert opinion)-- Row 7: nce--- Row 8: --Konsens-- Row 9: ----",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 2)",
      "text": "Row 1: evidence-based recommendation--2010 Row 2: grade--Operated patients and those after intrusive other therapies (comb-- Row 3: radiochemotherapy) and with pronounced consequential disorders should be given rehabilitation in Bez--- Row 4: context factors (occupational situation, home care, leisure time--- Row 5: grade----)-- Row 6: --- Row 7: --2010: recommendation level D (missing or inconsistent studies, recommendation level--- Row 8: -expert opinion)- Row 9: nce---- Row 10: --Konsens-- Row 11: ---------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 3)",
      "text": "Row 1: Row 2: n. Pri- Row 3: rushes Row 4: Row 5: round Row 6: Row 7: Row 8:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 3)",
      "text": "Row 1: Row 2: Binding Row 3: Train to Row 4: valley Row 5: Row 6: Round to Row 7: Row 8: Row 9:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading and therefore recommended (evidence level 1b). It is true-> (from previous page)",
      "text": "Row 1: 16.1-Consensus-based recommendation-tested 2025 Row 2: EC-E After completion of a multimodal therapy (stage I-IIIC, OMD), which includes a local-level Row 3: ablative procedure (OP, RTx, CTx/RTx), a Row 4: a structured follow-up plan should be created for each patient.The structured follow-up plan- Row 5:",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading and therefore recommended (evidence level 1b). It is true-> (from previous page)",
      "text": "Row 1: 16.2-Consensus-based recommendation--tested 2025 Row 2: EC--In the course of a systemic therapy (stage IVA, IVB) a structured schedule/follow-up plan should be prepared for each patient--- Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 1)",
      "text": "Row 1: 16.1 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 1)",
      "text": "Row 1: 16.2 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 3)",
      "text": "Row 1 : Consensus-based recommendation-tested 2025 Row 2 : After completion of a multimodal therapy (stage I-IIIC, OMD), which includes a local Row 3: ablative procedure (OP, RTx, CTx/RTx), a Row 4: a structured follow-up plan should be created for each patient. The structured follow-up plan- Row 5: --- Row 6: should be suitable for recidivism, secondary carcinomas, complications and toxicity-- Row 7: to recognize the need of therapy and psychooncology and social counselling- Row 8:",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading and thus recommended (evidence level 1b). It is true-> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--In the course of systemic therapy (stage IVA, IVB) a structured schedule/follow-up plan should be prepared for each patient--- Row 3:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "Table under smoking, significantly increased [85]; [83] (evidence level 2b).",
      "text": "Row 1: 16.3-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-patients with lung carcinoma should be strongly motivated to stop using Ta-the Row 3: B-bak. Patients should be supported by effective help-the Row 4: to quit smoking.- Row 5: Level of Evidence-[63], [85], [83]- Row 6: 2b",
      "start_page": 481,
      "end_page": 481
    },
    {
      "heading": "Table under smoking, significantly increased [85]; [83] (evidence level 2b). In addition, has> (column 1)",
      "text": "Row 1: 16.3 Row 2: Empfeh Row 3: B Row 4: Level of Row 5: 2b Row 6: Row 7:",
      "start_page": 481,
      "end_page": 481
    },
    {
      "heading": "Table under smoking, significantly increased [85]; [83] (evidence level 2b). In addition, has> (column 2)",
      "text": "Row 1: Row 2: Hlungsg Row 3: Row 4: f Eviden Row 5: Row 6: Row 7:",
      "start_page": 481,
      "end_page": 481
    },
    {
      "heading": "Table under smoking, significantly increased [85]; [83] (evidence level 2b). In addition, has> (column 3)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: gradedPatients with lung carcinoma should be strongly motivated to stop using Ta- such Row 3: -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 481,
      "end_page": 481
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 16.4--Consensus-based recommendation--tested 2025 Row 2: EC---In patients after ablative local therapy (stage I-II and III,-- Row 3: radiation therapy/ radiation chemotherapy in stage I and II), postthe--- Row 4:---rapeutic complications occurring after surgery or radiation therapy-- Row 5:--- Row 6:--can, be captured and treated.-- Row 7:--Typically, this is done within the framework of an idea within 8 weeks--- Row 8:---- after completion of local therapy.-- Row 9:---Starker Consensus---- Row 10:-------",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 16.5-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In patients with NSCLC in stage III after ablative local therapy (Radio-Evidence-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-In patients with NSCLC in stage III after ablative local therapy (Radio-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Evidence-Recommence should be recorded and treated in post-therapeutic complications, Row 4:-Evidence-Evidence-Evidence-Evidence-Evence-Evidence-Evence-Evence-Evence.",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a>",
      "text": "Row 1: 16.6-Evidence-based recommendation-tested 2025 Row 2: Degree of recommendation- After locally ablative treatment of the NSCLC in stage III, a CT-thorax is to be performed to exclude a Row 3: A-progression (in order to begin the operation-row 4: -by Durvalumab).-- Row 5: Level of Evidence--[794], [795]- Row 6: 1a---- Row 7: ---- Row 8: --Starker Konsent-- Row 9: -----",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 16.4 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 16.5 Row 2: Recommendationg Row 3: A/B Row 4: Row 5: Level of Eviden Row 6: 1a Row 7: Row 8:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 1)",
      "text": "Row 1: 16.6 Row 2: Recommendationg Row 3: A Row 4: Level of Eviden Row 5: 1a Row 6: Row 7:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -In patients after ablative local therapy (stage I-II and III surgery,- Row 3: radiation therapy/ radiation chemotherapy in stage I and II), the postth-row 4:rapeutic complications that occur after surgery or radiation therapy Row 5: -- Row 6: can be captured and treated.- Row 7: -Typically, this occurs within the framework of an idea within 8 Woch-Row 8: - after completion of local therapy.- Row 9: -Starker Konsent-Row 10: ----",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedIn patients with NSCLC in stage III after ablative local therapy (rays-checked Row 3: radiation chemotherapy) the posttherapeutic complication-checked Row 4: which can occur after radiation therapy should be recorded and treated.- Row 5: -The first clinical idea after completion of radiation therapy should be done inside Row 6: 8 weeks.- Row 7: nce-checked[1757], [795]- Row 8:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 2)",
      "text": "Row 1: evidence-based recommendation-tested 2025 Row 2: grade-testedAfter locally ablative treatment of the NSCLC in stage III, a CT-thorax is to be performed to exclude Row 3: progression (in order to begin the deployment-down Row 4: degree-down of Durvalumab).- Row 5: level-down[794], [795]- Row 6: level-down Row 7: level-down Row 8: level-down Row 9: level-down Row 9: level-down",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: Row 2: Row 3: he- Row 4: ten Row 5: Row 6: hen Row 7: Row 8:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: Row 2: N- Row 3: n, Row 4: Row 5: alb Row 6: Row 7: Row 8: Row 9:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 16.7, \"Consensus-based recommendation\" tested 2025 Row 2: \"EK\" After completed multimodal therapy (including surgery or CTx/RTx) Row 3: \"The patients in the first 2 years quarterly (every 3 months), from the 3rd year \"Row 4: \"half-yearly\" and after 5 years in a screening program closed-\" Row 5: \"\" Row 6: \"\" will be \"sen. These intervals begin with the initial conception within 8 Wo-\" Row 7: \"\"\" after the completion of the therapy. At these follow-up appointments a dezi-\" Row 8: \"Anamnesis\", a physical examination and appropriate imaging ver-\" Row 9: \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 16.8, \"Consensus-based recommendation\", \"tested 2025 Row 2: EK\"In high-risk patients (e.g. EGF-R+, ALK+, ROS-1+, Adenocarcinomas with stage\", \"Row 3: \"III\") a Row 4: \"Schädel-MRT\" should be carried out on a regular basis according to the interdisciplinary treatment team.",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 16.7 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 16.8 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation, tested 2025 Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: --In high-risk patients (e.g. EGF-R+, ALK+, ROS-1+, Adenocarcinomas with stage-level Row 3: -III) a Row 4: -Schädel-MRT should be carried out regularly, according to the interdisciplinary treatment team.-- Row 5: --- Row 6: --Strong consensus-- Row 7: ----",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 16.9:Consensus-based recommendation--modified 2025 Row 2: EC--under a system therapy in stage IVA/B, response, side effect-- Row 3: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 487,
      "end_page": 487
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 16.9 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 487,
      "end_page": 487
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 487,
      "end_page": 487
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--modified 2025 Row 2:--under a system therapy in the IVA/B stage, response, side effect-- Row 3:-- and complaint image one month after completion of treatment by the Row 4:--the patient care team should be evaluated. Anamnese,-- Row 5:--- Row 6:---physical examination, CT-Thorax/Abdomen/Becken and, depending on the complaint--- Row 7:----image appropriate imaging methods (MRI skulls suspected of brain metasta------ Row 8:-------) should be carried out. After that, fixed re-conceptions should be carried out during ongoing Row 9:------maintenance therapy (NSCLC, SCLC) at least every 3-6 weeks.",
      "start_page": 487,
      "end_page": 487
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: Diagnostic methods--Indication Row 2: Bronchoscopy--High local recurrence risk (e.g. maschette resection) Row 3: PET-CT---Exclusion of metastases prior to re-thorax surgery-- Row 4:--grip Row 5: -- Row 6: MRT--Hirn and bone metastases Row 7: X-ray Thorax--Tumorkinetic Row 8: Thorax CT---Tumorkinetics and local expansion Row 9: Abdomensonography---Leber and adrenal metastases, paraaortal lymphoma Row 10: Abdomen CT----Abdomenelle Metastasen Row 11: Pulmonary function testing,---lung function limitation, Pneumonitis Row 12: CO diffusion capacity------ Row 13:---- Row 14: Laboratory parameters---------------------------------------------------------------------------------------------------",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: Diagn Row 2: Bronch Row 3: PET-CT Row 4: Row 5: MRT Row 6: Röntg Row 7: Torah Row 8: Abdom Row 9: Abdom Row 10: Lung Row 11: CO-Di Row 12: Laborp",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Nostic methods-Indication Row 2: hoscopy-High local recurrence risk (e.g. maschette resection) Row 3: T-Exclusion of metastases before re-thorax surgery-In-row 4: grip Row 5: - Row 6: -Brain and bone metastases Row 7: to Thorax-Tumorkinetic Row 8: ax CT-Tumorkinetics and local expansion Row 9: mensonography-Leber and adrenal metastases, paraaortal lymphomas Row 10 men CT-Abdominal metastases Row 11: function testing,-Lung function limitation, Pneumonitis Row 12: iffusion capacity-row 13:",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 17.1-Consensus-based recommendation-tested 2025 Row 2: EK-tested Every newly diagnosed patient with lung cancer should be presented in a thorax-onco-",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 17.2:Consensus-based recommendation-tested 2025 Row 2: EC-testedThe decisions made in the Thorax-Oncological Tumorboard should be based on the valid guidelines.Different therapeutic decisions- Row 4: should be justified and documented in the Tumorboard protocol.- Row 5:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 17.3:Consensus-based recommendation--tested 2025 Row 2: EC-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page)",
      "text": "Row 1: 17.4, Consensus-based recommendation, tested 2025 Row 2: EK, Clinical studies and resulting approvals often represent only the Row 3: a part of the patients to be treated. Therefore, according to the indi, Row 4: individual treatment situation, therapy modifications should be made to the benefit of the Patien-, Row 5: ,-- Row 6: ,---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 17.1 Row 2: EC Row 3: Row 4:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 17.2 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 17.3 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 1)",
      "text": "Row 1: 17.4 Row 2: EC Row 3: Row 4: Row 5:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--Every newly diagnosed patient with lung cancer should be presented in a thorax-onco--- Row 3:--logical tumor board.-- Row 4:--Stark Consensus-- Row 5:---",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation-tested 2025 Row 2: -The decisions made in the thoracic oncological tumor board should be based on the valid guidelines.Different therapeutic decisions- Row 4: -should be justified and documented in the tumor board protocol.- Row 5: -- Row 6: -Starker Konsent-Row 7: ---",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--The economic aspects of treatment should be incorporated into the treatment regimen with comparable effect--- Row 3:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <1a> (from previous page, column 3)",
      "text": "Row 1: Consensus-based recommendation--tested 2025 Row 2:--Clinical studies and resulting approvals often represent only-- Row 3:--a part of patients to be treated. Therefore, according to the indi--- Row 4:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading <18 Quality indicators>",
      "text": "The following are the following examples of the results of the study: EGFR-Mutati-Row 11: EGFR-Mutati-Row 12: and BRAF-Mutati-Row 1: and BRAF-Row 1: and BRAF-Row 1: and BRAF-Row 1: and BRAF-Row 1: and BRAF-Row 1: and BRAF-Row 1: and BRAF-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1: and BRAW-Row 1 and BRAW-Row 1 and BRAW-Row 1 and BRAW-Row 1:",
      "start_page": 492,
      "end_page": 492
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "In the case of the NSCLC stage IV and pre-defined quality target: Row 12: first-line therapy, Row 13: first-line therapy, Row 11: first-line therapy, NSCLC stage IV and pre-defined quality target: Row 12: first-line therapy, Row 12: first-line therapy, Row 13: first-line therapy, Row 14: first-line therapy, Row 14: with EGFR-TKI, Row 16: first-line therapy, Row 12: first-line therapy, Row 12: first-line therapy, Row 13: first-line therapy, Row 14: first-line therapy, Row 14: with EGFR-TKI, Row 16: first-line therapy, Row 12: first-line therapy, Row 12: first-line therapy, Row 12: first-line therapy, Row 13:",
      "start_page": 493,
      "end_page": 493
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "Row 1: Quality Indicator Row 2: Row 3: Row 3: Row mutations, NRG1 fusions Row 4: RH and HER2 (ERBB 2) mutations Row 5: Row 5: Row: EGFR mutation (modified 2022) Row 9: NSCLC stage IV first-line therapy NSCLC stage IV first-line therapy NSCLC stage IV first-line therapy NSCLC stage IV first-line therapy Row 12: EGFR mutation (modified 2022) Row 9: NWFR mutation EGFR mutation (del 19, Row 13: Row) Row 13: NSCLC stage IV and pre-Row 11: NWOLC first-line therapy Row 15: Row 16: EGFR TKI first-lined EGFR mutation (del 19, Row 13: L858R)",
      "start_page": 493,
      "end_page": 493
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "In addition, in addition, to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 493,
      "end_page": 493
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "In addition, it is important to note that, in order to achieve this objective, it is necessary to take into account the fact that, in order to achieve the objectives set out in this Decision, it is necessary to take into account the objectives set out in the Decision of the European Parliament and of the Council of 24 June 1999 on the implementation of the Decision of the European Parliament and of the Council on the conclusion of the Agreement between the European Economic Community and the European Atomic Energy Community on the conclusion of the Agreement between the European Atomic Energy Community and the European Atomic Energy Community on the conclusion of the Agreement between the European Atomic Energy Community and the European Atomic Energy Community on the one hand, and the European Atomic Energy Community on the other hand, and the European Atomic Energy Community on the one hand, and the European Atomic Energy Community on the other, on the other hand, and on the other hand, that the Council of the European Atomic Energy Community and the European Atomic Energy Community on the other hand, it is necessary to take into account the objectives set out in the Decision of the Agreement between the European Atomic Energy Community and the European Atomic Energy Community and the European Atomic Energy Community on the other hand.",
      "start_page": 494,
      "end_page": 494
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "Row 1: Quality indicator Row 2: Row 3: QI 5: Pretherapeutic Vorst Row 4: Count Row 5: Patients in denominator Row 6: Pretherapeutic in inter- Row 7: Disciplinary Row 8: Tumor conference presented Row 9: were Row 10: Denominator Row 11: All patients with initial diagnosis Row 12: Pulmonary carcinoma Row 13: Row 14: QI 6: Adjuvant Cisplatin-basi Row 15: IIIA1/A2 (tested 2022) Row 16: Count Row 17: Patients in denominator Row 18: Adjuvant Chemotherapy with Row 19: Cisplatin-based Row 20: Combination Row 21: Denominator Row 22: All patients with initial diagnosis Row 23: NSCLC Stadium II and Row 24: IIIA1/A2, ECOG 0/1, Row 25: R0-Resection and Lymphatickno Row 26: Tendissection Row 27: Row 7 Combined Radiomod: 32",
      "start_page": 494,
      "end_page": 494
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "Row 1: Row 1: Row 2: Row 3: Tllung Tumor Conference (modifizi- Row 4: Row: Row 8: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 14: Row 15: Row 16: Row 15: Row 16: Row 17: Row 17: Row 18: Row 23: Row 23: Row 19: Row 19: Row 19: Row 19: Row 20: Row 20: Row 16: Row 16: Row 21: Row 21: Row 22: Row 23: Row 23: Row 23: Row 19: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 27: Row 21: Row 21: Row 22: Row 22: Row 23: Row 23: Row 23: Row 23: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24",
      "start_page": 494,
      "end_page": 494
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 4: Row 4: Row: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row: Row 1: Row: Row 1: Row: Row 1: Row 1: Row 1: Row 1: Row: Row 1: Row: Row 1: Row: Row: Row 1: Row: Row: Row: Row: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row: Row:",
      "start_page": 494,
      "end_page": 494
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "The following is a summary of the results of the study carried out in the context of the study on the use of radiopharmaceuticals for the treatment of radiopharmaceuticals and radiopharmaceuticals.",
      "start_page": 495,
      "end_page": 495
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "Row 1: Quality indicator Row 2: Row 3: Denominator Row 4: All patients with initial diagnosis Row 5: NSCLC Stadium IIIA4, IIIB or Row 6: IIIC and ECOG Row 7: 0/1 Row 8: Row 9: QI 8: Combined Radiochemo Row 10: and T1-4N2-3M0 (Limited this Row 11: Counter Row 12: Pat. in the Denominator with simultaneous Row 13: Radiochemotherapy (Cispla- Row 14: tin/Etoposid) Row 15: Denominator Row 16: All patients with initial diagnosis Row 17: SCLC in the Tumor Stadia T3- Row 18: 4 N0-1 and Row 19: T1-4N2-3M0 (Limited disease) Row 20: QI 9: Full-body FDG-PET/CT Row 21: Count Row 22: Denominator Row 22: Denominator with Row 23: Full-body FDG-PET/CT to 25 Row.",
      "start_page": 495,
      "end_page": 495
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "Row 1: E-Reference-Recommendation Row 2: E-Row 3: E-Reference-Recommendation Row 3: E-Reference-Recommendation Row 1: E-Reference-Recommendation Row 2: E-Recommendation Row 3: E-Recommendation Row 4: E-Reference-Recommendation Row 5: E-Row 6: E-Reference-Recommendation Row 6: E-Reference-Recommendation Row 7: E-Row 8: E-Retherapy and Chemotherapy Row 9: E-Row 10: E-Remaining. Row 11: E-Row 12: E-Recommendation Row 16: E-Sequentially administered who-Row 17: E-Recommendation Row 18: Motherapy at SCLC in the Tu-Row 23 Tow 19: Ease) (modified with 2022) E-Row 20: E-Recommendation Row 20: E-Recommendation Row 21: E-Row 22: E-Recommendation Row 22: E-Row 18: E-Recomm.",
      "start_page": 495,
      "end_page": 495
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 3)",
      "text": "In addition, it is possible to frequently use Radiochem Row 5: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 495,
      "end_page": 495
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 4)",
      "text": "Row 1: ere Row 2: Row 3: mo- Row 4: m Row 5: OG Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: ens Row 12: Row 13: e Ra- Row 14: C Row 15: Row 16: Row 17: Row 18: Row 19: ens Row 20: Row 21: er- Row 22: at Row 23: Row 24: Row 25:",
      "start_page": 495,
      "end_page": 495
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "In addition, it is important to note that the number of patients who are subject to the following conditions is limited to the number of patients who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions and who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions as those who are subject to the same conditions.",
      "start_page": 496,
      "end_page": 496
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "22-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-Typical-T",
      "start_page": 496,
      "end_page": 496
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "In addition, in addition, there are 24 to to to To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To",
      "start_page": 496,
      "end_page": 496
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "Row-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-Dow-D",
      "start_page": 497,
      "end_page": 497
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "Row 1: Quality indicator Row 2: Row 3: QI 13: Maintenance therapy nac Row 4: Count Row 5: Patients of the denominator with be- Row 6: Gone Durvalumab-Thera- Row 7: pie Row 8: Denominator Row 9: All patients after definitive Row 10: Radiochemotherapy without Pro- Row 11: Gloss and with Row 12: PD-L1 expression of ≥ 1% on Row 13: Tumor cells Row 14: Row 15: QI 14: (Chemo)-Immuntherapi Row 16: Count Row 17: Patients of the denominator with Row 18: (Chemo) immunotherapy Row 19: Denominator Row 20: All patients with initial diagnosis Row 21: NSCLC Stadium IV and ECOG Row 22: 0-1 Row 23:",
      "start_page": 497,
      "end_page": 497
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 3: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 497,
      "end_page": 497
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Bow: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: 32, Row: Row: Row: Row: Row: Row: Row: 32, Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: 32, Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: 32, Row: Row: Row: Row:",
      "start_page": 497,
      "end_page": 497
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 4)",
      "text": "Row 1: ere Row 2: Row 3: Row 4: Row 5: Row 6: s- Row 7: per Row 8: he Row 9: Pro- Row 10: n Row 11: Row 12: Row 13: Row 14: Row 15: ens Row 16: Row 17: Im- Row 18: a- Row 19: Row 20: Row 21:",
      "start_page": 497,
      "end_page": 497
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "Row 1: Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 : Row 1 - Row 1 : Row 1 - Row 1 : Row 1 : Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1 - Row 1",
      "start_page": 498,
      "end_page": 498
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "Row 1: Quality indicator Row 2: Row 3: Row 4: QI 15: Prophylactic damage Row 5: M0 (new 2022) Row 6: Count Row 7: Patients of the denominator with pro- Row 8: phylactic cranial bestrah Row 9: lung after end Chemo- Row 10: Radiation therapy Row 11: Denominator Row 12: All patients with SCLC in the Row 13: Tumor stages T3-4 N0-1 M0 Row 14: and T1-4 N2-3 M0 Row 15: (Limited disease) and Remis- Row 16: session after chemo-ray-row 17: rapie Row 18: QI 16: Chemo-immune therapy Row 19: Count Row 20: Patients of the denominator with Row 21: Combination with PD-L1-Anti- Row 22: Body therapy",
      "start_page": 498,
      "end_page": 498
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "Row 1: Reference recommendation Row 2: Row 2: Row 3: Row 21: Row 23 24 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4",
      "start_page": 498,
      "end_page": 498
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 1: Row 4: Row 4: Row 5: Row 5: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 14: Row 15: Row 15: Row 16: Row 17: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 22: Row 23: Row 24: Row 25: Row 26: Row 26: Row 1 and Row 33: Row 33: Row 28: Row 34: Row 1a, Row 29: Row 29: Row 22: Row 30: Row 31: Row 31: Row 31: Row 32: Row 33: Row 4: Row 28: Row 28: Row 34, Row 1a, Row 29: Row 29: Row 30: Row 24: Row 25: Row 31: Row 31: Row 31: Row 24: Row 32: Row 33: Row 4; Row 33: Row 28: Row 28: Row 30: Row 30: Row 30: Row 30: Row 30: Row 24: Row 30: Row 30: Row 30: Row 24: Row 30: Row 24: Row 30",
      "start_page": 498,
      "end_page": 498
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 4)",
      "text": "Row 1: ge / wege Row 2: Row 3: Row 4: Row 5: Row 6: nsens Row 7: Row 8: prophylak Row 9: trahlung be Row 10: M0 and T1 Row 11: mission nac Row 12: herapie Row 13: Row 14: Row 15: Row 16: arcer Konse Row 17: Row 18:",
      "start_page": 498,
      "end_page": 498
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 5)",
      "text": "Row 1: ere Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: kti- Row 9: ei Row 10: 1-4 Row 11: ch Row 12: Row 13: Row 14: Row 15: Row 16: ens Row 17: Row 18:",
      "start_page": 498,
      "end_page": 498
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page)",
      "text": "Row 1: Quality Indicator-Reference-Recommendation-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Reference-Refer-Refer-Refer-Reference-Refer-Reference-Reference-Reference-",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 1)",
      "text": "Row 1: Quality indicator Row 2: Row 3: (Atezolizumab or Durva Row 4: mab) Row 5: Denominator Row 6: All patients with first diaphragm Row 7: SCLC Stad. IV and Chemot Row 8: rapie Row 9: (Platine/Etoposid)",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: alu- Row 4: Row 5: Row 6: gnose Row 7: the- Row 8: Row 9:",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 3)",
      "text": "Row 1: -Reference-Empfe Row 2: -- Row 3: --Contraindication Row 4:--primarily a Chem Row 5:--rapie with platinum/E Row 6: -- Row 7:--a PD-L1-Ant Row 8: e--zolizumab or D Row 9:--will be offered Row 10: -- Row 11: -- Row 12: --",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 4)",
      "text": "Row 1: tikörp Row 2: Row 3: n be Row 4: mo-Im Row 5: Etopo Row 6: tikörp Row 7: Durva Row 8: en. Row 9:",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 5)",
      "text": "Row 1: g Row 2: Row 3: stand, Row 4: mmunthe- Row 5: osid and Row 6: per (Ate- Row 7: alumab) Row 8: Row 9:",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 6)",
      "text": "Row 1: evidence basis / wide Row 2: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <18 Quality indicators> (from previous page, column 7)",
      "text": "Row 1: ere Row 2: Row 3: m- Row 4: po- Row 5: ör- Row 6: alu- Row 7: Row 8: Row 9:",
      "start_page": 499,
      "end_page": 499
    },
    {
      "heading": "table under heading <ICD-O-3>",
      "text": "In addition, in the event of a failure to comply with the requirements of the Directive, it is necessary to ensure that the provisions of this Directive are complied with in accordance with the provisions of this Directive.",
      "start_page": 500,
      "end_page": 500
    },
    {
      "heading": "table under heading <ICD-O-3> (column 1)",
      "text": "Row 1: Enter Row 2: Row 3: Klinisc Row 4: Questions Row 5: Macro Row 6: Row 7: Micros Row 8: Row 9: Beurte Row 10:",
      "start_page": 500,
      "end_page": 500
    },
    {
      "heading": "table under heading <ICD-O-3> (column 2)",
      "text": "Row 1: be Row 2: Row 3: Che Data/ Row 4: position Row 5: oscopia Row 6: Row 7: copy Row 8: Row 9: row 10:",
      "start_page": 500,
      "end_page": 500
    },
    {
      "heading": "table under heading <ICD-O-3> (column 3)",
      "text": "In addition, it is important to note that in the event of an accident at work, the risk of an accident at work may arise from the presence of an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work or from an occupational accident at work.",
      "start_page": 500,
      "end_page": 500
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page)",
      "text": "Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row: 25 - Row",
      "start_page": 501,
      "end_page": 501
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 1)",
      "text": "Row 1: Enter Row 2: Row 3: Klinisc Row 4: Questions Row 5: Macro Row 6: Row 7: Micros Row 8: Row 9: Beurte Row 10:",
      "start_page": 501,
      "end_page": 501
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 2)",
      "text": "Row 1: be Row 2: Row 3: che Angabe Row 4: Angabe Row 5: oskopie Row 6: Row 7: skopie Row 8: Row 9: Elung Row 10:",
      "start_page": 501,
      "end_page": 501
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: ben/ Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 501,
      "end_page": 501
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 4)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row: Row 9: Row 10: Row 11: Row 11: Row 12: Row 13: Row 14: Row 14: Row 15: Row 16: Row 17: Row 17: Row 17: Row 17: Row 17: Row 18: Row 19: Row 19: Row 20: Row 20: Row 21: Row 21: Row 21: Row 21: Row 22: Row 22: Row 23: Row 23: Row 23: Row 24: Row 25: Row 25: Row 25: Row 26: Row 26: Row 22: Row 22: Row 22: Row 23: Row 23: Row 23: Row 24: Row 24: Row 24: Row 25: Row 25: Row 26: Row 26: Row 27: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 25: Row 25: Row 25: Row 26: Row 27: Row 24: Row 24: Row 24: Row 30: Row 30: Row 24: Row 24: Row 30",
      "start_page": 501,
      "end_page": 501
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 5)",
      "text": "27 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 -",
      "start_page": 501,
      "end_page": 501
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page)",
      "text": "In addition, in order to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to: to:",
      "start_page": 502,
      "end_page": 502
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 1)",
      "text": "Row 1: Enter Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 502,
      "end_page": 502
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 2)",
      "text": "Row 1: be Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 502,
      "end_page": 502
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 502,
      "end_page": 502
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 5)",
      "text": "Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 16: Row 17: Row 17: Row 17: Row 17: Row 18: Row 18: Row 18: Row 19: Row 19: Row 19: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 17: Row 19:",
      "start_page": 502,
      "end_page": 502
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 6)",
      "text": "Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row:",
      "start_page": 502,
      "end_page": 502
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page)",
      "text": "In addition, in the following cases, the NSCLC Stadium Ib-IIIA to Tumorreek-Row 15:  to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 1)",
      "text": "Row 1: Enter Row 2: Row 3: Row 4: Row 5:",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 2)",
      "text": "Row 1: be Row 2: Row 3: Row 4: Row 5:",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 5)",
      "text": "Row 1: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 6)",
      "text": "Row 1: uerung Row 2: Row 3: esiongrading according to Row 4: ngehenter Radio- Row 5: Chemotherapy Row 6: O-3 Row 7: ltate to molecular Row 8: apiezeigen (as far as Row 9: dbar, i.e. as egän Row 10: er Report) Row 11:",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <ICD-O-3> (from previous page, column 7)",
      "text": "Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R",
      "start_page": 503,
      "end_page": 503
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4>",
      "text": "In the case of a patient with lung carcinogens, the number of risk factors (smoking, occupational noxes), the number of risk factors (smoking, occupational noxes), the number of questions (smoking, occupational noxes), the number of questions. The survey of a comprehensive and family anamnesis regarding the Row 9: the occupational anamnesis is required.",
      "start_page": 504,
      "end_page": 504
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (column 1)",
      "text": "Row 1: Version 3.0 Row 2: 3.1 Row 3: For each patient with lung carcinogen Row 4: Nom, anamnestic risk factor Row 5: rene (smoking, occupational noxies) to ask Row 6:. The survey of a comprehensive Row 7: the work history is required. Row 8: 2010: Recommendation Level D (Row 9: or inconsistent studies, Recommendation Row 10: based on expert opinion) Row 11: 4.5 Row 12: Compliance with statutory Work Row 13: Protection Regulations and Regulations Row 14: ensures in cooperation with a Row 15:ner permanent scientific Über- Row 16: Examination and Risk Assessment of Ge- Row 17: Driving agents a major minimy Row 18: Conformity with cancero- Row 19: gene Noxen at work. Row 20: 6.60 Row 21: A test on EGFR mutations in Row 22: Exonovine 19: Tumor Resection of the 24 Row 19: Gene Noxen at work.",
      "start_page": 504,
      "end_page": 504
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (column 2)",
      "text": "Row 1: Version 4.01 Row 2: .3.1 Row 3: . .In each patient with lung carcinogens Row 4: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 504,
      "end_page": 504
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (column 3)",
      "text": "Row 1: Row 1: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 12: Row 13: Row 13: Row 14: Row 24: Row 25: Row 17: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 23: Row 24: Row 25: Row 20: Row 26: Row 27: Row 28: Row 28: Row 29: Row 30: Row 30: Row 31: Row 31: Row 32: Row 33: Row 34: Row 35: Row 35: Row 36: Row 36: Row 37: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 33: Row 34: Row 35: Row 35: Row 35: Row 36: Row 38: Row 37: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 34: Row 35: Row 35: Row 35: Row 35: Row 35: Row 39 Row 38: Row 38: Row 37: Row 37 Row 37 Row 37: Row 39 Row 37: Row 37: Row 37: Row 38: Row 38: Row 38: Row 38: Row 37: Row 37: Row 37: Row 38: Row 38: Row 38; Row 38",
      "start_page": 504,
      "end_page": 504
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (column 4)",
      "text": "Row 1: ung Row 2: ziert Row 3: Row 4: Row 5: ziert Row 6: Row 7: Row 8: ziert Row 9: Row 10: Row 11: 024 Row 12:",
      "start_page": 504,
      "end_page": 504
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 504,
      "end_page": 504
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "24th day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of day of",
      "start_page": 505,
      "end_page": 505
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: Row 4: Row 5: 6.58 Row 6: On the basis of the available Row 7: Tumor tissue / Tumor cells of Row 8: all NSCLC in stage IV shall be mole- Row 9: Cular pathological studies Row 10: regarding all therapeutically relevan- Row 11: Ten molecular changes (according to Row 12: present state before First Line The Row 13: rapie as minimum requirement EGFR-Mu- Row 14: cations in exon 18-21, BRAF Row 15: V600 mutations, ALK-Fusions, ROS1- Row 16: fusions, RET-Fusions and NTRK1-3- Row 17: fusions). Row 18: Row 19: 6.61 Row 20: In the tissue samples of Therapy-nai- Row 21: ven patients in stage IV shall be parallel Row 22: to the molecular pathological subjects Row 23: Row 19: 6.61 Row 20: Row to be performed on the immunochemical compound Row 1: 24.",
      "start_page": 505,
      "end_page": 505
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: Version 4.01 Row 2: Row 6: Row 3: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R: R: Row: Row: Row: R: R: R: R: Row: R",
      "start_page": 505,
      "end_page": 505
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To To",
      "start_page": 505,
      "end_page": 505
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: ung Row 2: 024 Row 3: Row 4: ziert Row 5: Row 6: Row 7: ziert Row 8: Row 9:",
      "start_page": 505,
      "end_page": 505
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 505,
      "end_page": 505
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "One of the following is expected to be processed in Row 5: munzytochemical assay at Row 5: munzytochemical assay at Row 6: PD-L1 expression (TPS, s.u.).",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: should be used to treat patients in cell row 4: block technique with the following in- Row 5: muncytochemical examination on Row 6: PD-L1 expression (TPS, s.u.). Row 7: The result should be given as a percentage of memb- Row 8: ranny positive tumour cells (Tumour Row 9: Proportion Score, TPS) and as a percentage- Row 10: set of positive immune cells (Immun Cell Row 11: Score, IC Score). An ex- Row 12: tern quality assurance under Row 13: of ring trials should be demonstrated Row 14:. A corresponding sub-su- Row 15: chung (TPS) should also be used in patients in Row 16: Stage III with planned definitive Row 17: radiation chemotherapy. Row 18: in patients in early stages not Row 19: small-celled lung cancer after Row 20: complete TP determination: 22- Pow-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: Row 1: Row 1: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Twenty: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row:",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row 3: Row 4: Row 5: Row 6: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 14: Row 15: Row 16: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 23: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 38: Row 30: Row 31: Row 32: Row 32: Row 33: Row 33: Row 34: Row 35: Row 36: Row 37: Row 38: Row 39: Row 39: Row 40: Row 40: Row 40: Row: Row 40: Row",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: nderu Row 2: Row 3: modifiz Row 4: 024 Row 5:",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: ung Row 2: Row 3: decorated Row 4: Row 5:",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 506,
      "end_page": 506
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "In the case of tumours < 2cm in the through----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: 8.15 Row 3: In stage I/II, in sufficient Row 4: cardiopulmonary function, the radiok Row 5: Resection as lobectomy should be performed Row 6:. In tumours < 2cm in the Durc Row 7: meter, an anatomical Seg Row 8: mentresection can be performed Row 9: Row 10: 8.24 Row 11: NSCLC patients with resectable Tu Row 12: ren in stage II and ≥1% PD-L1-Ex- Row 13: pressure (without EGFR and ALK Altera Row 14: tion) and recommendation of an Inductio Row 15: therapy, should be offered a combined In Row 16: munchemotherapy Row 17: Row 18: 8.25 Row 19: After R0-resection and systematically Row 20: Lymph nodedissection, patient Row 21: with NSCLC in stage II Row 22: 23EC: Row 25.",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: he Row 4: kale Row 5: leads Row 6: ch- Row 7: Row 8: n. Row 9: Row 10: Row 11: umo- Row 12: - Row 13: a- Row 14: ons- Row 15: - Row 16: den. Row 17: Row 18: Row 19: her Row 20: en Row 21: Allge- Row 22: ante Row 23: Row 24: Row 25: Row 26: Row 27:",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Version 4.01 Row 2: 8.15 Row 3: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: Row 1: Row 1: Row 2: Row 2: Row: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 29: Row 30: Row 31: Row 31: Row 31: Row 22: Row 23: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 29: Row 29: Row 30: Row 31: Row 31: Row 31: Row 32: Row 24: Row 33: Row 33: Row 34: Row 35: Row 35: Row 36: Row 37: Row 38 Row: Row: Row 38: Row 31: Row 38: Row 31: Row 31: Row 32: Row 20: Row 20: Row 20: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 33 Row 24 Row 25 Row",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: ung Row 2: ziert Row 3: Row 4: Row 5: ziert Row 6: Row 7: Row 8: ziert Row 9: Row 10: Row 11: 024 Row 12:",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "Row 1: Version 3.0- Version 4.01-Change Row 2: -Resection an adjuvant therapy-- Row 3: -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: 8.28 Row 4: Patients with NSCLC Row 5: an activating E Row 6: Exon 19 Deletion, Ex Row 7: after complete rese Row 8: juvant Chemothera Row 9: Therapy with Osimert Row 10: be offered. Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: 8.29 Row 18: Patients with NSCLC Row 19: a PD-L1 Expressio Row 20: EGFR or ALK Altera Row 21: R0-Resection and du Row 22: juvant Chemothera Row 23: Therapy with Atezoliz Row 24: be offered. Row 25: Row 26:",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: in stage II and Row 5: EGFR mutation (only Row 6: xon 21 L858R) can Row 7: Ection and ad- Row 8: apie an adjuvant Row 9: tinib over 3 years Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: in stage II with Row 19: on ≥ 50 % (without Row 20: ation) should, according to Row 21: Rchleder ad- Row 22: apie, an adjuvant Row 23: to theab over 1 year Row 24: Row 25: Row 26:",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Version 4.01 Row 2: Resection an adjuvant therapy Row 3: with osimertinib over 3 years. Row 5: with Osimertinib over 3 years. Row 5: with Osimertinib over 3 years. Row 5: with Osimertinib over 3 years. Row 5: with Osimertinib over 3 years. Row 5: with Osimertinib over 3 years. Row 5: with Osimertinib over 3 years. Row 5: with Osimeridib over 3 years. Row 5: with Ostimeridib over 3 years. Row 5: with Ostimeridib over 3 years. Row 13: with Ostimeridib over 8 years. Row 13: with Ostimeridib over 4 years. Row 13: with Ostimeridib over 3 years. Row 13: with Ostimeridib over 8 years. Row 14: with Ostimeridib over 8 years.",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: Row 1: Row 1: Row 2: Row 3: Row 3: Row 4: Row 5: Row: Row 12: Row 13: Row 14: Row 15: Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 25: Row 26: Row 27: Row 28: Row 29: Row 29: Row 30: Row 31: Row 31: Row 31: Row 31: Row 32: Row 2024 Row 33: Row 35: Row 35: Row 36: Row 36: Row 37: Row 38: Row 38: Row 38: Row 38: Row 38: Row 39: Row 39: Row 39: Row 39: Row 38: Row 39: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 39 Row 39: Row 35: Row 35: Row 35: Row 35: Row 35: Row 36: Row 36: Row 36: Row 37: Row 39 Row: Row 39 Row: Row: Row 34: Row 24: Row 24: Row 24: Row 24: Row 24: Row 35: Row 24: Row 34 Row 24: Row 34 Row 34 Row 34 Row 34 Row: Row: Row: Row: Row 34: Row: Row 35: Row 34: Row 34: Row 34: Row 34: Row: Row: Row 35: Row 35: Row 35: Row",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: 024 Row 7: Row 8: 024 Row 9: Row 10: ziert Row 11: Row 12: Row 13: 024",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13:",
      "start_page": 508,
      "end_page": 508
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "The following are some of the things that can be said about it: The following are some of the things that can be said about it: The following are some of the things that can be said about it: The following are some of the things that can be said about it: The following are some of the things that can be said about it: The following are some of the things that can be said about it: The other things that can be said about it: The other things that can be said about it are: The other things that can be said about it: The other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it, the other things that can be said about it.",
      "start_page": 509,
      "end_page": 509
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: Row 4: 8.47 Row 5: Patients with NSCLC in stage IIIA1 Row 6: and IIIA2 and an activating EGFR Row 7: Mutation (exon 19 deletion only, exon Row 8: 21 L858R) can be offered a Row 10: adjuvant therapy with osimertinib Row 11: over 3 years after complete resek Row 9: tion and adjuvant chemotherapy. Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: 8.48 Row 20: Patients with NSCLC in stage IIIA with Row 21: a PD-L1 expression ≥ 50 % (without Row 22: EGFR or ALK alteration) should, according to Row 23: Row 23: R0-Resection and more performed",
      "start_page": 509,
      "end_page": 509
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "22-Row 1: Version 4.01 Row 2: Patients with NSCLC in stage II Row 3: - (without EGFR or ALK alteration) Row 4: - Row 5: - Should, after primary R0 resection Row 6: - and performed adjuvant Che- Row 7: -Motherapy, independent of PD-L1 Row 8: -Status an adjuvant therapy with Row 9: -Pembrolizumab over 1 year - Row 10: - To be used. Row 11: -8.50 Row 12: -Patients with NSCLC in stage Row 13: -IIIA1 and IIIA2 and one activate- Row 14: - EGFR mutation (Exon only 19 De-Row 15: -letion, Exon 21 L858R) are to be given Row 16: -IIIA1 and IIIA2 as well as one activate- Row 14: -3-Juvant Theotherapy ad.",
      "start_page": 509,
      "end_page": 509
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 21: New 20 Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 37: Row 29: Row 30: Row 30: Row 31: New 20 Row 32: Row 32: Row 33: Row 34: Row 35: Row 35: Row 36: Row 37: Row 37: Row 38: Row 38: Row 20",
      "start_page": 509,
      "end_page": 509
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: 024 Row 7: Row 8: 024 Row 9: Row 10: ziert Row 11: Row 12:",
      "start_page": 509,
      "end_page": 509
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 509,
      "end_page": 509
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "In addition, in the context of the first phase of the first phase of the first phase of the first phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the first phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase of the second phase",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Versio Row 2: adjuva Row 3: juvant Row 4: 1 year Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: 8.70",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: on 3.0 Row 2: anter Row 3: te The Row 4: r ange Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: 0 Row 2: Chem Row 3: erapie Row 4: ebote Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: Row 2: mothe Row 3: e with Row 4: en who Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: Row 2: erapie Row 3: Atez Row 4: rden. Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 2: e, a Row 3: zolizum Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 7)",
      "text": "Row 1: Row 2: e ad- Row 3: mab ü Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: About Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 9)",
      "text": "In the case of 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 24Dow: 1Dow: 1Dow: 24Dow: 24Dow: 1Dow: 1Dow: 24Dow: 24Dow: 1Dow: 24Dow: 24Dow: 24Dow: 24D",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 10)",
      "text": "Row 1: Row 1: Row 1: Row 2: Row 3: Row 3: Row 4: Row 5: Row 6: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 11)",
      "text": "Row 1: ung Row 2: Row 3: 024 Row 4: Row 5: 024 Row 6: Row 7: 024 Row 8: Row 9: 024 Row 10: Row 11:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 510,
      "end_page": 510
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "In the case of::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Patients with NSCLC in stage III, Row 3: according to decision in thorax oncologist Row 4: tumor board, not for an Ope- Row 5: ration or radio-chemotherapy geeig- Row 6: net are and have a PD-L1 expression ≥ Row 7: 50 %, can be given a therapy with Row 8: the PD-1 antibody Cemiplimab - Row 9: offer Row 10: Row 11: 8.77 Row 12: In NSCLC patients in stage IV with Row 13: plate epithelial carcinoma and PD-L1 Ex- Row 14: pressure < 50% and a good All- Row 15: common state (ECOG 0-1) should be offered a Row 16: chemo-immuntherapy with Row 17: the, e.g. a platinum-based combo- Row 18: onschemotherapy with Taxan Row 15: rabi- Row 19: rabi-",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "22-Dow 1: Version 4.01 Row 2: Patients with NSCLC in stage III, Row 3: Those with decision in thorax- Row 4: Oncological tumor board, not Row 5: For an operation or Radio-Che- Row 6: Are suitable, can be, off- Row 7: Depending on the PD-L1 status, an allei- Row 8: For an immuno-monotherapy or a Row 9: For a chemotherapy-immunotherapy offered Row 10: To be, every 3 weeks over 4 cycles followed Row 15: For a dose of cemiplimab every 3 weeks or Row 16: For a dose of chemo- Row 13: To be, therapy (in PD-L1 Expression ≥1%), Row 14: To be, every 3 weeks over 4 cycles followed Row 15: For a dose of cemiplimab every 3 weeks or Row 16: For a dose of cemiplimab: For a dose of PD-L1 Expression Row 17: For a dose of 1 to 50% none none none none none none none none none none none none none none none none none",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 20: Row 21: Row 22: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 37: Row 38: Row 38: Row 39: Row 39: Row 31: Row 32: Row 32: Row 33: Row 33: Row 34: Row 35: Row 36: Row 37: Row 38: Row 38: Row 39: Row 40 Row: Row 39: Row 39: Row 39: Row 39: Row 39: Row: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 39: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 38: Row 39 Row: Row 39: Row 39: Row 39: Row 39 Row: Row 39 Row: Row 39: Row 39: Row 39: Row: Row 39: Row 39: Row: Row 39: Row 39: Row: Row: Row 39: Row: Row: Row 13: Row 13: Row 13: Row 39",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: nderu Row 2: modific Row 3: 024 Row 4: Row 5: modific Row 6: 024 Row 7:",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: ung Row 2: ziert Row 3: Row 4: Row 5: ziert Row 6: Row 7:",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 511,
      "end_page": 511
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "In the case of NSCLCLC in the Row 8:  to stage 8:  to stage 8:  to stage 8: Row 8:  to stage 8:  to stage 9:  to Row 9:  to Row 9:  to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: V Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: Versio Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: on 3.0 Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: 0 Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 10)",
      "text": "Row 1: Version 4.01 Row 2: Platinum-based Chemotherapy + Row 3: Cemiplimab (at PD-L1 status ≥1%), Row 4: every 3 weeks over 4 cycles, followed Row 5: by Cemiplimab every 3 weeks Row 6:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 11)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 3: Row 4: Row 5: Row 6: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 30: Row 30: Row 31: Row 32: Row 33: Row 33: Row 34: Row 35: Row 36: Row 37: Row 38: Row 38: Row 39: Row",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 12)",
      "text": "Row 1: nderu Row 2: Row 3: eu 20 Row 4: Row 5: eu 20 Row 6: Row 7: eu 20 Row 8: Row 9: eu 20 Row 10:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 13)",
      "text": "Row 1: ung Row 2: Row 3: 024 Row 4: Row 5: 024 Row 6: Row 7: 024 Row 8: Row 9: 024 Row 10:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 14)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 512,
      "end_page": 512
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "In such cases, the autoimimimmune crane----\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Versio Row 2: Row 3: 8.88 Row 4: At NS Row 5: Plates Row 6: meinz Row 7: dicatio Row 8: should be a Row 9: chemo Row 10: Row 11: Row 12: Row 13:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "Row 1: on 3.0 Row 2: Row 3: Row 4: SCLC patients i Row 5: nepithelkarzino Row 6: condition (ECOG 0 Row 7: one against a Row 8: ine platinum based Row 9: otherapy given Row 10: Row 11: Row 12: Row 13:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: in stage IV m Row 5: om in guten All Row 6: 0-1) and Contra Row 7: ne Immunotherap Row 8: te Combination Row 9: be offered. Row 10: Row 11: Row 12: Row 13:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: lge- Row 6: ain- Row 7: pie Row 8: ns- Row 9: Row 10: Row 11: Row 12: Row 13:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: Version 4.01 Row 2: Patients with autoimmune disease Row 3: ,gen and good general condition Row 4: , (ECOG 0-1) may be offered an immuno- (Com- Row 5: ,binations-) therapy. Row 6: ,den if the autoimmune crane Row 7: ,kung is not life-threatening and Row 8: is not active. A close-knit mo- Row 9: ,nitoring is necessary in such cases especially Row 10: ,ders. Row 11: ,Patients with controlled hepatitis Row 12: ,B or C or a controlled Row 13: ,HIV disease and good Allge- Row 14: , my condition (ECOG 0-1) may be a Row 15: , , ,Immun- (combinations-) Therapy Row 16: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 5: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 14: Row 15: Row 16: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 20: Row 23: Row 23: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 38: Row 30: Row 31: Row 32: Row 32: Row 33: Row 34: Row 35: Row 36: Row 37: Row 38: Row 39: Row 39: Row 40: Row 40: Row: Row 40: Row: Row 40: Row: Row",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 7)",
      "text": "Row 1: nderu Row 2: Row 3: modifiz Row 4: 024 Row 5: Row 6: eu 20 Row 7:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 8)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: 024 Row 7:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 513,
      "end_page": 513
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page)",
      "text": "The following are not recommended for use in patients with NSCLC-patients with non-plat--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: 8.95 Row 4: In NSCLC patients with non-plat- Row 5: tenepithelial histology in UICC Sta- Row 6:dium IV and ECOG 0-1, which have no Row 7: therapeutic mutations and no Row 8: contraindications to check- Row 9: point inhibitors should be given, unab- Row 10: pending from PD-L1 status, in the first-row 11: nintherapy an immunotherapy Row 12:. Usually, this Row 13: is followed by a maintenance therapy Row 17: with Pemetrexed and Pembrozumab Row 18: Carmetrexed + Pemb- Row 15: rolizumab, every 3 weeks over 4 cycles, Row 16: cycles followed by a maintenance therapy Row 17: with Pemetrexed and Pembrozumab Row 18: Carmatexed + Pemetrexed + Pebrezumab Row 15: rolizumab, all 3 weeks over 4 cycles, Row 16: cycles followed by a maintenance therapy Row 17: with Pemetrexed + Pembrozumab Row 18: 24: Carboplatin + Pemb",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 2)",
      "text": "In addition, in the case of NSCLC patients with non-plat- Row 7:  totenepithelelelel histology in the UICC Row 8:  to Stadium IV as well as ECOG 0-1 which Row 9:  to be offered no therapyable mutations and Row 10:  to be given no contraindication against Row 11:  to have checkpoint inhibitors, Row 12:  to soll, independent of the PD-L1 status, Row 13:  to be offered in the first line therapy a chemo- Row 14:  to be offered in the first line therapy a chemo- Row 14: to be  to be given in the first line therapy. Row 15:  to be followed by  to be followed by  to be followed by  to be followed by  to be followed by  to be followed by to be followed by to be followed by to be followed by to be followed by to be followed by to be followed by to be followed by to be followed by to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 5: Row 6: Row 20: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 23: Row 24: Row 25: Row 26: Row 27: Row 28: Row 38: Row 30: Row 31: Row 32: Row 46: Row 33: Row 33: Row 41: Row 41: Row 35: Row 36: Row 37: Row 38: Row 39: Row 39: Row 40: Row 40: Row: Row 40: Row: Row",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 4)",
      "text": "Row 1: nderu Row 2: Row 3: modifiz Row 4: 024 Row 5:",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 5)",
      "text": "Row 1: ung Row 2: Row 3: decorated Row 4: Row 5:",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <19.3 Overview of changes in version 4> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 514,
      "end_page": 514
    },
    {
      "heading": "table under heading <*Cave: not yet approved>",
      "text": "In addition, the first four cycles could be used: Row 9: Pemetrexed in maintenance every 3rd Row 10: Weeks should be continued if there was Row 11: Row 11: Row 11: Row 12: Row 13: Row 13: Row 14: Row 14: Row 11: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 1)",
      "text": "Row 1: Versio Row 2: Row 3: Row 4: Row 5: Row 6: 8.108 Row 7: At NS Row 8: Deletie Row 9: Living Row 10: The Er Row 11: That. Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 2)",
      "text": "Row 1: on 3.0 Row 2: Row 3: Row 4: Row 5: Row 6: 8 Row 7: SCLC Stadiu Row 8: erten Tum Row 9: daten bev Row 10: rstlinienthe Row 11: Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: around IV Row 8: moren Row 9: forward Row 10: erapie Row 11: Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: V shall Row 8: up Row 9: down Os Row 10: e an Row 11: Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: te at Row 8: Round Row 9: Simert Row 10: ebote Row 11: Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: i Exon Row 8: Row 9: tinib Row 10: en we Row 11: Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: n 19 Row 8: Over Row 9: in Row 10: er- Row 11: Row 12:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 8)",
      "text": "Row 1: Version 4.01 Row 2: The first four cycles were used Row 3: The first four cycles were used. Row 4: The platinum-based chemotherapy + Row 5: The cemiplimab (at PD-L1 status ≥1%), Row 6: Every 3 weeks over 4 cycles, followed Row 7: The combination of Cemiplimab every 3 weeks. (In Row 8: The approval study could also Row 9: The pemetrexed in maintenance all 3 Row 10: The weeks continued when Row 11: The combination partner to Platinum in Row 12: The first four cycles was used Row 13: The first four cycles were used. Row 14: The NSCLC patients with non-plat Row 16: The NSCLC patients with non-plat Row 16: The first four cycles were offered Row 13: The first four cycles were used Row 13: The first four cycles were used. Row 14: The first four cycles were used Row 19: The first three cycles were used in Row 19: The first seven years of the first twenty years of the first twenty years of the first twenty-four years of the first twenty-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-four-",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 9)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 5: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 22: Row 23: Row 23: Row 20 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 38: Row 30: Row 30: Row 31: Row 32: Row 32: Row 33: Row 33: Row 34: Row 35: Row 36: Row 37: Row 38: Row 39: Row 39: Row 31: Row 40 Row: Row: Row 40 Row: Row: Row 40",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 10)",
      "text": "Row 1: nderu Row 2: Row 3: eu 20 Row 4: Row 5: modifiz Row 6: 024 Row 7:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: no approval yet> (column 11)",
      "text": "Row 1: ung Row 2: Row 3: 024 Row 4: Row 5: ziert Row 6: Row 7:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 515,
      "end_page": 515
    },
    {
      "heading": "table under heading <*Cave: not yet approved>",
      "text": "In particular, in the case of the NSCLC Stadium IV with EGFR, Row 5: first line TKI of effectiveness and toxicity of approved TKI, Row 9: and toxicity of approved TKI, (Afatinib, Dacomitinib, Erlotinib, Erlotinib, Erlotinib in combination with Erlotinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib, Ervitinib in combination with Ervitinib.",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 1)",
      "text": "Row 1: Version 3.0 Row 2: 8.109 Row 3: At NSCLC Stadium IV with L858R-Mu Row 4: onen, due to survival Row 5: and/or efficacy data, the survival Row 5: and/or efficacy data should be based on the Au Row 6: choice of first line TKI of Effekavit Row 7: and toxicity of the approved TKI Row 8: (Afatinib, dacomitinib, erlotinib, erlotinib, Gef Row 9: nib, osimertinib, erlotinib in combination Row 10: union with bevacizumab, erlotinib in Ko Row 11: bination with ramucirumab) depend on the EGF Row 12:. Row 13: Row 13: Row 14: Row 14: 8.112 Row 15: Patients with NSCLC Stadium IV and Row 16: joint mutations in EGFR of the Gru Row 17: 1 should be treated with the EGF Row 18: TKI osimertinibib or Afatinib given Row 14: 19: ten ten ten. Row 19: be given. Row. Row to be given. Row: Row: 22: 22: twenty twenty twenty twenty twenty twenty twenty twenty: be given given to be offered with twenty twenty be offered with twenty twenty twenty twenty twenty be offered with twenty twenty twenty",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 2)",
      "text": "Row 1: Row 2: Row 3: utati- Row 4: s- Row 5: us- Row 6: tat Row 7: Row 8: fiti- Row 9: na- Row 10: om- Row 11: ig Row 12: Row 13: Row 14: Row 15: d un- Row 16: uppe Row 17: FR- Row 18: bo- Row 19: Row 20: Row 21: nse- Row 22: a Row 23: ns- Row 24: ung Row 25: time Row 26: Row 27:",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 3)",
      "text": "In the case of EGSCLC Stadium IV with EGFR Row 4: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGFR Row: EGRL Row: EG Row: EGFR Row: EGR Row: EGFR Row: EG 24: EGFR Row: EGFR Row: EGFR Row: EGB Row: EGB Row: Eg: Eg: Eg: EGC Row: Eg: Eg: Eg: E",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 4)",
      "text": "In addition to::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 13:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 5)",
      "text": "Row 1: ung Row 2: ziert Row 3: Row 4: Row 5: ziert Row 6: Row 7: Row 8: ziert Row 9: Row 10:",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 516,
      "end_page": 516
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "In addition, it is recommended to use a combination therapy with Pati---EGFR-mutated NSCLC Stadium IV---Row 12: Carboplatin, Bevacizumab and Atezoli----0-1 in particular a Row 13: can be offered for combination therapy with Paci--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: Row 8: Row 7: Carboplatin, Bevacizumab and Atezoli- Row 8: can be offered as chemoimmun therapy. Row 9: Row 10: 8.122 Row 11: In case of acquired resistance to a Row 12: ALK inhibitor, a comprehensive Row 13: resistance test should be carried out. Row 14: Resistance testing should be taken into account in the Out Row 15: selection of the following ALK inhibitor Row 16: Row 17: 8.135 Row 18: In case of systemic Progress (with and Row 19: without ZNS metastases) under Therapy Row 20: if no Row 21: One G2032R resistance is present, Row 22: Row 22: Row can be offered as an alternative therapy with Lorov-Row.",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "24-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row-Row",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "In addition, the following row: 40 to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: ziert Row 7: Row 8: Row 9: ziert Row 10: Row 11:",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "Row 1: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog: Hedgehog.",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: 8,136 Row 4: In case of detection of \"off Row 5: dependent resistance Row 6: potentially systemic Row 7: (e.g., activating KIT Row 8: the use of potent Row 9: substances, according to Dis Row 10: Thorax-oncological Row 11: depending on the approval Row 12: ten become Row 13: Row 14: Row 15: Row 16: Row 17: 8,138 Row 18: patients with NSCLC Row 19: detected BRAF Row 20: should be a combinati Row 21: and trametinib an Row 22: Non-V600 mutations Row 23: should be in a Thor Row 24: tumor board besproc Row 25:",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: f-target\", ROS1- Row 5: c-mechanisms, Row 6: h therapierbar si Row 7: T-mutation), Row 8: ntiell effective Row 9: scussion into a Row 10: en Tumorboard, Row 11: sungstatus ange Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Stadium IV with Row 19: F-V600-Mutatio Row 20: ion aus Dabrafe Row 21: eboten. Row 22: s+ NSCLC Patien Row 23: rax-oncological Row 24: chen. Row 25:",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: -un- Row 5: , the Row 6: ind Row 7: lte Row 8: n Row 9: in Row 10: , un- Row 11: ebo- Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: on Row 20: enib Row 21: Row 22: nten Row 23: hen Row 24: Row 25:",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "In the case of the following cases: Row 17: Row 18: Row 14: Row 14: Row 15: Row 16: Row 17: Row 17: Row 18: Row 14: Row 14: Row 14: Row 14: Row 15: Row 16: Row 17: Row 18: Row 18: Row 19: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21: Row 21",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: Row 1: Row 1: Row 2: Row 3: Row 3: Row 4: Row 5: Row 5: Row 6: Row: Row 7: Row 2024 Row 8: Row 9: Row 10: Row 10: Row 11: Row 12: Row 12: Row 13: Row 14: Row 15: Row 15: Row 16: Row 17: Row 17: Row 18: Row 19: Row 19: Row 19: Row 20: Row 21: Row 22: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 36: Row 37 Row 29: Row 30: Row 30: Row 31: Row 2024 Row 32: Row 33: Row 33: Row 35: Row 35: Row 36: Row 40 Row 38: Row 38: Row 39 Row: Row 39 Row: Row: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 5: Row 3: Row 5: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 3: Row 39 Row 39 Row: Row 39 Row: Row 39: Row: Row 39 Row: Row: Row 39: Row: Row: Row: Row: Row: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 1: Row 7: Row",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 6)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: 024 Row 7: Row 8: ziert Row 9: Row 10:",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "Row 1: Version 3.0- Version 4.01-Change Row 2: Non-V600 Mutations+ NSCLC Pati---Row 3: To be approved in a molecular--Row 4: To be approved in a molecular--Row 4: To be approved in a molecular--Row 4: To be approved in a molecular--Row 4: To be approved in a molecular--Row 4: To be approved in a molecular---Row 9: Patients with NSCLC stage IV with to be approved in a NSCLC stage IV and in a Row 10: To be approved in a RET fusion, RET fusion should be delayed----------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: 8.141 Row 4: Patients with NSCLC stage IV with Row 5: detected RET fusion is to be offered late- Row 6: tens after failure of a first-line Row 7: rapie a therapy with a specific Row 8: schen RET inhibitor (Selpercatinib or Row 9: Pralsetinib). Row 10: 8.145 Row 11: Patients with NSCLC stage IV with an egg Row 12: ner KRAS-G12C mutation is to be offered after Ver- Row 13: say at least one system therapy Row 14: a targeted therapy Row 15: - is currently approved (02/22) Row 16: Sotorasib. Row 17: Row 18: Row 19: Row 20: Row 21: 8.146 Row 22: Considering the dynamics of the development Row 23: lung new personalized therapy Row 24: sets should be aimed at Row 17: Row 18: Row 19: Row 20: Row 21: 8.146 Row 22: In view of the dynamics of the development Row 23: Row 24: Row 24: Row 17: Row 17: Row 17: Row 17: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row 24: Row",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "Row 1: Version 4.01 Row 2: Non-V600 Mutations+ NSCLC Pati- Row 3: Diffusions should be discussed in a molecular Row 4: RET-Fusion. Row 5: RET-Fusion should be offered in Row 10: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-Inhibitor: RET-In: RET-RET-In: RET-In: RET-RET-In: RET-RET-RET-",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 1: Row 2: Row 3: Row 4: Row 5: Row 5: Row 6: Row 7: Row 7: Row 8: Row 2024 Row 9: Row 10: Row 10: Row 11: Row 12: Row 12: Row 13: Row 14: Row 15: Row 16: Row 16: Row 17: Row 17: Row 20: Row 19: Row 20: Row 21: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 29: Row 29: Row 30: Row 31: Row 38: Row 38: Row 32: Row 33: Row 24: Row 34: Row 35: Row 35: Row 35: Row 35: Row 36: Row 2024 Row 29: Row 30: Row 30: Row 31: Row 38: Row 38: Row 38: Row 38: Row 32: Row 32: Row 33: Row 24: Row 25: Row 34: Row 35: Row 35: Row 35: Row 35: Row 36: Row 24: Row 30: Row 30: Row 30: Row 30: Row 31 Row 31: Row 31: Row 38: Row 32: Row 32: Row 32: Row 33: Row 33 Row 33: Row 33: Row 33: Row 33: Row 33: Row 33: Row 33: Row 33: Row 33: Row 24: Row 24: Row 24: Row 25: Row 27: Row 27:",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: ziert Row 7: Row 8: Row 9: 024 Row 10: Row 11: ziert Row 12: Row 13:",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13:",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "Row 1: Version 3.0-Version 4.01-Change Row 2: a comprehensive genotyping on-In particular, in patients with wild-type configura-- Row 3: other known driver mutations----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: a comprehensive genotyping on Row 3: other known driver mutations Row 4: take place in order to enable such a targeted therapy in Row 6: scope of approval (if necessary for further Row 7: mutations with approved Medica Row 8: menten) , a study or in Off-La Row 9: bel-Use. This analysis Row 10: should include especially KRAS mutations, Row 11: HER2(ERBB2) mutations and MET-amp- Row 12: lifications. Before Row 13: reason of dynamic development in Row 14: precision soncology should include Row 15: a comprehensive analysis of potential Row 16: therapeutic driver mutations and Row 17: a result of mutationsana- Row 18: lysis based therapy offer to Row 19: the patient (including Thorax-Oncolo- Row 20: therapeutic driver mutations and Row 17: a result of mutation-Row 16.",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "Row 1: Version 4.01 Row 2: In patients with wild type configura- Row 3: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "Row 1: Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 5: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 14: Row 15: Row 16: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 23: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 28: Row 38: Row 39: Row 39: Row 31: Row 32: Row 32: Row 33: Row 41: Row 41: Row 35: Row 36: Row 37: Row 38: Row 39: Row 39: Row 40: Row 40: Row: Row 40 Row: Row",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "Row 1: nderu Row 2: Row 3: modifiz Row 4: 024 Row 5: Row 6: eu 20",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: 024",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:",
      "start_page": 520,
      "end_page": 520
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "In the course of a systemic thera----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- the structured course---------------------------- the structured course------------------------------------ to to to to to to-----------------------------------------",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: 16.4 Row 8: In patients after curative Row 9: should the posttherapists Row 10: cations that occur after Operat Row 11: Radiotherapy Row 12: capture and be treated Row 13: clinical presentation Row 14: after completion of the Therap Row 15: close of a lung radio Row 16: and the CO diffusion cap Row 17: recommended. 2010: Empfeh Row 18: (weak recommendation) Row 19: Row 20: Row 21:",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "Row 1: Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: er Therapi Row 9: chen Kom Row 10: tion or Row 11: n kann, Row 12: en.",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: ie Row 9: mpli- Row 10: Row 11: er- Row 12: ste Row 13: en Row 14: Ein- Row 15: ung Row 16: CO) Row 17: d C Row 18: Row 19: Row 20: Row 21:",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "22 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 48 - 24 - 24 - 24 - 24 - 24 - 24 - 24 - 24 -",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: Row 1: Row 2: Row 3: Row 3: Row 4: Row 5: Row 6: Row 6: Row 7: Row 8: Row 9: Row 9: Row 10: Row 11: Row 12: Row 13: Row 13: Row 14: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 19: Row 20: Row 21: Row 22: Row 23: Row 23: Row 24: Row 25: Row 26: Row 27: Row 27: Row 28: Row 38: Row 30: Row 30: Row 31: Row 32: Row 32: Row 33: Row 33: Row 34: Row 35: Row 36: Row 37: Row 38: Row 39: Row 39: Row 31: Row 40 Row: Row: Row 40",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 6)",
      "text": "Row 1: nderu Row 2: Row 3: eu 20 Row 4: Row 5: modifiz Row 6: 024 Row 7: Row 8: eu 20 Row 9:",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 7)",
      "text": "Row 1: ung Row 2: Row 3: 024 Row 4: Row 5: ziert Row 6: Row 7: Row 8: 024 Row 9:",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9:",
      "start_page": 521,
      "end_page": 521
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "Row 1: Version 3.0-Version 4.01-Change Row 2:--Exclusion of progression a CT--- Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 522,
      "end_page": 522
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: Row 3: 16.7 Row 4: After curative therapy, the Pa- Row 5: tients should be searched in the first 2 years quarter- Row 6: annually, from the second year half-yearly, and Row 7: once a year after 5 years lower- Row 8:. These intervals begin Row 9: with the initial conception 4-6 weeks Row 10: after completion of therapy. At these Row 11: follow-up appointments are a determined Row 12: anamnesis, a physical sub-Row 13: Chung and appropriate imaging Rev 14: driving. 2010: Empfeh- Row 15: Degree of lung C (Schwach Recommendation) Row 16: Row 17: 15.5 Row 18: A general screening on brain meta- Row 19: stasen cannot be recommended, Row 20: for high risk patients according to Row 21: the therapist's condition, however, Row 22: 2010: Recommendation Row 17: 15.5 Row 18: A general screening on brain meta- Row 19: stasen can not be recommended, Row 20: for high risk patients according to Row 21: The therapist's condition. Row 22: 2010: Recommendation Row 23 (Fe Row 23)",
      "start_page": 522,
      "end_page": 522
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "Row 1: Version 4.01 Row 2: The exclusion of a progression of a CT- Row 3: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 522,
      "end_page": 522
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "Row 1:  to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to",
      "start_page": 522,
      "end_page": 522
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "Row 1: ung Row 2: Row 3: ziert Row 4: Row 5: Row 6: ziert Row 7: Row 8: Row 9: ziert Row 10: Row 11:",
      "start_page": 522,
      "end_page": 522
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 522,
      "end_page": 522
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page)",
      "text": "Row 1: Version 3.0\"Version 4.01\"Version Row 2: After that, fixed re-up- and imaging procedures (MRT Skull- and Row 3: postulate at least every 3 months in case of suspicion of brain metastases) should follow Row 4:. In patients with the option to perform. After that, fixed Row 5: further therapies is a shortening of re-introductions in luke- and Row 6: follow-up intervals to 6 to 8 Wo- and Row 7: should be useful. Here, geeig- and Row 10: disease should be performed at least every 3-6 weeks. Row 8: nete examination procedures for right- and success. In patients under run- and Row 9: time recording of a progress of the system therapy are CT Kontrol- and Row 10: disease.",
      "start_page": 523,
      "end_page": 523
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 1)",
      "text": "Row 1: Version 3.0 Row 2: After this, fixed re-row 3: positions should be followed at least every 3 months. In patients with the option on Row 5: further therapies is a shortening Row 6: the follow-up intervals to 6 to 8 Wo-Row 7: useful. Here should then be appropriate Row 8: nete examination procedures for the right Row 9: timely recording of a progress of the Row 10: disease. Row 11: 2010: Recommendation level D (Missing Row 12: or inconsistent studies, recommendation Row 13: based on expert opinion) Row 14:",
      "start_page": 523,
      "end_page": 523
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 2)",
      "text": "Row 1: Version 4.01 Row 2: Image-giving procedures (MRI Skull Row 3: In case of suspicion of brain metastases) Row 4: After that, fixed Row 5: Re-presentation of luke Row 6: In case of maintenance therapy (NSCLC, Row 7: In case of suspicion of brain metastases) at least every 3-6 weeks Row 8: In case of patients under run- Row 9: In case of system therapy CT Kontrol Row 10: In case of continuous interval of 6 to 9 Row 11: In case of maintenance, Row 12: In case of appropriate examination Row 13: In case of early detection of a Row 14: In case of disease and Row 15: In case of failure, Row 16: In case of systemic therapy, change should be carried out- Row 17: In case of failure.",
      "start_page": 523,
      "end_page": 523
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 2: Row 3: Row 4: Row 5: Row 6: Row 6: Row 7: Row 8: Row 9: Row 10: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 16: Row",
      "start_page": 523,
      "end_page": 523
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 4)",
      "text": "Row 1: nderu Row 2:",
      "start_page": 523,
      "end_page": 523
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 5)",
      "text": "Row 1: ung Row 2:",
      "start_page": 523,
      "end_page": 523
    },
    {
      "heading": "table under heading <*Cave: not yet approved> (from previous page, column 6)",
      "text": "Row 1: Row 2:",
      "start_page": 523,
      "end_page": 523
    }
  ]
}